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ABSTRACT

Walter Jeske
Loyola University Chicago

Heparin is a mixture of glycosaminoglycan chains which is used to prevent
thrombosis in a number of clinical indications. Heparin is known to promote the
inhibition of blood coagulation via the plasmatjc cofactors antithrombin ill (ATilI) and
heparin cofactor II (HCII).
The objective of this dissertation was to examine the importance of heparin
cofactors in the mediation of the anticoagulant and antithrombotic effects of heparin. To
achieve this goal, synthetic heparin analogues exhibiting a more selective interaction with
heparin cofactors were studied using a number of in vitro systems and in vivo models.
Three analogues were selected for this study. The pentasaccharide representing
the minimal ATill binding sequence of heparin was observed to inhibit factor Xa but not
thrombin via activation of ATIIl. Aprosulate mhibited thrombin via HCII but did not
exhibit activate ATill. GL-522-Y-l also promoted the inhibition of thrombin via HCII
but did not interact with ATiii.
The in vitro actions of each agent were investigated in plasma based clotting
assays, Plasmatic and non-plasmatic amidolytic protease generation assays and in
endothelial cell cultures. The in vivo phannacologic actions were studied in terms of

iv

antithrombotic and hemorrhagic activities in a rabbit stasis thrombosis model, a rat
jugular vein clamping model of thrombosis and a rabbit ear bleeding model. The impact
of the administration of synthetic heparin analogues on plasma TFPI levels was assessed
in several species. TFPI antigen levels were also measured in primates and as part of two

phase I human trials with aprosulate.
From these studies, it was observed that ATIII plays a primary role in mediating
heparin's anticoagulant and antithrombotic actions. In both models of thrombosis, agents
capable of interacting with ATill proved more potent than those which solely inhibited
thrombin via HCII. Interaction with plasma based SERPINs was not predictive of
hemorrhagic potential as both pentasaccharide and aprosulate failed to produce
hemorrhage. These results also indicate a relative urrimportance of HCII mediated
thrombin inhibition in the mediation of anticoagulant and antithrombotic activities. While
aprosulate and GL-522-Y-1 were observed to :inhibit thrombin via HCII with similar
potencies the in vitro and in vivo activities of these agents were widely divergent
suggesting the importance of mechanisms other than protease inhibition by ATiil and
HCII for the mediation of the biologic effects of these agents.
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CHAPTER I
LITERATURE REVIEW
A.Overview of Blood Coagulation

1. Introduction
Hemostasis as defined by Virchow in the last century is a fine balance between
blood flow, humoral factors, and cellular elements of the vascular system. Today,
biotechnology has advanced our understanding of the thrombotic process and its
regulation. Whereas in the past, heparin and warfarin have been the sole antithrombotic
agents available, specific sites in the thrombotic network can now be targeted. Antibodies
against specific platelet receptors as well as specific antithrombin and anti-Xa agents are
being developed. Mutations of endogenous inhibitors have been identified as causes of
congenital thrombophilias. The use of heparin has also advanced. Heparin is no longer
solely a surgical anticoagulant, but is used to treat a variety of conditions including
venous thrombosis, unstable angina and myocardial infarction and is used in procedures
such as angioplasty and stent implantation. The mechanism of heparin's action has
become more complex with the discovery of tissue factor pathway inhibitor.
Blood normally is maintained in the fluid state so that nutrients can be delivered
to the various tissues of the body. When the integrity of the vascular system has been
compromised, it becomes necessary for the blood to clot. The initial response to a break
in the continuity of the vasculature is the formation of the platelet plug. Platelets in the
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flowing blood rapidly adhere to the exposed subendothelial vessel wall matrix and
become activated. During this activation process, components of the platelet a and B
granules (ATP, ADP, factor V, 5-HT) are released causing further platelet aggregation.
Also during these morphologic changes, activated platelets express protein and cell
receptors and procoagulant phospholipids are expressed upon their surface.
The negatively charged phospholipid phosphatidylserine is asymmetrically
distributed in mammalian cell membranes, primarily on the inner leaflet. Upon exposure
to collagen or thrombin, the distribution of phospholipids changes with increasing
phosphatidylserine in the external membrane leaf (Bevers et al., 1985). The increased
expression of phosphatidylserine on the outer leaflet of the membrane creates a
procoagulant surface on which several steps of the coagulation cascade take place.
The platelet plug initially arrests the loss of blood. This, however, is not a
permanent blockade. The formation of a fibrin based clot acts to stabilize the initial
platelet plug. The coagulation system is a complex network of zymogens which must be
activated to ultimately form the fibrin strands of the blood clot. Upon activation, most
of these coagulation proteins are converted into active serine proteases which are similar
to trypsin and chymotrypsin. Traditionally, coagulation has been viewed as having two
distinct branches (Davie et al., 1964; Macfarlane et al., 1964), the intrinsic and the
extrinsic pathways. Today it has been established that the two pathways are linked prior
to the generation of factor Xa (Osterud et al., 1977). A schematic of the coagulation
cascade is depicted in Figure 1.
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Figure I. Schematic of the coagulation cascade. The formation of the fibrin clot can be
initiated in one of two ways. Activation of the contact system results in the sequential
activation of factors XII, XI, IX, X and II. Exposure of tissue factor leads to activation
of factors IX and X via a complex with factor Vlla. Solid arrows indicate enzymatic
conversion. Broken arrows indicate inhibition. Factors in parenthesis are act as cofactors.
ATIII primarily inhibits in the intrinsic pathway. TFPI regulates the extrinsic pathway.
HCII is limited to inhibiting thrombin.
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2.Intrinsic Pathway of Coagulation
In the intrinsic pathway, factor XII becomes activated in the contact phase of
coagulation. This occurs when factor XII, factor XI, prekallikrein, and high molecular
weight kininogen come together on a negatively charged surface. While this reaction can
take place in the laboratory on a negatively charged surface such as glass or kaolin, the
physiologic surface is unknown. It has been proposed that this could be a tissue rich in
collagen or sulphatides (Scully et al., 1992). By binding to the negatively charged
surface, factor XII is converted to its active form through an unknown mechanism. The
formation of factor XIIa is amplified by a positive feedback loop. Factor XIIa is capable
of converting prekallikrein to kallikrein. Likewise, kallikrein converts factor XII to its
active form. Factor XIIa also converts factor XI to factor Xla which in turn activates
factor IX. Factor IX along with its cofactor factor VIII, calcium ions, and phospholipid
membranes form the "tenase" complex which converts factor X to factor Xa thereby
initiating the common pathway of coagulation. The phospholipid membrane in these
complexes serves to lower the Km of the reaction. The phospholipid allows the enzyme
to become saturated more easily and serves to localize the coagulation response to where
it is most needed. The cofactor, factor V, increases the catalytic efficiency of the enzyme
(Hemker et al., 1991). Factor Xa joins with its cofactor factor V, calcium ions and
phospholipid membranes to form the prothrombinase complex. The prothrombinase
complex then acts to convert prothrombin into the active enzyme thrombin. Factors V
and VIII are activated through proteolytic cleavage by factor Xa or thrombin. They are
not, however, active proteases. Factor V is believed to have two rate enhancing effects
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on the prothrombinase complex. In the prothrombinase complex, factor Xa and factor V
are present in stoichiometric amounts resulting in an unknown alteration in the active site
of factor Xa which increases its catalytic efficiency (Mann et al., 1988). Factor V also
binds to prothrombin thus sequestering it at the site of assembly of the prothrombinase
complex. Overall, these two actions of factor V result in a 300,000-fold increase in the
rate of prothrombin conversion.
Thrombin serves many functions in coagulation. First, thrombin cleaves the
soluble protein fibrinogen to generate the insoluble fibrin monomer. Fibrinogen circulates
as a disulfide-linked dimer containing two A-0! chains, two B-6 chains and two gamma
chains. Cleavage of fibrinogen by thrombin results in the release of fibrinopeptides A and
B and the exposure of charged domains at opposite ends of the molecule (Roberts et al.,
1992). Exposure of these charged domains leads to polymerization of the monomers. The
release of fibrinopeptides A and B occur at different rates with fibrinopeptide A
preferentially removed in mammalian systems (Blomback et al., 1958; Shainoff et al.,
1960). Removal of fibrinopeptide A leads to end-to-end fibrin polymerization whereas
loss of fibrinopeptide B allows side-to-side polymerization of the end-to-end linked
monomers (Laurent et al., 1958). It is these monomers which are cross-linked by the
transaminase factor XIIIa to form the meshwork of the thrombus. Thrombin also acts to
augment its own generation by being a part of several positive feedback loops in the
coagulation cascade. In these loops, thrombin activates factors XII, XI, VIII, and V. By
activating the precursors to its own generation, thrombin greatly amplifies its own
generation. Thrombin also activates platelets (Coughlin et al., 1992), activates the
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inhibitor Protein C through binding with thrombomodulin (Esmon et al., 1989), and
stimulates activated endothelial cells to release tissue plasminogen activator (Olsen et al.,
1992).

3. Extrinsic Path way of Coagulation
The extrinsic pathway of coagulation is activated when circulating factor VII
encounters tissue factor. Tissue factor is a transmembrane glycoprotein which is normally
expressed by subendothelial fibroblast-like cells which surround the blood vessel. An
intact endothelium normally shields the circulating blood from exposure to tissue factor.
The tissue factor molecule consists of a 219 amino acid hydrophilic extracellular domain,
a 23 amino acid hydrophobic region which spans the membrane, and a 21 amino acid
cytoplasmic tail which anchors the molecule to the cell membrane (Bach et al., 1988;
Mc Vey et al., 1994). Other sites of tissue factor expression include activated monocytes,
activated endothelial cells, and atherosclerotic plaques.
Factor VII exhibits a weak procoagulant activity on its own, typically accounting
for about 1-2 % of the total factor VII/VIIa activity (Morrisey et al., 1993). Upon binding
to tissue factor, a 10,000,000 fold increase in factor VIIa enzymatic activity is observed
(Edgington et al., 1991). Both factor Vll and factor VIIa bind to tissue factor with equal
affinity (Nemerson et al., 1988). How factor VII is initially activated is not known,
though it is hypothesized that factor Xa can activate factor VII in a back activation
reaction. The factor VIia - tissue factor complex: can then activate factor X leading to the
generation of thrombin and ultimately to the formation of fibrin strands.
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It has been shown in 1977 and more recently appreciated that the tissue factor -

factor Vila complex also activates factor IX to factor IXa, thus interacting with
"intrinsic" pathway enzymes (Osterud et al., 1977). This is believed to be important for
maintaining the clotting process. Direct activation of factor X by factor Vila - tissue
factor can rapidly initiate coagulation, but both of these enzymes are quickly inhibited
by the endogenous inhibitor tissue factor pathway inhibitor. By activating factor IX, the
tissue factor - Vila complex initiates two path ways for thrombin generation. The small
amounts of factor Xa generated prior to TFPI inhibition are sufficient to cleave
prothrombin and generate a small amount of thrombin. This thrombin is then capable of
back-activating factors V, VIII and possibly XI, thereby sustaining clot formation through
generation of thrombin via the intrinsic pathway. It has been observed that the activation
of factor X by the factor IXa-VIII complex in the presence of calcium and phospholipids
is 50 times greater than by the tissue factor-VIia complex (Mann et al., 1990). Factor

XI activation has been shown to occur in the presence of thrombin and a polyanion
cofactor (Naito et al., 1991; Gailani et al., 1991). Activation with the cofactor has been
observed to be poor. A physiologic cofactor has not been elucidated. lt has been reasoned
that if the direct activation of factor X by VIia - tissue factor is the sole source of
thrombin generation, there would be no manifestation of hemophilia, a genetic deficiency
of either factor IX or factor VIII.

4. Role of Platelets

Platelets are disc-shaped, anuclear cells which circulate in a non-adhesive state
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in the undamaged circulation (Packham, 1994). These cells contain a contractile system
and a number of storage granules. The a storage granules contain platelet factor 4 (PF4),
J3-thromboglobulin, platelet derived growth factor (PDGF), fibrinogen, factor V, and von
Willebrand factor (Kaplan et al., 1981). The dense or fl-granules contain ATP, ADP, and
serotonin (Holm sen et al., 1987; Niewiarowski et al., 1987).
The first step toward platelet aggregation is platelet adhesion. Normally,
platelets do not adhere to the vessel walls due to the non-thrombogenic properties of the
endothelium. Endothelial cells produce heparan sulfate (to activate antithrombin III),
thrombomodulin (for activation of protein C), plasminogen activators (to induce fibrin
degradation) and TFPI (to inhibit tissue factor activity). In addition, these cells also
produce prostacyclin (PGI2) which inhibits platelet activation by raising platelet cAMP
levels and endothelial derived relaxing factor (EDRF; NO) which inhibits platelet
activation through a cGMP dependent mechanism. When this antithrombotic continuum

of cells is interrupted by vascular injury, platelets adhere to the exposed subendothelial
tissues.
Following adhesion, platelets become activated. In this activation process, there
is a morphologic shape change in the platelet, with pseudopod formation observed. This
brings about a change in the conformation of the glycoprotein IIb/IIIa receptor on the
platelet surface which allows for fibrinogen binding (Packham, 1994). Fibrinogen binding
serves as a bridge which links individual platelets into larger aggregates. An increase in
cytosolic calcium levels leads to activation of internal platelet enzymes with the
subsequent release of platelet granule con ten ts. The formation of these platelet aggregates
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is the process of primary hemostasis, the first step to arrest blood loss.
The release of platelet granule contents leads to further platelet activation and
aggregation and an activation of coagulation. Most of the known aggregating agents cause
release of the platelet storage granule contents. These agonists include thrombin, ADP,
collagen, TXA2 , platelet activating factor, serotonin, epinephrine, immune complexes,
and fibrinogen (Packham, 1994). Thrombin is the most potent aggregating agent, capable
of causing platelet aggregation without any contribution from thromboxane A2 or ADP
(Packham, 1994). Serotonin and epinephrine do not induce aggregation on their own, but
synergistically promote aggregation induced by other agents (Coller et al., 1992; Hourani
et al., 1991; Siess et al., 1989).
Platelet membranes contain a variety or receptors for the various agonists
including the thrombin receptor, the TXA 2 receptor, 5-HT2 receptors, and a 2-adrenergic
receptors. In addition, a number of glycoproteins present on the membrane serve as
receptors for collagen (GP Ia/Ila), fibrinogen (GP IIb/IIIa), van Willebrand factor (GP
lb) and fibronectin (GP IIb/IIIa) (Coller et al., 1992; Hourani et al., 1991; Siess et al.,
1989). A high molecular weight chondroitin sulfate proteoglycan has been shown to be
released from the surface of the platelet during the aggregation process (Nader, 1991).
This proteoglycan contains homopolymers of 4-0 chondroitin sulfate which inhibit ADP
induced aggregation of platelets.
Activated platelets also provide a procoagulant surface on which several
reactions of the coagulation cascade take place. Unstimulated platelets provide only a
minimally effective surface on which the "tenase" and prothrombinase complexes can
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assemble (Zwaal et al., 1989; Wiedman et al., 1986; Esmon, 1993). This is due to the
bilayer partitioning of various phospholipids. In unstimulated platelets, the outer leaflet
of the membrane consists of mostly phosphatidylcholine while the inner leaf contains
most of the phosphatidylserine. Two mechanisms have been proposed for maintaining this
distribution (Sandberg, et al., 1985; Tilly et al., 1990). When platelets are stimulated to
release their granular contents, the procoagulant phospholipids are brought to the surface
as the granules fuse to the membranes (Zwaal et al., 1989). This expression of
phosphatidylserine on the outer leaflet along with factor V release from the a-granule
greatly accelerates the formation of thrombin (Tracy et al., 1992; Miletich et al., 1977;
Ittyerah et al., 1981).
Platelet activation leads to the formation of platelet derived microparticles
derived from the platelet surface. These microvesicles typically account for 25 to 30 %
of platelet procoagulant activity and factor V binding sites (Sandberg et al., 1985; Sims
et al., 1989).

5. Role of Platelet Integrins
A number of the glycoproteins on the surface of the platelet belong to the
superfamily of adhesive protein receptors known as integrins. Integrins are a/B
heterodimer protein complexes which are present on the surface of adherent cells of most
species (Bogaert et al., 1987; DeSimone et al., 1988; Marcantonio et al., 1988). These
integrins mediate cell-cell and cell-matrix interactions involved in a diverse number of
biologic functions (Hynes et al., 1987; Takada et al., 1987). Integrins are divided into
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subfamilies based on the identity of the fl-subunit. The first two subfamilies of integrins,
the VLA complexes and the Leu-Cams, are found on white cells and mediate various
leukocyte aggregation responses (Hemler et al., 1983; Anderson et al., 1987). Platelets
contain two members of the third subfamily of integrins, glycoprotein Ilb/Illa or Pselectin and the vitronectin receptor (Cheresh et al., 1987; Lam et al., 1989; Bray et al.,
1987; Zimrin et al., 1988).
Integrins function by interacting with a number of extracellular glycoprotein
ligands such as fibronectin, laminin, collagen, vitronectin, fibrinogen, and von
Willebrand's factor (Bennett et al., 1991). Integrins are capable of binding several
ligands and the nature of the ligand specificity is not known.
Platelet membranes contain five integrin-like receptors which are involved in the
formation of the primary hemostatic plug. These include VLA-2, VLA-5, VLA-6,
glycoprotein IIb/IIIa and the vitronectin receptor. Of these, GP IIb/IIIa is the most
abundant (Phillips et al., 1991). VLA-2 (GPJafIIa) is the binding site for collagen on the
platelet surface (Staatz et al., 1989). VLA-5 and VLA-6 are responsible for the binding
to vitronectin and laminin, respectively (Hemler et al., 1988; Fischel et al., 1988). The
extent to which these receptors contribute to platelet adhesion in vivo is not known. The
physiologic function of the vitronectin receptor is not known.
Platelet aggregation requires that platelets become activated by at least one
platelet agonist, the presence of functional GPJlblllla molecules and the presence of at
least one GPIIb/IIIa ligand (Shattil et al., 1981 ). Lack of GPilbfIIIa complexes leads to
the congenital bleeding disorder known as Glanzmann's thrombasthenia (Bennett et al.,
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1979). In nonactivated platelets, GPIIb/IIIa is capable of binding only immobilized
fibrinogen. Platelet activation allows plasma-borne adhesive proteins to bind to GPIIb/llla
complexes (Jackson et al., 1993). The activation of the lib/Illa complex occurs by an
unknown mechanism though the number of receptors on the membrane is not altered by
activation (Phillips et al., 1991). Fibrin polymers bind to the activated GPIIb/Illa
complexes and anchor the platelet plug in place.
Recent studies have shown that the binding ofligands to GPilb/Illaalso activates
a number of cellular processes important for platelet stimulation (Phillips et al., 1991)
including the synthesis of 3-phosphorylated phosphatidylinositols, the release of
arachidonic acid, and the increase in plasma calcium levels. Stimulation of these
processes allows for bidirectional signalling between the intracellular and extracellular
compartments.

6. Role of Leukocytes
Leukocytes typically express minimal amounts of procoagulant activity in the
unstimulated state (Drake et al., 1989). Cytokines such as interleukin-1 (IL-1) and tumor
necrosis factor (TNF) can elicit the expression of tissue factor on endothelial and
mononuclear cells (Carlsen et al., 1988). Monocyte procoagulant activity is also induced
by endotoxin, the complement system, phorbol esters, prostaglandins, and a number of
other agonists (Edwards et al., 1992). Procoagulant activity associated with leukocytes
is not limited to the expression of tissue factor. Several monocyte/macrophage derived
procoagulant activities have been characterized. These include tissue factor (Gregory et
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al., 1989; McGee et al., 1990, Schwartz et al., 1981), factor VII (McGee et al., 1989;
Chapman et al., 1985), and factor XIII (Weisberg et al., 1987). In addition, some
monocytes and macrophages have been shown to express functional factor V/Va
(Rothberger et al., 1984) and to possess binding sites for factor X (Altieri et al., 1988).
The factor Xa binding site on leukocytes has been shown to be the integrin CD1lb/CD18
(Altieri et al., 1988). Not only does this integrin bind factor X, but it also proteolytically
activates factor X to Xa, allowing for initiation of coagulation on the surface of the
monocytes and neutrophils (Altieri et al., 1988b). Monocytes have also been shown to
contain a receptor for the factor IXa/VIII complex which allows the reactions of the
intrinsic pathway of coagulation to take place on the surface of the monocyte (McGee et
al., 1991).
Prothrombin has been shown to be efficiently activated on the cell surface of
monocytes and lymphocytes (Tracy et al., 1983; Tracy et al., 1985). As with platelets,

the prothrombinase activity on monocytes is increased with activated monocytes as
compared to the non-activated cells (Robinson et al., 1992).
It has been stated that when coagulation takes place on the surface of leukocytes,

it " ... assumes the aspects of a broad inflammatory mechanism, directly influencing
cellular motility and adhesion, phagocytosis, cell-cell communication, and normal or
deregulated cellular growth" (Altieri et al., 1993). Fibrin formation not only forms the
basis for a blood clot, but can also serve to limit the inflammatory response. In addition,
products of the coagulation process such as thrombin, fibrinopeptides, and fibrin
degradation products have chemotactic and mitogenic properties (Perdue et al., 1981;
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Senior et al., 1986; Shavit et al., 1983).
Studies have indicated that leukocytes play a critical role in the activation of
coagulation in patients with septicemia and in animal models of acute lung injury
(Okajima et al., 1991; Car et al., 1991). One study has presented direct evidence
indicating the role of tissue factor expression on activated endothelial cells on in vivo
thrombogenesis (Nawroth et al., 1986).

7. Role of Cytokines
Cytokines produced during inflammatory responses as in sepsis lead to several
alterations of

the hemostatic system. Primarily affected are the endothelium and

leukocytes. Following an injection of endotoxin, it has been shown that there is an
increase in tissue factor expression on monocytes leading to the formation of the VIIatissue factor complex. (Edgington et al., 1992; ten Cate et al., 1994). Cytokines such as
interleukin- I (IL-1) and tumor necrosis factor (TNF) are known to alter the
antithrombotic properties of the endothelium. Among these changes is an increased
expression of adhesion molecules for neutrophils and lymphocytes on the endothelium
(Savage et al., 1993; Redl et al., 1994; Waage et al., 1993). Both cell types are capable
of directly damaging the endothelium (Savage et al., 1993). Damage to the endothelium
leads to both an activation of coagulation (Levi et al., 1993; Maruyama, 1994) and to
delayed alterations in the balance of fibrinolytic activators and inhibitors (Gertler et al.,
1992), both of which can promote thrombus formation.
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B. Endoe;enous Inhibitors of Coa211lation

1. Antithrombin ill
Antithrombin III is a single chain glycoprotein with a molecular weight of
approximately 58,000 Da (Mourey et al., 1990). The primary structure of this serine
protease inhibitor (SERPIN) has been determined by protein and cDNA sequencing of
clones from several species (Beck et al., 1982; Chandra et al., 1983; Petersen et al.,
1979; Prowchownil et al., 1983; Sheffield et al., 1992; Stackhouse et al., 1983). Normal
plasma levels of antithrombin III are approximately 2 to 3 µM (Conrad et al., 1983).
In the beginning of the century, it was suspected that a natural inhibitor of
thrombin was present in the plasma (Howell, 1918). The first hints of antithrombin Ill's
existence were detected shortly after the discovery of heparin when it was discovered that
heparin required a cofactor to exhibit its anticoagulant activity (Howell, 1925; Brinkhous
et al., 1939). At this point, the molecule was termed heparin cofactor (Brinkhous et al.,
1939). It was not until the late 1960's that Abildgaard demonstrated that the proteins
antithrombin and heparin cofactor were one in the same (Abildgaard et al., 1968).
Antithrombin III is a member of the SERPIN superfamily of proteins which
includes the inhibitors a 2 -antiplasmin, a 1-antichymotrypsin, and a 1-proteinase inhibitor
(Pizzo et al., 1994). Antithrombin III is considered to be the primary inhibitor of
coagulation (Pratt et al., 1991) and targets most coagulation proteases as well as the
enzymes trypsin, plasmin, and kallikrein (Bjork et al., 1986; Travis et al., 1983).
Inhibition takes place when a stoichiometric complex between the active site serine of the
protease and the ARG393-SER294 bond of antithrombin III forms (Rosenberg et al.,
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1973; Jornvall et al., 1979; Damus et al., 1973; Owen et al., 1975).
The tertiary structure of antithrombin III resembles

~.-antitrypsin

in that it is

folded into N-terminal domain helices and 13-sheets. This tertiary structure is maintained
by the formation of three disulfide bonds (Mourey et al., 1990). Four glycosylation sites
exist on human antithrombin III, two of which are suspected to actually contain
carbohydrate chains. The glycosylation of these sites appears to effect heparin binding
to the inhibitor (Brennan et al., 1987; Brennan et al., 1988).
The efficient inhibition of proteases by antithrombin III requires heparin as a
cofactor. Without heparin, the inhibition rate constants for thrombin and factor Xa have
been estimated to be 1 x 103 and 3 x 103 L/mol sec- 1, respectively. In the presence of
heparin, these rates of inhibition are accelerated to 3 x 107 and 4 x 106 L/mol sec- 1,
respectively, for thrombin and factor Xa (Jordan et al., 1980). The binding site for
heparin is located on the N-terminal domain of the molecule.
Two mechanisms have been proposed to account for heparin's ability to catalyze
the antiprotease actions of antithrombin III. The first suggests that heparin binds to
antithrombin III and causes a conformational change at the active site (Rosenberg et al.,
1973). The second model, the ternary complex or template model, proposes that heparin
acts catalytically by binding both antithrombin III and the serine protease, thereby
bringing them in close proximity (Bjork et al., 1986). Both models may be operative
depending upon the serine protease being inhibited. Conformational changes of ATIII
upon heparin binding have been observed spectroscopically (Villaneuva et al., 1979;
Shore et al., 1989; Rosenberg et al, 1973). Furthermore, the ability of a pentasaccharide
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region of heparin to promote the antithrombin III mediated inhibition of factor Xa
supports this model. The inhibition of thrombin appears to be better explained by the
template model. Conformational changes induced by heparin binding do not alter the
reactivity of antithrombin III towards thrombin (Peterson et al., 1987). In addition,
heparin pentasaccharides do not promote thrombin inhibition. Rather, chains of greater
than 18 saccharide units are needed for this inhibition. Kinetic studies indicate that
heparin must bind both thrombin and antithrombin HI (Nesheim et al., 1986; Hoylaerts
et al., 1984). It is not clear if one binding must precede the other for optimal inhibition
to occur (Griffith et al., 1982; Pletcher et al., 1983).
Deficiency of antithrombin III predisposes

the patient to thrombotic

complications. Antithrombin III deficiencies can be the result oflow protein levels or due
to functionally abnormal molecules. Low protein levels can be brought about by reduced
synthesis or an increased turnover of the molecule. Functional deficiencies can be
brought about by mutations in either the reactive site or heparin binding sites. A number
of such mutations have been documented (Erdjument et al., 1988; Lane et al., 1987;
Stephens et al., 1987; Bock et al., 1985; Koide et al., 1984; Owen et al., 1987; Borg et
al., 1988; Chang et al., 1986)

2. Heparin Cofactor Il
Heparin cofactor II is a second plasma SERPIN which has resemblance to
antithrombin III in that it is activatable by glycosaminoglycan binding. This protein has
also been called antithrombin BM (Wunderwald et al., 1982), dermatan sulfate cofactor
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(Abildgaard et al., 1984) and human leuserpin 2 (Ragg et al., 1986). The existence of
this second inhibitor and heparin cofactor was first shown by Briginshaw in 1974
(Briginshaw et al., 1974a, b). Whereas· antithrombin III is observed to have progressive
antithrombin activity and to also inhibit factor Xa, the second cofactor exhibits only weak
progressive activity and does not inhibit factor Xa. Tollefsen observed two different
thrombin inhibitor complexes, one of which could not be identified with antisera to
known protease inhibitors (Tollefsen et al., 1981 ). Several clinical studies observed a
discrepancy between heparin cofactor activity levels and plasma antithrombin Ill antigen
levels (Friberger et al., 1982; Griffith et al., 1983). The existence of the inhibitor was
confirmed when the protein was isolated from human plasma (Tollefsen et al., 1982) and
from Cohn fraction IV (Wunderwald et al., 1982). The heparin cofactor II protein has
a molecular weight of 62,000 to 72,000 Da depending upon the methodology used
(Tollefsen et al., 1982; Tran et al., 1986).
Like antithrombin III, heparin cofactor II inhibits proteases by forming a 1: 1
stoichiometric complex with the enzyme. The protease attacks the reactive site of heparin
cofactor II located on the C-terminus, resulting in the formation of a covalent bond.
Heparin cofactor II has a higher protease specificity than antithrombin III. Of the
coagulation enzymes, heparin cofactor II is known only to inhibit thrombin (Travis et al.,
1983). Additionally, heparin cofactor II has been shown to inhibit chymotrypsin (Church
et al., 1985) and leukocyte cathepsin G (Parker et al., 1985). This protease specificity
appears to be due to the active site bond present in heparin cofactor II. Whereas

antithrombin III contains an Arg-Ser bond as its active site, heparin cofactor II is unique
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in containing a Leu-Ser bond. This suggests than another portion of the heparin cofactor
II molecular may be required for protease binding.
As in the case of antithrombin III, the inhibition of protease activity by heparin
cofactor II is promoted by glycosaminoglycan binding. Whereas the activation of
antithrombin III is dependent upon the presence of a specific sequence in the heparin
chain, heparin cofactor II can be activated by a wide variety of agents. Heparins,
heparans, and dermatan sulfate all promote thrombin inhibition via heparin cofactor II.
Agents with relatively little sulfation such as chondroitin 4-0- or 6-0-sulfate, keratan
sulfate or hyaluronic acid do not activate heparin cofactor II. Heparan sulfate containing
0. 97 sulfates per disaccharide has been shown to be a better activator of heparin cofactor
II than heparan sulfate containing 0.67 sulfates per disaccharide (Tollefsen et al., 1989).
In addition, sulfated, synthetic agents are able to activate heparin cofactor II. Both
pentosan polysulfate (Scully et al., 1984; Scully et al., 1986) and dextran sulfate
(Yamagishi et al., 1984) have been shown to activate heparin cofactor II.
Both dermatan sulfate and heparin have been fractionated in order to study their
heparin cofactor II binding characteristics. In studies performed by Tollefsen et al.
dermatan sulfate octasaccharides with higher negative charge have been shown to bind
to heparin cofactor II better than those with a lower charge (Tollefsen et al., 1986).
Although these octasaccharides bind to heparin cofactor II, dermatan sulfate chains of 12
to 14 saccharides are required to promote thrombin inhibition. This is consistent with the
template model of inhibition. Heparin has been fractionated by charge density and
subsequently on an ATIII-Sepharose column into high and low affinity fractions (Hurst
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et al., 1983). It has been observed that for a given charge density, antithrombin III
affinity is unrelated to the ability of the fraction to activate heparin cofactor II. High and
low affinity fractions equally activated heparin cofactor II when charge density is
constant. To date, definitive data supporting the existence of a minimally required
sequence to activate heparin cofactor II has not been reported.
Rogers et al. have probed the role of thrombin exosites in the heparin cofactor
II mediated inhibition of this enzyme (Rogers et al., 1992). In the absence of
glycosaminoglycan, thrombin variants recognize antithrombin III and heparin cofactor
II to a similar degree, indicating that neither the autolysis loop nor the B-loop of
thrombin is required for SERPIN/protease interaction. Upon addition of heparin, the
interaction of antithrombin III with the thrombin variants is not altered suggesting the
importance of the anion binding exosite II for the heparin bridge between thrombin and
antithrombin III. These same studies indicate the importance of anion binding exosite I
for the inhibition of thrombin by heparin cofactor II as gamma thrombin, lacking this
site, is not inhibited. Based on these results, a complex double bridge mechanism for
heparin cofactor II mediated thrombin inhibition has been postulated. In this mechanism,
heparin or dermatan sulfate binds to the glycosaminoglycan binding site on heparin
cofactor II and anion binding site I on thrombin. Upon heparin binding to heparin
cofactor II, the acidic domain is displaced and is free to interact with the B-loop region
of the anion binding exosite of thrombin, facilitating its rapid inhibition.
The normal plasma level of heparin cofactor II is approximately 1.2

± 0.2 µM

(Tollefsen et al., 1985). Two patients to date have been described as having heparin
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cofactor II deficiency related to thrombosis (Sie et al., 1985; Tran et al., 1985).

3. Tissue Factor Pathway Inhibitor
Tissue factor pathway inhibitor (TFPI) is one of the coagulation protease
inhibitors found endogenously within the vasculature. TFPI has alternately been known
as lipoprotein associated coagulation inhibitor (LACI) or extrinsic pathway inhibitor
(EPI). This 42 kDa inhibitor has been shown to contain three Kunitz domains tandemly
linked between a negatively charged amino terminus and a positively charged carboxy
terminus (Girard et al., 1989). The active site of the first Kunitz domain binds to the
active site of the VIia - tissue factor complex while the active site of the second Kunitz
domain binds to the active site of factor Xa. Mutation of the active site of the third
Kunitz domain has no effect on the inhibition of either factor VIIa or factor Xa.
Modification of the second Kunitz domain has also been shown to result in a loss of
inhibition of tissue factor-VIIa activity. In experiments where the third Kunitz domain
has been truncated, TFPI still inhibits factor VIia tissue factor complexes on cell surfaces
in culture (Hamamoto et al., 1993). The carboxy terminus of TFPI is required for the
optimal inhibition of factor Xa (Wesselschmidt et al., 1992; Nordfang et al., 1991),
perhaps effecting the rate at which TFPI can bind to Factor Xa. No difference is
observed between the inhibition of factor VIIa - tissue factor by full-length TFPI or by
a truncated form of TFPI (Wesselschmidt et al., 1992). Two studies have examined the
kinetics of TFPI inhibition of factor Xa (Lindhou t et al., 1993; Huang et al., 1993). Both
studies have indicated that more than just the second Kunitz domain is required for factor
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Xa binding as the association rate constants for full-length TFPI are higher than for
carboxy-terminus or Kunitz 3 truncated TFPI. The third Kunitz domain has recently been
shown to contain a second heparin binding site (Enjyoji et al., 1995).
TFPI has been cloned from a number of species including humans, rabbits, rats,
and monkeys (Sprecher et al., 1994; Warn-Cramer et al., 1992; Kamei et al., 1994; Wun
et al., 1988; Enjyoji et al., 1992). Monkey TFPI was observed to be similar in structure
and function to human TFPI. Rabbit TFPI was shown to have a weaker antiprotease
activity compared to human TFPI and not to associate with lipoproteins (Warn-Cramer
et al., 1992).
In normal tissues of the vasculature, TFPI is produced by megakaryocytes and
the endothelium (Werling et al., 1993). Once produced, this TFPI is stored in three
intravascular pools. These pools are located in the plasma, in platelets, and bound to the
endothelium (Lindahl et al., 1992). The smallest pool of TFPI is found in the platelets,
accounting for less than 2.5 % of the intravascular total. This small pool of TFPI is
released upon platelet activation (Novotny et al., 1988). 10 to 50 % of the intravascular
TFPI is in the plasma. Most plasma based TFPI is bound to plasma lipoproteins
(Novotny et al., 1991; Braze et al., 1987). Approximately 5 % of the plasma pool of
TFPI circulates in the free form (Novotny et al., 1989; Lindahl et al., 1991). The
lipoprotein bound TFPI is reported to be of relatively low inhibitory activity (Lindahl et
al., 1991). The largest pool of TFPI is found bound to the endothelial surface (Novotny
et al., 1991; Sandset et al., 1988; Lindahl et al., 1990). This pool can account for 50 to
90% of the total intravascular TFPI.

23
The TFPI pool bound to the endothelium has been shown to be heparin
releasable in a number of studies (Ariens et al., 1994; Warn-Cramer et al., 1993; Bara
et al., 1993; Holst et al., 1993; Novotny et al., 199 ld). Venous occlusion (Sandset et al.,
1988) and agents such as DDAVP which induce exocytosis of endothelial granular
proteins (Warr et al., 1989) do not cause the release of TFPI. Repeated heparin
administration is observed to release similar amounts of TFPI (Ariens et al., 1994) with
no tachyphylaxis. It is believed that the endothelial pool of TFPI is bound to
glycosaminoglycans on the surface of the endothelium. Heparin injection, then, is thought
to displace TFPI from the endogenous glycosaminoglycans. The amount of TFPI in the
plasma following heparin administration is determined by the heparin concentration. TFPI
levels 2 to 10 fold baseline have been reported following heparin and low molecular
weight heparin administration. The chemical nature of the low molecular weight heparin
also effects the degree of TFPI release. It has been shown that when different LMWHs
are administered at the same anti-Xa unit dosage, plasma TFPI levels vary by as much
as 30 % (Vogel, 1995). Neutralization of heparin by protamine sulfate or protamine
chloride results in a dramatic decrease in plasma TFPI levels (Harenberg et al., 1993;
Hoppensteadt et al., 1995).
TFPI acts in vitro as an anticoagulant when measured by a number of assays.
Both the thromboplastin induced clotting time and the activated partial thromboplastin
time are prolonged by TFPI (Lindahl et al., 1991b; Lindahl et al., 1991c). Factor Xa
based assays such as the Heptest and the amidolytic anti-Xa assay are also affected by
recombinant TFPI (Kristensen et al., 1992). Higher amounts of TFPI are required in the
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prothrombin time and APTI for prolongation of the clotting time than are needed in the
Heptest•. The prothrombin time is a more sensitive assay for the anticoagulant effects of
TFPI than is the APTI, suggesting that the main in vitro inhibitory effect of TFPI is the
inhibition of factor Vlla (Lindahl et al., 1991d). Co-supplementation of heparin and
rTFPI to plasma in vitro has differing effects depending upon the assay used. Kristensen
observed that heparin and rTFPI additively prolong the Heptest• clotting time. It has been
shown that the prolongation of the APTI and PT assays by heparin and TFPI is
synergistic (Valentin et al., 1991; Wun et al., 1992). A study by N ordfang et al.,
however, suggest that the increased effect of TFPI in the presence of heparin is due to
heparin antithrombin III complexes as addition of heparin exhibited no effect in
antithrombin III deficient plasma (Nordfang et al., 1993). The rate of Xa inhibition by
rTFPI was observed to increase 2.5 fold upon the addition of heparin (Broze et al.,
1988), though not with full-length TFPI (Wesselschmidt et al., 1992).
TFPI, when administered to rabbits, has been shown to have an antithrombotic
effect when thromboplastin was used as a thrombogenic challenge (Day et al., 1990).
TFPI was also shown to be an effective inhibitor when thrombosis was induced in rabbit
jugular veins by endothelial destruction and restricted blood flow (Holst et al., 1994).
The antithrombotic and antiprotease actions of TFPI have been tested in several other
animal models. Warn-Cramer et al. investigated the effect of immunodepletion of TFPI
in factor VIIa and Xa induced coagulation in rabbits (Warn-Cramer et al., 1993b). These
rabbits were observed to be sensitized to the procoagulant effects of factor Vlla, but not
factor Xa in the absence of factor Vila. Two studies have indicated that TFPI

25
administration reduces the lethal effects of E. coli administration in a septic shock model
in baboons (Carr et al., 1995; Creasey et al., 1993). These studies also indicated that
TFPI may have an anti-inflammatory effect as an attenuation of the IL-6 response was
also observed. Administration of TFPI has been observed to prevent reocclusion of
arteries in dogs following clot lysis with t-PA (Haskel et al., 1991). Topical
administration of TFPI has been shown to prevent thrombosis in a rabbit model of
vascular trauma (Khouri et al., 1993).

4. Protein C
The protein C pathway is one of the natural anticoagulant systems which keeps
blood in the fluid state. When thrombin is formed, it stimulates coagulation and its own
formation by activating factors V and VIII through proteolytic cleavage (Jenny et al.,
1994; Kane et al., 1988). Factors VIiia and Va bind to negatively charged phospholipids
on activated platelets and act as binding sites for factors IXa and Xa, respectively,
allowing for formation of the "tenase" and prothrombinase complexes (Mann et al.,
1990).
Thrombin can also act to limit its own procoagulant activity. When thrombin is
m circulation, it binds a high affinity receptor on the endothelium known as
thrombomodulin (Esmon et al., 1981). The ~for this binding is 0.2 to 0.5 x 10-9 M
(Owen et al., 1981). Thrombomodulin is a membrane spanning protein containing
multiple functional domains and a molecular weight of approximately 60,000 Da
(Dahlback et al., 1995). When thrombin binds to thrombomodulin, a change in substrate
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specificity is noted. While this complex is a potent activator of protein C, the bound
thrombin no longer cleaves fibrinogen, is not able to activate other coagulation proteases
such as factors V and VIII and does not activate platelets (Esmon et al., 1982; Esmon
et al., 1983). The thrombin-thrombomodulin complex is a 20,000 fold better activator
of protein C than is free thrombin (Esmon et al., 1981; Owen et al., 1981).
Thrombomodulin is present on the endothelium in most arteries, veins, and capillaries
(Maruyama et al., 1985; DeBault et al., 1986).
Protein C is a vitamin K-dependent zymogen identified by Stenflo (Stenflo et al.,
1976) which has been shown to be identical to autoprothrombin Ila (Seegers et al.,
1976). Upon activation, protein C exhibits anticoagulant properties (Kisiel et al., 1977;
Kisiel et al., 1979). Alterations of thrombin' s substrate specificity upon binding to
thrombomodulin are thought to be due both to steric hinderance of thrombin's active site
and to conformational changes in the active site (Musci et al., 1988; Ye et al., 1991;
Holtin et al., 1991). Protein C is made up of disulfide linked heavy and light chains and
has a molecular weight of approximately 62,000 Da (Beckman et al., 1982; Foster et al.,
1984). Protein C derives its anticoagulant properties from its ability to cleave and
inactivate membrane bound forms of factors Va and Vllla (Esmon et al., 1992; Esmon
et al., 1993; Walker et al., 1992). Factors V and

vur as well as non-membrane bound

forms of factors Va and VIIIa are not cleaved by protein C.
Protein C requires two cofactors in order to express its anticoagulant activity,
protein S and factor V. Protein S is another vita.min K dependent plasma protein whose
free form expresses protein C cofactor activity for the degradation of factors Va and
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Vllla (Dahlback et al., 1994). Protein S is a single chain, 70,000 Da glycoprotein
(Dahlback et al., 1995), which has the highest affinity for negatively charged
phospholipids among vitamin K dependent proteins (Nelsestuen et al., 1978). Protein S
forms a 1: 1 complex with protein C on the lipid membrane which may account for its
ability to increase the affinity of activated protein C for such membranes (Walker et al.,
1981; Walker et al., 1984). Though the mechanism of action of protein S is not
completely understood, it may be related to its ability to make factors Va and VIila
available for proteolytic cleavage by activated protein C (Regan et al., 1994; Solymoss
et al., 1988). Less is known about factor V's role as an activated protein C cofactor,
though it is hypothesized that factor V and protein S may synergistically act to localize
protein C activity to the surface of membranes (Shen et al., 1994; Dahlback et al.,
1994b).
As low levels of protein C activation peptide are found in healthy individuals,
it is suggested that protein C is constantly activated to a small degree (Bauer et al.,
1984). Protein C administration has been shown to inhibit both arterial and venous
thrombosis in animal models (Gruber et al., 1990; Arnljots et al., 1994; Wakefield et al.,
1993). Heterozygous protein C deficiency or activated protein C resistance due to factor
V mutation are thought to explain 60 to 70 % of the cases of familial thrombophilia
(Dahlback et al., 1995).

5. Protease Nexins
Protease nexins 1 and 2 are endogenous serine protease inhibitors which have
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molecular weights of 43 and approximately 100 kDa, respectively (Preissner et al., 1988;
van Nostrand et al., 1992). Both protease nexin 1 and protease nexin 2 have effects on
the coagulation system. Based on cell culture studies, protease nexin 1 appears to be
produced by fibroblasts, smooth muscle cells, and epithelial cells (Baker et al., 1980;
Knauer et al., 1983; Eaton et al., 1983). Protease nexin 1 has a 30 percent sequence
homology with antithrombin III and like ATUI, has a high affinity heparin binding site.
Heparin binding to protease nexin 1 accelerates protease inhibition (Baker et al., 1987;
Kruithof et al., 1988). Protease nexin 1 appears to be limited to the extravascular
compartment as human plasma contains only small amounts of this inhibitor (20 pM)
(Preissner et al., 1988). Protease nexin 1 inhibits several serine proteases including
thrombin, urokinase, plasminogen activator, and activated protein C (Hermans et al.,
1993; Scott et al., 1983; Bergman et al., 1984). Upon formation of a stable complex with
the target protease, the complex binds back to the cells where it is internalized and
degraded (Cunningham et al., 1992). The physiologic role of protease nexin 1 appears
to be related to protection of the extracellular matrix from degradation by urokinase and
plasminogen activator (Rao et al., 1989). This is supported by the fact that protease nexin
1 binds tightly to the extracellular matrix, thereby localizing its activity (Farrell et al.,
1988).
Protease nexin 2 is identical to the secreted form of the amyloid precursor
protein containing the Kunitz-type serine protease inhibitor domain (van Nostrand et al.,
1989; Oltersdorf et al., 1989). Protease nexin 2 circulates in blood stored as a platelet
a-granule protein which is secreted upon platelet activation (van Nostrand et al., l 990a).
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Protease nexin 2 inhibits trypsin- and chymotrypsin-like serine proteases and is also a
potent inhibitor of factor Xia (Smith et al., 1990; van Nostrand et al., 1990a, 1991a,
1991b; Sinha et al., 1990). Its location in platelets and its ability to inhibit factor Xia
suggests a role in regulating blood coagulation for protease nexin 2.

6. Other Inhibitors
A number of other serine protease inhibitors are known to play a role in
modulating physiologic functions. Plasminogen activator inhibitors serve to limit the
normal activation of the fibrinolytic process. High levels of PAI-1 are associated with an
increased risk of thromboembolic disease (Reilly et al., 1994). PAI-1 has also been
shown to regulate the degradation of extracellular matrix which may be important in
modulating cancer invasion. a 2-Antiplasmin rapidly inhibits the fibrinolytic activity of
plasmin (Edelberg et al., 1994). ai-Macroglobulin has been described as a "panproteinase
inhibitor" in light of evidence that it interacts with nearly any proteinase (Borth, 1992).
In addition, a 2-macroglobulin may play a role in inflammation and immune reactions
through its ability to regulate the distribution and activity of numerous cytokines
including transforming growth factor B, tumor necrosis factor a, platelet derived growth
factor, and several interleukins (LaMarre et al., 1991; Chaudhuri et al., 1993; Chu et
al., 1994; Borth, 1994; Bonner et al., 1995). The complement and contact systems are
regulated by c 1-esterase inhibitor through the inhibition of complement components Clr
and Cls (Hack et al., 1994; Zahedi et al., 1993). Deficiency of c 1-esterase inhibitor is
associated with angioedema (Carreer, 1992). Histidine-rich glycoprotein has been shown
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to bind to plasminogen an interfere with its interaction with fibrin (Lijnen et al., 1980;
Munkvad, 1993). Additionally, histidine-rich glycoprotein is known to bind to heparin
and related glycosaminoglycans (Lijnen et al., 1983). High levels of this protein have not
been definitively linked to thrombosis (Engesser et al., 1987).

C. Heparin
1. Discovery of Heparin

Heparin was first discovered in 1916 by Jay McLean while he was studying the
procoagulant actions of phospholipids (McLean, 1916). In these early years, heparin was
initially thought to be a phospholipid as it was isolated using procedures designed to
separate phospholipids. Today we know that heparin is a glycosaminoglycan structurally
related to the dermatans and chondroitins. More specifically, heparin has been defined
as " ... a family of polysaccharide species, whose chains are made up of alternating, 1-4
linked and variously sulfated residues of uronic acid and D-glucosamine" (Casu, 1989).
The uronic acid residues are either L-iduronic acid or D-glucuronic acid. The
glucosamine residues are either N-sulfated or N-acetylated. Typically, the iduronic acid
moieties are 2-0 sulfated whereas the glucosamine residues contain 6-0 sulfate groups
and a small proportion are 3-0 sulfated (Brenkowski et al., 1985).

2. Chemistry of Heparin
Heparin is synthesized by a number of tissues and mast cells as part of a high
molecular weight proteoglycan (molecular weight =

750 to 1000 kDa). This
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proteoglycan consists of a peptide core which is composed of 20 to 25 residues each of
glycine and serine (Robinson et al., 1978). Attached to this peptide are 15 polysaccharide
chains with molecular weights ranging from 60 to 100 kDa. The polysaccharide chains
are attached to the peptide core via a galactosyl-galactosyl-xylosyl trisaccharide sequence
(Lindahl et al., 1972).
The polysaccharide chains are formed by stepwise transfer of D-glucuronic acid
and N-acetyl-D-glucosamine from their UDP sugar nucleotide forms to the non-reducing
end of the polysaccharide chain (Heiting et al., 1972; Heiting et al., 1973; Forsee et al.,
1981). Presumably these sugar moieties are polymerized directly to the linkage region
of the protein core. The alternating sequence of glucuronic acid and hexosamine is due
to the substrate specificity of the glycosyl transferases (Lindahl et al., 1989). Following
polysaccharide chain elongation, the polymer undergoes a series of modification
reactions.
Heparin is structurally heterogeneous due to incomplete structural modifications.
Four enzymatic modifications of the polysaccharide backbone occur following its
synthesis. The majority of the N-acetyl groups on the glucosarnine residues are removed
(Hook et al., 1975). The N-deacetylated glucosamines are subsequently sulfated. In the
next step, D-glucuronic acid residues are epimerized to L-iduronic acid units by uronosyl
C-5 epimerase (Lindahl et al., 1976; Malmstrorn et al., 1980). During the epimerization
process, most iduronic acids are 2-0 sulfated. Finally, 3-0 and 6-0 sulfate groups are
added onto the glucosamine units. Previous N-sulfation allows more efficient 0-sulfation
to occur (Lindahl et al., 1989). Several more recent studies have indicated that chain
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elonation and modification may occur simultaneously during heparin synthesis (Lidholt
et al., 1989; Linholt et al., 1992)
Nuclear resonance spectroscopy involves the measurement of radiofrequency
radiation absorption by a given sample when it is placed in a strong magnetic field. The
nuclei of many atoms act as magnetic dipoles in that they can be aligned either with or
against the magnetic field. These nuclei include 1H,

13

C,
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F, and 31 P. 1H and 13C are the

most commonly studied nuclei due to their abundance in organic materials. The ground
state of a nuclei is the energy level when the dipole is aligned along the magnetic field.
The excited state occurs when the nuclei are aligned against the magnetic field. Transfer
of nuclei from the ground to the excited state occurs when nuclei absorb radiofrequency
radiation. The amount of power which is absorbed is dependent not only on the
molecular properties of the given sample, but also upon the surrounding magnetic field.
The surrounding magnetic field includes the field produced by the instrument as well as

any field produced by adjacent nuclei. Adjacent nuclei can either shield (decrease) of
deshield (increase) the magnetic field produced by the instrument. Resonance frequencies
of nuclei vary depending upon the chemical environment of the nuclei. This is expressed
in terms of a chemical shift (o). Chemical shift is usually given in ppm and is
independent of the applied magnetic field. As there is no way of measuring the strength
of the magnetic field at a given nucleus without shielding, chemical shifts are determined
relative to an internal standard. The chemical shifts of nuclei are dependent upon the
nearby chemical structures. Structural characteristics of a molecule can be elucidated
using this technique as the various protons (1H) and

13

C nuclei are present in different
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environments with respect to the local charge density and, therefore, are excited to
different extents by the introduction of the radiofrequency pulse.
Monodimemsional spectroscopy of polysaccharides such as heparin is often of
limited value due to the intrinsically broad signals and the large number of overlapping
signals. Bidimensional spectroscopy is a more useful technique as it allows for the
correlation of two similar (1H - 1H) or different (1H - 13 C) nuclei in a manner such that
the signals relating to intramolecular interactions can be identified. These are termed
homonuclear and heteronuclear correlations.

3. Biologic Effects of Heparin - Non-anticoagulant
Heparin is a strongly anionic polyelectrolyte which at physiologic pHs contains
three acidic functional groups which are fully dissociated; -OSQ3·, -NHS03-, and

-coo-

(Nieduszynski, 1989). Owing to this fact, heparin has a large number of pharmacologic
properties. Among these are its antilipemic and antihemolytic actions (Bradshaw et al.,
1975; Levy et al., 1958). Heparin is also known to inhibit a variety of enzymes including

myosin ATPase, RNA dependent DNA polymerase, elastase, and renin (Cruz et al.,
1967; Neuhoff et al., 1970; Sealey et al., 1967). Heparin inhibits tumor growth

(Lippman et al., 1965; Folkman et al., 1985). Additionally, heparin exhibits antibacterial
and antiviral properties (Corrigan et al., 1977; Vaheri et al., 1964).

4. Pharmacokinetics of Heparin
Heparin 1s administered either by intravenous infusion or by subcutaneous
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injection. Upon entering the blood stream, heparin binds to a variety of plasma proteins,
thereby lowering its bioavailability and producing a variable anticoagulant response
(Hirsh et al., 1976). These proteins include histidine rich glycoprotein, platelet factor 4,
vitronectin, and von Willebrand factor (Lane, et al., 1986; Lijnen et al., 1983; Peterson
et al., 1987; Holt et al., 1985; Preissner et al, 1987; Dawes et al., 1991; Sobel et al.,
1991). Heparin exhibits a complex pharmacokinetics and is cleared by two mechanisms.
The rapid, saturable phase of elimination is thought to be due to receptor mediated
internalization of heparin by endothelial cells and macrophages (Glimelius et al., 1978;
Mahadoo et al., 1978; Friedman et al., 1974). A slower, nonsaturable renal mechanism
also clears heparin from the plasma (de Swart et al., 1982; Olsson et al., 1963;
Bjomsson et al., 1982). The anticoagulant effect of heparin is therefore not linearly
related to dose when in the therapeutic range (Hirsh et al., 1994). The biologic half-life
of heparin increases from 30 minutes following an IV bolus dose of 25 U/kg to 150
minutes following a dose of 400 U/kg (de Swart et al., 1982; Olsson et al., 1963;
Bjomsson et al., 1982).

5. Clinical Use of Heparin
Heparin is used in the therapy of several cardiovascular disorders including
prevention and treatment of venous thromboembolism, treatment of unstable angina,
acute myocardial infarction, cardiac and vascular surgery, coronary angioplasty, stent
implantation, and as an adjunctive agent during thrombolysis. Heparin is also the
anticoagulant of choice during pregnancy.
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Studies have demonstrated that there is a reduction in mortality in patients
receiving heparin for the treatment of pulmonary embolism (Barritt et al., 1960; Brandjes
et al., 1992). In addition, recurrent thrombosis was not common during the
heparinization period, but increased significantly when heparin was stopped and no other
anticoagulant therapy was utilized (Hull et al., 1979; Lagerstedt et al., 1985). Heparin
is effective in treating venous thrombosis. This effectiveness has been shown to be
dependent upon the anticoagulant effect achieved (Hull et al., 1986; Turpie et al., 1989).
Heparin is also effective prophylactically, reducing the risk of venous thrombosis and
pulmonary embolism 60 to 70 percent (Clagett et al., 1988; Collins et al., 1988).
Heparin is effective short-term in preventing acute myocardial infarction and recurrent
refractory angina in patients with unstable angina (Theroux et al., 1990; Theroux et al.,
1992; Neri Serneri et al., 1990). This beneficial effect is lost upon cessation of heparin
therapy. In patients with previous myocardial infarction, heparin administration has been
shown to significantly reduce reinfarction and death when compared to untreated controls
(Neri Serneri et al., 1987). Heparin has been tested as an adjunct in thrombol ytic therapy
where it appears to increase patency during the initial stages of recanalization by
preventing rethrombosis (Bleich et al., 1990; de Bono et al., 1992). Heparin is the
anticoagulant of choice in pregnancy as it does not cross the placental barrier and is not
known to cause unwanted effects on the fetus (Hirsh et al., 1994; Hyers et al., 1992).

6. Effect of Heparin on Platelets
The effect of heparin on platelets is controversial. Studies by Ellison and
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Thomson have shown that heparin decreases the threshold for ADP and epinephrine
induced aggregation and enhances the platelet release reactions by these agonists (Ellison
et al., 1978; Thomson et al., 1973). Treatment with heparin was also observed to
increase platelet retention on cellophane membranes. Other studies have indicated the
opposite effects on platelets. Besterman showed that irreversible aggregation induced by
collagen and epinephrine was reduced in patients treated with 2500 to 5000 U of
unfractionated heparin (Besterman et al., 1973). In these same patients, no effect to a
slight increase in aggregation was observed with ADP (Zucker et al., 1977). Heiden
demonstrated a loss of [14 C]-5-HT release in PRP of individuals treated with 100 U/kg
heparin in response to collagen, epinephrine, and ADP (Heiden et al., 1977). An indirect
mechanism was suggested to account for this observation based on the finding that in

vitro addition of heparin caused no effect on aggregation (Eika et al., 1972). Salzman et
al. have shown that concentrations of heparin as low as 10 µg!mL induces aggregation
in platelet rich plasma, but not in washed platelets (Salzman et al., 1980).
Heparin administration is also known to cause an adverse effect on platelets
known as heparin induced thrombocytopenia (HIT). Type I HIT occurs early in heparin
treatment and causes a transient reduction in platelet count. Patients usually remain
asymptomatic. Type II HIT is a more severe thrornbocytopenia of delayed onset. This
form of HIT often results in thrombosis and is associated with a high degree of mortality.
While the exact mechanism is unknown, it appears that an IgG antibody is generated
whose F-ab portion binds to the heparin/PF4 complex. Optimal platelet activation occurs
when heparin and platelet factor 4 are in near equimolar concentrations. The Fe portion
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of the antibody binds to the Fella receptor on the platelet surface and activates the
platelets. The differences in response to these heparin/PF4 antibodies may be due to
differences in the genotype of the Fella receptor. Studies have indicated that the IgG
antibody:heparin:PF4 complex forms in solution an then binds to the platelet Fella
receptor on platelets.

7. Chemically Modified Heparins
a. Hypersulfated heparins
The anticoagulant and antithrombotic actions of heparins containing higher than
normal degrees of sulfation have been examined in several studies. In a laser model of
thrombosis, a supersulfated low molecular weight heparin was observed to require a 10
fold lower dose than native heparin or low molecular weight heparin to achieve a
comparable antithrombotic effect (Krupinski et al., 1990). In another study, oversulfation
of low molecular weight heparin was observed to reduce the ex vivo anticoagulant activity
relative to LMWH which has not been oversulfated. Addition of sulfate groups, however,
did not effect the antithrombotic activity in a rat venous stasis-thrombosis model and did
not significantly increase the bleeding time (Naggi et al,, 1987). The release of
lipoprotein lipase by the supersulfated low molecular weight heparin was twice that of
heparin. In a pure biochemical system, the inhibition of thrombin via heparin cofactor
II by supersulfated low molecular weight heparin was approximately 100 fold stronger
than for low molecular weight heparin (Jeske et al., 1995).
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b. Desulfated heparins
N- and 0- desulfated heparins have to be examined for a number of
pharmacologic properties. In general, a reduction in the sulfation of heparin results in
a decrease in the given biologic activity. N- and 6-0-desulfation significantly decreased
the antiviral activity of heparin with respect to herpes simplex I binding (Herold et al.,
1995). Heparin potentiates the binding of vascular endothelial growth factor (VEGF 165)
to its cellular receptors. 0- and N- desulfated heparins potentiated this binding to a lesser
extent (Soker et al., 1994). Rajtar demonstrated that N- desulfated heparins were less
effective at inhibiting platelet function than native heparin (Rajtar et al., 1993). Both
fully desulfated heparin and N-desulfated heparin lack the ability to bind heparin binding
growth factor (Belford et al., 1992).
The anticoagulant and antithrombotic effects of desulfated heparins have also
been examined. A partially N-desulfated heparin has been shown to have no measurable
anticoagulant or antiprotease activity, but to dose-dependently impair thrombogenesis in
vivo (Sache et al., 1989). A completely N-desulfated heparin derivative lacked both in
vitro and in vivo activity (Inoue et al., 1976). Other investigators have shown that N-

desulfated heparins have minimal anticoagulant activity (Bjornsson et al., 1988;
Danishefsky et al., 1977). N-desulfated heparin has been shown to be cleared
approximately 6 fold faster than native heparin (Bjornsson et al., 1988). The weak
anticoagulant activity is attributable to the lack of interaction with antithrombin III
(Danishefsky et al., 1977).
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8. Low Molecular Weight Heparin
The depolymerization of heparin either chemically by nitrous acid degradation,
benzylation - alkaline hydrolysis, or peroxidative cleavage, or enzymatically using
heparinase results in the production of another clinically useful drug known as low
molecular weight heparin. Low molecular weight heparins exhibit several distinct
properties which differentiate them from standard unfractionated heparin. Through the
depolymerization process, the molecular weight is reduced to approximately one third
that of the parent material (Fareed, 1995). This is important for two reasons. First, the
largest heparin chains are not well absorbed following subcutaneous administration. The
bioavailability of heparin is only 20 to 30 percent (Fareed, 1995). The bioavailability of
LMWH is nearly 100 percent when measured using an amidolytic anti-Xa assay. The
smaller molecular size of the LMWHs also has an effect on the biologic activity of these
agents. The LMWHs have a lower anticoagulant potency than unfractionated heparin.
This is a reflection of the lower antithrombin activity of these agents. Heparin exhibits
a 1: 1 ratio of antithrombin to anti-Xa activity whereas for LMWHs the ratio ranges from
1:2 to 1:4 depending upon the molecular weight composition of the given LMWH (Hirsh
et al., 1994).
LMWHs are the agents of choice in European countries for the prophylaxis of
deep venous thrombosis due to their efficacy and safety. Owing to their high
bioavailability, LMWHs exhibit a sustained pharmacologic effect such that once daily
dosing is sufficient to keep the patient in an antithrombotic state. Heparin, in contrast,
requires 2 or 3 daily injections to achieve a similar effect (Fareed, 1995). Due to their
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near complete availability and limited plasma protein binding (Sobel et al., 1991; Lane
et al., 1986; Lijnen et al., 1983; Dawes et al., 1991), LMWHs exhibit predictable
clinical effects and do not require daily monitoring of plasma levels (Handeland et al.,
1990). Heparin levels are monitored frequently using the APTT assay. There has also
been the suggestion that LMWHs may cause less hemorrhagic side-effects, less
osteoporosis, and decreased cytopenia relative to standard heparin (Fareed, 1995).
Low molecular weight heparins have been examined for their efficacy in the
treatment and prevention of venous thromboembolism. In general surgical patients,
randomized trials have indicated that LMWH is both effective and safe. Statistically
significant reductions in thromboembolic mortality was observed without a significant
increase in major hemorrhage. Most clinical trials indicate a bleeding effect which is
equal to or less than that caused by heparin (Ockelford et al., 1989; Pezzuoli et al.,
1989; Kakkar et al., 1985; Bergqvist, 1988). In orthopedic patients, LMWHs have
exhibited equal or superior efficacy compared to low dose heparin (Planes et al., 1988;
Eriksson et al., 1991), adjusted dose heparin (Leyvraz et al., 1991; Dechavanne et al.,
1989), warfarin (Heit et al., 1991), and dextran (Bergqvist et al., 1991). In medical
patients, LMWHs have been shown to reduce the risk of thromboembolism relative to
placebo (Prins et al., 1987; Turpie et al., 1987) and heparin (Green et al., 1990; Turpie
et al., 1992). LMWHs have been shown to be effective in treating established
thrombosis, both preventing further extension of the thrombus and enhancing its
regression (Hull et al., 1992; Prandoni et al., 1992).
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D. Non-heparin Glycosaminoglycan Agents

1. Heparan Sulfate
Heparan sulfate has a backbone which is structurally similar to heparin. Heparan
sulfate generally contains more than 20 % N-acetylated glucosamine and nearly equal
amounts of N- and 0-sulfation. In contrast, the ratio of 0- to N-sulfation in heparin is
almost 4 to 1 (Gallagher et al., 1985; Lindahl et al., 1991). Like heparin, heparan sulfate
primarily inhibits proteases via activation of antithrombin III and has been shown to
catalyze the formation of thrombin-antithrombin complexes (Hatton et al., 1978) and also
to exhibit anti-factor Xa activity (Thomas et al., 1979). As it does not completely inhibit
prothrombin activation, it is much less effective than heparin. The antithrombotic dosage
of heparan sulfate has been shown to be approximately 500 to 600 µglkg compared with
60 to 70 µglkg for heparin (Ofosu, 1989) ..

2. Dennatan Sulfate
Dermatan sulfate is a glycosaminoglycan polymer of iduronic acid and Nacetylated galactosamine. Due to a difference in the molecular backbone, dermatan
sulfate is unable to interact with antithrombin III (Ofosu et al., 1985), but rather
complexes with heparin cofactor II to mediate thrombin inhibition (Tollefsen et al.,
1983). The anticoagulant potency of dermatan sulfate is less than that of heparan sulfate
(Teien et al., 1976; Ofosu et al., 1984). Anticoagulant activity as measured by the APTT
and thrombin time is nearly undetectable (Sie et al., 1991). Dermatan sulfate inhibits
thrombin as it is formed rather than preventing its generation (Ofosu et al., 1989). It has
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been shown that thrombin generation inhibition by dermatan sulfate is much less than for
an equigravimetric amount of heparin (Merton et al., 1987). At a dosage of 150 µg/kg,
dermatan sulfate caused a 28 % inhibition of thrombin generation compared to an 83 %
inhibition by heparin. While dermatan octasaccharides bind heparin cofactor II, 12 to 14
residues are required for thrombin inhibition. Dermatan sulfate chains with a higher
charge density appear to bind to heparin cofactor II better than those with a lower
charge.
Dermatan sulfate is active in vivo as an antithrombotic agent in the rabbit stasis
thrombosis model, but to a lesser extent than heparin (Merton et al., 1987). Though both
agents inhibited thrombus formation to the same extent at an equigravimetric dosage of
150 µg/kg after 10 minutes of stasis, dermatan sulfate was ineffective at inhibiting
thrombus formation following 20 minutes stasis time at a dose 8 times higher than that
of heparin. The advantage dermatan sulfate has over heparin as an antithrombotic agent
is a lower risk of bleeding complications (Fernandez et al., 1986); Desnoyers et al.,
1989). Dermatan sulfate has been shown not to significantly increase bleeding versus a
saline control at doses which are antithrombotically effective.
It is thought that the decreased bleeding seen with dermatan sulfate is a result

of its minor effects on platelets. Sie et al. have shown that while thrombin induced
platelet aggregation is inhibited by dermatan sulfate in the presence of heparin cofactor
II, arachidonic acid, ADP and collagen induced aggregations were not effected (Sie et
al., 1982). In addition, it has been shown that dermatan sulfate has a smaller effect on

heparin induced thrombocytopenic serum induced platelet aggregation than did heparin
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(Hoppenstead t et al. , 1991).

3. Chondroitin Sulfate
Chondroitin sulfate is a glycosaminoglycan which consists of alternating Dglucuronic acid and N-acetylated D-galactosamine residues. The galactosamine residues
are typically 4-0 or 6-0 sulfated (Casu et al., 1991). Chondroitin sulfate has a lower
degree of sulfation than the heparin or heparan-type glycosaminoglycans, with a sa3/COO- ratio equal to 1. Due to a low degree of sulfation, and the lack of iduronic acid
moieties, chondroitin sulfate does not have strong interactions with the endogenous
coagulation inhibitors antithrombin III or heparin cofactor II or with lipoprotein lipase
or low density lipoproteins as heparin does (Casu et al., 1991). Chondroitin sulfates are
typically found in cartilage. Chondroitin sulfate has been used in the treatment of
osteoarthritis as it inhibits elastase and hyaluronidase in the synovial fluid which can
damage joint cartilage (Pepitone et al., 1991). The anticoagulant activity of chondroitin
sulfate is minimal, with potency designated as less than 5 USP IU/mg and 5 anti-factor
Xa U/mg by the Yin and Wessler test (Bianchini et al., 1985).
The antithrombotic activity of chondroitin sulfate and its oversulfated derivatives
was examined in a rat model of thrombosis and was observed to be minimal (Pescador
et al., 1991). Oversulfation of the molecules also did not enhance the negligible
anticoagulant activity of the native chondroitin sulfate. The chondroitin sulfate present
in Org 10172 was not observed to enhance the antithrombotic effect of the high affinity
material present in the preparation (Zammit et al., 1994).
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Chondroitin sulfate has been shown to have several biologic functions. Evidence
has been presented indicating that chondroitin sulfate proteoglycans interact with the
herpes simplex virus (Banfield et al., 1995). Chondroitin sulfate offers neuroprotective
effects against glutamate induced neuronal cell death (Okamoto et al., 1994) and may
play a role in neuronal patterning (Brittis et al., 1992). Chondroitin sulfate has been
shown in vitro to inhibit the activation of the complement system (Biffoni et al., 1991).
This potency was related to the sulfate content of the chondroitin. Chondroitin sulfate
exhibits in vitro anti-HIV-1 activity (Jurkiewicz et al., 1982). When administered to
cholesterol fed rabbits, chondroitin sulfate suppressed cholesterol deposition in the aorta
due to a decrease in plasma LDL cholesterol and to a change in arterial metabolism
(Matsushima et al., 1987). Chondroitin sulfate E was shown to be a weak activator of
heparin cofactor II, accelerating the inhibition of thrombin approximately 200 fold. In
addition, chondroitin sulfate may exhibit some anticoagulant activity due to a interference
in the thrombin-fibrinogen interaction (Scully et al., 1986).

E. Homoloeues of Heparin
1. K-5 Derived Agents
Heparin-like agents can be derived from bacterial polysaccharides. The K5
capsular polysaccharide from E. coli is a polymer of glucuronic acid and N-acetylated
glucosamine. This is the same chemical structure as N-acetyl heparosan, a precursor in
mammalian heparin formation (Casu et al., 1992). To make a heparin-like substance, this
precursor is first deacetylated with hydrazine (Jann et al., 1992) and then N-sulfated. The
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resultant sulfamino heparosan undergoes C5 epimerization to produce iduronic acid
moieties (Kusche et al., 1991) and finally 0-sulfation produces a substance resembling
mammalian heparin. NMR analysis of the resultant polysaccharides indicate strong
signals characteristic of N-sulfated groups, glucosamine and glucuronic acid residues
(Jann et al., 1992). These modified polysaccharides have also been shown to contain the
3-0 sulfate group on glucosamine which is required for high affinity heparin binding to
ATIII (Casu et al, 1994). These agents have been shown to produce similar in vitro
anticoagulant and in vivo antithrombotic effects as low molecular weight heparin (Fareed
et al., 1995).

2. Pentosan Polysulfate
Pentosan polysulfate is a linear polymer of sulfated 1-4 linked B-xylopyranose
units which is derived from the bark of the beech tree (Aspinsall, 1959). All available
hydroxyl groups on pentosan are sulfated. The molecular weight of pentosan polysulfate
preparations is in the range of that of the low molecular weight heparins (4 to 6.5 kDa).
Like unfractionated heparin, pentosan polysulfate has multiple pharmacologic
actions. It has been widely utilized as an antilipemic agent (Barrowcliffe et al., 1986),
shown to selectively inhibit HIV-1 replication (Baba et al., 1988) and to have anti-tumor
effects in animals (Well stein et al., 1991).
A number of investigators have examined the anticoagulant actions of pentosan
polysulfate. Unlike heparin, pentosan polysulfate prevents coagulation independently of
AT-III (Fischer et al., 1982; Scully et al., 1983). Pentosan polysulfate has been shown
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to inhibit coagulation by two mechanisms. Firstly, pentosan polysulfate prevents thrombin
generation through its ability to inhibit the thrombin dependent activation of factor V
(Ofosu et al., 1987). Thereby, pentosan polysulfate inhibits the formation of the
prothrombinase complex and the generation of thrombin. Secondly, pentosan polysulfate
promotes the inhibition of preformed thrombin via HC-II (Scully et al., 1984).
Consequently, pentosan polysulfate has been shown to have low anticoagulant potency

in vitro (Scully et al., 1983; Soria et al., 1980). The potency of pentosan polysulfate has
been reported as 12 anti-Ila U/mg and 8 anti-Xa U/mg.
Despite its low anticoagulant activity, a number of investigators have
demonstrated the antithrombotic efficacy of this agent. In a rabbit model of stasisthrombosis, pentosan polysulfate was shown to inhibit factor Xa, thrombin, and
thromboplastin induced thrombogenesis to varying degrees. Thromboplastin was most
potently inhibited (van Ryn-McKenna et al., 1989). Similarly in rats, pentosan
polysulfate was observed to dose-dependently increase the number of laser injuries
required to induce thrombogenesis, though at much higher doses than were required for
heparin or low molecular weight heparin (Krupinski et al., 1990).
The major side effects of pentosan polysulfate are reported to be similar to those
of heparin.

A recent report has indicated that pentosan polysulfate induced

thrombocytopenia and thrombosis in patients receiving repeated administrations of the
agent (Tardy-Poncet et al., 1994). Positive cross-reactivity with heparin and low
molecular weight heparin was observed in a large number of these cases.
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3. Sulfated Mucopolysaccharides
Sulfated mucopolysaccharides are mixtures of glucosaminoglycans and
galactosaminoglycans extracted from cartilage. These substances are frequently used in
rheumatology for the treatment of joint degeneration. Several of these agents have also
been tested for their effects on the hemostatic system. Gorog et al. demonstrated that a
high concentration of a galactosaminoglycan caused a concentration dependent inhibition
of platelet reactivity. In addition, doses from 1 to 10 mg/kg were seen to inhibit
thrombus formation in a laser model of thrombosis (Gorog et al., 1987). Bauer et al.
examined the anticoagulant properties of three mucopolysaccharides used clinically to
treat degenerative joint diseases (Bauer et al., 1983). Arteparon was observed to have an
in vitro anticoagulant potency one quarter that of heparin as measured by the APTT. In
vivo administration of this agent confirmed its anticoagulant properties.

F. Synthetic Heparin

Analo~ues

1. Pentasaccharide
By measuring the antithrombin III affinity of a series of heparin fragments, it
was determined that the minimal antithrombin III binding sequence resides in an irregular
region of heparin and is a pentasaccharide (Rosenberg et al., 1979; Lindahl et al., 1979;
Choay et al., 1980). In the irregular region of heparin, 25 to 30 percent of the
glucosamine residues contain a unique 3-0 sulfate group. The importance of this sulfate
group to both the in vitro anticoagulant and the in vivo antithrombotic activities has been
demonstrated (Walenga et al., 1988). Subsequent to its discovery, this pentasaccharide
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was chemically synthesized (Petitou et al., 1986). Higher yields of the methyl aglycoside derivative of the pentasaccharide have been achieved (Petitou et al., 1987). The
chemical structure of this pentasaccharide is depicted in Figure 2. This derivative exhibits
the same biologic properties as the native agent.
By allometry, it has been estimated that the half-life of pentasaccharide in
humans is approximately 14 hours (Herault et al., 1995a). The first clinical study
performed in man with pentasaccharide has confirmed the long duration of action of this
agent following subcutaneous administration (Boneu et al., 1995). Half-lives of 13.1 to
13.9 hours were observed in healthy volunteers. The peak plasma concentrations were
linearly related to dose and plasma clearance was observed to be three fold higher than
that of typical low molecular weight heparins. This agent has been reported to exhibit a
very good tolerance with no prolongation of the bleeding time, APTT, or PT. Van
Amsterdam has shown that there is a rapid clearance of unbound pentasaccharide from
the plasma, but that antithrombin III bound pentasaccharide is cleared similarly to
endogenous antithrombin III (van Amsterdam et al., 1993). This was also observed
following administration of the highest dose in the study of Boneu.
The inhibition of thrombin generation was studied following subcutaneous
administration to normal volunteers (Lormeau et al., 1995). In this study, thrombin
generation was observed to be inhibited for periods of up to 18 hours. TFPI release was
not observed with subcutaneously administered pentasaccharide doses as high as 12,000
anti-Xa units. It was concluded from this study that thrombin generation by
pentasaccharide is mediated exclusively through selective ATHI mediated inhibition of
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Figure 2. depicts the chemical structure of a methyl a-glycoside derivative of the high ATIII
affinity binding pentasaccharide of heparin. The pentasaccharide contains the unique 3-0 sulfate
group required for binding to antithrombin ID. The molecular weight of this agent is 1728 Da.
This structure was adapted from Petitou et al., 1991.
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factor Xa.
Studies have shown that the pentasaccharide has no measurable activity in the
prothrombin time or in the APTT assays. In addition, pentasaccharide was seen to be
ineffective in both coagulant and amidolytic antithrombin assays (Walenga et al., 1985).
This pentasaccharide does exhibit a very high anti-factor Xa potency (Choay et al.,
1983). Pentasaccharide has been shown to concentration dependently inhibit thrombin
generation in normal human plasma (Lormeau et al., 1993). Thrombin generation
following extrinsic pathway activation was more potently inhibited than following
intrinsic pathway activation. This weaker inhibition of the intrinsic pathway is likely due
to the pentasaccharide's inability to inhibit factor V and factor VIII formation (Ofosu et
al., 1991). It has been shown both in vitro and in vivo that thrombin generation is not
completely inhibited by pentasaccharide. At doses of pentasaccharide which completely
prevented thrombus formation in a modified Wessler model, thrombin generation was
only inhibited sixty percent (Walenga et al., 1988). Clots formed in this model contain
predominantly red cells and fibrin, but few platelets. The thrombi formed in the arteriovenous shunt model contain red cell, fibrin strands, and a large amount of platelets.
Pentasaccharide was able to inhibit thrombus formation in both models. Hobbelen showed
that pentasaccharide dose-dependently inhibited thrombosis caused by various triggers in
a rat thrombosis model (Hobbelen et al., 1990). Additionally, this study had shown that
pentasaccharide causes a smaller increase in blood loss than heparin at antithrombotically
active doses. Impaired thrombin generation rather than anti-Xa activity was observed to
correlate with prevention of stasis induced thrombus formation (Thomas et al., 1989).
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The antithrombotic effect of this agent was also tested in baboons using a
modified arterio-venous shunt in which both arterial-type and venous-type thrombi can
form (Cadroy et al., 1993). While both types of thrombi were inhibited by
pentasaccharide, higher doses of the agent were needed to achieve a comparable level of
inhibition on the arterial side. The pentasaccharide was also observed to have no effect
on platelet function as measured by the template bleeding time. The pentasaccharide has
been observed to reduce thrombus formation following an electrical stimulation injury
in rabbit carotid arteries. This agent was also observed to enhance clot lysis induced by
tissue plasminogen activator.
A series of structural analogues of the native pentasaccharide sequence have
been synthesized (Meulemen et al., 1991). The analogues contain an additional 3-0
sulfate group on glucosamine residue H. Additionally, some of the analogues also
contained a 3-0 or 4-0 sulfate group on glucosamine residue D. All of the analogues
with additional 3-0 sulfate groups were observed to exhibit a higher anti-Xa potency than
the native pentasaccharide (1230 anti Xa U/mg vs. 700 anti-Xa U/mg). The higher
specific activity is proposed to be due to a tighter two site binding to antithrombin III.
As expected, all of the analogues were active in a rat stasis thrombosis model. The
duration of the antithrombotic effect was four to five times longer than the natural
pentasaccharide. The half-life of the anti-Xa activity of the modified analogues was
approximately twice that of the natural pentasaccharide. Other pentasaccharide analogues
have been reported (Herault et al., 1995b). Conversion of the N-sulfate groups to 0sulfates has been shown to increase antithrombin III affinity 2 fold. 0-methylation leads
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to an 8 fold increase in affinity.

2. Aprosulate
Sulfated bis-aldonic acid amides are a new class of synthetic low molecular
weight polyanions whose anticoagulant and antithrombotic activity is dependent on their
chemical structure. These agents are synthesized by conversion of aldonic acids to their
corresponding cyclic ester, or lactone. Two such lactone molecules are linked via amide
bonds with an alkylene diamine. The intermediate is then fully sulfated using a pyridineS03 complex resulting in a homogeneous product (Klauser et al., 1991). Lactobionic, Dgluconic, L-mannonic, D-galactonic, milibionic, and maltobionic acids were used as
starting materials and were linked by alkylene diamine bridges ranging from 2 to 12 units
in length. The compound which has shown the best anticoagulant and antithrombotic
profile is one which is produced by linking two lactobionic acid moieties with a
trimethylene diamine (Klauser et al., 1991). This compound is known as aprosulate. The
chemical structure of aprosulate is depicted in Figure 3. The series of compounds is
characterized by a defined structure and has been shown to have limited dispersity
(Klauser et al., 1991). The molecular weights of these compounds are lower than those
of the low molecular weight heparins with the molecular weight of aprosulate being 2388
Da.
The anticoagulant properties of several aldonic acid amides has been reported
(Raake et al., 1991; Jeske et al., 1993; Sugidachi et al., 1994). These agents exhibited
activity in the APTT and Heptest" assays indicating that they inhibit the intrinsic
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Figure 3 depicts the chemical structure of aprosulate. Its structure is characterized by two fully
sulfated disaccharides linked via amide bonds by a propylene chain. One saccharide of each
disaccharide is in open chain conformation. The molecular weight of aprosulate is 2388 Da. This
structure was adapted from Raake et al., 1991.
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coagulation pathway enzymes. This activity was low when compared to heparin. Activity
in a chromogenic anti-Xa was 200 times less than that of heparin (Raake et al., 1991).
Fareed et al. examined the pharmacodynamics of aprosulate with the purpose
of determining the usefulness of various assay methods for determining the amount of
aprosulate in plasma samples. In this study, Rhesus monkeys (Macaca mulatta) were
given aprosulate by both intravenous and subcutaneous injection, with blood samples
drawn over a period of six hours (Fareed et al. , 1991). Both the APTT, 5U thrombin
time and the Heptest" were dose-dependently prolonged by aprosulate. The amidolytic
activity of thrombin was inhibited only up to 30 minutes post-injection. This data
indicates that aprosulate is absorbed following subcutaneous administration. Based on this
data, the biologic half-life of aprosulate was estimated to be 45 minutes.
Protamine sulfate is a heterogeneous mixture of polybasic proteins derived from
various types of fish (Meischer et al., 1874) which is used clinically to neutralize the
anticoagulant effects of heparin. In vitro, ex vivo, and in vivo neutralizations of
aprosulate have been examined. With the in vitro samples, complete neutralization in the
Heptest" and thrombin time assays was observed when a two to four fold gravimetric
excess of protamine was used. Despite this high level of protamine, the APTT values
remained elevated (Hoppensteadt et al., 1991). Aprosulate's effects on the amidolytic
anti-Ila and anti-Xa assays were completely neutralized by equigravimetric amounts of
protamine. Protamine effectively neutralized aprosulate when an intravenous injection of
aprosulate was followed by an equigravimetric intravenous injection of protamine as
measured using the Heptest" or thrombin time (Hoppensteadt et al., 1991; Kijowski et
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al., 1994). It has also been demonstrated that protamine dose-dependently neutralizes the
antithrombotic activity of aprosulate as measured in a rat jugular vein clamping model
of thrombosis. A 2.5 fold gravimetric excess of protamine was required to completely
neutralize the antithrombotic activity (Raake et al., 1993). The anticoagulant activity of
aprosulate was not effected by high concentrations of the native heparin inhibitor, platelet
factor 4 {Klauser et al., 1991).
The mechanism of action of aprosulate has been examined in several studies.
Aprosulate was seen to inhibit approximately 50 % of thrombin activity in the presence
of plasma when 5 to 20 µg/mL of the agent was used. If purified antithrombin III was
substituted for the plasma, aprosulate was completely ineffective at inhibiting thrombin.
This is in contrast to heparin which was observed to be more potent in the presence of
purified antithrombin Ill. To further examine aprosulate's interaction with antithrombin
III, the APTT was measured with and without the presence of rabbit anti-antithrombin
III antibodies. Addition of the antibodies had no effect on the prolongation of the APTT
by aprosulate whereas heparin's ability to prolong the APTT was almost completely
neutralized in the presence of the antibodies (Klauser et al., 1991). Aprosulate is able to
dose-dependently inhibit thrombin when incubated with purified heparin cofactor II
(Hoppensteadt et al., 1988; Jeske et al., 1993b). This was seen to be a slow reaction,
with 15 minutes of incubation needed to achieve full inhibition. Ofosu et al. demonstrated
that aprosulate was able to inhibit intrinsic prothrombin activation by a mechanism
similar to that of dermatan sulfate, via heparin cofactor II. Even at high concentrations,
aprosulate was unable to prevent the onset of tissue factor dependent factor X and factor
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v activation.

The lag time for intrinsic prothrombin activation was, however, increased

by aprosulate. Though several bis-aldonic acid amides were shown to release tissue
plasminogen activator in an isolated pig ear perfusion model, aprosulate did not
(Klocking et al., 1991).
Aprosulate is an effective antithrombotic agent in vivo in several animal models.
In the Harbauer model (Harbauer et al., 1984) of venous thrombosis in rabbits, 1 mg/kg
intravenously administered aprosulate was observed to almost completely prevent
thrombosis. The same effect was observed two hours post-subcutaneous administration
of the same dose. This effect was stronger than that seen with an equigravimetric dose
of heparin (Raake et al., 1989). A significant inhibition of thrombus formation in this
model was seen to last at least six hours following subcutaneous administration. In a rat
jugular vein clamping model (Raake et al., 1989), aprosulate was observed to be an
effective anti thrombotic agent (Raake et al., 1991). A dose of 1 mg/kg was effective in
preventing thrombosis. With increasing doses, an increased number of clampings was
required to elicit thrombus formation. Aprosulate was less potent than heparin in
preventing thrombosis in this model. Aprosulate has been shown to be effective in an
arterio-venous shunt model of thrombosis (Sugidachi et al., 1993). The hemorrhagic
effect of aprosulate has been examined in a rat tail transection model. Antithrombotically
effective doses of aprosulate were not associated with significant bleeding risks.
Aprosulate has been administered to humans in two phase I clinical trials. In the
first trial, ascending doses from 0.25 to 2.0 mg/kg were administered to healthy
individuals on alternate days. Both the APTT and the Heptest" were dose-dependently
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elevated. No effect was observed on the thrombin time. There was no indication of a
thrombocytopenic response during this study (Papoulias et al., 1993). In the second trial,
three doses of aprosulate were studied in a repeated administration protocol for a period
of one week. In this study, an increase in plasma TFPI antigen levels was observed
following each administration of aprosulate. The TFPI antigen level was observed to
correlate with the plasma aprosulate levels (Jeske et al., 1995).

3. GL-522-Y-1
GL-522-Y-l is a synthetic sulfonated calix[8]arene which exhibits weak
antithrombotic properties. This compound does not have a saccharidic backbone like
heparin, yet maintains a degree of antithrombotic activity. The chemical structure of GL522-Y-1 is depicted in Figure 4. Unlike heparin, GL-522- Y-1 exhibits its anticoagulant
activity in global clotting assays only at very high concentrations. Additionally, negligible
activity is observed in chromogenic antithrombin and anti-factor Xa assays at these
concentrations (Jeske et al., 1992). GL-522-Y-1 exhibits no affinity to antithrombin III
and only a weak affinity for heparin cofactor II. This compound does inhibit factor Xa
and thrombin generation as measured in amidolytic, fibrinogen deficient plasma systems.
GL-522-Y-1 is a protease generation inhibitor following both intrinsic and extrinsic
pathway activation. This inhibition was observed to be more potent than that of either
pentasaccharide or aprosulate. Additionally, this inhibition was observed at lower
concentrations than were required to activate heparin cofactor II. The mechanism by
which this agent achieves this inhibition is not known.
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Figure 4 depicts the chemical structure of GL-522-Y-1. This agent is not saccharidic in nature
but rather is a cyclic polymer of phenol residues alternately separated by a methyl group. The
charge density of this agent is derived from sulfone groups rather than sulfate groups as found
in heparin. The molecular weight of this agent is 1488 Da.
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GL-522-Y-l has been shown to be effective as an antithrombotic agent in the
rabbit stasis thrombosis model (Jeske et al., 1993a). This agent was effective following
both intravenous and subcutaneous administration (Lee et al., 1993). GL-522-Y-1 was
also observed to be effective in a laser injury model of thrombosis following intravenous
and oral administration (Giedrojc et al., 1993). The antithrombotic activity following oral
administration was observed to have a duration of six hours. Administration of GL-522Y-1 to primates (Macaca fascicularis) resulted in an increase in plasma functional TFPI
levels (Jeske et al., 1993b).

G. Factor Xa Inhibitors
1. DX-9065a
The synthetic factor Xa inhibitor DX-9065a is currently being investigated. This
amidinonaphthalene derivative exhibits high specificity for factor Xa over thrombin and
other coagulation proteases. The k; for factor Xa was determined to be 41 nM versus 2.3
µM for plasma kallikrein, 21 µM fort-PA, 23 µM for plasmin, and > 2000 µM for
thrombin (Hara et al., 1994). Trypsin is also inhibited by DX-9065a. Both free factor Xa
as well as factor Xa found in the prothrombinase complex on platelets was inhibited by
DX-9065a. Moreover, this inhibition has been shown to be independent of antithrombin
III. DX-9065a demonstrates several advantages over other heparin-like antithrombotics.
First, this agent is reported to be absorbed orally. It has been shown that the PT, APTT,
and anti-Xa activity in blood samples drawn 30 to 240 minutes post-oral administration
to rats are dose-dependently increased. Second, as DX-9065a does not directly inhibit
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thrombin and has minimal effects on platelet response to known aggregants, almost no
effect was observed on the bleeding time in rats (Tanabe et al., 1993). This compound
has also been examined for its ability to abrogate disseminated intravascular coagulation
(DIC) induced by endotoxin or thromboplastin administration to rats (Yamazaki et al.,
1994). In both models, oral administration of DX-9065a inhibited the reduction of
platelet counts and fibrinogen levels characteristic of DIC.

2. Antistasin
Antistasin is a 119 amino acid protein which has been isolated from the saliva
of the leech Haementaria officinalis (Nutt et al., 1988). This protein is a slow, tightbinding inhibitor of factor Xa with an estimated dissociation rate constant of 0.3 nM
(Dunwiddie et al., 1989). Antistasin is a selective inhibitor of factor Xa, with no
observed inhibition of thrombin at concentrations 1000 fold higher than that of thrombin
(Vlasuk et al., 1991; Ohta et al., 1994). Antistasin inhibits factor Xa in a manner similar
to other serine protease inhibitors in which a rigid, substrate-like reactive site is
presented to the enzyme (Hoffman et al., 1992). Studies have shown that antistasin has
a specific and saturable binding site for heparin (Manley et al., 1992; Brankamp et al.,
1992). In contrast to LMWHs, antistasin is capable of dose-dependently prolonging the
APTT, suggestive of an ability to inhibit prothrombinase bound factor Xa (Vlasuk et al.,
1991).
Antistasin has been studied in several animal models for its in vivo
antithrombotic effects. In a rabbit model, antistasin was observed to reduce angiographic
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restenosis following balloon angioplasty (Ragosta et al., 1994). In a dog model, coadministration of recombinant antistasin with tPA dramatically reduced the time to
reperfusion (Mellott et al., 1992). In a monkey model of mild DIC, 1 mg/kg recombinant
antistasin was shown to be comparably effective to 1000 U/kg unfractionated heparin in
reducing fibrinopeptide A generation. This effect was observed to have a duration of at
least 5 hours (Dunwiddie et al., 1992). Platelet and fibrinogen deposition onto a Dacron
graft in a femoral arteriovenous shunt can be completely inhibited by antistasin infusion
(Schaffer et al., 1992). In models of thrombosis, recombinant antistasin was observed to
be as effective as conventional heparin therapy in preventing venous thrombosis (Vlasuk
et al., 1991). Additionally, antistasin is effective in arterial models of thrombosis where
heparin has limited effects (Hauptmann et al., 1993 ). While template bleeding times are
not increased by antistasin administration (Schaffer et al., 1992), its clinical utility may
be limited by the generation of neutralizing antibodies following repeated administration
(Dunwiddie et al., 1992).

CHAPTER Il
STATEMENT OF PURPOSE

It is the purpose of this dissertation to test the hypothesis that antithrombin III and
heparin cofactor II are not the sole mediators of the anticoagulant and antithrombotic
actions of heparin.
Heparin has long been used clinically for the prevention and treatment of
thrombosis. In more recent times, the use of heparin has expanded to include treatment
of angina and myocardial infarction and is used extensively in cardiovascular surgery and
invasive cardiologic procedures such as coronary angioplasty. In addition, depolymerized
forms of heparin known as low molecular weight heparins have been developed for a
variety of thrombotic indications. It has been initially established that the plasma serine
protease inhibitor antithrombin III is required for the mediation of the anticoagulant
activity of heparin (Abildgaard, 1968). The activities of other plasma serine protease
inhibitors are also known to be modulated by heparin.
To study the role of endogenous serine protease inhibitors in the mediation of
heparin's anticoagulant and antithrombotic activities, a systematic approach using
synthetic heparin analogues is utilized. These analogues offer the advantage of being
chemically homogeneous substances. As these agents exhibit varying degrees of
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interaction with antithrombin III and heparin cofactor II, they produce a more specific
and targeted range of functional properties inherent to heparin.
For this dissertation, three low molecular weight analogues of heparin have been
selected for both the biochemical and pharmacologic studies. These include a heparin
pentasaccharide, a sulfated bis-lactobionic acid amide (aprosulate), and a cyclic aromatic
polysulfonate derivative (GL-522-Y-l). Their activities in biochemical and biologic
assays are compared with those of unfractionated heparin.
Pentasaccharide, which mimics the minimal sequence in heparin that binds with
high affinity to AT-III, has been selected for study in this dissertation as it selectively
interacts with ATIII. This molecule has been shown to exhibit relatively little interaction
with HCII. This agent, produced synthetically through a collaboration between Sanofi
Recherche, France and Organon, Oss, the Netherlands, is a potent catalyst for the AT-III
mediated inhibition of factor Xa. Unlike the larger heparin chains of which it is normally
a part, this molecule is too small to catalyze thrombin inhibition. Despite its different
mechanism of action, pentasaccharide exhibits potent antithrombotic actions in animal
models.
Aprosulate is a synthetic polyanion developed by Luitpold-Pharma (Munich,
Germany) whose backbone is saccharidic in nature though structurally dissimilar to that
of heparin and pentasaccharide. This agent has been selected for study as it has been
shown to lack the sulfate conformation required to activate AT-III, but to potently
catalyzes the HCII mediated inhibition of thrombin. Aprosulate has also been shown to
be an effective antithrombotic agent in animal models.
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GL-522-Y-1 has been developed by Genelabs, Inc., Redwood City, CA, as an
antithrombotic agent. GL-522-Y-1 has been selected for study as it is structurally distinct
from the other polyanions chosen. GL-522-Y-l is not saccharidic in nature and derives
its polyanionic character from sulfonate rather than sulfate groups. Despite these
chemical differences, GL-522-Y-1 has been shown to potentiate thrombin inhibition via
HCII. Like aprosulate, this agent has been shown to be unable to catalyze the AT-III
mediated inhibition of either factor Xa or thrombin.
Physical characterization of these agents has been performed using gel permeation
chromatography (GPC), nuclear magnetic resonance spectroscopy (NMR), and mass
spectrometry (MS). GPC analysis provides data concerning molecular mass and
molecular weight distribution of each agent. This is particularly important for
unfractionated heparin as it is a mixture of various size glycosaminoglycan chains. NMR
and mass spectral analysis of these compounds has provided additional information on
the structural and molecular characteristics of these agents.
The in vitro biochemistry of the synthetic heparin analogues has been defined
using a variety of assays. These included a battery of clotting and amidolytic antiprotease
assays designed to examine various steps of the coagulation cascade. The effects on the
intrinsic pathway are investigated using the activated partial thromboplastin time (APTT).
Effects on the extrinsic pathway are investigated using the prothrombin time (PT). The
common pathway of coagulation is iinvestigated using the thrombin time, Heptest®, and
amidolytic anti-factor Ila and anti-factor Xa assays.
Interactions of the various analogues with the endogenous SERPINs is examined
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using amidolytic assays in which the ability of each agent to mediate inhibition of factor
Xa or thrombin via antithrombin III or heparin cofactor II activation is examined in a
concentration dependent manner.
Protease generation inhibition assays provide a useful set of data to explain the
mechanism of action of the synthetic analogues as well as to determine the relative
importance of heparin cofactor II and antithrombin III activation for the inhibition of
these processes. Plasmatic and defined non-plasmatic amidolytic assay systems are
utilized for these purposes. Non-plasmatic systems provide the opportunity to study the
effect of each agent on protease generation in the absense of ATIII and HCII.
As platelets play an important role in the hemostatic process (forming the primary
hemostatic plug, catalyzing several reactions of the coagulation cascade, releasing
procoagulant or heparin neutralizing compounds), the effects of the synthetic analogues
on various platelet functions are also investigated. Agonist specific platelet aggregation
inhibition is assessed by determining the individual modulatory profile of these agents in
platelet rich plasma. The potential for each of these analogues to produce platelet
activation in a heparin induced thrombocytopenia screening assay is also investigated.
The in vivo pharmacology of the heparin analogues is examined using valid
models of thrombosis and bleeding. The activity of each agent is determined in a dose
dependent manner in order to compare the potency of each agent. Two models of
thrombosis are utilized. In the rabbit model of stasis thrombosis, thrombus formation is
induced by the administration of activated coagulation factors and a stasis of blood flow
in a segment of jugular vein. In the rat model of jugular vein clamping, thrombus
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formation is triggered by vascular damage. The rat model offers the advantage of
maintaining blood flow through the damaged area over the experimental course. The
rabbit model offers the advantage of allowing the drawing of several blood samples over
the course of the experiment for ex vivo analysis of coagulation parameters. By
measuring various SERPIN mediated events (anti-Ila activity, anti-Xa activity, APTT,
PT) ex vivo in blood samples taken during the thrombotic models, the relative importance
of these actions to producing the antithrombotic state can be more clearly elucidated.
In the rabbit ear bleeding model, the number of red blood cells lost in a given
period of time is quantitated and used as a measure of hemorrhagic potential in terms of
a bleeding index.
The effects measured in these in vivo models are compared to heparin cofactor
II and antithrombin III mediated activities, activity in in vitro systems, and ex vivo
clotting activities. Since these analogues are structurally defined, their actions are
presented in terms of molar dosage and a comparison of the activities can be readily
achieved.
Tissue factor pathway inhibitor (TFPI) has been shown to be an important
mediator of the pharmacologic actions of heparin. The effect of the heparin analogues
on plasma TFPI levels has been assessed in several animal models. An assay to measure
functional TFPI levels in rabbit samples obtained during the stasis-thrombosis
experiments has been optimized. Additionally the effect of intravenous administration of
pentasaccharide and GL-522-Y-1 on TFPI levels in non-human primates is also assessed.
The effect of aprosulate on plasma TFPI levels has been assessed in human volunteers
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as part of two phase I clinical studies.
By characterizing the actions of the selected heparin analogues in parallel with
unfractionated heparin, the importance of SERPIN activation for the antithrombotic and
bleeding effects of these agents is determined. The data obtained from the current
research provids a defined biochemical and pharmacologic basis for understanding the
molecular mechanisms by which heparin mediates its antithrombotic actions and bleeding
effects.

CHAPTER ID
MATERIALS AND METHODS

A. Materials
1. Unfractionated Heparin

Unfractionated porcine mucosa! heparin (lot H410) was obtained from Sanofi
Pharma, Paris, France. The molecular weight of this heparin was approximately 10.5
kDa. The potency of this preparation was 160 IU/mg when cross referenced to
International Standard #3. The heparin was provided as a white powder and was stored
in a desiccator at room temperature. Stock solutions were made in physiologic saline as
needed. Unused solutions were stored at 1 °C and were discarded after two weeks. The
molecular profile of this heparin is depicted in Appendix 1. Product specifications are
listed in Appendix 2.

2. Pentasaccharide

The pentasaccharide representing the minimal antithrombin III binding sequence
( 0-(2-deox y-2-sulfamido-6-0-sulfo-a-D-gl ucopyranos yl)-( 1-4 )-0-(13-Dglucopyranosyluronic

acid)-( 1-4 )-0-(2-deoxy-2-sulfamido-3, 6-di-0-sulfo-a-D-

glucopyranosy1)-( 1-4)-0-(2-0-sulfo-a-L-idopyranosy1uronic acid)-) 1-4 )-2-deoxy-2-
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sulfamido-6-0-sulfo-D-glucopyranose decasodium salt (SR90107A lot JMS07046) was
obtained from Sanofi Pharma, Paris, France. The molecular weight of this
pentasaccharide is 1. 724 kDa. The potency of this compound was designated at 650 aXa
units/mg in human plasma. Stock solutions were made in physiologic saline as needed.
Unused portions of the solutions were frozen at -70 °C for future use. The molecular
profile of this heparin is depicted in Appendix 1. Product specifications are listed in
Appendix 2.

3. Aprosulate
Aprosulate,
(Hexadecasodium

lot 90416/7172, is a sulfated bis-lactobionic acid amide
trimeth ylenebis-[4-0-13-D-galactopyranosy1-D-gluconoylamino

octasulfate]) obtained from Luitpold-Pharma, Munich, Germany. Its molecular weight
is 2.388 kDa. The potency of aprosulate was determined to be 4.6 USP units/mg using
the USP XXII method. Purity of this substance was determined to be greater than 99. 7
%. It was provided as a colorless powder whose solubility in water was determined to

be up to 60 %• This agent is not soluble in methanol, ethanol, or acetone. Stock solutions
were made in physiologic saline as needed. Unused solutions were stored at 1 °C and
were discarded after two weeks. The molecular profile of this heparin is depicted in
Appendix 1. Product specifications are listed in Appendix 2.

4. GL-522-Y-1
GL-522-Y-1, a sulfonated calix[8]arene, (Lot Sabinsa #4) was obtained from
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Genelabs Inc. (Redwood City, CA). This compound has a molecular weight of 1.488
kDa. Purity was determined to be greater than 99 % by reverse-phase ion pairing HPLC
following two recrystallizations. The solubility of GL-522-Y-l in water is greater than
1000 mg/mL. The material was provided as a white powder which was reconstituted in
physiologic saline as needed. Unused solutions were stored at l °C and were discarded
after two weeks. The molecular profile of this heparin is depicted in Appendix 1. Product
specifications are listed in Appendix 2.

5. Reagents
a. Enzymes
Human thrombin (Fibrindex®) was purchased from Ortho Diagnostics (Raritan,
NJ). The lyophilized material was reconstituted in physiologic saline (Baxter Healthcare
Corp., Deerfield, IL) prior to use with the remaining material frozen in aliquots at -70
°C. Bovine factor Xa was obtained from Enzyme Research Laboratories (South Bend,
IN) and was stored in aliquots at -70 ° C. This material was reconstituted in Tris buffer
(50 mM Tris, 175 mM NaCl, 7.5 mM EDTA; pH = 8.4 at 25 °C) immediately prior
to use.

b. Substrates
Chromogenic

substrates,

Spectrozyme

TH

(HDCT-Ala-Arg-pNA)

Spectrozyme FXa (CH30CDHG-Gly-Arg-pNA), were obtained from

and

American

Diagnostica (Greenwich, CT). They were reconstituted in deionized water to
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concentrations of 1.0 and 2.5 mM, respectively, for use in the amidolytic antiprotease
assays.

c. Clotting Assays
Reagents for the APTI, 0.025 M CaC12 and a micronized silica based APTI
reagent, were purchased from Organon Teknika (Parsippany, NJ). The APTI reagent
was reconstituted by the addition of 5 mLs of sterile, deionized water. 0.025 M CaC12
was used at 37 °C. Once reconstituted, the APTI reagents were refrigerated (4 °C) for
periods of up to one week.
Thromboplastin C®, used in the PT and protease generation assays, was obtained
from Baxter Healthcare, Dade Division (Miami, FL). ISI = 2.69. Each bottle was
reconstituted with 20 mLs of sterile, distilled water, gently shaken, and allowed to sit for
20 minutes prior to use. Once reconstituted, the thromboplastin reagent was refrigerated
(4 °C) for periods of up to one week.
Reagents for the Heptest®, bovine FXa and Recalmix®, were purchased from
Haemochem (St. Louis, MO). Both were obtained in lyophilized form and each vial was
reconstituted with 2 mLs of deionized water prior to use. Recalmix®, an optimized
mixture of CaC12 and brain cephalin in a bovine plasma fraction was used at 37 °C.
Bovine factor Xa was used at room temperature. Once reconstituted, the Heptest®
reagents were refrigerated (4 °C) for periods of up to one week.
Purified human AT-III was obtained from Kabi Vitrum (Stockholm, Sweden).
It was stored in aliquots of 500 U/mL at -70 °c and was diluted with physiologic saline
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to obtain desirable concentrations immediately prior to use.
Purified HC-11 (lot 1180) was obtained from Diagnostica Stago (Gennevieres,
France) in lyophilized form. Each vial contained 100 µg of HC-11 purified from human
plasma and was reconstituted with 200 µL of physiologic saline to make a 500 µglmL
solution. Biologic activity was designated as 1.6 U/vial.
Tris (hydroxymethyl)aminomethane (Trizma base and Trizma HCl) was
purchased from Sigma (St. Louis, MO). Buffers of various pHs and osmolality were
prepared as described in Methods.
Fibrinogen deficient plasma was purchased from George King Biomedical
(Overland Park, KS). Fibrinogen levels were less than 25 mg/dL.
Actin®, activated cephaloplastin reagent, was purchased from Baxter Healthcare,
Dade Division (Miami, FL). Once reconstituted, the Actin® reagent was refrigerated (4
°C) for periods of up to one week.
Konyne® brand of prothrombin complex concentrate was purchased from Cutter
Laboratories (Berkeley, CA). This reagent contains purified human coagulation factors
II, VII, IX, and X in a stabilized matrix.
FEIBA® brand of activated prothrombin complex concentrate was purchased
from Immuno, AG (Vienna, Austria) in lyophilized form. Each bottle was reconstituted
with 20 mLs of sterile water prior to use with any remaining portions frozen in aliquots
of 25 U/mL at -70 °C. This complex concentrate contains purified human coagulation
factors II, VIIa, IX, and X in a stabilized matrix.
d. Anesthetics
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Ketaset®, ketamine hydrochloride, was purchased from Aveco Co. Inc. (Fort
Dodge, IA) as a 100 mg/mL injectable solution. Rom pun®, xylazine, was purchased from
Mobay Corporation (Shawnee, KS) as a 100 mg/mL injectable solution.
Beuthanasia®-D, a solution of sodium pentobarbital and phenytoin sodium, was
obtained from Schering-Plough Animal Health, Kenilworth, NJ.

e. Other agents
Physiologic saline, obtained from Baxter Healthcare (Deerfield, IL), contained
308 mOsmol/L NaCl at a pH of 5.5. Sterile irrigation water prepared by distillation was
obtained from Baxter Healthcare Corp., Deerfield, IL.
Celite coagulation tubes were purchased from International Technidyne (Edison,
NJ). Each evacuated tube contained 12 mg of diatomaceous earth and was designed to
activate 2 mLs of blood.
Mineral oil was obtained from Sigma (St. Louis, MO).
Albumin was obtained from Sigma (St. Louis, MO).
Sodium sulfate was purchased from Mallinkrodt (Paris, KY).

6. Major Instrumentation
Beckman DU®-7 spectrophotometer (Beckman Instruments Inc., Fullerton CA);
ACL 300 Plus fast kinetics coagulation analyzer (Coulter, Hialeah, FL); fibrometers®
(Becton Dickinson and Co, Rutherford, NJ); Multistat III centrifugal analyzer
(Instrumentation Laboratory, Lexington, MA); Thrombelastograph CTEG model #3000
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(Hellige GmbH, Freiburg, Germany); ACT machine (International Technidyne, Edison,
NJ), model 801; Light microscope (model BH-2, Olympus); HPLC (Waters, Lexington,
MA), consisting of a VAX 3100 computer, a LACIE interface module, two model 510
HPLC pumps, a 712 WISP autoinjector, a model R401 differential refractometer, and
a model 484 tunable absorbance detector; platelet aggregometer (BioData Corporation,
Hatboro, PA) and an IBM compatible personal computer linked to a Hewlett Packard
(San Diego, CA) Laserjet Illsi printer for wordprocessing, statistical analysis, and
graphics were used in these studies.

7. Animals

Male, White New Zealand rabbits (2.5 to 3.5 kg, 10 to 12 weeks of age)
obtained from LSR Industries Inc. (Union Grove, WI) were housed in individual cages
in the Animal Research Facility of Loyola University Medical Center (AAALAC
accredited effective 3/9/93; PHS Animal Welfare Assurance ID # A 3117-01). The
rabbits were fed a diet of standard rabbit chow and had free access to water. The ambient
temperature was kept at 65 °F with approximately 45 % humidity. The animals were
kept on a 12 hour light/dark cycle with the light period beginning at 7:00 a.m. All
experiments were performed during the animals light cycle. Rabbits were anesthetized
during all procedures with ketamine (50 mg/kg intramuscularly) and xylazine (25 mg/kg
intramuscularly). Beuthanasia®-D, Schering-Plough Animal Health, Kenilworth, NJ was
administered at a dose of 0.1 mL/kg for euthanasia.
Male Sprague-Dawley rats (300 to 400 g, 73 to 121 days in age) were obtained
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from Harlan Industries, Indianapolis, IN and were housed two per cage in the Animal
Research Facility of Loyola University Medical Center (AAALAC accredited effective
3/9/93; PHS Animal Welfare Assurance ID# A 3117-01). The rats were fed a diet of
standard rat chow and had free access to water. The animals were kept on a 12 hour
light/dark cycle with the light period beginning at 7:00 a.m. All experiments were
performed during the animals light cycle. The rats were anesthetized with an
intraperitoneal injection of urethane (15 % in physiologic saline) for all procedures. Rats
were euthanized with a 0.1 mL/kg intravenous injection of Beuthanasia®-D.

B. Physical Characterization of Aeents
1. Molecular Weight Profile by Gel
Permeation Chromatography (GPC)
Calibration curves made using three different types of calibrators were prepared
by running the appropriate compounds on a Waters 845 GPC-HPLC system (MilliporeWaters, Lexington, MA, U.S.A.) equipped with Expert Ease® software designed for
polymer analysis. Each calibrator was dissolved in 0.5 M Na2S04 to give a final
concentration of 10 mg/mL. The HPLC system consisted of a VAX 3100 computer
(Digital Corp.), a LACIE interface module, two Waters model 510 HPLC pumps, a
Waters model 712 WISP autoinjector, a model 401 differential refractometer (RI), and
a Waters 484 tunable absorbance detector. The UV and the RI detector were linked in
series, with the outlet end of the columns attached to the UV detector.
20 µL of each sample was injected onto a tandem column system (TSK 2000 I
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TSK 3000, Tosoh Haas, Tokyo, Japan) for analysis. The mobile phase, 0.5 M Na 2S04 ,
was pumped through the columns at a flow rate of 0.5 mL/minute. All analyses were
made at room temperature. The run time for each sample was set at 65 minutes. UV
determinations were made at 234 nm. The system was equilibrated each morning using
freshly degassed mobile phase until a stable baseline was obtained.
Nineteen narrow range calibrators of known molecular weight were supplied by
Choay Laboratories, Roen, France. They were prepared by fractionation of heparin on
Ultragel

AcA44

agarose

acrylamide

(LKB-Produkteur

AB)

gel

permeation

chromatographic columns. The narrow range fractions were further analyzed for their
molecular weights by running them through TSK G2000 SW and TSK 3000 SW
analytical gel permeation columns which had been calibrated against other well defined
reference standards. The weights of these fractions were found to be: 22,500; 17,300;
14,800; 12,900; 11,500; 10, 100; 8,650; 7,540; 6,670; 6, 150; 5,730; 5,360; 5,000;
4,530; 4,000; 3,410; 2,440; 1,880 and 1,320 Da. These molecular weights were
confirmed by viscometry, LALLS, or sedimentation analysis.
The log molecular weight of each calibrator was plotted against its retention
time. Using the Expert Ease® software, a third order polynomial regression equation was
fitted to the data points to give an expression in the form :

log M. W. = D0
where

+

D 1(RT)

+ D2(RT) 2 + D 3(RT) 3

M.W. = calculated molecular weight and
RT = sample retention time
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D0 , D 1 , D 2 , and D3 = coefficients calculated in the curve fitting process

The molecular weight profile of each agent was determined based on this
calibration curve. The molecular weight profile consisted of the parameters weight
average molecular weight, number average molecular weight, peak molecular weight, and
dispersity.

2. 1H and 13C Nuclear Magmetic Resonance (NMR) Spectra
Proton (1H) NMR spectra of aprosulate, GL-522-Y-1, heparin, and pentasaccharide were
detected with an AC300 or AMX 500 NMR spectrometer (Bruker, Germany) at either
300 or 500 MHz in collaboration with Professor B. Casu (Ronzoni Institute, Milan,
Italy). Carbon 13 (13 C) spectra were detected using an AC300 NMR spectrometer at 75
MHz. For this analysis, the samples were dissolved in 99.9% deuterium oxide at
concentrations varying from 1 to 10 % depending upon the sample and the magnetic
field. For aprosulate and heparin, spectra were obtained at a temperature of 313 K. The
spectra of GL-522-Y-1 were obtained at 300 K while those of pentasaccharide were
obtained at 298 K. Proton spectra were made at 300 MHz and 13 C spectra were made at
75 MHz. All chemical shifts were given in ppm downfield from at internal sodium-3(trimethylsilyl)-propionate standard.

3. Mass Spectral Analysis
Mass spectra of aprosulate and GL-522-Y-1 were obtained using a Finnigan
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MAT900 2-sector mass spectrometer equipped with an Antek cesium ion gun. For the
analysis, an aliquot of the sample was dissolved in 1 µL of solvent and added to 1 µL
of matrix on a probe tip. The matrix for these analyses was triethanolamine. The probe
tip was subsequently inserted into the ion source of the mass spectrometer. The sample
was ionized by liquid secondary ion mass spectrometry. All data was collected in the
negative ion mode.

C. In vitro Biochemical and

Pharmacolo~ic

Profile

The comparative in vitro biochemical and pharmacologic analysis of heparin and
its synthetic analogues was carried out utilizing biochemically defined, normal human
pooled plasma and normal rabbit pooled plasma based assays. In addition, protease
generation assays were carried out utilizing fibrinogen deficient plasma and activated and
non-activated prothrombin complex concentrate supplemented systems. The modulatory
actions of each of these agents were investigated utilizing endothelial cell cultures and
platelet rich plasma harvested from citrated whole blood obtained from human
volunteers.

1. SERPIN Activity Assays
a. Antithrombin III (AT-III)
The ability of an agent to mediate antiprotease activity via AT-III was measured
utilizing an amidolytic substrate assay run on the ACL-300+ fast kinetics analyzer. Test
agents were diluted in saline and placed in sample cups such that the final assay
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concentrations ranged from 0 to 40 µM. 12.5 µL of a 1.25 U/mL human AT-III solution
was added to the sample cups such that the final concentration of AT-III in the assay was
0.0625 U/mL. The first reagent consisted of 1.25 U/mL thrombin or 0.625 nkat/mL
factor Xa in Tris buffer (50 mM Tris, 175 mM NaCl, 7.5 mM EDTA, pH = 8.4@ 25
°C). The second reagent consisted of0.5 mM Spectrozyme TH or 1.25 mM Spectrozyme
FXa. The instrument was programmed such that 100 µL of sample and 100 µL of
reagent 1 were placed into individual compartments in a reaction rotor. These reagents
were incubated at 37 °C for 1 minute and were then mixed together. 50 µ.L of reagent
2 was then added to the rotor and the reaction rotor was spun at 1200 r.p.m. Optical
density readings at 405 nm were made continuously for all cells for 60 seconds. The data
was downloaded for analysis to an IBM PC containing the Instrument Laboratories
research program. A printout of the change in optical density with time was obtained.
Percent inhibition and maximal reaction rates were determined.
Potency evaluations were made by comparing IC 50 values for each agent in both
systems. IC50 values were calculated in the following manner: Data from each individual
run was plotted as percent inhibition relative to saline versus concentration (µM).
Regression analysis was performed on the linear portion of each curve. The agent
concentration resulting in 50 % maximal inhibition was extrapolated from the best fit
line. The mean and standard deviation of the extrapolated IC50 's was determined.
Statistical differences between the respective IC 50 's were determined by one way ANOVA
followed by the Newman-Keuls test.
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b. Heparin Cofactor II CHC-II)
The ability of an agent to mediate antiprotease activity via HC-II was measured
utilizing an amidolytic substrate assay run on the ACL-300+ fast kinetics analyzer.
Agents were diluted in saline and placed in sample cups such that the final assay
concentrations ranged from 0 to 40 µM. 4.2 µL of a 500 µglmL human HC-II solution
was added to the sample cups such that the final concentration of HC-II in the assay was
8.4 µg/mL. The first reagent consisted of human thrombin diluted to 2.08 U/mL with
Tris buffer (50 mM Tris, 175 mM NaCl, 7.5 mM EDTA, pH = 8.4@ 25 °C). The
second reagent consisted of 0.625 mM Spectrozyme TH. The instrument was
programmed such that 100 µL of sample and 50 µL of reagent 1 were placed into
individual compartments in a reaction rotor. These reagents were incubated at 37 °C for
1 minute and were them mixed together. 100 µ.L of reagent 2 was then added to the rotor
and the reaction rotor was spun at 1200 r.p.m. Optical density readings at 405 nm were
made continuously for all cells for 60 seconds. The data was downloaded for analysis to
an IBM PC containing the Instrument Laboratories research program. A printout of the
change in optical density with time was obtained. Percent inhibition and maximal reaction
rates were determined.
Potency evaluations were made by comparing IC50 values for each agent. IC50
values were calculated in the following manner: Data from each individual run was
plotted as percent inhibition relative to saline versus concentration (µ.M). Regression
analysis was performed on the linear portion of each curve. The agent concentration
resulting in 50 % maximal inhibition was extrapolated from the best fit line. The mean

81
and standard deviation of the extrapolated IC50 's was determined. Statistical differences
between the respective IC 50 's were determined by one way ANOVA followed by the
Newman-Keuls test.

2. Anticoagulant Profile
a. Activated Partial Thromboplastin Time CAPTT)
The APTT is a global clotting assay which is used to measure inhibition of
coagulation factors in the intrinsic pathway and is commonly used to monitor heparin
therapy. The assay was performed in the following manner. 100 µL of APTT reagent
was added to 100 µL of test plasma and was incubated for 5 minutes at 37 °C. Clotting
time was measured using a Fibrometer® (BBL, Cockeysville, MD) following the addition
of 100 µL of prewarmed 0.025 M CaC12 • Measurement of clotting time was stopped at
300 seconds as clotting times beyond 300 seconds were outside of the linear range of the
instrument.

b. Heptest®
The Heptest® (Haemochem, St. Louis, MO) is an assay which is used to
measure clotting times after the addition of purified bovine factor Xa. The assay was
performed in the following manner. 100 µL of plasma was added to 100 µL of bovine
factor Xa and was incubated for 2 minutes at 37 °C. Clotting time was measured with
a Fibrometer® (BBL, Cockeysville, MD) after the addition of 100 µL of prewarmed
Recalmix®. Measurement of clotting time was stopped at 300 seconds as clotting times
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beyond 300 seconds were outside of the linear range of the instrument.

c. 5 U Thrombin Time (5 U TT)
The 5 U thrombin time measures the time needed to convert fibrinogen to fibrin
by preformed thrombin. The assay was performed in the following manner. 200 µL of
plasma was equilibrated to 37 °C for 3 minutes. The clotting time was measured with
a Fibrometer® (BBL, Cockeysville, MD) following the addition of 100 µL of human
thrombin. This thrombin had previously been calibrated to 5 U/mL by adjusting its
concentration such that the clotting time of pooled normal human plasma was 18 to 20
seconds. Measurement of clotting time was stopped at 300 seconds as clotting times
beyond 300 seconds were outside of the linear range of the instrument.

d. Prothrombin Time (PT)
The PT is a global clotting test which is used to measure inhibition of
coagulation factors in the extrinsic pathway (FVIIa and FXa). This assay is commonly
used to monitor oral anticoagulant therapy. The assay was performed in the following
manner. 100 µL of plasma was incubated at 37 °C for 3 minutes. Clotting time was
measured using a Fibrometer® (BBL, Cockeysville, MD) following the addition of 200
µL of prewarmed Thromboplastin C® (Dade, FL). Measurement of clotting time was
stopped at 300 seconds as clotting times beyond 300 seconds were outside of the linear
range of the instrument.
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3. Amidolytic Antiprotease Assays
a. Anti-thrombin assay (Anti-Ila)
Residual thrombin activity was measured using a amidolytic substrate based
assay on a Beckman spectrophotometer. Anticoagulant present in the plasma sample
would inhibit a given portion of the available added thrombin. Any remaining thrombin
would cleave the amidolytic substrate and release p-nitro aniline. The reaction was
followed by monitoring the change in the amount of free chromophore (pNA) at an
optical density of 405 nm. The assay was performed in the following manner. 400 µL
of buffer (50 mM Tris, 175 mM NaCl, 7.5 mM EDTA, pH= 8.4@ 25 °C) and 25 µL
of the test plasma was prewarmed for 1 minute at 37 °C in a quartz cuvette. 25 µL of

10 U/mL thrombin was then added. Thrombin for this assay was calibrated to give an
optical density change of 0.65 to 0. 75 mau/min in a saline control. Following an
incubation time of exactly 1 minute, 50 µL of a 1 mM solution of the amidolytic
substrate Spectrozyme TH was added and the change in optical density was measured for
1 minute. Percent inhibition was determined in relation to unsupplemented baseline
plasma using the following formula:

% I = {(delta 0.D. baseline - delta O.D. sample) I delta O.D. baseline}

* 100

%

b. Anti-factor Xa assay (Anti-Xa)
Residual factor Xa activity was measured using a chromogenic substrate assay
developed by Hoppensteadt et al. (Hoppensteadt et al., 1985). Anticoagulant present in
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plasma may inhibit a given fraction of added factor Xa. Any residual factor Xa was able
to cleave an amidolytic substrate to release p-nitro aniline. The reaction was monitored
by measuring the change in the amount of free chromophore (pNA) by measuring the
change in optical density at 405 nm. The assay was performed in the following manner.
375 µL of buffer (50 mM Tris, 175 mM NaCl, 7.5 mM EDTA, pH = 8.4@ 25 °C)
was incubated with 25 µL of the plasma sample for 2 minutes at 37 °C. 50 µL of bovine
FXa was added. Prior to running the assay, an aliquot of factor Xa was reconstituted in
reaction buffer such that in a saline control a change in absorbance of 0.65 to 0. 75
mau/min was observed. Following a 2 minute incubation at 37 °C, 50 µL of
Spectrozyme FXa (2.5 mM) was added and the change in optical density at 405 nm was
measured for 1 minute. Percent inhibition was determined in relation to unsupplemented
baseline plasma using the following formula:

% I = {(delta O.D. baseline - delta O.D. sample) I delta O.D. baseline} * 100 %

4. FVIII:C assay
Factor VIII coagulant (FVIII:C) activity was determined using an amidolytic
assay (Coatest Factor VIII, USA Helena Laboratories, Beaumont, TX) in which a
purified FVIII solution (4 U/mL) was supplemented with the agent being studied over a
concentration range of 0 to 100 µM. 300 U of lyophilized FVIII (Armour, Kankakee, IL)
was reconstituted with 15 mLs of physiologic saline and was stored in 0.5 mL aliquots
at -70 °C. Immediately prior to the experiment, 0.2 mLs of the 20 U/mL aliquot was
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diluted with 0.8 mL of Owren's Verona! Buffer (pH = 7.35

± 0.1; American Dade,

Aguada, Puerto Rico). 40 µL of each sample was incubated with 420 µL of buffer (0.05
M Tris + 0.2 % bovine albumin; pH = 7.3) and 200 µL of a solution containing factor
IXa, factor X, and phosphatidylserine for 5 minutes. 100 µL of CaC12 (0.025 M) was
added and the solution was incubated for another 5 minutes. 200 µL of the factor Xa
substrate, Spectrozyme Xa (2. 7 mM) was added and the change in absorbance at 405 nm
was measured for 60 seconds. Percent inhibition was determined in relation to a saline
control using the following formula:

% I = {(delta O.D. baseline - delta O.D. sample) I delta O.D. baseline}

* 100

%

5. Protease Generation Assays
a. Fibrinogen Deficient Plasma
Inhibition of thrombin and factor Xa generation was measured utilizing an
amidolytic substrate method (Kaiser et al., 1992) run on the ACL-300+ fast kinetics
analyzer. Agents were diluted in saline to the appropriate concentrations and placed in
the sample cup carousel. Reagent position 1 contained fibrinogen deficient plasma diluted
1:8 in Tris buffer (pH = 8.5, 100 mM Tris base adjusted with HCl). Reagent position
2 contained Actin (Dade,, Miami, FL) diluted 1: 1 with Spectrozyme TH or Spectrozyme
FXa (1 mM made in 0.025M CaC12) for measuring intrinsic IIa and Xa generation or
Thromboplastin C® diluted 1:6 with the chromogenic substrates for measuring extrinsic
thrombin and FXa generation. 60 µL of sample and 60 µL of reagent 1 were pipetted
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into the rotor and were incubated at 37 °C for 5 minutes. 60 µL of reagent 2 was
pipetted into the rotor and the rotor was spun at 1200 r.p.m. 1040 optical density
measurements were made over a period of 999 seconds for each cuvette. This data was
downloaded to an IBM PC for analysis by the IL research program. Kinetics curves were
generated. Percent inhibition was determined according to the following formula:

% I = {(delta O.D. baseline - delta O.D. sample) I delta O.D. baseline} * 100 %

b. Prothrombin Complex Concentrate Based (Konyne) System
Thrombin and FXa generation inhibition were measured in a non-plasma system
in which a prothrombin complex concentrate provides the necessary coagulation factors
for the reaction in the absence of plasma. This system used Konyne® brand of
prothrombin complex concentrate (Cutter Laboratories, Berkeley, CA), containing factors
II, VII, IX, and X. This amidolytic assay was run on the Multi-stat III centrifugal
analyzer. The reagents were added to the rotor in the following order. 25 µL of the drug
dilution (0 to 100 µM in saline) and 140 µL of buffer (Thromboquant aPTT buffer,
Boehringer Mannheim, GmbH, Mannheim, Germany, lot 1313205) was added to the
outer well of the reaction rotor. 10 µL of the same buffer and 25 µL of Konyne® (10
U/mL) were added to the inner well of each cuvette. 25 µL ofThromboplastin C® (Dade,
FL) diluted 1: 10 with 0.025 CaC12 was added to the outer well. Immediately before the
rotor was placed in the instrument, 25 µL of Spectrozyme TH or FXa made at 2.5 mM
in deionized water was added to the outer well. The rotor was incubated for 30 seconds
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at 37 °C before optical density readings at 405 nm were made. The rotor was spun at
600 r.p.m. Optical density was read once every 60 seconds for a period of twelve
minutes. Data printouts contained optical density readings at each time point as well as
the overall optical density change. The data was plotted as kinetic curves (Ll O.D. vs.
time) and as % inhibition relative to saline control vs. concentration (µM). Percent
inhibition is calculated as above.

c. Activated Prothrombin Complex Concentrate (FEIBA~ System
Thrombin and FXa generation inhibition were measured in a non-plasmatic
system in which an activated prothrombin complex concentrate provided the necessary
coagulation factors for the reaction in the absence of plasma. This system used FEIBA®
brand of prothrombin complex concentrate containing factors II, VIia, IX, and X. This
was an amidolytic assay run on the Multi-stat III centrifugal analyzer. The reagents were
added in the following order. 25 µL of the drug dilution (0 to 100 µMin saline) and 140
µL of buffer (Thromboquant aPTT buffer, Boehringer Mannheim, GmbH, Mannheim,
Germany, lot 1313205) was added to the outer well of the reaction rotor. 10 µL of the
same buffer and 25 µL of FEIBA® (10 U/mL) were added to the inner well of each
cuvette. 25 µL of Thromboplastin C® (Dade, FL) diluted 1 : 10 with 0.025 CaC12 was
added to the outer well. Immediately before the rotor was placed in the instrument, 25
µL of Spectrozyme TH or FXa made at 2.5 mM in deionized water was added to the
outer well. The rotor was incubated for 30 seconds at 37 °C before optical density
readings (405 nm) were made. The rotor was spun at 600 r.p.m. Optical density was
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read once every 60 seconds for a period of twelve minutes. Data printouts contained
optical density readings at each time point as well as the overall optical density change.
The data was plotted as kinetic curves (.1 0.D. vs. time) and as % inhibition relative to
saline control vs. concentration in µM.

6. Endothelial Cell Culture System
Rabbit aortic endothelial cells were grown to confluence in F 12 culture medium
supplemented with fetal calf serum. Confluence was achieved after approximately 2
weeks. Immediately prior to the experiment, serum factors were washed out of the
cultures with fresh F12 medium. The experimental media consisted of 900 µL of F12
medium

+

35

S (made by adding 125 µL

35

S to 20 mLs of F12 medium) and 100 µL of

the stock polyanion solution. Stock solutions of 0.001 to 1.0 mg/mL for the various
polyanions were utilized. Controls were treated with 100 µ.L of F12 medium in place of
the polyanion solution. The experimental media remained with the cells for a period of
20 hours at which time the media was removed and the cells were washed. Both the cells
and the culture media were frozen for future analysis.
To analyze the newly synthesized glycosaminoglycans in the media and the cells,
cells were removed from the freezer and 250 µ..L of a Superase solution was added to
degrade the cellular proteins. The cells were stirred and scraped into a tube containing
250 µL of Tris HCl buffer and 10 µ.L of a non-labelled chondroitin sulfate

+

heparan

sulfate + dermatan sulfate standard. In separate tubes, 100 µ.L of the media + 10 µL
Superase

+

10 µL of the standard solution were added. These solutions were incubated
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overnight. Heparan sulfate, chondroitin sulfate and dermatan sulfate were separated by
agarose gel electrophoresis in PDA buffer and visualized by toluidine blue staining. Each
gel was run for 30 minutes. Newly synthesized heparan and chondroitin sulfate in each
sample was quantitated using scintillation counting of the respective bands.

7. In Vitro Supplementation to Freshly Drawn Human Blood
Each heparin analogue was supplemented to freshly drawn human blood at a
final concentration of 0.25 µM. Stock solutions of each agent were prepared at 2.5 µM
in physiologic saline. 500 µLs of each stock solution was placed in individual
polypropylene syringes. Blood was drawn from normal human volunteers via the
antecubital vein using a double syringe technique. After discarding the initial 2 mLs of
blood, blood was drawn to the 5 mL mark in the syringes containing the test agent.
These syringes were gently inverted to mix the blood and test agent. Celite and saline
activated clotting times were performed to determine the anticoagulant activity of each
agent. TEG analysis was also performed to assess the ability of each agent to effect clot
formation.

8. Effect of Heparin Analogues on Platelet Function
a. Agonist Induced Platelet Aggregation
The effects of the synthetic heparin analogues on platelet function were assessed
by platelet aggregometry. In the first set of experiments, blood was drawn from 10
volunteers (5 males and 5 females) using a double syringe technique to avoid
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contamination by tissue factors released upon venipuncture. Standard venipuncture was
performed using a 21 gauge Butterfly® (3/4 x 12" tubing) infusion set (Abbott Hosp.
Inc., North Chicago, IL). 9 mL of blood was drawn into a 10 mL polyethylene syringe.
The blood was immediately transferred to plastic test tubes containing 1 mL of 3.8%
sodium citrate. The blood was mixed by gentle inversion. Platelet rich plasma (PRP) was
prepared by spinning the citrated blood at 800 r.p.m. for 15 minutes at room
temperature. PRP was carefully removed and kept in capped plastic tubes. The remaining
blood was spun further at 1200 x g for 15 minutes to obtain platelet poor plasma (PPP).
PPP was used to blank the aggregometer (BioData Corporation, Hatboro PA).
Aggregations were performed in the following manner. 450 µL of platelet rich plasma
was pipeted into the aggregometer tubes and allowed to incubate at 37 °C for 2 to 4
minutes to assure that the platelets do not self aggregate. 50 µ.L of agonist was pipetted
into each tube. The agonists which were tested included ADP (1.15 and 0.58 µg/mL),
collagen (0.8 µg/mL), epinephrine (10 µg/mL), arachidonic acid (300 µg/mL), and
human thrombin (1 U/mL). All agonist concentrations are final assay concentrations.
Platelet rich plasma was supplemented with each analogue at a concentration 10 µM. The
aggregation profile was analyzed according to two parameters: maximum percent
aggregation and slope. Saline supplementation was used as a control.

b. Heparin Induced Thrombocytopenia Screening
The synthetic analogues were also analyzed for their ability to promote heparininduced thrombocytopenia (HIT) according to the method of Brace (Brace et al., 1990).
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290 µL of PRP and 160 µL of heat inactivated HIT serum were warmed in a cuvette for
1 to 2 minutes at 37 °C. 5, 10, or 20 µL of a 1 mgfmL solution of the analogue being
tested was then added. The aggregation response was monitored for 30 minutes. The
inactivated HIT serum was made by allowing the blood of known heparin-induced
thrombocytopenic individuals to clot. The clotted blood was then centrifuged and the
serum drawn off and aliquoted for use in this screening.

D. In vivo

Phannacolo~ic

studies:

The in vivo pharmacologic studies were carried out in established models of
rabbit stasis thrombosis and rabbit ear bleeding, and a rat jugular vein clamping model
of thrombosis. Both intravenous and subcutaneous dosing protocols were utilized. To
measure the pharmacodynamics of parenterally administered heparin and its analogues,
whole blood investigations employing ACT and TEG were performed. In addition, ex
vivo analysis of blood samples included global anticoagulant profiling and the
measurement of functional TFPI.

1. Rabbit Stasis Thrombosis Model
The modified stasis thrombosis model of Fareed (Fareed et al., 1985) was used
to study the in vivo antithrombotic effects of the synthetic heparin analogues. Male white
New Zealand rabbits (2.5 to 3.5 kg) were administered Ketaset® (ketamine
hydrochloride) at a dose of 50 mg/kg and Rompun® (xylazine) at a dose of 25 mg/kg
intramuscularly to induce anesthesia. When the rabbits appeared too lightly anesthetized
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during the procedure, an additional injection of Ketaset® (25 mg/kg) was given. A
scalpel, forceps, and cautery were used to isolate the jugular veins from the facia while
causing minimal trauma to the vessels. A 2 cm segment of each jugular vein, including
the bifurcation, was isolated. The right carotid artery was cannulated for the purpose of
obtaining blood samples. When long circulation times were employed, baseline samples
were drawn via the medial ear artery. Heparin analogues were administered either
subcutaneously in the abdominal region or intravenously via the marginal ear vein. 7.5
U/kg FEIBA® was administered via the marginal ear vein as a thrombogenic challenge.
The FEIBA® was allowed to circulate for exactly 20 seconds before the jugular vein
segments were ligated to induce stasis. After 10 minutes of stasis time, the left vein
segment was excised, opened, and the clot graded according to the following scale. +0
is scored when the blood in the segment is completely unclotted.

+ 1 is scored when a

small number of microscopic clots are present in largely unclotted blood. +2 is scored
when a larger number of small clots are present.

+ 3 is

scored when a single large clot

is present with few unclotted blood cells. +4 is scored when a solid clot with no
unclotted blood is present. The right jugular segment was removed after 20 minutes of
stasis time and the clots were graded using the above scale. One blue top tube (4.5 mLs
blood in 0.5 mLs of 3.8 % sodium citrate) and one red top tube (3 mLs whole blood)
were drawn at baseline, post-drug, and 6 minutes post-FEIBA®. The blue top tube was
spun at 1200 x g for 20 minutes to obtain platelet poor plasma. This plasma was
aliquoted and frozen at -70 °C for future analysis using the PT, APTT, TT, Heptest®,
anti-Ila, anti-Xa, and functional TFPI assays. The blood saved in a red top tube was
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analyzed immediately for activated clotting time and by thrombelastography. 5 rabbits
per drug per dose were used. Controls were run using saline. Following each
experiment, the rabbit was euthanized with an intravenous injection of 0.1 mL/kg
Beuthanasia®-D.

2. Rabbit Ear Bleeding Model
The rabbit ear bleeding model (Cade et al., 1984) was used to evaluate the
hemorrhagic potential of each agent. A white New Zealand male rabbit was anesthetized
with 25 mg/kg Rompun® (xylazine) and 50 mg/kg Ketaset® (ketamine hydrochloride)
intramuscularly. The rabbit's ear was immersed in a physiological saline bath kept at 37
°C. Using transillumination, an area was selected which was free of major blood vessels.
A #20 Bard-Parker scalpel blade (Becton Dickinson AcuteCare, Franklin Lakes, NJ) was
used to make 5 uniform, full thickness incisions through the ear. The ear was
immediately re-immersed in the saline bath for 10 minutes. After 10 minutes, the saline
bath was collected and bottled. The red blood cells in each sample were counted using
a Hycel red cell counter. The rabbit ear was bandaged as necessary and the rabbit was
allowed to recover in its cage for minimally one week prior to use in the rabbit stasis
thrombosis model.

3. Rat Jugular Vein Clamping Model of Thrombosis
Male Sprague-Dawley rats were anesthetized using an i.p. injection of 1 mL/100

g body weight of a 15 % solution of urethane (Raake et al., 1989). The skin on the neck
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was shaved and an incision was made centrally above the trachea. The right jugular vein
was isolated and covered with ultrasound transmission gel. A bi-directional Doppler
probe was used to measure blood flow through the vessel. The jugular vein was clamped
using a mosquito forceps for 1 minute and then released in order to measure flow.
Clamping of the blood vessel caused endothelial damage and initiated clot formation.
Blood flow was measured for five minutes between clampings. This process was repeated
until no flow was measured at five minutes post-clamping. The effectiveness of the
antithrombotic agent was determined by the number of clampings required to cause
vascular occlusion.

4. Ex Vivo Analysis of Anticoagulant Activity
a. Activated Clotting Time (ACT)
2 mLs of blood freshly drawn via carotid catheter was added to blood
coagulation tubes containing 12 mg celite to activate clotting. The tube was agitated
vigorously for a few seconds and immediately inserted into a Hemochron® test well. The
time taken for the blood to clot was displayed digitally on the face of the instrument.

b. Thrombelastography (TEG)
The TEG automatically recorded viscoelastic changes in a sample of whole blood
as the sample clotted. The resultant profile was a measure of the kinetics of clot
formation. This analysis was sensitive to all of the interacting cellular and plasmatic
components in a given sample of blood that may affect the rate or structure of the
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clotting sample. The procedure was as follows. A clean cup and pin were placed in the
instrument and were maintained at 37 °C. Three minutes after being drawn, 360 µL of
the blood was placed in the test cup and the pin was lowered into the cup. A thin layer
of mineral oil was carefully placed on the blood surface to prevent drying. As a clot
forms, the deflection of the pin as it moves in the cup was recorded. Four parameters
were measured from the profile: R-time, RK-time, maximum amplitude, and divergence
angle. R-time was measured as the distance in millimeters from the start of the tracing
until there was a 2 mm divergence. This was the point of reproducible clot formation.
RK-time was the distance in millimeters from the beginning of the tracing until a 20 mm
divergence was reached. This was the time to a standard clot firmness. The maximum
amplitude corresponded to the maximum shear modulus of the clot. Divergence angle
was measured by drawing a tangent line from the point of initial divergence along the
maximum curvature of the tracing. The size of the angle was directly related to the
kinetics of clot formation.

5. Ex Vivo Analysis of Functional TFPI in Rabbits
Levels of TFPI activity in rabbit plasma samples were measured usmg an
amidolytic assay based on that of Sandset (Sandset et al., 1987). In this assay, 300 to 400
µL of test plasma was heated in a plastic test tube at 56 °C in a water bath for 15
minutes to inactivate endogenous coagulation enzymes and to precipitate fibrinogen.
Following heating, the samples were cooled for 1 minute on ice and then centrifuged for
10 minutes at 1200 x g. The supernatant plasma was diluted 1 to 20 in TFPI buffer (0.1
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M NaCl, 0.05 M Tris HCl, 0.01 M trisodium dicitrate; pH = 8.0). These dilutions were
then kept on ice until assayed. The following reagents were placed into each reaction
tube: 50 µL of 0.025 U/mL human factor VII, 50 µ.L of Thromboplastin C+ diluted 1
to 20 in TFPI buffer, 50 µL of 0.025 U/mL human factor X, and 50 µL of 0.075 M
CaC12 • Each tube was vortexed and incubated at 37 °C. After 5 minutes, 50 µL of the
plasma dilution was added to each tube. After vortexing, the tubes were incubated for
40 minutes at 37 °C. 50 µL of 0.4 U/mL factor X was added to each tube. Following
vortexing, the tubes were incubated for 20 minutes at 37 °C. 50 µL of 3.25 mM
Spectrozyme Xa was added to each tube. Following a 15 minute incubation period, 200

µL of 50 % acetic acid to each tube was added to stop the amidolytic reaction. 200 µL
of each sample was pipetted onto a microtiter plate and the optical density was read at
410 nm. Percent inhibition was measured relative to the appropriate baseline sample.

F. Other In Vivo Animal Models
Primate studies, using Macaca fascicularis and Macaca mulatta, provided the
opportunity to measure TFPI antigen levels utilizing a modified ELISA technique.

I. Effect of GL-522-Y-1 on TFPI Levels in Non-human Primates
Three male Cynomolgus monkeys (Macaca fascicularis), weighing 2.5 to 5.0
kg, received 10 mg/kg GL-522-Y-l intravenously via the cephalic vein. Blood was drawn
via a 12 inch catheter placed in the saphenous vein under ketamine ( 10 mg/kg) anesthesia
using a double syringe technique. Following the draw, blood was placed into a tube
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containing 3.8 % sodium citrate. The final ratio of blood to citrate was 9: 1. Within 30
minutes of collection, the blood sample was centrifuged to make platelet poor plasma.
The sample was aliquoted and frozen at - 70 °C. Samples were collected at baseline, 5,
15, 30, 60, 120, 240, and 360 minutes post-administration. TFPI levels were measured
using functional and immunologic assays.

2. Effect of Pentasaccharide on TFPI Levels in Non-human Primates
Three monkeys (Macaca mulatta), anesthetized with 10 mg/kg ketamine and
ranging in weight from 7 to 13 kg, received penta.saccharide at doses of either 100, 250,
or 500 µglkg intravenously via the saphenous vein. Blood was drawn using a double
syringe technique via a butterfly needle placed in the saphenous vein. Following the
draw, the blood was placed into a tube containing 3.8 % sodium citrate. The final ratio
of blood to citrate was 9: 1. The blood was kept on ice until centrifugation to make
platelet poor plasma. The plasma samples were aliquoted and frozen at - 70 °C. Samples
were collected at baseline and at 5 and 60 minutes post-administration. TFPI levels were
measured using an immunologic assay.

G. Human Trials with Aprosulate
In conjunction with two phase I studies carried out in collaboration with
Luitpold-Pharma, TFPI levels were measured after aprosulate administration. To relate
the TFPI levels with the anticoagulant effects, Heptest® and APTI were also measured.
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t. Dose Finding Study with Bis-Lactobionic Acid Amide - Phase I (DELPHn
Plasma samples used in this study were obtained in the DELPHI phase-I clinical
trial of aprosulate conducted by Inveresk Clinical Research, Ltd. (Edinburgh, Scotland)
under the sponsorship of Luitpold Pharma GmbH (Munich, Germany). This study was
performed for the purpose of assessing the local and systemic tolerance of different doses
of aprosulate after subcutaneous application and to measure the kinetics of this agent as
well as any changes in coagulation parameters (Papoulias et al., 1993).
The DELPHI study was an open, non-randomized tolerance study in which
twelve normal, healthy male volunteers received increasing dosages of aprosulate over
a period of 16 days. On day 0 of the study, screenings were performed to confirm the
eligibility of the volunteers. On Day 1 of the study, each volunteer received an injection
of placebo in order to assess the normal circadian variations in each person's baseline
measurements. Aprosulate dosing began on day 2 with a dose of 0.25 mg/kg. Blood
samples for the determination of coagulation and clinical chemistry parameters were
drawn 1, 2, 4, and 10 hours post-administration. On the ensuing washout day, blood
samples were obtained at 4 and 10 hours. Increasing doses of aprosulate (0.5, 0.75, 1.0,
1.5, and 2.0 mg/kg) were subsequently administered on alternate days, separated by
intervening washout days.
Blood samples were collected in citrated tubes (1 part 3.8 % citrate to 9 parts
whole blood) and centrifuged within 20 minutes at 2000 x g for 20 minutes at 4 to 8 °C.
Plasma was separated, aliquoted, and frozen at -70 °C for future analysis. Aliquots were
shipped to Loyola University Medical Center (Maywood, IL) on dry ice and were stored

99
at -70 °C. Samples were later thawed and batch analyzed for TFPI antigen levels.

2. Phase I-Study for the Assessment of the Laboratory Values
after Repeated Daily Application of Aprosulate (PALLAS)
Plasma samples used in this study were obtained in the PALLAS phase-I clinical
trial of aprosulate conducted by Inveresk Clinical Research, Ltd. (Edinburgh, Scotland)
under the sponsorship of Luitpold Pharma GmbH (Munich, Germany). This study was
performed for the purpose of assessing the effects of repeated administration of
aprosulate on hematologic parameters.
Four dosing regimens were utilized in this study, with 6 healthy, human, male
volunteers randomized into each group. The treatments included : 35 mg aprosulate
b.i.d., 70 mg aprosulate b.i.d., 70 mg aprosulate o.d. +placebo (saline) o.d., and 40
mg Enoxaparin® o.d.
25.50

+ placebo.

The average age for the treatment groups ranged from

± 3.72 to 27.83 + 3.24 years (mean + S.E.M.). The difference in the ages of

the groups was not statistically significant. The injectable drugs were administered
subcutaneously every 12 hours for a duration of 7 days. Volunteers could be removed
from the study prior to 7 treatment days according to preset safety criteria. Blood
samples were drawn at baseline, 15, 30, 45, 60 minutes, 2, 4, 8, and 12 hours on days
1 and 7 of the study. Samples were drawn at 2 and 12 hours on days 2 and 3 and at 12
hours on days 4 through 6 of the study. The majority of the blood samples were drawn
on the first and seventh days of the trial in order to determine the effects of repeated

aprosulate administration on various hematologic parameters.
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Blood samples were collected in citrated tubes (1 part 3. 8 % citrate to 9 parts
whole blood) and centrifuged within 20 minutes at 2000 x g for 20 minutes at 4 to 8 °C.
Plasma was separated, aliquoted, and frozen at -70 °C for future analysis. Aliquots were
shipped to Loyola University Medical Center (Maywood, IL) on dry ice and were stored
at -70 °C. Samples were later thawed and batch analyzed for TFPI antigen levels.

a. ELISA TFPI Assay
TFPI antigen levels were determined using Imubind® TFPI ELISA kits
(American Diagnostica, Greenwich, CT). This was a sandwich, enzyme-linked
immunoassay which utilized a murine anti-TFPI monoclonal as the capture antibody and
a biotinylated antibody I streptavidin conjugated horseradish peroxidase complex for
detection of the captured TFPI. The detection limit of the kit was stated as 200 pg
TFPl/mL. Six TFPI standards ranging in concentration from 0 to 10 ng/mL diluted in
deionized water were used to construct a calibration curve. A full-length recombinant
TFPI which was expressed in E. coli was used as the calibration standard. This rTFPI
contained a full carboxy tail, but was lacking the native glycosylation. The molecular
weight of the rTFPI was approximately 32 kDa. rTFPI was provided by Dr. T.C. Wun
(Monsanto Inc, St. Louis, MO). Optical density readings and standard curve calculations
were made using a Dynatech MR7000 system (Dynatech Laboratories, Inc, Chantilly,
VA).
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H. Data Processine and Statistical Analysis
The experimental data obtained in this dissertation is presented as the mean
standard deviation for the biochemical results and mean

± SEM for

±

the pharmacologic

results in order to indicate the precision of the data and to facilitate the comparison
between each agent. The results obtained from the biochemical experiments were
analyzed using a repeated measures two way analysis of variance. Data which did not
meet the criteria for parametric statistics (normality of distibution and equality of
variance) were analyzed using the Friedman two way analysis of variance by ranks. This
analysis was used to determine statistically significant differences between the effects of
the different heparin analogues. If a significant difference was noted using the two way
analysis of variance in a given assay system, the concentration response data for each
individual agent was analyzed by one way analysis of variance followed by a post hoc
Newman Keuls analysis to determine the statistical significance of the effect of each
concentration relative to a vehicle control.

Designations of potency in a given assay

system such as IC50 , ED 50 , etc. were compared using a one way analysis of variance with
a post hoc Newman Keuls analysis. In all cases a p value < 0.05 was considered
statistically significant. Degrees of freedom, F-ratios, and computed p values are
presented for each analysis.
For the analysis of the data obtained from the stasis-thrombosis model, the
Kruskal-Wallis H test with a post hoc Mann-Whitney U test was utilized. Standard
parametric analysis of variance techniques were not applicable with this data because the
clot scores assigned in this model are subjectively designated; there were not necessarily
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equal differences between the numerical scores used to grade the clots.

CHAPTER IV
RESULTS
A. Physicochemical Characterization of Various A&ents
Used in this Research
The three synthetic analogues used in this investigation present diverse chemical
and molecular characteristics. Unlike heparin, these agents are homogeneous and
obtained by synthetic methods. Molecular mass distribution studies were carried out using
HLPC. NMR analysis utilizing both 1H and

13

C detection modes was performed on all

agents. Since pentasaccharide and heparin represent multicomponenet agents, mass
spectral analysis was only performed on GL-522-Y-1 and aprosulate.

1. High Performance Liquid Chromatography (HPLC) Profile
The molecular weights of aprosulate, G L-522-Y-1, heparin, and pentasaccharide
were determined by gel permeation chromatography using three different calibrations of
the columns. Elution profiles of each agent are depicted in Appendix 2. The first
calibration consisted of 19 heparin fractions with previously characterized molecular
weights. The agent was detected in the mobile phase by either an ultraviolet or a
refractive index detector. The results obtained with the UV detector are depicted in Table
10. The molecular weights of the synthetic analogues determined by HPLC were all
lower than the known formula weights. The molecular weight of aprosulate was closest
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to its true formula weight, lower by only 1.3 %. The molecular weights of GL-522-Y-1
and pentasaccharide were somewhat farther from their true weights. The molecular
weight of heparin was calculated to be 10. 5 kDa in this analysis. Dispersity, a measure
of the homogeneity of the sample, was highest for heparin.
The higher dispersity of heparin was more dramatically seen in the data
obtained with the nineteen calibrators using the refractive index detector. This is depicted
in Table 11. The dispersities of the synthetic analogues were less than 1.1 whereas that
of heparin was greater than 1.3. The molecular weights obtained with the RI detector
were all lower than those obtained with the UV detector, and thus further from the
known formula weights.
Two other calibrators developed for the detennination of the molecular weight
of low molecular weight heparins were also used to analyze the molecular weight profiles
of these agents. The results of these analyses are depicted in Tables 12 and 13. GL-522y -1 was not analyzed with these calibrants due to the unusual elution profile it exhibited.
The molecular weights of aprosulate and pentasaccharide were much different from their
formula weights ( > 25 %) . The molecular weight determined for heparin with these two
calibrants varied widely from 9.9 kDa with the HMC calibrant to 12.8 kDa with the
F913B calibrant. Dispersity values were consistent with those obtained with the 19
heparin fraction calibrators. The dispersity of heparin was high in both cases, consistent
with the polycomponent nature of heparin. The dispersity values for aprosulate and
pentasaccharide were less than 1.1.

105

2. Nuclear Magnetic Resonance (NMR) Spectra
Figure 5 depicts the 13 C spectra of unfractionated heparin. This spectra contains
signals typical of a heparin-like agent. Between 55 and 60 ppm are signals indicative of
the presence of C-N bonds of glucosamine residues. Between 60 and 69 ppm are signals
indicative of the presence of primary alcohol groupings of the aminosugar rings. From
70 to 80 ppm are signals from secondary alcohols on both the uronic and amino sugar
rings. Anomeric carbon signals appear between 95 and 105 ppm. Methyl groups appear
at 24 ppm and carboxyl signals are at 177 ppm. No extraneous signals from potential
glycosaminoglycan contaminants such as dermatan sulfate or heparan sulfate are noted.
By comparing the signal intensities for the glucuronic N-sulfate at carbon 2 and the
glucuronic 0-sulfate at carbon 3, it is possible to estimate the relative amount of high
affinity ATIII binding sites present in a given sample of heparin. For this preparation,
it is estimated that 7 % of the heparin chains contain the 3-0 sulfate group required for
high affinity ATIII binding. The

13

C signal assignments for unfractionated heparin are

presented in Table 14.
By integrating the area under the peaks at 62 and 69 ppm under controlled
conditions, it is possible to determine the ratio of 6-0-S03 to 6-0H. In this heparin, the
glucosamine residues are 76 % 6-0 sulfated. The ratio of glucosamine N-sulfate to
glucosamine N-acetate is determined by comparing the integrals at 60 and 56 ppm,
respectively. This heparin is 88 % N-sulfated by this analysis. The % total iduronic acid
(sulfated and unsulfated) relative to total uronic acid is 71 %.
Figure 6 depicts the 1H NMR spectrum of heparin. This spectrum contains

A-C-2-NSO
IdA-C-l-2SO

A-C-1-NSO

3

3

*
**
***

***

**
-c-2-NAc
.._..__,,J.
f

---.

,~- .. _.... ~ ..,

"1-l"T

r .. ,.,,~-1 "Tl-• •-.--..

:·

JCH 3

·~~,_,.,.,,_~~

J._.,.,,.._,,_,,.AI

: ; - • .,. ....

A-C-3-0S0
3
A-C-6-0H
A-C-6-oso 3

, ,., ,..-,
10

t-•

1

'··,·~·-,

-•

J ..,-..- •--,.·.· ' • ., 1 • ' •

""

's'• ,-, --.

-o • ,_,_..,. . \ ·-•-. -...,..___._, •..,.

~.,.___....

1 •-o-----.--r•·..--• ,.,.. - - . 11

'
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peaks typically associated with heparin. The assignments of some of the major peaks are
found in Table 15. The strong peaks at 4.5 ppm is that of the solvent, HOD. Of note are
two peaks labelled with an asterisk which derive from the protons attached to C-1 and
C-2 of the 3-0 sulfated glucosamine. The intensity of these peaks is markedly less than
of the same peaks in the pentasaccharide spectrum.
Figure 7 depicts the 1H NMR spectrum of the synthetic ATIII binding
pentasaccharide. It is important to note the signals for the 3-0 sulfated aminosugar
residue required for high affininy ATIII binding which are labelled by asterisks in the
figure. These chemical shifts are listed in Table 16.
Figure 8 depicts the 13 C NMR spectrum of the ATIIl binding pentasaccharide.
Most notable are the peaks labelled by asterisks which belong to the carbons of the 3-0
sulfated glucosamine residue. These chemical shifts are listed in Table 17.
In the aprosulate molecule, there are eleven distinct protons on the sugar
moieties, five are located on the open chain sugar and six are located on the closed ring
sugar. Assignment of the proton spectra is made by homonuclear correlation. With this
technique, magnetization transfer is limited to pairs of protons which are located on
adjacent carbon atoms.
The 13C spectra of aprosulate is depicted in Figure 10. Peaks belonging to each
of the carbon atoms in the open and closed ring sugar moieties are present. No
extraneous signals are observed, indicating that the material is pure. A table relating
chemical shift to 13 C nucleus assignment is presented in Table 18.
In Figure 11, the 1H spectra are placed on both the x and y axes. The series of
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are observed.
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peaks on the diagonal correspond to those of the original 1H spectra. Groups of peaks off
the diagonal illustrate linkage between those peaks on the diagonal. By analyzing the
linkage pattern, it is possible to make the proton assignments as labelled in Figure 9. A
table relating chemical shift to proton assignments is presented in Table 19.
The 13C spectra of GL-522-Y-1 is relatively simple due to the symmetry in the
molecular structure. There are only five distinct carbon signals observed for this agent.
The 13 C spectra is pictured in Figure 12. The 13C NMR signal assignments are tabulated
in Table 20. The signal for the methylene bridge carbon atom is located at 33 ppm. The
benzyl ring carbons are shifted further downfield. The C-H benzyl carbon exhibits a
signal at 128.8 ppm. The C-CH2 benzyl carbon exhibits a peak at 130.8 ppm. The C-OH
benzyl carbon exhibits a peak at 138 ppm. The

C-HSO~

benzyl carbon is shifted furthest

downfield, with a signal at 155.5 ppm.
The 1H spectra for GL-522-Y-1 is given in Figure 13. Two distinct signals for
protons are observed. These are tabulated in Table 21. The protons of the methylene
bridging group are located at approximately 4.2 ppm. The benzyl protons are shifted
farther downfield at approximately 7.7 ppm. The peak at 4.7 ppm belongs to residual
protons present in the deuterium oxide solvent.

3. Mass Spectral Analysis
In mass spectral analysis, samples are bombarded with a stream of electrons.

This bombardment results in a fragmentation of the sample. The molecular fragments are
detected based on their mass to charge ratio. As most species are singly charged, the
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fragment mass can be determined. The mass spectrum of GL-522-Y-1 is presented in
Figure 14. From this spectrum it is observed that the molecular ion peak is at 1489.1 Da
and corresponds to the intact GL-522-Y-1 (C8) molecule. The masses of some of the
more prominent peaks are labelled in the figure. The next most prominent peak is that
of the C4 species. Peaks are also observed at 926 and 1118 Da corresponding to the 5
and 6 benzyl ring species. A small degree of desulfonation is also evident. The peak at
1410 corresponds to the loss of one -S03 group from the intact GL-522-Y-1 molecule.
Figure 15 depicts the mass spectrum of aprosulate. Aprosulate is a symmetrical
molecule consisting of two fully sulfated disaccharides linked by a three member carbon
chain. Upon bombardment, aprosulate is cleaved between the amide nitrogen and the
alkyl linker region. The peak at 1172.8 Dais that of one half the aprosulate molecule,
the fully sulfated disaccharide. The peak at 1132 corresponds to the loss of the amide
group from this disaccharide. The regularly spaced peaks at 545, 687, 829, and 971 Da
represent progressive desulfation of the disaccharide components of aprosulate.

B. In Vitro Study Results
Heparin is both a functionally and chemically heterogeneous drug. It exhibits
multiple interactions with plasmatic proteins, platelets, and other cells. The endogenous
interactions of heparin are largely mediated by antitbrombin ill and heparin cofactor II,
resulting in direct antiprotease activity and protease generation inhibition. Heparin also
directly or indirectly influences the function of endothelial cells and platelets. In this
section, defined experimental systems have been used to determine the effects of various
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heparin analogues and to demonstrate the relative contribution of HCII and ATIII in
mediating various plasmatic and cellular effects in in vitro settings.

1. ATIII Mediated Antiprotease Actions
Serpin mediated inhibition of thrombin and factor Xa was determined using
amidolytic assay systems. These plasma-free systems contained purified enzyme
(thrombin or factor Xa), purified serpin (ATilI or HCII), amidolytic substrate, and
varying concentrations of heparin or synthetic heparin analogue. IC50 values were
determined by linear regression of the straight line portion of the concentration response
curves. Concentrations producing 50 % maximal inhibition were extrapolated from the
best fit lines. Individual data from these assays are presented in Tables 20 to 23.
The antithrombin ill mediated inhibition of thrombin was only potentiated by
unfractionated heparin as seen in Figure 16 (Friedman two way ANOVA; chi-square =
73.89, dF = 31, p < 0.0001). Heparin potently inhibited the amidolytic activity of
thrombin in this assay with an IC50 value calculated as 0.87

+

0.12 nM. Pentasaccharide

produced a small ( < 15 %) but statistically significant inhibition of thrombin via
antithrombin ill at concentrations above 0.18 µM. Neither aprosulate nor GL-522-Y-1
exhibited a significant inhibition of thrombin via antithrombin m.
Concentration response curves for the antithrom bin ill mediated inhibition of
factor Xa are depicted in Figure 17. Both heparin and pentasaccharide were observed to
potently inhibit the amidolytic activity of factor Xa (Friedman two way ANOVA; chisquare

=

85.50, dF

=

31, p < 0.0001). Heparin was three fold more potent than

121

100

80

o Ap rosulcte
• GL-522-Y-1

c

0

Heoari n
Pentasccchcride

-::
•

60

..0

.s::

c

40
20
T

T

*

...

;..--!..,.
...,,,-.....,.
TI

..

T
..,.
,:,....--I ,..,.
~,_-'!-1 ,~ -,;.-~vt:=:::e.=,..,..=::::e:~---;:;

0 '----~---------~---~-------"-'"""-----'-'--"""--=-_..;.~-.
O.OOOi
0.001
0.01
0.1
1
10

Con centra ti on (µ1V1)

Figure 16. Effect of aprosulate, GL-522-Y-1, heparin, and pentasaccharide on the
ATIII mediated inhibition of thrombin. The ATJJJ mediated inhibition of thrombin was
determined using a plasma-free amidolytic assay system. All results represent the
mean ± one standard devation of three observations. Heparin was the only agent
observed to inhibit thrombin via ATIII. Statistical differences between agents was
determined using the Friedman two ANOVA (Friedman chi-squared= 75.89, dF =
31, p < 0. 0001). Statistical differences relative to control were determined by one
way ANOVA followed by the Newman Keuls multiple comparison test for each agent.
• p < 0.05 was considered to be statistically significant. IC50 values were calculated
where possible to compare the potencies of the various agents. Data are compiled in
Tables 20 through 23.
Heparin : IC50 = 0. 87

± 0.12 nM

Aprosulate : p = 0.636; ANOVA
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Figure 17. Effect of aprosulate, GL-522- Y-1. heparin and pentasaccharide on the
ATIII mediated inhibition of factor Xa. The ATIII mediated inhibition of factor Xa
was determined using a plasma-free amidolytic assay system. All results represent the
mean ± one standard deviation of three observations. Heparin more potently inhibited
factor Xa than did pentasaccharide. Neither aprosulate not GL-522-Y-1 were observed
to significantly inhibit Xa. Statistical differences between the agents were determined
using the Friedman two ANOVA (Friedman chi-square = 85.50, dF = 31, p <
0.0001). Statistical differences relative to control were determined by one way
ANOV A followed by the Newman Keuls multiple comparison test for each agent. •
p < 0.05 was considered to be statistically significant. IC50 values were calculated
where possible to compare the potencies of the various agents. Data are compiled in
Tables 20 through 23.
Heparin : IC 50

= 0.007 ±

0.003 ,uM; p

Pentasaccharide : IC50 = 0.024

= 0. 004 v~.

± 0. 004 JLM

GL-522-Y-1 : p = 0.316; ANOVA
Aprosulate: p = 0.640; ANOVA

pentasaccharide
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pentasaccharide with a calculated IC 50 value of 0.007

+

0.003 µM vs. 0.024

± 0.004

µM for pentasaccharide (t-test, p = 0.004). The inhibition by each agent plateaued at 97
to 98 % relative to control. GL-522-Y-1 promoted a weaker concentration dependent
inhibition of factor Xa. At an assay concentration of 27 µM, a 25 percent inhibition of
factor Xa activity was noted. The inhibition of factor Xa by GL-522-Y-1 was not
statistically significant (ANOVA; p = 0.316). Aprosulate did not promote the
antithrombin III mediated inhibition of factor Xa (ANOVA; p = 0.640).

2. HCII Mediated Antiprotease Actions
Concentration response curves for the heparin cofactor II mediated inhibition
of thrombin are depicted in Figure 18. Heparin, aprosulate, and GL-522-Y-1 exhibited
a concentration dependent inhibition of thrombin activity (Friedman two way ANOVA;
chi-square = 91.97, dF = 31, p < 0.0001). Heparin exhibited the highest potency (IC 50
= 0.051

± 0.003 µM) of the three agents and was approximately 20 fold more potent

than either aprosulate or GL-522-Y-1 (ANOVA, Newman Keuls; p
and GL-522-Y-1 exhibited similar potencies (IC50 = 1.23
respectively; p

+

< 0.05). Aprosulate

0.22 vs. 0.84

± 0.09 µM,

< 0.05) Maximal inhibition of thrombin activity plateaued at

approximately 80 percent for each agent. No significant differences in the maximal effect
of any agent were noted (ANOVA; p

= 0.239). Only the highest concentration of

pentasaccharide tested exhibited a significant inhibition of thrombin via heparin cofactor
II. It should be noted that the concentrations of heparin required to promote thrombin
inhibition by heparin cofactor II were nearly two orders of magnitude higher than those
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Figure 18. Effect of aprosulate, GL-522-Y-l, heparin, and pentasaccharide on the
HCII mediated inhibition of thrombin. The HCII mediated inhibition of thrombin was
determined using a plasma-free amidolytic assay system. All results represent the
mean ± one standard deviation of three observations. The rank order potency for
thrombin inhibition was observed to be heparin > GL-522-Y-1 > aprosulate >
pentasaccharide. Statistical differences between agents were determined using the
Friedman two way ANOVA (Friedman chi-square = 91.97, dF = 31, p < 0.0001).
Statistical differences relative to control were determined by one way ANOVA
followed by the Newman Keuls multiple comparison test for each agent. * p < 0.05
was considered to be statistically significant. lC 5() values were calculated where
possible to compare the potencies of the various agents. Data are compiled in Tables
20 through 23.
Heparin: IC 50 = 0.051 ± 0.003 µ.M; p < 0.05 vs. aprosulate and GL-522-Y1
GL-522-Y-1: IC50 = 0.84
Aprosulate : IC50 = 1.23

± 0.09 µ.M;

± 0.22 µ.M

p

< 0.05 vs. aprosulate
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TABLE 1
POTENCY COMPARISON OF APROSULATE, GL-522-Y-1, HEPARIN, AND
PENTASACCHARIDE IN SERPIN ACTIVITY ASSAYS

~o

(µM)

ATIIl/Ila

ATlll/Xa

Aprosulate

> 16.8

> 16.8

1.2

GL-522-Y-1

> 26.9

> 26.9

0.8 ± 0.1

Heparin

0.87 ± 0.12#

Pentasaccharide

> 0.7

HCII/Ila

± 0.2

0.51 ± 0.01

0.24

± 0.004

> 23.2

All values represent the mean ± one standard deviation of three individual trials. IC50
values were determined by extrapolation from the regression line of the straight line
portion of the concentration reponse curve. ' results are expressed in nM.
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required for thrombin inhibition by antithrombin ill.

3. Global Anticoagulant Profile
a. Studies in Supplemented Normal Human Plasma Systems
The global anticoagulant effects of heparin, pentasaccharide, aprosulate, and
GL-522-Y-1 were determined following supplementation to normal human pooled plasma
using the prothrombin time (PT), activated partial thromboplastin time (APIT), Heptest®,
and 5 U thrombin time (5U TI). Each drug was supplemented to pooled plasma in four
separate trials and the clotting times were detennined as described in "Materials and
Methods". Pooled plasma was made by mixing citrated platelet poor plasma from at least
five healthy volunteers. Agent concentrations were expressed as micromolar (µM)
amounts of agent supplemented to plasma. In the PT, AP1T, and Heptest® assays, the
final assay concentration of each agent was one third that of the plasma concentration.
In the 5U TI, the final assay concentration is two thirds that of the plasma concentration.
Micromolar concentrations for the synthetic heparin analogues were determined using
their known formula weights. The weight average molecular weight of heparin as
determined by gel permeation chromatography was used to calculate the micromolar
concentrations of heparin. Individual clotting and antiprotease data is tabulated in Tables
24 to 27. In each assay, statistically significant differences between agents was
determined using the Friedman two way ANOV A. If a significant difference was found,
significant differences for treatment relative to control for each agent were determined
using one way ANOVA followed by the Newman-Keuls multiple comparison test.
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Figure 19 describes the anticoagulant effects of heparin and the synthetic
heparin analogues as measured by the prothrombin time assay (PT). Only heparin was
observed to prolong the clotting time (Friedman chi-square

=

114.70, dF

= 35, p <

0.0001). Potency of each agent was determined by comparing the plasma concentrations
which prolonged clotting time to 100 seconds. Where possible, these concentrations were
extrapolated from the best fit regression curves of the data. Other concentrations were
extrapolated from the concentration vs. clotting time curves. Potencies of aprosulate, GL522-Y-1, heparin, and pentasaccharide are compared in Table 2. Doubling of the baseline
clotting time was observed at a plasma heparin concentration of approximately 2 .5 µM
and a 100 second clotting time was achieved at a plasma concentration of 6.2

± 2.1 µM.

None of the synthetic analogues were able to double the clotting time in the PT despite
plasma concentrations 16 to 27 fold higher than the effective heparin concentration.
The APIT was a more sensitive measure of the anticoagulant effects of heparin
and the synthetic analogues as observed in Figure 20. A statistically significant difference
between agents was observed (Friedman chi-square = 133.46, dF = 35, p

< 0.0001).

As the concentration-response curves were not parallel, the slopes of the straight line
portions of the curves were calculated by least squares regression. The slope of the
heparin curve was approximately 40 fold higher than that calculated from the aprosulate
curve (454 vs 11.5 s/µM). Neither pentasaccharide nor GL-522-Y-1 exhibited a potent
anticoagulant effect in this assay. Using the concentration which brought about a 100
second clotting time as an index of potency, it was observed that heparin was 10 fold
more potent than aprosulate (0.30

±

0.08 vs. 3.1

±

0.4 ,uM, respectively). Both
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Figure 19. Comparative anticoagulant effect of heparin and three synthetic heparin
analogues as measured by the prothrombin time. Aprosulate, GL-522-Y-l, heparin,
and pentasaccharide were supplemented to normal human plasma over a concentration
range of 0 to 100 µg/mL. Plasma concentrations were converted to µM amounts using
the molecular weight of each agent as described previously. All results represent the
mean ± one standard deviation of four observations. Heparin was the only agent
observed to prolong the clotting time in this assay. A statistical difference between
agents was determined using the Friedman two way ANOVA (Friedman chi-square
= 114.90, dF = 35, p < 0.0001). Statistically significant differences between
treatment and control for each agent were determined by one way ANOVA followed
by the Newman-Keuls test. Results were considered to be statistically significant if p
< 0.05. ·indicates statistical significance relative to unsupplemented control plasma.
Data are compiled in Tables 24 through 27.

Figure 20. Comparative anticoagulant effect of heparin and three synthetic heparin
analogues as measured by the activated partial thrornboplastin time. Aprosulate, GL522-Y-l, heparin, and pentasaccharide were supplemented to normal human plasma
over a concentration range of 0 to 100 µ.g/mL. Plasma concentrations were converted
to µM amounts using the molecular weight of each agent as described previously. All
results represent the mean ± one standard deviation of four observations. Clotting
times were dose-dependently prolonged with a rank order potency of heparin >
aprosulate > GL-522-Y-1 > pentasaccharide. A statistical difference between agents
was determined using the Friedman two way ANOV A (Friedman chi-square =
133.46, dF = 35, p < 0.0001). Statistically significant differences between treatment
and control for each agent were determined by one way ANOVA followed by the
Newman-Keuls test. Results were considered to be statistically significant if p <
0.05. • indicates statistical significance relative to unsupplemented control plasma.
Data are compiled in Tables 24 through 27.
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pentasaccharide and GL-522-Y-1 were notably weaker, with Conc100• greater than 50 µM.
This data is presented in Table 2.
In the Heptest® assay, all agents exhibited concentration dependent anticoagulant
effects with the exception of GL-522-Y- l. A statistically significant difference between
the effects of the various agents was observed (Friedman chi-square= 132.94, dF = 35,

p < 0.0001). Concentration response curves are depicted in Figure 21. As with the
APIT, the log concentration vs. clotting time curves were not parallel. Heparin was the
most potent agent on a molar basis (calculated slope = 229 s/ µM). The concentrationresponse curves for heparin and aprosulate appeared to parallel each other though 25 fold
more aprosulate than heparin was required to achieve a 100 second clotting time. The
curve for pentasaccharide did not parallel those of heparin or aprosulate (Conc 100• = 1.1

+

0.9 µM). GL-522-Y-l doubled the Heptest® clotting time only at the highest

concentration tested (67 µM).
The 5 unit thrombin time (5U TT) was the most sensitive assay for heparin with
a slope of 850 s/ µM. The response to aprosulate in this assay was considerably weaker.
Comparison of the Conc 100• values for heparin and aprosulate indicate that 90 fold more
aprosulate was required to achieve a 100 second clotting time. GL-522-Y-1 did not
produce a statistically significant increase :in thrombin clotting time whereas
pentasaccharide significantly increased clotting times only at concentrations above 58
µM. Concentration response curves are depicted in Figure 22. A statistically significant

difference between the effects of the various agents was observed (Frieman chi-square
= 110.14, dF = 35, p < 0.0001).
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Figure 21. Comparative anticoagulant effect of heparin and three synthetic heparin
analogues as measured by the Heptest®. Aprosulate, GL-522-Y-1, heparin, and
pentasaccharide were supplemented to normal human plasma over a concentration
range of 0 to 100 µglmL. Plasma concentrations were converted to µM amounts using
the molecular weight of each agent as described previously. All results represent the
mean ± one standard deviation of four observations. The rank order potency for
Heptest® prolongation was observed to be Heparin > pentasaccharide > aprosulate
> GL-522-Y-1. A statistical difference between agents was determined using the
Friedman two way ANOVA (Friedman chi-square= 132.94, dF = 35, p < 0.0001).
Statistically significant differences between treatment and control for each agent were
determined by one way ANOV A followed by the Newman-Keuls test. Results were
considered to be statistically significant if p < 0. 05. • indicates statistical significance
relative to unsupplemented control plasma. Data are compiled in Tables 24 through
27.
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Figure 22. Comparative anticoagulant effect of heparin and three synthetic heparin
analogues as measured by the 5 unit thrombin time. Aprosulate, GL-522-Y-1, heparin,
and pentasaccharide were supplemented to normal human plasma over a concentration
range of 0 to 100 µg/mL. Plasma concentrations were converted to µM amounts using
the molecular weight of each agent as described previously. All results represent the
mean ± one standard deviation of four observations. Heparin was observed to more
potently prolong the thrombin time than aprosulate. Pentasaccharide and GL-522-Y-1
had no effect on the clotting time in this assay. A statistical difference between agents
was determined using the Friedman two way ANOV A (Friedman chi-square =
110.14, dF = 35, p < 0.0001). Statistically significant differences between treatment
and control for each agent were determined by one way ANOVA followed by the
Newman-Keuls test. Results were considered to be statistically significant if p <
0.05. * indicates statistical significance relative to unsupplemented control plasma.
Data are compiled in Tables 24 through 27.
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TABLE 2
PLASMA CONCENTRATIONS OF SYNTHETIC HEPARIN ANALOGUES
REQUIRED TO PROLONG NORMAL HUMAN PLASMA CLOTTING
TIMES TO 100 SECONDS

PT

APTT

± 0.4**

8.0 ± 0.7

+ 6.4

> 67

Aprosulate

> 42

3.1

GL-522-Y-1

> 67

53.9

Heparin

6.2 ±

0.30

Heptest

± 0.05**

0.32

± 0.03#

2.1*

> 58

Pentasaccharide

> 58

1.1 ± 0.9#

SUTT

7.2

+

0.3

> 67
0.08 ±
0.05##

> 58

The potencies of aprosulate, GL-522-Y-1, heparin, and pentasaccharide were
compared by extrapolating the concentrations of each agent which caused a
prolongation of the clotting time to 100 seconds. Results represent the mean ± 1
standard deviation of 4 determinations. In cases in which agents did not prolong the
clotting time to 100 seconds, the highest concentration tested is presented. Statistical
Comparison of these values was made by one way ANOV A followed by the Student
Newman-Keuls multiple comparison test for each assay. p < 0.05 was considered
statistically significant.
PT:

*

p < 0.05; heparin vs. aprosulate, GL-522-Y-1, and pentasaccharide

APTT : ** p < 0.05; aprosulate and heparin vs. GL-522-Y-1
p > 0.05; aprosulate vs. heparin
Heptest®

< 0.05; heparin and pentasaccharide
aprosulate
p > 0.05; pentasaccharide vs. heparin

5U IT : ## p

<

#

p

0.05; heparin vs. aprosulate

vs.
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b. Studies in Supplemented Normal Rabbit Pool Plasma Systems
The global anticoagulant effects of heparin, aprosulate, GL-522-Y-1, and
pentasaccharide were determined following supplementation to nonnal rabbit plasma
using the prothrombin time, activated partial thromboplastin time, Heptest®, and 5 unit
thrombin time. Each agent was supplemented to pooled normal rabbit plasma on three
occasions and clotting times were determined as described in "Materials and Methods".
Pooled normal rabbit plasma was made by mixing citrated platelet poor plasma obtained
from at least five virgin male New Zealand white rabbits. Agent concentrations were
expressed as ,uM amounts based on the known molecular formula weights for the
synthetic analogues and the weight average molecular weight determined by gel
permeation chromatography for heparin. Concentration response data for each agent is
tabulated in Tables 28 to 31. The potency of each agent was assessed by determining the
plasma concentration of each agent which prolonged the various clotting times to 100
seconds. A comparison of these potencies is made in Table 3.
Figure 23 depicts the concentration response curves for aprosulate, GL-522-Y-1,
heparin, and pentasaccharide in the prothrombin time assay. The baseline clotting time
of rabbit plasma was observed to be 6.3

± 0.4 seconds. Only heparin produced a

concentration dependent increase in clotting time (Friedman chi-square

= 84.01, dF =

35, p < 0.0001). At the highest concentration tested, a 2.5 fold increase over baseline
was observed. None of the synthetic analogues was able to prolong the PT over the
concentration ranges tested.
The APTT was a more sensitive assay to measure the anticoagulant activity of
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heparin and the synthetic analogues. Concentration response curves are depicted in Figure
24. A statistically significant difference between the effects of the various agents was
observed (Friedman chi-square= 102.21, dF = 35,p < 0.0001). Heparin was the most
potent agent in this assay, prolonging the clotting time beyond 300 seconds at
concentrations above 0.30 µM. The concentration of heparin required to prolong the
clotting time to 100 seconds was estimated from the concentration-response curves to be
0.15

± 0.03 µM.

Aprosulate also achieved a clotting time greater than 300 seconds over

the concentration range tested. The concentration needed to reach 100 seconds was
approximately 25 times that of heparin at 3.9 ± 1.1 µM (p > 0.05 vs. heparin).
Pentasaccharide exhibited a relatively weaker concentration dependent prolongation of
clotting time, reaching 100 seconds at a concentration of 32.4 ± 6.4 µM (p < 0.05 vs.
heparin and aprosulate). GL-522-Y-1 did not signiflcan11y prolong the APTT over the
concentration range tested.
In the Heptest® assay, heparin produced the most potent anticoagulant activity,
reaching 100 seconds at a concentration of 1 .9

+

0.1 J.'M and prolonging clotting time

beyond 300 seconds at concentrations greater than 0. 60 µM. Pentasaccharide produced
a linear increase in clotting time with increasing dose, though did not reach 300 seconds
over the concentration range tested. The concentra1fon to elevate the clotting time to 100
seconds was determined to be 3.7 ± 0.2 µ.M pentasaccharide (p > 0.05 vs. heparin).
Aprosulate did not prolong the Heptest® at plasma concentrations below 10 µM. A 100
second concentration of 23. 8 ± 6. 7 µM (p < 0 .OS -vs. heparin and pentasaccharide).
GL-522-Y-1 did not prolong the Heptest® clotting time at concentrations up to 67 µM.
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Figure 23. Comparative anticoagulant effect of heparin and three synthetic heparin
analogues as measured by the prothrombin time. Aprosulate, GL-522-Y-1, heparin,
and pentasaccharide were supplemented to normal rabbit plasma over a concentration
range of 0 to 100 µg/mL. Plasma concentrations were converted to µM amounts using
the molecular weight of each agent as described previously. All results represent the
mean ± one standard deviation of three observations. Heparin was the only agent
observed to prolong the clotting time in this a.ss.ay. A statistical difference between
agents was determined using the Friedman two way ANOVA (Friedman chi-square
= 84.00, dF = 35, p < 0.0001). StatisticaJly significant differences between
treatment and control for each agent were determined by one way ANOV A followed
by the Newman-Keuls test. Results were considered to be statistically significant if p
< 0.05. ·indicates statistical significance relative to un.supplernented control plasma.
Data are compiled in Tables 28 through 31.
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Figure 24. Comparative anticoagulant effect of heparin and three synthetic heparin
analogues as measured by the activated partial thromboplastin time. Aprosulate, GL522-Y-1, heparin, and pentasaccharide were supplemented to normal rabbit plasma
over a concentration range of 0 to 100 ,uglmL. Plasma concentrations were converted
to µM amounts using the molecular weight of each agent as described previously. All
results represent the mean ± one standard deviation of three observations. The agents
prolonged the clotting time with a rank order potency of heparin > aprosulate >
pentasaccharide. GL-522-Y-1 did not prolong the clotting time over the concentration
range tested. A statistical difference between agents was determined using the
Friedman two way ANOVA (Friedman chi-square = 102.21, dF = 35, p < 0.0001).
Statistically significant differences between treatment and control for each agent were
determined by one way ANOVA followed by the Newman-Keuls test. Results were
considered to be statistically significant if p < 0.05. "indicates statistical significance
relative to unsupplemented control plasm.a.. Data are compiled in Tables 28 through
31.
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This data is presented in Figure 25. A statistically significant difference between the
effects of the various agents was observed (Friedman chi-square = 94.10, dF = 35, p

< 0.0001).
Heparin exhibited a strong anticoagulant effect in the 5 U thrombin time assay
as depicted in Figure 26. At the lowest concentration tested, 70 nM, clotting times
exceeded 300 seconds. Aprosulate was the only other agent capable of prolonging the
clotting time beyond 300 seconds. A concentration to prolong clotting time to 100
seconds of 5.5

± 0 µM was determined for aprosulate. Pentasaccharide produced a weak

prolongation of the clotting time ( < 2 fold baseline) at the highest concentrations tested.

GL-522-Y-1 did not prolong the thrombm time. A statistically significant difference
between the effects of the various agents was observed (Friedman chi-square = 98.67,
dF = 35, p < 0.0001).

4. Anti protease Prorde
a. Studies in Nonna! Human Plasma Systems
Thrombin and factor Xa inhibition by heparin, aprosulate, pentasaccharide, and

GL-522-Y-1 was assessed following supplementation of each agent to nonnal human
plasma. Amidolytic assays using specific substrates were utilized such that enzyme
inhibition was detennined by measuring changes in optical density of the sample. Percent
inhibition was calculated relative to 11nsupplemen1ed NHP. IC50 and Ic;5 values were
detennined by perfonning linear regression on the straight line portion of each individual
concentration versus percent inhibition curve. IC5JIC 25 values were detennined by
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Figure 25. Comparative anticoagulant effect of heparin and three synthetic heparin
analogues as measured by the Hepte~rt®. Aprosulate, GL-522-Y-1, heparin, and
pentasaccharide were supplemented to normal rabbi.t plasma over a concentration
range of 0 to 100 µg/mL. Plasma concentrations were converted to µM amounts using
the molecular weight of each agent as described previously. All results represent the
mean ± one standard deviation of three observations. The agents prolonged the
clotting time with a rank order potency of heparin > pentasaccharide > aprosulate.
GL-522-Y-1 did not prolong the clotting ti me in this assay. A statistical difference
between agents was determined using the Friedman two way ANOVA (Friedman chisquare = 94.10, dF = 35, p < 0.0001). Sta.tisbcally signi.ficant differences between
treatment and control for each agent were determined by one way ANOVA followed
by the Newman-Keuls test. Results were considered to be statistically significant if p
< 0. 05. • indicates statistical significance relative to uns upplernented control plasma.
Data are compiled in Tables 28 through 3 L.
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Figure 26. Comparative anticoagulant effect of heparin and three synthetic heparin
analogues as measured by the 5 unitthrombin time. Aprosulate, GL-522-Y-1, heparin,
and pentasaccharide were supplemented to normal rabbit plasma over a concentration
range of 0 to 100 µglmL. Plasma concentrations were converted to µM amounts using
the molecular weight of each agent as described previously. All results represent the
mean ± one standard deviation of three observations. The agents prolonged the
clotting time with a rank order potency of heparin > aprosulate > pentasaccharide.
GL-522-Y-l did not prolong the clotting time in this assay. A statistical difference
between agents was determined using the Friedman two way ANOVA (Friedman chisquare = 98.67, dF = 35, p < 0.0001). Statistically significant differences between
treatment and control for each agent were determined by one way ANOV A followed
by the Newman-Keuls test. Results were comidered to be statistically significant if p
< 0.05. ·indicates statistical significance relative to unsupplemented control plasma.
Data are compiled in Tables 28 through 31 .
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TABLE 3
PLASMA CONCENTRATIONS OF SYNTHETIC HEPARIN ANALOGUES
REQUIRED TO PROLONG NORMAL RABBIT PLASMA CLOTIING
TIMES TO 100 SECONDS

PT

Aprosulate

> 42

GL-522-Y-1

> 67

Heparin

> 10

Pentasaccharide

> 58

APIT

Heptest

5UTT

+

23.8 ± 6.7

5.5 ± 0

> 67

> 67

1.9 ± 0.1#

< 0.8

3.7 ± 0.2#

> 58

3.9

>

1.1"

67

0.15 + 0.03·

32.4

+ 6.4

The potencies of aprosulate, GL-522-Y-1, heparin, and pentasaccharide were
compared by extrapolating the concentrations of each agent which caused a
prolongation of the clotting time to 100 seconds. Results represent the mean ± 1
standard deviation of 3 determinations. Jn cases in which agents did not prolong the
clotting time to 100 seconds, the highest concentration tested is presented. Statistical
Comparison of these values was made by one way ANOVA followed by the Student
Newman-Keuls multiple comparison test for each assay. p < 0.05 was considered
statistically significant.
APTT : • p < 0.05; aprosulate and heparin vs.
p > 0.05; aprosulate vs. heparin
Heptest®

pentasaccharide

< 0.05; heparin and pentasaccharide
aprosulate
p > 0.05; pentasaccharide v.s. heparin
#

p

vs.

142
interpolation from the regression curves. A correlation coefficient greater than 0.92 was
obtained for each regression line. Potencies of aprosulate, Gl-522-Y-1, heparin, and
pentasaccharide are compared in Table 4.
Heparin was the most potent thrombin inhibitor in this assay system, with an
IC 50 value calculated to be 0.144

± 0.003 µM. Aprosulate was the only heparin analogue

to inhibit thrombin, though its effects were much weaker than those of heparin. At
concentrations as high as 40 µ.M, the inhibition of thrombin by aprosulate was less than
50 % (Figure 27). The IC 25 value for aprosulate was detennined to be 1.95
This was 28 fold higher than the value determine for heparin (0.069

± 0.05 µ.M.

± 0.002

µM).

Neither pentasaccharide nor GL-522-Y-1 displayed a significant inhibition of thrombin.
A statistically significant difference between the effects of the various agents was
observed (Friedman chi-square = 89.29, dF

=

31, p

< 0.0001).

Heparin and pentasaccharide inhibited factor Xa amidolytic activity in a
concentration dependent manner. This is depicted in Figure 28. The inhibition of factor
Xa by pentasaccharide was observed to be slightly weaker than that for heparin. The IC50
value for pentasaccharide was two fold higher than that for heparin (0.83
0 .40

± 0.03

vs.

± 0. 02 µ.M). Neither aprosulate nor GL-522-Y -1 promoted the inhibition of factor

Xa. A statistically significant difference between the effects of the various agents was
observed (Friedman chi-square = 86.76, dF

=

31, p

< 0.0001).

b. Studies in Normal Rabbit Pool Plasma Systems
Amidolytic assays were prefonned to assess each agents antiprotease activity.
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Figure 27. Comparative antiprotease effect of heparin and three synthetic heparin
analogues as measured by the amidolytic anti-Ila assay. Aprosulate, GL-522-Y-1,
heparin, and pentasaccharide were supplemented to normal human plasma over a
concentration range of 0 to 100 µ.g)mL. Plasma concentrations were converted to µM
amounts using the molecular weight of each agent as described previously. All results
represent the mean ± one standard deviation of four observations. The rank order
potency of thrombin inhibition was heparin > aprosulate > GL-522-Y-1.
Pentasaccharide did not promote the inhibition of thrombin. A statistical difference
between agents was determined using the Friedman two way ANOV A (Friedman chisquare = 89.29 dF = 35, p < 0.0001). Statistically significant differences between
treatment and control for each agent were determined by one way ANOVA followed
by the Newman-Keuls test. Results were considered to be statistically significant if p
< 0.05. ·indicates statistical significance relative to unsupplemented control plasma.
Data are compiled in Tables 24 through 27.
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Figure 28. Comparative antiprotease effect of heparin and three synthetic heparin
analogues as measured by the amidolytic anti-Xa assay. Aprosulate, GL-522-Y-1,
heparin, and pentasaccharide were supplemented to normal human plasma over a
concentration range of 0 to 100 µg/mL. Plasma concentrations were converted to µ.M
amounts using the molecular weight of each agent as described previously. All results
represent the mean ± one standard deviation of four observations. Heparin exhibited
a higher anti-Xa potency than pentasaccharide. GL-522-Y-l and aprosulate were not
observed to inhibit Xa activity. A statistical difference between agents was determined
using the Friedman two way ANOVA (Friedman chi-square = 86. 76 dF = 35, p <
0.0001). Statistically significant differences between treatment and control for each
agent were determined by one way ANOVA followed by the Newman-Keuls test.
Results were considered to be statistically significant if p < 0.05. • indicates statistical
significance relative to unsupplemented control plasma. Data are compiled in Tables
24 through 27.
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TABLE4
IC50 VALVES FOR SYNTHETIC HEPARIN ANALOGUES IN AMIDOLYTIC
ANTIPROTEASE ASSAYS IN NORMAL HUMAN PLASMA

Anti-Ila

Aprosulate

GL-522-Y-1

Heparin

Pentasaccharide

1.05

+ 0.05

> 67

Anti-Xa

> 42µM

µM

> 67 µM

µM

0.14 ± 0.01 µ.M•

0.40

± 0.02 µM**

> 58 µ;M

0. 83

± 0.03 µM

The potencies of aprosulate, GL-5 22- Y -1, heparin, and pentasaccharide were
compared in amidolytic antiprotease assays by determining the IC50 values for each
agent from the concentration vs. % inhibition curves_ Results represent the mean ±
1 standard deviation of 4 determinations. In cases where the agent did not promote
inhibition, the highest concentration tested is presented. Statistical significance was
determined using the Student's t-test (p < 0.05).
a!Ia: *p < 0.001; heparin vs. aprosulate
aXa: **p < 0.001; heparin vs. pentasaccbaride
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Concentration-response curves for the antithrombotic activity of each agent are depicted
in Figure 29. Only heparin exhibited a potent inhibition ofthrombin. Inhibition plateaued
at 90 % at concentrations above 1.2 µ,M. The IC!io for heparin was calculated to be 120

± 10 nM. Aprosulate, GL-522-Y- l, and pentasaccharide exhibited small inhibitions of
thrombin at the highest concentrations tested. A statistically significant difference
between the effects of the various agents was observed (Friedman chi-square = 77.83,
dF = 35, p

< 0.0001).

In the anti-Xa assay, heparin and pentasaccharide both exhibited potent
inhibition of Xa activity. This data is depicted in Figure 30. Maximal inhibition of
approximately 95 % was achieved at concentrations greater than 3 µM. Heparin was
more potent than pentasaccharide. The lC!io for heparin was determined to be 0.36
0.02 µM. The IC 50 for pentasaccharide was detenn:ined to be 2.10

± 0.51

±

µM (p =

0.004 vs. heparin). Neither aprosulate nor GL-522-Y-1 exhibited an anti-Xa activity. A
statistically significant difference between the effects of the various agents was observed
(Friedman chi-square = 86.78, dF = 35, p < 0.0001). The potencies of each agent in
the amidolytic assays are listed in Table 5.

5. FVIll:C Mediated Factor Xa Generation
Figure 31 depicts the concentration response curves for the effect of heparin,
aprosulate, GL-522-Y-1 and pentasaccharide on the FVIII:C mediated generation of
factor Xa. All agents exhibited a concentration dependent inhibition of factor Xa
amidolytic activity. The effects of the different agents were compared using the Friedman
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Figure 29. Comparative antiprotease effect of heparin and three synthetic heparin
analogues as measured by the amidolytic anti-Ha assay. Aprosulate, GL-522-Y-1,
heparin, and pentasaccharide were supplemented to normal rabbit plasma over a
concentration range of 0 to 100 µg/mL. Plasma concentrations were converted to µM
amounts using the molecular weight of each agent as described previously. All results
represent the mean ± one stalldard deviation of three observations. Thrombin was
most potently inhibited by heparin. IC 5() values for aprosulate, GL-522-Y-1, and
pentasaccharide could not be calculated from this data. A statistical difference between
agents was determined using the Friedman two way ANOV A (Friedman chi-square
= 77.83, dF = 35, p < O.OOOL). Statistically significant differences between
treatment and control for each agent were determjned by one way ANOV A followed
by the Newman-Keuls test. Results were considered to be statistically significant if p
< 0.05. ·indicates statistical significance relative to unsupplemented control plasma.
Data are compiled in Tables 28 through 3 L
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Figure 30. Comparative antiprotease effect of heparin and three synthetic heparin
analogues as measured by the amidolytic anti-Xa assay. Aprosulate, GL-522-Y-1,
heparin, and pentasaccharide were supplemented to normal rabbit plasma over a
concentration range of 0 to 100 µg/mL. Plasma concentrations were converted to µM
amounts using the molecular weight of each agent as described previously. All results
represent the mean ± one standard deviation of three observations. Heparin exhibited
a higher anti-Xa potency than did pentasaccharide. Aprosulate and GL-522-Y-1 did
not promote the inhibition of Xa activity. A statistical difference between agents was
determined using the Friedman two way AN OVA (Friedman chi-square = 86. 78, dF
= 35, p < 0.0001). Statistically significant differences between treatment and control
for each agent were determined by one way ANOVA folJowed by the Newman-Keuls
test. Results were considered to be statistically significant if p < 0.05. • indicates
statistical significance relative to unsupplemented control plasma. Data are compiled
in Tables 28 through 31.
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Figure 31. Comparison of the effect of heparin analogues on the FVIII: C mediated
generation of factor Xa. This effect was measured wjth a plasma-free amidolytic assay
system in which only agent, FVIJI, FIXa, FX and FXa substrate were present. All
results represent the mean ± one standard deviation of three observations. All agents
inhibited Xa amidolytic activity in a concentra6on dependent manner. A statistical
difference between agents was determined by Friedman two ANOVA (Friedman chisquare = 91.59, dF = 31, p < 0.0001). IC50s were calculated in order to compare
the potencies of each agent. IC 50s were compared using one way ANOVA followed
by the Newman-Keuls multiple comparison test. Data are compiled in Tables 32
through 35.
Heparin: IC 50 = 0.0016
Pentasaccharide: IC50

±

0.0003 µM; p < 0.05 vs. GL-522-Y-1

< 0.45 µ.M

Aprosulate: IC 50 = 1.13

± 0. 68 µM; p < 0 .05 vs. GL-522-Y-1

GL-522-Y-1: IC 50 = 25.66

± 0.94 µ.M
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two way ANOVA. A significant difference was observed between the agents (Friedman
chi-square

=

91.59, dF

= 31, p <

0.0001). In this system, FVIII, FIXa and FX were

incubated with a phosphatidylserine containingphospholipid. The generation of factor Xa
could then be measured in the absence of the extrinsic and contact pathway enzymes.
Heparin strongly inhibited the generation of Xa amidolytic activity, reaching 100 %
inhibition at concentrations above 10 nM. I C5() values were determined by extrapolation
from the regression line of the linear portion of the curve. The IC50 for heparin was
determined to be 1.6

± 0.3 nM (p < 0.05 vs. GL-522-Y-1). Aprosulate and GL-522-Y-

1 were also able to attain maximal inhibition. The IC50 values for these agents were
significantly higher than for heparin. IC50 values of 1.13

±

0.94 µM (p

+

0.68 (p

< 0.05) and 25.66

< 0.05) were determined for aprosulate and GL-522-Y-1.

Pentasaccharide also inhibited the generation of factor Xa in this system. The
concentration response curve for pentasaccharide was much flatter than for the other
agents. A change in % inhibition from 53 % to 82 % was observed over a concentration
range of 0.45 to 58 µM. As a plateau in percent inhibition was not achieved with
pentasaccharide over the concentration range tested, an IC 50 value was not determined.
Raw data is tabulated in Tables 32 to 35.

6. Protease Generation in Fibrinogen Deficient Plasma
The inhibition of thrombin and factor Xa generation by heparin, aprosulate, GL522-Y-1, and pentasaccharide was determined using amidolytic assays in which protease
formation was initiated by either thromboplastin (extrinsic pathway) or Actin®, an ellagic
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TABLE 5
IC 50 VALUES FOR SYNTHETIC HEPARJN ANALOGUES IN AMIDOLYTIC
ANTIPROTEASE ASSAYS IN NORMAL RABBIT PLASMA

Anti-Ila

Anti-Xa

Aprosulate

> 42 µ.M

> 42µM

GL-522-Y-1

> 67 µ.M

> 67 µM

Heparin

Pentasaccharide

0.12

± 0.01 µ.M

> 58 µM

0.36

± 0.02 µM*

2.10

± 0.51 µM

The potencies of aprosulate, GL-522-Y-1, heparin, and pentasaccharide were
compared in amidolytic antiprotease assays by detennining the IC50 values for each
agent from the concentration vs. % inhibition curves. Results represent the mean ±
1 standard deviation of 3 determinations. In cases where the agent did not promote
inhibition, the highest concentration tested is presented. Statistical significance was
determined using the Student's t-test (p < 0.05).
aXa: *p = 0.004; heparin vs. pentasaccharide
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acid reagent (contact system). Concentration response data for each agent is tabulated in
Tables 36 to 39. Figure 32 illustrates the concentration response curves for the inhibition
of Xa generation following activation of the extrinsic pathway. A statistically significant
difference between the effects of the various agents was noted (Friedman chi-square =
87.84, dF = 35, p < 0.0001). Both heparin and GL-522-Y-1 were observed to
concentration dependently inhibit Xa formation. Both agents were able to completely
inhibit Xa generation. Comparison of the IC50 values for heparin and GL-522-Y-1
showed that heparin was significantly more potent than GL-522-Y-1 (0.56 ± 0.04 vs.
6.57 ± 1.77 µM; t-test; p = 0.004). Neither aprosulate nor pentasaccharide was able
to promote Xa generation inhibition following extrinsic pathway activation.
Both heparin and GL-522-Y-1 also inhibited the formation of thrombin
following extrinsic pathway activation as shown in Figure 33. A statistically significant
difference between the effects of the various agents was noted (Friedman chi-square =
82.33, dF = 35, p < 0.0001). The concentration response curves were not parallel, with
that of GL-522-Y-1 showing a more gradual rise. TheIC 50 for heparin (2.10 ± 0.07 µM)
was significantly lower than that calculated for GL-522-Y-1 (8.00 ± 1.87 µM; t-test; p
= 0.005). Aprosulate exhibited a weak inhibition at high concentrations. Pentasaccharide

did not inhibit thrombin generation following activation of the extrinsic pathway. Heparin
was relatively more potent at inhibiting Xa generation than Ila generation following
extrinsic activation (p < 0.001). While the IC51)for GL-522-Y-1 mediated Xa generation
inhibition was lower than that for Ila generation inhibition, this difference was not
statistically significant.
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Figure 32. The effect of aprosulate, GL-522-Y-1. heparin, and pentasaccharide on
thrombin generation following activation of the extrinsic pathway. Thrombin
generation was measured using an amidolytic assay in fibrinogen deficient plasma.
Percent inhibition was calculated relative to unsupplemented control. All results
represent the mean ± one standard deviation of three observations. A statistically
significant difference between the effects of the various agents was noted (Friedman
chi-square = 82.33, dF = 35, p < 0.000 L). Heparin was observed to more potently
inhibit thrombin generation than GL-5 22- Y -1 in this system. Neither aprosulate not
pentasaccharide exhibited an inhibitory effect in this assay. IC 50 values were
determined to compare the potency of the various agents. Statistical comparison of the
IC 50 s was made by one way ANOVA followed by the Newman-Keuls multiple
comparison test. • p < 0.05 was considered statistically significant vs. control. Data
are compiled in Tables 36 through 39.
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Figure 33. The effect of aprosulate, GL-522-Y-1, heparin, and pentasaccharide on
factor Xa generation following activation of the extrinsic pathway. Factor Xa
generation was measured using an a.midolytic assay in fibrinogen deficient plasma.
Percent inhibition was calculated relative to unsupplemented control. IC50 values were
determined to compare the potency of the various agents. All results represent the
mean ± one standard deviation of three observations. A statistically significant
difference between the effects of the various agents was noted (Friedman chi-square
= 87.84, dF = 35, p < 0.0001). Heparin was observed to more potently inhibit
thrombin generation than GL-522-Y-l :in this system. Neither aprosulate not
pentasaccharide exhibited an inhibitory effect in this assay. Statistical comparison of
the IC50 values was made by one way ANOVA followed by the Newman-Keuls
multiple comparison test. • p < 0.05 was considered statistically significant vs.
control. Data are compiled in Tables 36 through 39.
Heparin (IC 50 = 0.56
; p = 0.004

± 0.04 µM) vs. GL-522-Y-l (JC 50

= 6.57

± 1.77 µM)
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Thrombin generation following intrinsic pathway activiation was inhibited by
GL-522-Y-l, aprosulate and heparin in a concentration dependent manner as shown in
Figure 34. A statistically significant difference between the effects of the various agents
was noted (Friedman chi-square = 85. 76, dF = 35, p < 0.0001). GL-522-Y-l was the
most efficacious agent, completely inhibiting thrombin generation at concentrations above
10 µM. Inhibition by aprosulate plateaued at approximately 75 % over the concentration
range tested. The potency of these agents was not statistically dlfferent (3.51
aprosulate vs. 2.89

+ 0.83 µM GL-522-Y-l;p =

± 1.22 µM

0.507). Heparin exhibited less activity

in this assay with maximal inhibition peaking at 30 % at concentrations greater than 4
µM (IC50 = 0.7 µM).

All agents were active at inhibiting factor Xa generation following intrinsic
pathway activation. A statistically significant difference between the effects of the various
agents was observed (Friedman chi-square

=

101.50, dF = 35, p

< 0.0001). Both

aprosulate and GL-522-Y-1 inhibited Xa generation greater than 90 % relative to
unsupplemented control. The potencies of these agents were not statistically different
(IC 50 = 1.28

± 0.66

µM aprosulate

vs. 1.46 ± 0.33 µ.M GL-522-Y-l; t-test; p =

0.694). Pentasaccharide also exhibited a concentration dependent inhibition of Xa
generation, though weaker than either aprosulate or GL-522-Y-l. IC25 values were
calculated assuming that pentasaccharide would reach the same maximal level of
inhibition as aprosulate or GL-522-Y-1 at the appropriate concentration. No statistical
differences were noted between the IC25 values for aprosulate and GL-522-Y-l (0.95
0.43 vs. 0.93

±

±

0.32 µM, respectively). Both were significantly lower than that
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determined for pentasaccharide (12.44

± 6.19 µM; p <

0.05). This data is depicted in

Figure 35.
The potencies of the test agents in the various systems are compared in Table
6. Following activation of the intrinsic pathway, aprosulate was more potent at inhibiting
the generation of Xa than Ila (IC50 = 1.28

± 0.66 vs. 3.51 ± 1.22 ~M; p

= 0.050).

The IC50 for GL-522-Y-1 mediated Xa generation inhibition was lower than for Ila
generation, though not statistically significant. Heparin was more efficacious at inhibiting
Xa generation compared to Ila generation. In the intrinsically activated systems, heparin
was more than 100 fold more potent at inhibiting Xa generation compared with thrombin
generation. Overall, aprosulate and GL-522-Y-1 were more potent at inhibiting
intrinsically activated generation than following extrinsic activation. Pentasaccharide
demonstrated minimal ability to inhibit protease generation in these systems. IC 50 values
for pentasaccharide were greater than 3 3 ,u.M :in all four systems.

7. Protease Generation in Non-plasmatic Systems
The inhibition of thrombin and factot Xa generation by aprosulate, GL-522-Y-1,
heparin and pentasaccharide was examined in non-plasmat:ic systems in which native and
activated prothrombin complex concentrates provided the necessary coagulation factors.
Two different prothrombin complex concentrates were used, one containing factor VII
(Konyne®) and one containing factor VIIa (FEIBA~. Figure 36 depicts the concentration
response curves for thrombin generation inhibition in the FEIBA® based system. Both
heparin and GL-522-Y-1 were able to concentratfon dependently inhibit thrombin
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Figure 34. The effect of aprosula.te, GL-522-Y-1, heparin, and pentasaccharide on
thrombin generation following activation of the intrinsic pathway. Thrombin
generation was measured using an amidolytic assay in fibrinogen deficient plasma.
Percent inhibition was calculated relative to unsupplemented control. IC50 values were
determined to compare the potency of the various a.gents. All results represent the
mean ± one standard deviation of three observations. A statistically significant
difference between the effects of the various agents was noted (Friedman chi-square
= 85.76, dF = 35,p < 0.0001). Statistical comparison of the IC 50 values was made
by one way ANOVA followed by the Newman-Keuls multiple comparison test. • p <
0.05 was considered statistically significant vs. control. Data a.re compiled in Tables
36 through 39.
Aprosulate (IC50 = 3.51
µM); p = 0.507

±

1 .22 µM)

\JS.

GL-522-Y-L (IC50 = 2.89

±

0.83
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Figure 35. The effect of aprosulate, GL-5 22- Y -1, heparin, and pentasaccharide on
factor Xa generation following activation of the intrinsic pathway. Factor Xa
generation was measured using an amidolytic assay in fibrinogen deficient plasma.
Percent inhibition was calculated relative to unsuppJemented control. IC50 values were
determined to compare the potency of the various agents. All results represent the
mean ± one standard deviation of three observations. A statistically significant
difference between the effects of the various agents was noted (Friedman chi-square
= 101.50, dF = 35, p < 0.0001). Statistical comparison of the IC 50 values was made
by one way ANOVA followed by the Newman-Keuls multiple comparison test. • p <
0.05 was considered statistically significant vs. control. Data are compiled in Tables
36 through 39.
Aprosulate (IC 50 = 1.28
µM) ; p = 0.694

± 0. 66 J,.tM)

l'J.

GL-522-Y-1 (IC 50 = 1.46

± 0.33

TABLE 6
POTENCY EVALUATION OF HEPARIN ANALOGUES IN PROTEASE GENERATION SYSTEMS IN FIBRINOGEN
DEFICIENT PLASMA

Extrinsic

Intrinsic

Ila

Aprosulate

>

33.3

Ila

Xa

> 33.3

3.51

±

Xa

1.22

1.28

± 0.66

1.46

± 0.33

GL-522-Y-1

8.00

± 1.87

6.57

± 1.77

2.89 ± 0.83

Heparin

2.10

± 0.07

0.56

± 0.04

> 33.3

<

0.26

33.3

> 33.3

>

33.3

Pentasaccharide

> 33.3

>

IC 50 values were detennined by extrapolation from the best fit regression lines of the straight line portion of the concentration
response curves.
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formation in this system. Both heparin and GL-5 22-Y -1 reached levels of thrombin
inhibition of approximately 85 %• Heparin was observed to be approximately 10 fold
more potent than GL-522-Y-l. Neither aprosulate nor pentasaccharide demonstrated
substantial inhibition of thrombin generation in this system.
Figure 37 depicts the concentration response curves for factor Xa generation in
the FEIBA® based system. GL-522-Y-1 was the only agent to demonstrate significant
inhibition of Xa generation. At concentrations greater than 10 µM GL-522-Y-l, more
than 75 % inhibition was observed. Neither aprosulate, pentasaccharide, nor heparin
produced any inhibition of Xa generation.
Figure 38 depicts the concentration response curves for the inhibition of
thrombin generation in the Konyne® based system. Aprosulate, GL-522-Y-1 and heparin
all inhibited thrombin generation in a dose-dependent fashion. Heparin produced the most
potent inhibition of thrombin generation, reaching 50 % inhibition at a concentration of
3 µM. Aprosulate and GL-522-Y- l produced somewhat weaker inhibitory effects than
heparin. Neither agent reached a level of 50 3 inhibition at concentrations up to 70 µM.
Pentasaccharide did not produce an inhibition of thrombin generation.
Figure 39 depicts the concentration response curves for the inhibition of factor
Xa generation in the Konyne® based system. As in the other non-plasmatic systems, GL522-Y-1 and heparin produced a concentration dependent inhibition of Xa generation.
The slope of the heparin response curve was flatter than that of the GL-522-Y-1 response
curve. Neither aprosulate nor pentasaccharide were able to inhibit Xa generation.

Figure 36. Effect of aprosulate, GL-522-Y-1, heparin, and pentasaccharide on the
inhibition of thrombin generation in a FEIBA® based system. All results represent the
mean(± one standard deviation) percent inhibition relative to unsupplemented control
of three determinations. Heparin more potently inhibited thrombin generation in this
system than did GL-522-Y-l. Neither aprosulate nor pentasaccharide exhibited an
inhibitory effect in this assay. Statistical compari.som versus control were made by one
way ANOVA followed by the Newman Keuls test. p < 0.05 was considered
statistically significant.

By ANOVA,
aprosulate; p = 0. 704
GL-522-Y-1; p < 0.001
heparin; p < 0.001
pentasaccharide; p = 0.548
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Figure 37. Effect of aprosulate, GL-522-Y-1, heparin, and pentasaccharide on the
inhibition of factor Xa generation in a FEIBA ® based system. AU results represent the
mean ( ± one standard deviation) percent inhibition relative to unsupplemented control
of three determinations. GL-522-Y-1 was the only agent to exhibit an inhibitory effect
in this assay. Statistical comparisons versus control were made by one way ANOV A
followed by the Newman Keuls test_ ·p < 0.05 was considered statistically
significant.
By ANOVA,

aprosulate; p = 0. 823
GL-522-Y-1; p < 0.001
heparin; p = 0.013
pentasaccharide; p = 0 .911
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Figure 38. Effect of aprosulate, GL-522-Y-l, heparin, and pentasaccharide on the
inhibition of thrombin generation in a Konyne® based system. All results represent the
mean(± one standard deviation) percent inhibition reJative to unsupplemented control
of three determinations. Thrombin generation was inhibited in this system with a rank
order potency of heparin > GL-522-Y-1 > aprosulate. Pentasaccharide did not
exhibit an inhibitory effect in this assay. Statistical comparisons versus control were
made by one way ANOV A followed by the Newman Keuls test. "p < 0.05 was
considered statistically significant.

By ANOVA,
aprosulate; p = 0. 017
GL-522-Y-1; p < 0.001
heparin; p < 0.001
pentasaccharide; p = 0.5 43
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Figure 39. Effect of aprosulate, GL-522-Y-l, heparin, and pentasaccharide on the
inhibition of factor Xa generation in a Konyne® based system. All results represent
the mean ( + one standard deviation) percent inhibition relative to unsupplemented
control of three determinations. Heparin and GL-522-Y-l exhibited an inhibitory
effect in this assay. Aprosulate and pentasaccharide displayed no effect on Xa
generation. Statistical comparisons versus control were made by one way ANOV A
followed by the Newman Keuls test. p < 0. 05 was considered statistically
significant.

By ANOVA,
aprosulate; p < 0.001
GL-522-Y-1; p < 0.001
heparin; p < 0.001
pen tasaccharide; p = 0. 35 2
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8. Effect of Analogues on Heparan Sulfate 1 Dermatan Sulfate
Synthesis in Cell Culture
The effect of aprosulate, GL-522-Y -1, heparin, and pentasaccharide on the
modulation of glycosaminoglycan synthesis by endothelial cells was examined in cultured
rabbit endothelial cells. Agents were supplemented to the culture media for 18 hours
prior to analysis. Glycosaminoglycan synthesis was quantitated by measuring the amount
of 35S present in the chondroitin sulfate and hepara.n sulfate bands of the culture media
and cell homogenates separated by gel electrophoresis.

35

S was measured by scintillation

counting. Concentration response data is presented in Tables 40 to 43.
Figure 40 depicts the concentration-response curves for aprosulate on the
synthesis of chondroitin and heparan sulfates in cultured rabbit endothelial cells. In panel
A it is observed that incubation of endothelial cells with aprosulate concentration
dependently increased the amount of chondroitin sulfate in the culture media. None of
the levels measured in the aprosulate treated cultures reached statistical significance
relative to control. Panel B depicts the concentration-response curves for the synthesis
of heparan sulfate as measured in the culture media of rabbit endothelial cells. A
concentration-dependent increase in CPM's was observed_ A concentration of 41 µM was
determined to double the amount of CPM's relative to baseline. Aprosulate increased the
amount of chondroitin sulfate associated w i1h the endothelial cells at concentrations
greater than 4.2 µM (panel C). Aprosulate had no effect on cell associated heparan
sulfate levels (panel D).
The effect of GL-522-Y-1 on the synthesis of glycosaminoglycans by cultured
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Figure 40. Effect of aprosulate on glycosarninoglycan synthesis in endothelial cell
culture. Concentration-response curves for the effect of aprosulate on the synthesis of
chondroitin sulfate in culture media (panel A), heparan sulfate in culture media (panel
B), chondroitin sulfate associated with endothelial cells (panel C), and heparan sulfate
associated with endothelial cells (panel D) are depicted. The results represent the mean
(± SEM) C.P.M. 's of three independent measurements as determined by scintillation
counting. Aprosulate was observed to concentratfon dependently increase the synthesis
of chondroitin sulfate and heparan sulfate as measured in the culture media. The
synthesis of chondroitin sulfate associated with the endothelial cells was increased at
concentrations greater than 10 µ.M. Statistical comparisons were made by one way
ANOVA followed by the Newman-Keuls test. (CS Med; dF = 17, F = 10.5, p =
0.0005. HS Med; dF = 17, F = 21.2, p < 0.0001. CS Cell; dF = 17, F = 25.4,
p < 0.0001. HS Cell; dF = 17, F = 2.56, p = 0.0847). *p< 0.05 vs.
unsupplemented control was considered statistically significant. Data are compiled in
Table 40.
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endothelial cells is depicted in Figure 41. GL-522-Y-1 supplementation did not have an
effect on the amount of chondroitin sulfate measured in the cell culture media. Heparan
sulfate was greatly increased by incubation with GL-522-Y-l. In panel Bit is observed
that GL-522-Y-1 produced a concentration-dependent increase in heparan sulfate over a
concentration range of 0.07 to 33.5 µ.M. Increase in the GL-522-Y-l concentration above
33.5 µM did not further enhance heparan sulfate production. Heparan sulfate levels at
33.5 and 67 µM were signifcantly greater than control. A concentration of 4.5 µM was
determined to double the number of CPM' s relative to unsupplemented control. As seen
in panels C and D, GL-522-Y-1 also increased the synthesis of chondroitin and heparan
sulfate associated with the endothelial cells. In both ins1ances, significant increases in
synthesis were observed at concentrations above 0. 67 µM.
Figure 42 depicts the concentration-response curves for the modulation of
glycosaminoglycan synthesis by heparin. Heparin did not significantly alter the
production of chondroitin sulfate as measured in the culture media or associated with the
endothelial cells or the production of heparan sulfate associated with the endothelial cells.
As depicted in panel B, heparin concentration-dependently increased the amount of
heparan sulfate released to the culture media. Concentrations greater than 0.95 µM were
observed to significantly increase heparan sulfate production compared to control. A
concentration of 3.3 µM was determined to double the number of CPM's relative to
unsupplemented control.
The concentration-response curves for the modulation of glycosaminoglycan
synthesis in endothelial cell culture by pentasaccharide are depicted in Figure 43.
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Figure 41. Effect of GL-522-Y-1 on glycosaminogly can synthesis in endothelial cell
culture. Concentration-response curves for the effect of GL-522-Y-1 on the synthesis
of chondroitin sulfate in culture media (panel A), heparan sulfate in culture media
(panel B), chondroitin sulfate associated with endothelial cells (panel C), and heparan
sulfate associated with endothelial cells (panel D) are depicted. The results represent
the mean (± SEM) C.P.M. 's of three independent measurements as determined by
scintillation counting. GL-522-Y-1 significantly increased the production of
chondroitin sulfate and heparan sulfate associated with the endothelial cells and
heparan sulfate content in the culture media at concentrations above 10 µM. Statistical
comparisons were made by one way ANOVA followed by the Newman-Keuls test.
(CS Med; dF = 17, F = 1.80, p = 0.1867. HS Med; dF = 17, F = 31.6, p <
0.0001. CS Cell; dF = 17, F = 16.5, p < 0.0001. HS Cell; dF = 17, F = 28.3,
p < 0.0001). ·p < 0.05 vs. unsupplemented control was considered statistically
significant. Data are compiled in Table 4 L
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Figure 42. Effect of heparin on glycosaminoglycan synthesis in endothelial cell
culture. concentration-response curves for the effect of heparin on the synthesis of
chondroitin sulfate in culture media (panel A), heparan sulfate in culture media (panel
B), chondroitin sulfate associated with endothelial cells (panel C), and heparan sulfate
associated with endothelial cells (panel D) are depicted. The results represent the mean
(± SEM) C.P.M. 's of three indepeadent mea..surements as determined by scintillation
counting. Heparin dose-dependently increased heparan sulfate content as measured in
the culture media. Statistically significant increases were observed at concentrations
greater than 1 µM. Chondroitin sulfate synthesis was not effected by heparin
supplementation. Statistica..l comparisons were made by one way ANOV A followed by
the Newman-Keuls test (CS Med; dF = J 7, F = 0.959, p = 0.4793. HS Med; dF
= 17, F = 59.9, p < 0.0001. CS Cell; dF = 17, F = 2.44, p = 0.0950. HS Cell;
dF = 17, F = 0.655, p = 0.6636). ·p < 0.05 vs. unsupplemented control was
considered statistically significant. Data are compiled in Table 42.
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Pentasaccharide did not significantly effect the production of chondroitin or heparan
sulfate as measured in the culture media (panels A and B). While trends for increasing
levels of chondroitin and heparan associated with the endothelial cells were observed, no
statistically significant differences relative to unsupplemented control were determined.

9. Studies in Native Human Whole Blood
Whole blood was drawn into syringes containing representative amounts of
aprosulate, pentasaccharide, or GL-522-Y-1 to result in a final concentration of 25 µ.M.
The anticoagulant activity of these agents was determined by ACT and TEG. Figure 44
depicts the results of the celite ACT analysis. The effect of heparin at 0.25 µ.M was
included for comparison. All agents were observed to significantly increase the clotting
time compared with saline supplementation. A baseline clotting time 110

± 12 seconds

was observed. Pentasaccharide and GL-522-Y- l prolonged clotting times to nearly 200
seconds. Aprosulate produced a significantly higher clotting time compared to
pentasaccharide and GL-522-Y-l (p < 0.05). Supplementation of 25 µ.M aprosulate
resulted in a clotting time of 290 seconds. Heparin was not included in the statistical
analysis due to the 100 fold lower concentration used.
Two parameters of the TEG were used to compare the effects of aprosulate,
GL-522-Y-1, or pentasaccharide supplementation. Figure 45 depicts the effect on K-time,
or time to standard clot firmness. The K-time of saline supplemented whole blood was
measured as 10.5 mm. Aprosulate doubled the K-time (p < 0.05). GL-522-Y-1 did not
prolong the K-time relative to control. The K-time for pentasaccharide supplemented
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Figure 43. Effect of pentasaccharide on glycosaminoglycan synthesis in endothelial
cell culture. Concentration-response curves for the effect of pentasaccharide on the
synthesis of chondroitin sulfate in culture media (panel A), heparan sulfate in culture
media (panel B), chondroitin sulfate associated with endothelial cells (panel C), and
heparan sulfate associated with endothelial cells (panel D) are depicted. The results
represent the mean (± SEM) C.P.M. 's of three independent measurements as
determined by scintillation counting. Pentasaccharide supplementation was not
observed to effect the synthesis of heparan sulfate. Chondroitin sulfate associated with
the cells was observed to be concentrntjon dependently increased, though statistical
significance was not achieved. Statistical comparisons were made by one way
ANOVA followed by the Newman-Keuls test. (CS Med; dF = 17, F = 0.964, p =
0.4770. HS Med; dF = 17, F = 11.0,p = 0.0004. CS Cell; dF = 17, F = 9.86,
p = 0.0006. HS Cell; dF = 17, F = 3.63, p = 0.0313). *p < 0.05 vs.
unsupplemented control was considered statistically significant. Data are compiled in
Table 43.
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Figure 44. Anticoagulant effect of aprosulate, GL-522-Y-1, heparin and
pentasaccharide on freshly drawn whole blood supplemented with each agent at a final
concentration of 25 µM (0.25 µ.M for heparin) using the celite ACT. Blood from 10
volunteers was used to test each agent. All re~ults represent the mean + one standard
deviation. A control clotting time of UO ± 12 seconds was observed. Statistical
comparisons were made by one way ANOVA followed by the Newman Keuls test. All
treatments produced significant increases in clotting time compared to saline
supplementation. Aprosulate produced the ~trongest anticoagulant action of the
synthetic analogues, increasing clotting time~ approximately 100 seconds longer than
pentasaccharide or GL-522-Y-1.
Aprosulate vs. pentasaccharide; p < 0.05
Aprosulate vs. GL-522-Y-l;p < 0.05
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samples was not determinable as the blood did not begin to clot over the 45 minute test
period.
Figure 46 depicts the effects of heparin analogue supplementation on the angle
measured on the TEG tracings. The angle :in control samples was 47.4

± 4.1 °. Both

aprosulate and GL-522-Y-1 significantly reduced the angle relative to control (p < 0.05)
indicating a slower clot formation. The angle in aprosulate supplemented blood was 26.0

±

2.0° compared with 43.8

±

4.1° for GL-522-Y-l supplemented blood. The angle

determined from aprosulate treated samples was significantly lower than that determined
for GL-522-Y-1 treated blood_ (p < 0.05). The angle was not determinable for
pentasaccharide treated samples.

10. Studies in Platelet Based Systems
a. Agonist Induced Platelet Aggregation
The effects of aprosulate, GL-522-Y-1, heparin and pentasaccharide on agonist
induced platelet aggregation were examined in a platelet rich plasma system in response
to epinephrine, ADP, arachidonic acid, thrombin, and collagen. All test agents were
supplemented to the plasma at a :fmal concentration of IO ,ug/mL. Agonists were used at
concentrations listed in "Materials and Methods". Maximal percent aggregation as well
as the slope of the aggregation response were detennined from the tracings. These results
are tabulated in Tables 44 and 45. Figure 47 depicts a comparison of the effect of
aprosulate, GL-522-Y-1, heparin, and pentasaccharide on thrombin induced aggregation.
In panel A, a comparison of the aggregation response is observed. Thrombin caused a
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Figure 45. Effect of heparin analogues on the TEG following ex vivo supplementation.
TEG analysis was performed on freshly drawn blood supplemented with either
aprosulate, GL-522-Y-1, or pentasaccharide at a final concentration of 25 µM. The
results represent the mean + one standard deviation of the K-time determined on 10
volunteers in each treatment group. Statistical comparisons were made by one way
ANOVA followed by the Newman Keuls multiple comparison test. GL-522-Y-1 did
not prolong the K-time relative to control. Aprosulate doubted the K-time relative to
saline supplemented controls. Blood supplemented with pentasaccharide did not clot
over the course of the experiment, thereby preventing a determination of K-time on
these samples.
Aprosulate vs. control; p < 0.05
Aprosulate vs. GL-522-Y-l; p < 0.05
GL-522-Y-1 vs. control; p > 0.05
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Figure 46. Effect of heparin analogues on the TEG following ex vivo supplementation.
TEG analysis was performed on freshJy drawn blood supplemented with either
aprosulate, GL-522-Y-1, or pentasaccharide at a :final concentration of 25 µM. The
results represent the mean + one standard deviation of the angle determined on 10
volunteers in each treatment group. Statistical comparisons were made by one way
ANOV A followed by the Newman Keuls multiple comparison test. Aprosulate
supplementation resulted in a larger decrease in angle than did supplementation of GL522-Y-1. The angle could not be calculated on pentasaccharide supplemented samples
as the blood did not clot over the course of the ex.periment.
Aprosulate vs. controJ; p < 0 .OS
Aprosulate vs. GL-522-Y-l;p < 0.05
GL-522-Y-1 vs. control; p < 0.05

176
94 % aggregation response in saline supplemented PRP. Both aprosulate and heparin
significantly attenuated the aggregation response (p

< 0. 05) relative to saline

supplemented plasma. Addition of 10 µ.gJmL aprosulate to the PRP resulted in a 50 %
decrease in the aggregation response. 10 µ.gJmL heparin almost completely inhibited the
proaggregatory actions of thrombin. In the heparinized PRP, only 7 % aggregation was
noted. Neither GL-522-Y-1 nor pentasaccharide were able to inhibit thrombin induced
platelet aggregation at the concentration tested. In panel B, the slopes of the aggregation
responses in the presence of test agent are compared. As with the aggegation response,
only aprosulate and heparin were able to significantly reduce the slope of the aggregation
response. The aggregation response in aprosulate supplemented plasma exhibited a slope
which was one third that measured in control PRP. The responses to epinephrine, ADP,
arachidonic acid,

and collagen

were

not significantly effected by

analogue

supplementation.

b. Heparin Induced Thrombocytopenia Screening
The effect of aprosulate, GL-522-Y-l, heparin and pentasaccharide in a heparin
induced thrombocytopenia screening assay is depicted in Figure 48. In this assay, platelet
rich plasma is incubated with the test agent and serum from a known HIT positive pool.
Platelet aggregation upon addition of the test agent and the serum indicates a positive
HIT potential. Both heparin and aprosulate concentration dependently increased the
degree of platelet aggregation. In PRP supplemented with only HIT positive serum, 8.3

± 1.1

% aggregation was observed. At concentrations above 11 ,ug/mL, aprosulate and
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Figure 47. Effect of aprosulate, GL-522-Y-l, heparin and pentasaccharide on platelet
aggregation in a platelet rich plasma system. The results represent the mean + SEM
of 10 donors for each agent. All test agents were supplemented to plasma at a final
concentration of 10 µglmL. Statistical comparisons were made by one way ANOV A
followed by the Newman Keuls multiple comparison test (aggregation; dF = 49, F
= 532.0, p < 0.0001. slope; dF = 49, F = 410.6, p < 0.0001). *p < 0.05 vs.
control was considered statistically significant. Data are compiled in Tables 44 and 45.
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Figure 48. Comparative effect of synthetic heparin analogues ina heparin induced
thrombocytopenia screening assay. In this assay, platelet aggregation is induced by the
test agent and serum from a heparin induced thrombocytopenic individual. All results
represent the mean ± SEM of 10 blood donors. Statistical comparisons between agent
and control were made using one way ANOVA followed by the Newman Keuls
multiple comparison test. *p < 0. 05 was considered statistically significant. Data are
compiled in Table 46.
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heparin produced significantly higher levels of aggregation than control (p < 0.05).
Neither pentasaccharide nor GL-522-Y-1 produced a significant increase in the amount
of platelet aggregation measured in this assay. At a concentration of 22 µ.g/m.L, heparin
and aprosulate produced a comparable 22 % level of aggregation. At equigravimetric
concentrations, aprosulate produced a stronger aggregation response than either GL-522Y-1 or pentasaccharide (p < 0. 05; ANOV A). Aggregation levels determined in these
studies are tabulated in Table 46.

C. In ViJJo Study Results
The in vivo studies are designed to demonstrate the relative antithrombotic and
hemorrhagic effects of these analogues after intravenous and subcutaneous adminstration.
Well defined animal models were used to detennine the dose response of the
antithrombotic and bleeding effects. In addition, the plasmatic pharmacodynamic response
which is related to the ATIII and HCII mediated effects was also investigated. The role
of functional TFPI in relation to the observed pharmacologic action was investigated by
measuring the release of this agent.

1. Dose-response in the Rab bit Stasis thrombosis Model

Following Intravenous Admjuistration
A rabbit model of stasis thrombosis was used to assess the antithrombotic
activity of heparin, aprosulate, GL-522-Y-1, and pentasaccharide. In this model, clots
were formed in response to a stasis of blood flow in the jugular vein segment and a
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hypercoagulable state induced by injection of an activated prothrombin complex
concentrate.
In the intravenous dose-response study, test agents were administered via the
marginal ear vein following drawing of the baseline blood sample. Control animals were
administered saline at a dose of 0. 1 mL/kg. The thrombogenic challenge was
administered after a 5 minute drug circulation time. Clots were scored visually after 10
or 20 minutes stasis time according to the scale described in "Materials and Methods".
Statistical differences between the clot scores obtained in treated and control animals
were assessed using the Kruskal-Wallis non-parametric analysis of variance. Specific
comparisons were made using the Mann-Whitney U test. All agents produced a dosedependent decrease in clot score. Potency was evaluated by fitting the individual data
points to a straight line by least squares regression. ED 5() values were extrapolated from
these regression lines based on a clot score at 10 minutes stasis time of 2.9 in saline
treated control animals. Clot scores for each intravenous treatment are tabulated in Table

47.
Dose response curves for the antithrombotic activity measured after a 10 minute
stasis time following intravenous administration are depicted in Figure 49. Heparin was
observed to be the most potent of the agents tested with an ED50 value of 1. 7 nmol/kg.
Doses greater than or equal to 2. 4 nmol/kg produced a statistically significant reduction
in thrombus formation (p

< 0.05). Pentasaccharide was the most potent of the synthetic

analogues with an ED50 value of 20 nmollkg. Statistical significance was achieved relative
to control at doses higher than 14 nmol!kg. The ED.s<J in aprosulate treated animals was
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Figure 49. Comparison of the antithrombotic actions of heparin analogues in a rabbit
model of stasis thrombosis. The antithrombotic activity of aprosulate, GL-522-Y-1,
heparin, and pentasaccharide were determined using the rabbit stasis thrombosis
model. Dose-response curves of the clot scores obtained following a stasis time of 10
minutes are depicted. Drug was allowed to circulate for 5 minutes prior to the
administration of the thrombogenic challenge. 7.5 Ulkg FEIBA was used as a
thrombogenic challenge. The results represent the mean ± S.E.M. of 5 rabbits per
treatment group. Saline treatment resulted in a mean clot score of 2.9 ± 0.1. All
agents produced a dose-dependent antithrombotic action. The rank order potency of
antithrombotic activity was observed to be heparin > pentasaccharide > aprosulate
> GL-522-Y-1. Statistical comparisons were made using the Kruskal-Wallis nonparametric analysis of variance following by the Mann-Whitney U test. ·p < 0.05 vs.
control. ~ < 0.01 vs. control. Data are compiJed in Table 47.
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determined to be 93 nmol/kg. Aprosulate doses greater than 104 nmol/kg produced
significant antithrombotic effects. GL-522-Y-1 was the weakest of the agents tested with
an ED50 equal to 662 nmol/kg. All doses tested produced a significant antithrombotic
action. The slope of the GL-522-Y-1 dose-response curve was noted to be different from
those of the other agents.
Figure 50 presents the dose-response curves for the antithrombotic actions of
the synthetic heparin analogues after a 20 minute stasis time. A much weaker
antithrombotic activity was observed following 20 minutes stasis time compared to the
10 minute stasis time point. AdditionaUy, a weak dose-response was observed where only
the highest doses of heparin and pentasaccharide resulted in clot scores less than 2.
Aprosulate produced a statistically significant reductfon in clot score after 20 minutes of
stasis only at a dose of 209 nmol!kg (p < 0.05 vs. control). Both heparin and
pentasaccharide also significantly inhibited clot formation after 20 minutes stasis at the
highest dose tested (p

< 0.01 vs. control). GL-522-Y-1 was ineffective at inhibiting

thrombus formation after 20 minutes stasis. ED 50 values based on this data were not
calculated.

2. Dose-resp.onse in the Rabbit Stasis Thrombosis Model
Following Subcutaneous Administration
Relatively higher doses of each agent were required to prevent thrombus
formation following subcutaneous administration. Dose response curves for the
antithrombotic activity are depicted in Figure 5 L The antithrombotic activity was
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Figure 50. Comparison of the antithrombotic ac6ons of heparin analogues in a rabbit
model of stasis thrombosis. The antithrombotic actjvity of aprosulate, GL-522-Y-1,
heparin, and pentasaccharide were determined using the rabbit stasis thrombosis
model. Dose-response curves of the dot scores obtained following a stasis time of 20
minutes are depicted. Drug was allowed to circulate for 5 minutes prior to the
administration of the thrombogenic challellge. 7.5 Ulkg FEIBA was used as a
thrombogenic challenge. The results represent the mean ± S.E.M. of 5 rabbits per
treatment group. Saline treatment resulted in a mean dot score of 3.6 ± 0.3. The
rank order potency of antithrombotic activity was observed to be heparin >
pentasaccharide > aprosulate > GL-522-Y-I. Statistical comparisons were made
using the Kruskal-Wallis non-parametric analysis of variance following by the MannWhitney U test. *p < 0.05 vs. control. 11p < 0.01 vs. control. Data are compiled in
Table 47.
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Figure 51. Comparison of the antithrombotic actions of heparin analogues in a rabbit
model of stasis thrombosis. The antithrombotic activity of aprosulate, GL-522-Y-1,
heparin, and pentasaccharide were determined using the rabbit stasis thrombosis
model. Dose-response curves of the clot scores obtained following a stasis time of 10
minutes after subcutaneous administration a.re depicted. An absorption time of 2 hours
was utilized prior to administration of the thrombogenic challenge. 7.5 U/kg FEIBA
was used as a thrombogenic challenge. The results represent the mean ± S.E.M. of
5 rabbits per treatment group. Saline treatment resulted in a mean clot score of 2.9
+ 0.1. All agents produced a dose-dependent decrease in clot score. The rank order
potency of antithrombotic activity was observed to be heparin > poo.tasaccharide >
aprosulate > GL-522-Y-l. Statistical comparisons were made using the KruskalWallis non-parametric analysis of variance following by the Mann-Whitney U test. *p
< 0.05 vs. control. #p < 0.01 vs. contro1. Data are compiled in Table 48.
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measured two hours post- administration of the test agent. Each agent was able to prevent
thrombus formation in a dose-dependent manner. Individual clot scores for the various
agents studied are presented in Table 48. Potency was evaluated as described above. The
same rank order potency was observed as in the intravenous study. Heparin was the most
potent with an ED50 calculated to be 0.043 µmol/kg. Doses greater than 0.048 µmollkg
resulted in significant reductions of clot scores (p

< 0.01). The ED50 for pentasaccharide

was approximately three fold higher at 0.12 µmol/kg. All doses of pentasaccharide tested
produced significant reductions in clot score. Aprosulate and GL-522-Y-1 were
considerably weaker with ED50 values of 2.2 and 12.3 ,umol/kg, respectively.
After 20 minutes stasis time following subcutaneous administration, heparin,
aprosulate and pentasaccharide exhibited a progressive, dose-dependent decrease in clot
score with increasing dose as shown in Figure 52. Such an effect was not observed in
GL-522-Y-1 treated rabbits as all clot scores remained greater than 3 regardless of dose
(p = 0.408; Kruskal-Wallis). ED50 values for heparin, aprosulate, and pentasaccharide

were determined to be 0.058, 2.74, and 0.17 ,arnollkg, respectively based on a clot score
of 3. 6 for the saline treated control animals. Doses greater than 2 µmol/kg aprosulate
significantly reduced clot scores compared to control. Only the highest doses of heparin
and pentasaccharide produced a significant reduction in clot score.

3. Time Dependent Antithromboiic Effects in the Rabbit Stasis
Thrombosis Model Following Intravenous Administration
The time dependence on the antithrombotic activity of heparin analogues was
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Figure 52. Comparison of the antithrombotic actions of heparin analogues in a rabbit
model of stasis thrombosis. The antithrombotic activity of aprosulate, GL-522-Y-1,
heparin, and pentasaccharide were determined using the rabbit stasis thrombosis
model. Dose-response curves of the clot scores obtained following a stasis time of 20
minutes after subcutaneous administration are depicted. An absorption time of 2 hours
was utilized prior to administration of the thrombogenic challenge. 7.5 U/kg FEIBA
was used as a thrombogenic challenge. The results represent the mean ± S.E.M. of
5 rabbits per treatment group. Saline treatment resulted in a mean clot score of 3.6
+ 0.3. Clot scores were decreased in a dose-dependent manner by heparin,
pentasaccharide and aprosulate. GL-522-Y-l administration did not effect the clot
score. The rank order potency of antithrombotic activity was observed to be heparin
> pentasaccharide > aprosulate > GL-522-Y-L Statistical comparisons were made
using the Kruskal-Wallis non-parametric analysis of variance following by the MannWhitney U test. ·p < 0.05 vs. control. i;p < 0.0 l vs. control. Data are compiled in
Table 48.
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Figure 53. Comparison of the antithrombotic activ1ty of heparin analogues as
determined using the rabbit stasis thrombosis model. The time-dependence on the
antithrombotic activity of the synthetic heparin analogues was determined by
administering an equally antithrombotic dose of each agent intravenously and
determining clot scores at various time points post-administration. 10 minutes stasis
time was utilized. Each point represents the mean ± SEM of 5 rabbits. The duration
of antithrombotic activity was shortest for heparin. Pentasaccharide produced a
statistically significant antithrombotic effect at time points out to 240 minutes postadministration. Statistical comparisons were made using the Kruskal-Wallis test
followed by the Mann-Whitney U test. 'p < 0.05 vs. control. lfp < 0.01 vs. control.
No statistical differences were noted between clot scores at 5 minutes circulation time.
Data are compiled in Table 49.
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determined by varying the circulation time after administration of a selected
antithrombotic dose of each agent. Individual clot scores are tabulated in Table 49. The
time-response curves following intravenous administration are depicted in Figure 53. No
statistical differences were noted in the clot scores determined after 5 minutes circulation
time for the various agents (p = 0. 680). The antithrombotic activity of heparin was the
shortest lived of the agents tested. By 60 minutes, a statistically significant antithrombotic
effect was no longer obtained. Aprosulate did not exhibit any antithrombotic actions 2
hours after administration. Both GL-522-Y- l and pentasaccharide exhibited a significant
antithrombotic effect at 2 hours (p < 0.05, pentasaccharide vs. control and GL-522-Y-l

vs. control). Pentasaccharide maintained its antithrombotic effect at 4 hours. GL-522-Y-1
was not tested at this time point.
After 20 minutes stasis time, the antithrombotic activity of these agents was
rapidly diminished. By 60 minutes, all agents failed to produce significant antithrombotic
effects relative to control. These time-response curves are depicted in Figure 54.

4. Time Dependent Antithrombotic Effects in a Rabbit Stasis
Thrombosis Model Following Sub cutaneous Administration
The time-response curves for

aprosulate,

GL-522-Y-1, heparin,

and

pentasaccharide following subcutaneous administration are depicted in Figure 55.
Individual clot scores are tabulated in Table 50. At 2 honrs post-administration, all agents
exhibited equivalent antithrombotic activity (p = 0.184). The antithrombotic activities
of heparin and GL-522-Y-1 were rapidly diminished. By 4 hours post-administration, an
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Figure 54. Comparison of the antithrombobc actLv1ty of heparin analogues as
determined using the rabbit stasis thrombosis model. The time-dependence on the
antithrombotic activity of the synthetic heparin analogues was determined by
administering an antithrombotically effective dose of each agent intravenously and
determining clot scores a various time points post-administration. 20 minutes stasis
time was utilized. Each point represents the mean ± SEM of 5 rabbits.
Antithrombotic activity was rapidly diminished at circulation times greater than 5
minutes. Statistical comparisons were made using the Kruskal-Wallis test followed by
the Mann-Whitney U test. • p < 0.05 vs. control. 'p < 0.01 vs. control. Data are
compiled in Table 49.
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Figure 55. Comparison of the anti.thrombotic act1v1ty of heparin analogues as
determined using the rabbit stasis thrombosis model. The time-dependence on the
antithrombotic activity of the synthetic heparin analogues was determined by
administering an antithrombotically effective dose of each agent subcutaneously and
determining clot scores a various time points post-administration. 10 minutes stasis
time was utilized. Each point represents the mean + SEM of 5 rabbits. The
antithrombotic activity of GL-522- Y-1 and heparin was diminished after a 4 hour
circulation time whereas aprosulate and penta:saccharide continued to produce a
significant antithrombotic effect. Stati:stical comparison:s were made using the KruskalWallis test followed by the Mann-Whitney U test. "p < 0.05 vs. control. #p < 0.01
vs. control. No statistical differences were noted between clot scores at 5 minutes
circulation time. Data are compiled in Table 50.
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average clot score of 2 .4 was observed in GL-522-Y -1 treated rabbits. This clot score
was not significantly different from control. The antithrombotic activity of heparin was
no longer present after a four hour circulation time. The antithrombotic activities of
aprosulate and pentasaccharide decreased at a slower rate than for heparin or GL-522-Y1. After a four hour circulation time, both agents produced a significant antithrombotic
effect (p

< 0.01 for aprosulate and p < 0.05 for pentasaccharide). By 6 hours post-

administration, the antithrombotic activity of aprosulate and pentasaccharide was no
longer significantly different from control.
The relative thrombogenic effects in this model at 20 minutes stasis time were
stronger than the ones observed at 10 minutes stasis. Time-response curves are depicted
in Figure 56. At 2 and 4 hours post administration of aprosulate, significant reductions
in clot score were achieved (p < 0.01 andp < 0.05, respectively). Clot scores in these
animals were less than 2. At all time points tested following GL-522-Y-1, heparin, and
pentasacharide administration, a significant reduction in clot score was not observed.
The potencies of each agent follow:ing intravenous and subcutaneous
administration are compared in Table 7. Potency was evaluated by extrapolating the dose
which produced a clot score one half that observed in saline treated rabbits from the dose
response curves for each agent. Following intravenous administration, heparin exhibited
the highest potency. The potencies ofpentasaccharide, aprosulate and GL-522-Y-1 were
observed to be 12, 55, and 390 fold higher than heparin, respectively. Following
subcutaneous administration, the potency of pentasaccbaride was only 3 fold higher than
that of heparin. Aprosulate and GL-522-Y-1 were considerably weaker, exhibiting
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Figure 56. Comparison of the an tithrombotic actlvtty of heparin analogues as
determined using the rabbit stasis thrombosis model. The time-dependence on the
antithrombotic activity of the syntlletic heparin analogues was determined by
administering an antithrombotically effectlve dose of each a.gent subcutaneously and
determining clot scores a various time points post-administration. 20 minutes stasis
time was utilized. Each point represents the mea.n ± SEM of 5 rabbits. Statistical
comparisons were made using the Kruskal-Wal]js test followed by the Mann-Whitney
U test. • p < 0.05 vs. control. #p < 0.01 vs. control. Data are compiled in Table 50.

193

TABLE 7
ED50 VALVES FOR SYNTHETIC HEPARIN ANALOGUES FOLLOWING
INTRAVENOUSANDSUBCUTANEOUSAD:MINISTRATION
IN A RABBIT STASIS TIIRO:MBOSrs MODEL
IV (nmoUkg)

SC (µmol/kg)

Aprosulate

93.4

2.20

GL-522-Y-l

662.4

Heparin

Pentasaccharide

12.3

1. 7

0.043

20.6

0.12

Potency of each agent is compared by detennining the dose which inhibits 50 % clot
formation. This was achieved by fitting the mdividual concentration - clot score points
to a straight line. Doses providing 50 % inhibition were extrapolated from the curves
based on a clot score of 2.9 ± 0.1 for saline treated animals after 10 minutes stasis
time.
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Figure 57. Comparison of the antithrombotic activity of heparin analogues in a rat
model of thrombosis. Jugular patency was assessed by Doppler flow measurement.
Data presented represents the mean + SEM for 5 rats in each treatment group. Saline
treated control rats required 4.4 ± 0.3 clampings on average for jugular occlusion.
All agents were administered via the left femoral vein 5 minutes prior to the initiation
of clamping. Each agent produced a dose-dependent increase in clamping number. The
rank order potency of antithrombotic activity in this model was observed to be heparin
> pentasaccharide > aprosulate > GL-522-Y- L. Sta.Ustical comparisons were made
by one way ANOVA followed by the Newman-Keuls multiple comparison test. *p <
0.05 vs. control. Data are compiled in Table 5 L.
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potencies of 2.2 and 12.3 µmol/kg, respectively.

5. Dose-response in the Rat Jugular Vein Clamping Model
Following Intravenous Administration
Figure 57 depicts the dose-response curves for heparin, aprosulate, GL-522-Y-1
and pentasaccharide in a rat jugular vein clamping model of thrombosis following
intravenous administration. An increasing number of clampings is reflective of the
antithrombotic activity of an agent. Saline treated control rats required 4.4

± 0.3

clampings on average to cause jugular occlusion. Clamping numbers for each intravenous
administration are tabulated in Table 51.
Increasing aprosulate dosages from 0.1 to 1.0 µmol/kg dose-dependently
increased the number of clampings required for occlusion compared to control. Statistical
analysis of this data using one way ANOVA followed by the Newman-Keuls multiple
comparison test indicated that the clamping numbers for the three highest doses were
significantly higher than control (p < 0.05). GL-522-Y-1 was antithrombotically active
at approximately 10 fold higher doses than aprosulate. A dose-dependent increase in
clamping number was observed over a dose range of 1.9 to 7. 8 ,amol/kg. Increasing the
dose beyond 7. 8 µmol/kg did not significantly increase the number of clampings required
for occlusion (7.8 µmol/kg vs. 11.6 p.moUkg, p = 0.751). Heparin also increased the
number of clampings for occlusion in a dose-dependent manner over a dose range of 12
to 95 nmol/kg. At a dose of 95 nmol/kg, the number of clampings exceeded 15.
Pentasaccharide dose-dependently increased the number of clampings needed to occlude
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Figure 58. Comparison of the antithrombotic activity of heparin analogues in a rat
model of thrombosis. Jugular patency was assessed by Doppler flow measurement.
Data presented represents the mean ± SEM for 5 rats in each treatment group. Saline
treated control rats required 4.4 ± 0. 3 clamping.s on average for jugular occlusion.
All agents were administered subcutaneously 2 hours prior to the initiation of
clamping. Each agent produced a dose-dependent increase in clamping number. The
rank order potency of antithrombotic actiYity in this model was observed to be
pentasaccharide > heparin > aprosulate > GL-522-Y-1. Statistical comparisons were
made by one way ANOV A followed by the Newman-Keuls multiple comparison test.
·p < 0.05 vs. control. Data are compiJed in Table 52.
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the vessel. At all doses tested the number of clampings in pentasaccharide treated rats
was significantly higher than in control treated rats (p < 0.05).
To compare the potency of each agent, linear regression was performed on the
log dose vs. clamping number curves. 5 points were used at each dose. The clamping
numbers for the highest dose of GL-522-Y-1 were not used in this analysis as they did
not fit a straight line. Correlation coefficients greater than 0. 80 were obtained for each
set of data. The dose which doubled the baseline number of clampings was extrapolated
from these curves and used as an index of potency. By this analysis, heparin was
observed to be the most potent agent, requiring a dose of 25 nmol/kg to achieve a level
of 8.8 clampings. Pentasaccharide was approximately 3 fold less potent, and aprosulate
required approximately 10 fold more drug to achieve the same effect. GL-522-Y-1 was
the least potent agent, requiring 3. 8 µmol/kg to double the baseline number of clampings.
These potency values are compared in Table 8.

6. Dose-response in the Rat Jugular Vein Clamping Model
Following

Subcutam~ous

Administration

Figure 57 depicts the dose-response curves for heparin, aprosulate, GL-522-Y1, and pentasaccharide in a rat jugular vein clamping model 2 hours following
subcutaneous administration. All agents produced a dose-dependent increase in clamping
number, though the rank order potency was somewhat different than following
intravenous administration. The clamping numbers for all subcutaneous treatments are
tabulated in Table 52. All doses of aprosnla.te produced a statistically significant increase
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TABLE 8
DOSES OF SYNTIIETIC HEPARIN ANALOGUES REQUIRED TO DOUBLE
BASELINE CLAMPING NlThffiERS

IV (,uM)

SC (µM)

Aprosulate

0.28

2.09

GL-522-Y-1

3.84

7.07

Heparin

0.025

0.145

Pentasaccharide

0.071

0.106

Data points for each agent were fitted to a straight line by linear regression.
Treatments producing clamping numbeis which did not fit a straight line (0.012
µmollkg heparin and 13.88 µmol/kg GL-522-Y-1) were excluded from this analysis.
Doses which doubled the baseline c1amp:ing numbeI of 4.4 clampings were
extrapolated from each curve. Correlation coefficients greater than 0.80 were achieved
for each regression curve.
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in clamping number relative to control (p < 0.05; ANOVA followed by NewmanKeuls). A dose of 2. 09 µmo I/kg was detennined to double the baseline clamping number.
GL-522-Y-1 was again the weakest of the agents tested, requiring 7.1 µmol/kg to double
the baseline clamping number. Doses above 6. 7 µmol/kg significantly increased the
number of clampings relative to baseline. Heparin and pentasaccharide were notably
more potent than aprosulate or GL-522-Y-1. Heparin and pentasaccharide exhibited
nearly equal potency for doubling baseline clamping number (0.145 and 0.106 µmol/kg,
respectively). For this analysis, the data obtained. with the lowest dose of heparin, 0.012
µmol/kg, was not included as it did not fit a straight line.
When comparing the doses required for doubling the clamping number
following intravenous and subcutaneous adminst.ration, it was observed that both
pentasaccharide and GL-522-Y-1 are relatively well absorbed, exhibiting SC/IV ratios
of 1.49 and 1.84, respectively. Aprosulate and heparin were absorbed to a lesser degree
and therefore required higher doses subcutaneously to achieve a comparable effect
(SC/IV ratios of 7.5 and 5.8, respectively).

7. Dose-response in the Rabbit Ear Bleeding Model
Following Intravenous Administration
The hemorrhagic potential of aprosulate,

GL-522-Y-1,

heparin,

and

pentasaccharide was determined using a rabbit ear bleeding model. In this model, five
standardized incisions were made in the ear following drug administration, and blood
cells lost from these incisions were collected for ten minutes. The blood cells collected
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were quantitated by hemocytometer and used as an index of bleeding potential. Control
treated animals were administered a dose of 0. l mLJkg saline. Statistical comparisons
of red blood cell counts were made by one way ANOVA followed by the Newman-Keuls
test. p < 0.05 was considered to be statistically significant. Individual data are presented
in Tables 53 to 56.
Figure 59 depicts the dose-response curves for aprosulate, GL-522-Y-l,
heparin, and pentasaccharide in the rabbit ear bleeding model following intravenous
administration. The five standard1zed incisions were made 5 minutes following
administration of the test agent. Both heparin and GL-522-Y- l were observed to linearly
increase blood loss with increasing dose, though over a different concentration range.
Heparin increased blood loss over a concentration range of 0.02 to 0.10 µmollkg. At
doses of at least 0.10 µmolJkg, blood loss significantly higher than control was observed
(p

< 0.05). GL-522-Y-1 produced more blood loss over the concentration range tested.

Significantly higher bleeding compared to control was achieved with doses above 3.36
µmolJkg. Aprosulate produced a significant increase in blood loss compared to control

at all doses tested. This increase was approximately 225 % of control over a dose range
of 0.4 to 2.1 µmolJkg. No dose-dependency was observed. Pentasaccharide did not
increase blood loss at doses as high as 2. 9 1tm0Ukg.
To assess the potency of each agent in produc.ing a bleeding effect, a bleeding
index was calculated. This index was calculated as the dose required to elicit a blood cell
loss 3 times that measured in control treated animals. For heparin and GL-522-Y-1, the
dose response curves were fitted to a straight line by linear regression. The dose eliciting

201

0

1 .0

•
\l

,,.--...._
_J

"'-..

0.8

"'

Aprosulate

GL-522-Y-1
Heparin
Pentasaccharide

*

m

<

0

......-

0.6

x

'-..../

({)

u

0.4

CD

0::::

0.2
0.0
0.01

J

rrI

0. 1

f

1

·--·

10

Dose (µmol/kg)

Figure 59. Hemorrhagic effects of heparin analogues following intravenous
administration in a rabbit ear bleeding model. AU results represent the mean ± SEM
of 5 rabbits per treatment group. Heparin and GL-522· Y-1 exhibited dose-dependent
increases in blood loss. Neither aprosulate nor pentasaccharide treatment resulted in
significant increases in blood loss. Statistical differences were determined by one way
ANOVA followed by the Newman-Keuls test. A p-value less than 0.05 was
considered statistically significant. p < 0.05 vs. control. Data are compiled in Table
53.
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a loss of blood cells equal to 0.21 x 109

/

liter was extrapolated from the curve. For

heparin, this dose was 0.045 µmol/kg. The dose of GL-522-Y-1 was nearly 40 times
higher at 1. 79 µmol/kg. Neither aprosulate nor pentasaccharide reached this level of
blood loss at the highest dose tested. The bleeding :indices for each agent following
intravenous and subcutaneous administration are listed in Table 9.
At 15 minutes post-administration, only GL-522-Y-1 produced a significant
bleeding effect. The dose-response at 15 minutes was similar to that at 5 minutes for this
agent. Neither aprosulate, heparin, nor pentasaccharide produced a significant increase
in bleeding 15 minutes post administration.

8. Dose-response in the Rabbit Ear Bleeding Model
Following Subcutaneous Administration
Hemorrhagic potential was also studied two hours following subcutaneous
administration. In this study, aprosulate, heparin, and GL-522-Y-1 produced significant
dose-dependent increases in bleeding. In aprosulate treated animals, doses above 4
µmol/kg produced significant blood loss compared to control. The dose producing a three
fold increase in blood loss was higher than the highest dose tested (8.4 µmol/kg). GL522-Y-l produced significant increases :in blood loss at doses above 3.4 µmol/kg. The
dose producing a three fold increase :in blood loss was lower than the lowest dose tested
(1.7 µmol/kg). Heparin produced a dose-dependent increase in blood loss at doses above

0.5 µmol/kg. Statistically significant blood loss was observed at heparin doses above 0.95
µmol/kg. The dose which caused a three fold increase in blood loss was extrapolated to
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be 0.64 µmol/kg. Pentasaccharide did not cause significant bleeding at doses below 12
µmol/kg. These results are depicted in Figure 60.

9. Time Dependent Effeds in the Rabbit Ear Bleeding Model
Following Intravenous Administration
Time dependence on the bleeding effect was measured at various time points
following intravenous administration. This data is depicted in Figure 61. Aprosulate
treatment resulted in a small increase in blood loss (150 %) compared to control treated
animals. This effect was statistically significant at S and 30 minutes post-administration.
Blood loss returned to control levels by 60 minutes. GL-522-Y-1 exhibited significant
bleeding at all time points measured. The blood loss was higher at 60 minutes than at 5
minutes post-administration. Heparin administration produced a strong bleeding effect at

5 minutes post administration. This effect decreased with time to levels which were not
significant at 60 minutes. Pentasaccharide administration did not produce significant
increases in blood loss.

10. Time Dependent Effects in the Rabbit Ear Bleeding Model
Following Subcutaneous Administration
Time dependence on the hemorrhagic effects of heparin, aprosulate, and GL522-Y-1 were examined following subcutaneous administration. This data is depicted in
Figure 62. Treatment with 2.1 µmol/kg aprosulate resulted in a statistically significant
increase in blood loss at 1, 2, and 4 hours post-administration. By 6 hours, control levels
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Figure 60. Hemorrhagic effects of heparin analogues following subcutaneous
administration in a rabbit ear bleeding model. All results represent the mean ± SEM
of 5 rabbits per treatment group. Heparin and GL-522-Y-1 exhibited dose-dependent
increases in blood loss. Neither aprosulate nor pentasaccharide treatment resulted in
significant increases in blood loss. Sta.tistkal differences were determined by one way
ANOV A followed by the Newman-Keuls test. A p-value less than 0.05 was
considered statistically significant. p < 0.05 vs. control. Data are compiled in Table
54.
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TABLE 9
BLEEDING INDEX FOR APROSULATE, GL-522-Y-l, HEPARIN, AND
PENTASACCHARIDE IN A RABBIT EAR BLEEDING MODEL
IV (µmol/kg)

SC (µmol/kg)

> 2.09

> 8.38

GL-522-Y-l

1.79

< 1.68

Heparin

0.04

0.64

> 2.90

> 11.60

Aprosulate

Pentasaccharide

Bleeding index was calculated as the dose of a given agent which caused a three fold
increase in the number of RBC's lost relative to control. Values were extrapolated
from the best fit curve of the data. The regression curves exhibited correlation
coefficients greater than 0.94. The highest dose tested is tabulated where an agent did
not significantly increase the amount of bleeding relative to control.
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Figure 61. Time dependence on the hemorrhagic effect of heparin analogues following
intravenous administration in a rabbit ear bleeding model. Each time point represents
the mean ± SEM of 5 rabbits. Heparin exhibited a time-dependent decrease in blood
loss. Neither aprosulate nor pentasaccharide treatment resulted in significant increases
in blood loss. Statistical differences were determined by one way ANOV A followed
by the Newman-Keuls test. A p-value less than 0. 05 was considered statistically
significant. ·p < 0.05 vs. control. Data are compiled in Table 55.

207

1 .5

0

Aprosulate

":/

Heparin

•

GL-522-Y-1

,.---.....
_J

1 .0
""CJ)

*

(

0
..-x
....__,,
(fJ

u
m
er::

0.5
*
~

~

2

3

'*

'*

0

t~

0.0
0

4

5

~

•

6

7

Time (hrs.)

Figure 62. Time dependence on the hemorrhagic effect of heparin analogues following
subcutaneous administration in a rabbit ear bleeding model. Each time point represents
the mean ± SEM of 5 rabbits. Heparin, aprosuJate and GL-522-Y-1 exhibited timedependent decreases in blood loss. Pentasa.ccharide treatment was not examined.
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vs. control. Data are compiled in Table 5 6.
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Figure 63. Effect of intravenous administration of heparin analogues on the celite
ACT. Dose-response curves for aprosulate (pane] A), GL-522-Y-1 (panel B), heparin
(panel C), and pentasaccharide (panel D) in the celite ACT assay on rabbit blood are
presented. Blood was drawn at baseline and 5 minutes post intravenous administration
of the test agent. Fold increase is calculated relative to each individual baseline. Data
represents the mean ± SEM of 3 to 5 rabbits. Both aprosulate and GL-522-Y-1 were
observed to prolong the ACT in a dose-dependent fashion. Heparin and
pentasaccharide did not prolong the ACT over the dose range tested. Statistical
comparisons were made using one way ANOVA followed by the Newman-Keuls test.
"p < 0.05 vs. saline treatment is considered statistically significant. Data are compiled
in Table 57.
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of blood loss had been attained. At a dose of 3.4 µ.mol/kg, GL-522-Y-1 produced a
strong bleeding effect at 3 and 4.5 hours post-administration. By 6 hours, the blood loss
had returned to control levels. The bleeding effect induced by heparin administration was
also lost by 6 hours post-administration.

11. Ex Vivo Anticoagulant Responses
a. celite ACT
Blood samples were drawn from rabbits at baseline and at 5 minutes postadminstration of the test agent in the intravenous dose-response studies for determination
of the celite activated clotting time. Dose-response curves are depicted in Figure 63. In
panel A it is shown that aprosulate produces a weak dose dependent prolongation of the
activated clotting time over the range of 100 10 500 µ.glkg. At 500 ,ug/kg, the ACT was
prolonged 1.12 fold relative to baseline. None of these increases were statistically
significant compared to saline treatment. The dose response curve for GL-522-Y-1 is
shown in panel B. A dose dependent increase in clotting time was observed over a dose
range of 1. 0 to 5. 0 mg/kg with the clotting time reaching 1. 2 fold baseline at a dose of
5.0 mg/kg. All increases in clotting time induced by GL-522-Y-1 administration were

statistically significant relative to saline treatment (p

< 0.05). In panel C, the dose-

response curve for heparin is depicted. No significant changes in the ACT were observed
at heparin dosages which were antithrombotically effective (p > 0.05). Panel D depicts
the dose-response curve for pentasaccharide. A concentration dependent increase in
clotting time was observed with increasing dose from 12.5 to 50 ,ug/kg. These increases
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Figure 64. Effect of intravenous administration of heparin analogues on the celite
ACT. Dose-response curves for GL-522-Y-l (panel A), heparin (panel B), and
pentasaccharide (panel C) in the celite ACT assay on rabbit blood are presented.
Blood was drawn at baseline and 2 hours post subcutaneous administration of the test
agent. Fold increase is calculated relative to each individual baseline. Data represents
the mean ± SEM of 3 to 5 rabbits. Only GL-522-Y-1 was observed to dosedependently prolong the ACT following subcutaneous administration. Statistical
comparisons were made using one way ANOVA followed by the Newman-Keuls test.
*p < 0.05 vs. saline treatment is considered stabstically significant. Data are compiled
in Table 58.
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were not statistically significant (p

>

0. 05).

The dose-response curves for heparin, GL-5 22-Y-1, and pentasaccharide in the
celite ACT following subcutaneous administration are shown in Figure 64. GL-522-Y-1
was observed to increase the ACT in a dose-dependent fashion over the dose range of
10 to 30 mg/kg. At a dose of 30 mg/kg, the ACT was :increased to 1.2 fold baseline.
None of these increases was determined to be statistically significant (p > 0.05). Heparin
dosages from 250 to 1000 µg/kg produced a dose-independent increase in the ACT. Only
the clotting time at a dose of 500 µg!kg was statistically significant compared to saline
treated controls. Pentasaccharide did not significantly increase activated clotting times (p

> 0.05). Individual celite ACT clotting times are tabulated in Tables 57 and 58.

b. Thrombelastographic Analysis
Figure 65 depicts the effect of intraYenous administration of aprosulate, GL522-Y-1, heparin, and pentasaccharide on the TEG in whole rabbit blood. Data for the
R-time, or time to clot formation, are presented. All results are presented as fold increase
relative to baseline. Fold increase was detenn:ined using each individual rabbits baseline.
In panel A, the effect of aprosulate on R-time is shown. While a dose-dependent
prolongation of the time to clot was observed, statistical significance was not achieved
due to the high variability, particularly at the 500 µ.glkg dosage. Following a 500 µglkg
dosage, a mean fold increase of 4. 0 was detennined. In panel B it is observed that GL522-Y-1 also dose-dependently prolonged the R-time. As with aprosulate, wide variations
prevented these increases from being statistically significant. At a dose of 5.0 mg/kg, the
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Figure 65. Effect of intravenous administration of heparin analogues on the R-time of
the thrombelastograph. Both aprosulate and GL-522-Y-l dose-dependently prolonged
the R-time (panels A and B, respectively). Heparin and pentasaccharide elevated the
R-time in a dose-independent manner (panels C and D, respectively). Results represent
the mean ± SEM of 3 to 5 observations_ Statistical significance was assessed for each
agent using one way ANOVA followed by the Newman-Keuls multiple comparison
test. All p values are for treatment versus saline treated control animals. Data are
compiled in Table 59.
Aprosulate : p = 0.146

GL-52-Y-1 : p = 0.168
Heparin : p = 0.636
Pentasaccharide : p 0.388.
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Figure 66. Effect of subcutaneous adminjstration of heparin analogues (GL-522-Y-1
(A), heparin (B), and pentasaccharide (C)) on the R-time of the thrombelastograph.
Results represent the mean ± SEM of 3 to 5 observations. None of the agents were
observed to prolong the R-time following subcutaneous administration. Statistical
significance was assessed for each agent using one way ANOV A followed by the
Newman-Keuls multiple comparison test. All p values are for treatment versus saline
treated control animals. Data are compiled in Table 60.
GL-52-Y-1 : p = 0.842
Heparin : p = 0.113
Pentasaccharide : p = 0.251
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R-time was prolonged 2.3 fold baseline. The effect of heparin administration on the Rtime is shown in panel C. The R-tirne was prolonged at doses above 12.5 µg/kg in a
dose-independent manner. There was no difference in the prolongations produced by
12.5, 25, or 50 µglkg. Pentasaccharide also elevated the R-time in a dose-independent
manner. These results are depicted in panel D. Individual R-time values are presented
in Table 59.
Figure 66 depicts the effects of subcutaneous administration of GL-522-Y-1,
heparin and pentasaccharide on the R-time as measured by thrombelastography. The
dose-response curve for GL-522-Y-1 is pictured in panel A. Small changes in the R-time
were evident with high doses of GL-522-Y-1. Wide variation, particularly at a dose of
20 mg/kg prevented any statistically significant differences. Heparin increased the R-time
at all doses tested, though not in a dose-dependent manner (panel B). The smallest
increase in R-time was observed at a dose of 500 µglkg. At a dose of 1 mg/kg, heparin
prolonged the R-time to 2.5 fold baseline. As with heparin, a dose-independent increase
in R-time was observed following pentasaccharide administration. In panel C in is
observed that at the highest dose, the R-time was prolonged 1.6 fold over baseline. Rtime values are presented in Table 60.

c. Ex Vivo Anticoagulant Effects as Measured by the Global Clotting Assays
Blood samples were drawn at baseline and immediately prior to administration
of the thrombogenic challenge for the purpose of detennining anticoagulant activity at
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these time points. PT, APTI, Heptest®, and 2.5 U thrombin times were performed on
plasma derived from these samples. Due to the wide variation of the clotting parameters
among the rabbits, anticoagulant activity was expressed as fold increase over baseline.
This anticoagulant activity was plotted against clot score and a correlation coefficient for
each agent was determined. The clotting time data is presented in Tables 61 to 68.
Following intravenous administration, none of the agents dose-dependently
prolonged the prothrombin time. The APTf was dose-dependently increased by
aprosulate administration. At the highest dose tested, 500 µ.glkg, the APTT was increased
1.5 fold above baseline values. A correlation coefficient of 0.85 was observed between
clotting times in the APTI assay and clot scores following 10 minutes stasis time.
Administration of the other agents did not produce a dose-dependent increase clotting
time in this assay.
In the Heptest® assay, aprosulate was observed to increase the clotting time in

a dose-independent manner. Heparin and GL-522-Y-1 adrnini stration resulted in elevation
of the clotting time only at the highest dose tested. Both agents increased clotting times
to approximately 1.4 fold baseline. Pentasaccharide produced a dose-dependent elevation
of the Heptest® clotting time which demonstrated a strong correlation with the observed
antithrombotic activity (r = 0.97). At a pentasaccharide dose of 100 µglkg, the Heptest®
clotting time was 2. 7 fold baseline.
Pentasaccharide was the only agent which did not prolong the 2.5 U thrombin
time following administration. Aprosulate, GL-522-Y-l, and heparin all increased the
clotting time in this assay in a dose-dependent fashion. Correlation coefficients between

216
clotting time and clot scores were 0.87, 0.89 and 0.94 for aprosulate, GL-522-Y-1, and
heparin, respectively. Heparin exhibited the highest potency in the thrombin time assay,
prolonging the clotting time 3.2 fold baseline following a dose of 50 µg/kg. Aprosulate
increased clotting time 2.6 fold following a dose of 500 µ.g/kg. GL-522-Y-1
administration produced the least potent increase in thrombin time, elevating the clotting
time 1. 9 fold at a dose of 5000 µ.g/kg.
As following intravenous administration, none of the agents produced a dosedependent increase in prothrombin time following subcutaneous administration. In the
APTT assay, heparin was the only agent to dose-dependently prolong the clotting time.
This increase in clotting time correlated well with the clot scores determined after 10
minutes stasis (r = 0.98). The AP1T was increased 1.3 fold after a dose of 1 mg/kg
heparin.
In the Heptest® assay, both heparin and pentasaccharide were observed to dosedependently prolong the clotting time. For a given gravimetric dose of each agent,
pentasaccharide produced a larger increase in the clotting time. Following a dose of 1
mg/kg, heparin produced a 2 fold increase in clotting time relative to baseline whereas
administration of pentasaccharide at a dose of 250 µgfkg produced a similar prolongation.
In the case of both agents, the prolongation of the clotting time was highly correlated
with the antithrombotic activity in the stasis thrombosis model. Correlation coefficients
of 0. 98 and 0. 90 were determined for heparin and pentasaccharide, respectively.
In the 2.5 U thrombin time, heparin was the only agent observed to increase the
clotting time in a dose-dependent fashion. Following a dose of 1 mg/kg, the clotting time
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was increased more than 5 fold baseline. This prolongation of the clotting time correlated
well with heparin's antithrombotic activity (r = 0.99).

12. Ex Vivo Functional TFPI Levels
TFPI release was measured in rabbit plasma samples obtained during the rabbit
stasis thrombosis model. TFPI was measured using a modified functional assay on
baseline and post-drug samples. The post-drug samples chosen were those from rabbits
treated with the highest intravenous dosage of each agent. These treatments included 50

µglkg heparin, 100 µglkg pentasaccharide, 500 µg/kg aprosulate, and 5 mg/kg GL-522Y-1. At these doses, there was equivalent antithrombotic activity in the stasis thrombosis
model. TFPI levels expressed as U I mL were determined in each sample relative to a
calibration curve made by diluting normal rabbit pool plasma. NRP is designated as
having 1 U/mL TFPI. Fold increase over baseline was detennined for each post-drug
sample. Figure 67 depicts the results of this analysis. The largest increase in functional
TFPI levels were observed following heparin administration. Levels in the post-drug
samples were 180 % those in the baseline samples of the same rabbits. This increase in
TFPI by heparin was significantly larger than that observed in saline, aprosulate, or
pentasaccharide treated rabbits (p

< 0. 05). The synthetic analogues increased plasma

TFPI levels to varying degrees. Pentasaccharide administration produced the smallest
increase in TFPI levels. None of the increases produced by the synthetic analogues were
significantly higher than in the saline treated control rabbits.
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Figure 67. TFPI release by heparin analogues in rabbits following intravenous
administration. TFPI levels were determined using a modified functional assay. All
results are expressed as the mean ± SEM fold increase relative to baseline of n = 5
rabbits. Doses represent those producing maximal antithrombotic activity in the stasis
thrombosis model. Only heparin administration was observed to significantly increase
the functional TFPI levels measured in plasma. Statistical comparisons were made by
one way ANOV A (p = 0.008) followed by the Newman Keuls test. "p < 0.05 was
considered statistically significant.
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Figure 68. TFPI levels following intravenous administration of IO mg/kg GL-522-Y-1
to monkeys. TFPI levels were measured using an amidolytic functional assay (panel
A) and an immunologic assay (panel B). The results in panel A represent the mean
± SEM of 3 monkeys. TFPI levels were compared using one way ANOVA followed
by the Newman Keuls test. *p < 0.05 was considered statistically significant. The
results in panel B represent the TFPI levels in one of the monkeys analyzed with the
functional assay. Both functional and immunologic TFPI levels were observed to peak
5 minutes post-administration of GL-522-Y-1. Functional TFPI levels were no longer
observed to be significantly elevated form control at 240 minutes post-administration.
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D. Other In Vivo Studies in Various Animal Models
Non-human primates offer a unique opportunity to determine the modulation of
endogenous mediators such as TFPI after heparin administration. To determine the
relative release of TFPI by some of these analogues, non-human primates were used.
Newly developed immunologic methods along with functional assays for TPFI were
employed.

1. Effect of GL-522-Y-1 on TFPI Levels in Non-human Primates
The release of TFPI following intravenous administration of GL-522-Y-1 to

Macaca fascicularis was determined using both the functional and immunologic assays.
Three monkeys received an intravenous dose of 10 mg/kg GL-522-Y-l. Blood samples
were drawn at baseline and at 5, 15, 30, 60, 120, 240, and 360 minutes postadministration. Figure 68 depicts the time response curves of the plasma TFPI levels
following GL-522-Y-1 administration. In panel A, the functional TFPI levels expressed
as % Xa inhibition at various time points are shown. At 5 minutes post-administration,
a peak of 54

± 2.5

% Xa inhibition was observed. The TFPI level decreased to a level

below 40 % inhibition by 15 minutes and then progressively declined with time through
360 minutes. TFPI levels were significantly eleYated from 5 to 120 minutes postadministration (p < 0.05). A wide variation in the inhibition of functional TFPI activity
was observed in these monkeys. In panel B, a similar pattern of immunologic TFPI levels
was observed. Using the immunologic assay, TFPl levels were observed to peak 2.25
fold in relation to a human TFPI based standard at 5 minutes post-administration. TFPI
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Figure 69. TFPI levels following intravenous adminstration of pentasaccaharide to
monkeys. TFPI levels (panel A) were determined using an immunologic assay. The
results represent the mean ± SEM of I to 3 monkeys per treatment group. Post-drug
results were compared to baseline using ANOV A followed by the Newman Keuls test.
*p < 0.05 was considered statistically significant. TFPI antigen levels were not
effected by pentasaccharide administration. The Heptest® clotting time was dosedependently elevated at 5 and 60 minutes post-pen ta.saccharide administration.
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levels reached 100 % normal human plasma by 240 minutes post-administration. It is
unknown why the TFPI level in the baseline sample was unusually low.

2. Immunologic TFPI Levels in Primates Treated with Pentasaccharide
The release of TFPI following intravenous administration of pentasaccharide to

Macaca mulatta was determined by immunologic assay. Individual groups of monkeys
received an intravenous injection of pentasaccharide at a dose of either 100, 250, or 500
µg/kg. Blood samples were drawn at baseline and at 5 and 60 minutes post-administration
of pentasaccharide. These results are presented in Figure 69. In panel A, the effect of
increasing pentasaccharide dosage on plasma TFPI levels is shown. Baseline TFPI
antigen levels in monkey plasma were determined to be 16 ng/mL. No increase in TFPI
levels was observed at any of the pentasaccharide dosages studied despite a dosedependent increase in the Heptest® clotting time following administration. The effect of
the pentasaccharide dosages on the Heptest® are shown in panel B. Significant, dosedependent prolongations of the clotting time were observed at 5 and 60 minutes postadministration of 250 and 500 µg/kg pentasaccharide (p

< 0.05). Following

administration of 500 µg/kg pentasaccharide, Heptest® clotting times were increased up
to 9 fold baseline (p < 0.05 vs. control).

E. Human Trials with Aprosulate
To further validate the preclinical data obtained with aprosulate, TFPI levels
were measured with a newly developed immunologic assay in plasma samples obtained
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Figure 70. TFPI levels in human volunteers treated with ascending doses of
aprosulate. Volunteers received placebo, 0.75 mglkg and 2.0 mg/kg aprosulate
subcutaneously on days 1, 6, and 12, respectively, of the trial. TFPI levels 2 hours
post-administration of aprosulate were increased in a dose-dependent manner. TFPI
antigen levels were observed to decrease in samples drawn subsequent to 2 hours.
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from human trials. Two well developed studies carried out in human volunteers were
included. The anticoagulant effects were also investigated utilizing global clotting assays
to explain the contribution of TFPI for the mediation of these effects.

1. DELPill Study
TFPI levels were measured in DELPID trial samples using an ELISA based
assay for the quantitation of TFPI antigen. In this trial, volunteers received ascending
dosages of aprosulate subcutaneously for a period of 12 days. Blood samples were drawn
at baseline and at 2, 4, and 10 hours post-administration. As seen in Figure 70, on day

1 where volunteers were treated with placebo, no fluctuation in TFPI levels was
observed. TFPI levels were approximately 75 % that of a normal human plasma pool
which was used as a standard. On day 6, volunteers received 0. 75 mg/kg aprosulate
subcutaneously. At the two hour point, the TFPI levels were approximately 7 fold higher
than baseline. The TFPI levels gradually declined as the time post administration
increased. By 10 hours, TFPI levels had nearly returned to baseline. On day 12 of the
study where volunteers received 2.0 mg/kg aprosulate subcutaneously, TFPI levels were
9 .5 fold that of baseline. At four hours, TFPI levels remained 6 fold higher than
baseline.

2. PALLAS Study
The ability of aprosulate administration to increase plasma TFPI levels was
examined in plasma samples obtained from a phase I clinical trial of this agent in healthy,

225
Treatment Group: 35 mg Aprosulate b.i.d.
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Figure 71. Comparison of TFPI release following subcutaneous administration of 35
mg b.i.d. aprosulate on days 1 and 1 of the PALLAS study. Blood samples were
obtained at time points as described in "Materials and Methods". The results represent
the mean ± SEM of six human volunteers. Fold increase was calculated relative to
the pretreatment control level of each indi vidua1 volunteer. TFPI antigen levels were
observed to peak 45 to 60 minutes after administratjon of aprosulate. Significant
differences between days 1 and 7 were not observed. Statjstical differences were
determined by one way ANOVA followed by the Newman-Keuls multiple comparison
test. A p-value less than 0.05 was considered statisbcally significant. ·p < 0.05 vs.
baseline on Day 1. #p < 0.05 vs. baseline on Day 7.
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male volunteers. TFPI levels were determined using an ELISA assay. Statistical
comparisons between timepoints on the same day were made by one way ANOVA
followed by the Newman-Keuls test. Comparison between Day 1 and Day 7 were made
by t-test.
Figure 71 illustrates a comparison of the TFPI antigen (TFPI:Ag) levels
measured on Day 1 of treatment with those measured on Day 7 of treatment at the same
time points. On Day 1, TFPI levels were observed to rapidly increase following
subcutaneous administration of aprosulate. Peak TFPI:Ag levels, 2.5 fold baseline, were
measured at 45 minutes post-injection, with the TFPI:Ag levels declining over the next
12 hours. TFPI:Ag levels were significantly elevated over baseline up to the 4 hour time
point (p < 0.05 vs. baseline). At 12 hours, TFPI:Ag levels remained elevated
approximately 40 % over baseline. A similar increase in TFPI:Ag levels was observed
on Day 7 of the study. While the mean TFPI:Ag were slightly lower on Day 7, the levels
on Day 1 and Day 7 were not statistically different. Heptest® clotting times were also
determined on these samples. The anticoagulant activity measured by the Heptest®
exhibited a strong correlation with the TFPI antigen levels. Regression analysis of these
parameters indicated a correlation coefficient of 0. 92.
Figure 72 depicts the data on the comparison of the TFPI:Ag measured on Day
1 of treatment with those measured on Day 7 of treatment at the same time points in the
group of volunteers receiving 70 mg aprosulate once daily. On Day 1, the peak TFPI:Ag
level was achieved 60 minutes post-injection and was 2.6 fold baseline (p = 0.001 vs.
control). TFPI:Ag levels declined less rapidly foUowing the peak in the 70 mg o.d. group
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Figure 72. Comparison of TFPI release following subcutaneous administration of 70
mg o.d. aprosulate on days 1 and 7 of the PALLAS study. Blood samples were
obtained at time points as described in "Materials and Methods". The results represent
the mean + SEM of six human volunteers. FoJd increase was calculated relative to
the pretreatment control level of each individual volunteer. TFPI antigen levels were
observed to peak 45 to 60 minutes after administration of aprosulate. Significant
differences between the TFPI levels on days 1 and 7 were not observed. Statistical
differences were determined by one way ANOVA followed by the Newman-Keuls
multiple comparison test. A p-value less than 0. 05 was considered statistically
significant. *p < 0.05 vs. baseline on Day L "p < 0.05 vs. baseline on Day 7.
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Figure 73. Comparison of TFPI release following subcutaneous administration of 40
mg o.d. Enoxaparin® on days 1 and 7 of the PALLAS study. Blood samples were
obtained at time points as described in "Materials and Methods". The results represent
the mean ± SEM of six human volunteers. Fold increase was calculated relative to
the pretreatment control level of each individual volunteer. Statistical differences were
determined by one way ANOV A followed by the Newman-Keuls multiple comparison
test. A p-value less than 0.05 was considered statistically significant. ·p < 0.05 vs.
baseline on Day 1. #p < 0.05 vs. baseline on Day 7.
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than in the 35 mg b.i.d. group. At 8 hours, TFPI:Ag levels remained nearly 2 fold
baseline in the 70 mg o.d. group. All time points post-administration had TFPI:Ag levels
significantly elevated relative to baseline. A difference between Day 7 and Day 1
TFPI:Ag levels was more evident in this treatment group than in those volunteers treated
with the lower dose of aprosulate. The peak TFPI :Ag level on Day 7 was approximately
15 % lower on Day 7 than on Day 1. This difference, evident at all subsequent time
points, was not statistically significant. A good correlation between Heptest® clotting
times and TFPI:Ag levels was again observed (r = 0. 79).
Figure 73 illustrates the TFPI:Ag levels in the Enoxaparin® treated group of
volunteers on Days 1 and 7. Peak TFPI:Ag levels were observed at 45 minutes postadministration. Maximal levels were determined to be approximately 2.4 fold over
baseline on both Days 1 and 7. TFPI levels were significantly elevated compared to
baseline from 45 minutes to 8 hours post-administration. The TFPI:Ag levels measured
on Days 1 and 7 were nearly identical. By 12 hours, the TFPI:Ag levels returned to
baseline values. The correlation between anticoagulant activity and TFPI levels was 0.90.
Figure 74 depicts the results of the anticoagulant activity as measured by the
APTT in the plasma samples from volunteers treated with 35 mg b.i.d. aprosulate, 70
mg o.d aprosulate, and 40 mg o.d. Enoxaparin®. Enoxaparin® administration resulted in
a weak effect on the APTT which peaked 4 hours post-administration (p

< 0.05).

Aprosulate was observed to prolong the APTI to a greater degree than Enoxaparin® and
did so in a dose-dependent manner. Peak APITs in the aprosulate treated groups
occurrred at 45 minutes (35 mg b.i.d. aprosulate) and 60 minutes (70 mg o.d. aprosulate)
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Figure 74. Comparison of anticoagulant a.ctlv1ty as measured by the APTI in
PALLAS study samples. Blood samples were obtained at time points as described in
"Materials and Methods". The results represent the mean ± SEM of six human
volunteers. Statistical differences were determined by one wa.y ANOV A followed by
the Newman-Keuls multiple comparison test. Ap-value less than 0.05 was considered
statistically significant. ·p < 0.05; aprosulate 70 mg vs. aprosulate 35 mg. #p < 0.05;
aprosulate 70 mg vs. Enoxaparin®. ®p < 0.05; aprosulate 35 mg vs. Enoxaparin®.
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post-administration. Administration of 70 mg aprosulate produced significantly elevated
clotting times compared to Enoxaparin® treatment at times up to eight hours postadministration. The lower dose of aprosulate significantly elevated clotting times relative
to those in the Enoxaparin® treatment group only at 30 and 45 minutes postadministration. 70 mg aprosulate significantly prolonged AP'IT clotting times relative to
a 35 mg aprosulate treatment up to eight hours post-administration. Baseline AP1T
values were reachieved by 12 hours in each of the treatment groups.

CHAPTER V
DISCUSSION

Despite an incomplete understanding of its mechanism of action, heparin has
been used effectively as an antithrombotic agent for nearly 60 years. The study of
heparin's mechanism of action is complicated by the polycomponent and polyfunctional
nature of this agent. Heparin preparations which are used clinically contain components
which vary in molecular weight from 1,500 to 30, 000 daltons. In addition to the gradient
in molecular weight, heparin chains of a similar molecular weight can exhibit a
microheterogeneity in chemical structure in that the sulfation pattern of the
polysaccharide chains is not consistent. The specillc sequence of heparin required for
high affinity binding to antithrombin m is present in approximately 20 % of the chains
(Casu, 1989).
Heparin's primary mechanism of action involves the indirect inhibition of
coagulation proteases mediated by binding to the endogenous plasma protein antithrombin
ID. Heparin acts as a catalyst in this reaction, increasing the rate of inhibition of several
coagulation enzymes more than 1,000 fold (Jordan et al., 1980). The primary targets of
the heparin-antithrombin ID complex are factors Xa and Ila (thrombin). The inhibition
of these enzymes has been utilized both for the monitoring of heparin therapy and for the
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designation of potency of heparin preparations.
The potency of heparin is typically designated in relation to its anticoagulant or
antiprotease activity. Heparins are usually dosed based on their anti-Xa or antithrombin
units per milligram potency. Due to amplification reactions in the coagulation cascade,
the anti-Xa and antithrombin potencies of a given material are not necessarily equivalent.
Furthermore, the in vitro potency of heparin does not truly reflect this endogenous
actions.
Heparin therapy has traditionally been monitored using the activated partial
thromboplastin time (AP1T) (Noureddine, 1995). In this assay, a patient's plasma is
incubated with an activator of the contact system. The inhibition of each intrinsic
pathway enzyme by the heparin-antithrombin III complex contributes to the overall
anticoagulant activity observed. More specific assays are also used to monitor heparin.
In clotting assays such as the Heptest®, activated factor Xis added to the test plasma so
as to more specifically measure the common pathway of coagulation. Amidolytic assays
for specific coagulation factors are also employed. While these assays allow for the
monitoring of a specific activity of heparin, they are considered somewhat less
physiologic than the clotting assays as the test pJasma is diluted and the substrates used
only mimic the enzyme's natural substrate.
Higher doses of heparin used in cardiopulmonary bypass, angioplasty and other
indications are monitored using the activated clotting time. These tests are usually
performed on native whole blood in the presence of an activator. Heparin levels up to

5 U/mL can be measured using this test.

This test also measures the effect of TFPI
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which is released from the vascular sites.
Heparin produces several distinct effects on the coagulation system. The
anticoagulant effect of heparin is related to its ability to inhibit preformed serine
proteases through binding with endogenous plasma cofactors such as antithrombin ID and
heparin cofactor II. By inhibiting the proteolytic actions of the coagulation factors,
heparin also acts to limit further generation of these enzymes. The anticoagulant
properties of heparin can be measured in vitro. The antithrombotic activity of heparin
refers to the in vivo inhibition of thrombus fonnation. This property of heparin relates
not only to the SERPIN mediated inhibition of coagulation proteases but also to heparin's
ability to modulate endothelial function (heparan sulfate synthesis, TFPI release) and
interact with other cellular components of the vascular system. The inhibition of
hemostatic function by heparin following higher doses may be the result of heparin's
interactions with platelets and result in the hemorrhagic side effects observed with
heparin therapy.
The low molecular weight heparins are depol ymerized derivatives of porcine and
bovine mucosa! heparins (Fareed et al., 1995). These agents usually exhibit a molecular
weight in the range of 4000 to 6000 Da. A large proportion of the molecular components
of a given low molecular weight heparin is below 75 00 Da. Because of this difference
in molecular weight composition, low molecular weight heparins exhibit a relatively
weaker antithrombin activity. This is primarily due to the proportionately lower chain
lengths of these agents. Barrowcliffe et al. described the effect of chain length on the
relative antithrombin and anti-factor Xa potencies of heparins (Barrowcliffe et al., 1979).
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Consistent with this hypothesis, pentasaccharide only exhibits anti-Xa properties. While
aprosulate is also a low molecular weight analogue of heparin, it does have antithrombin
activity. The data in this dissertation clearly demonstrate that this antithrombin activity
was primarily mediated by HCII and not by ATill.

Because of endogenous

pharmacodynamic interactions, heparin and its analogues produce their effects by
modulating endogenous serpins in a differential manner.
Thus, while molecular weight dependence on the antithrombin/anti-factor Xa
activity in a given molecular species of heparin may be valid for the high ATIIl affinity
components, it does not hold true for the non-ATIII affinity components. Charge density
also plays an important role in the mediation of the antithrombin actions. As depicted in
Figure 75, the smaller oligosaccharide components in heparin are present in relatively
lower proportions whereas low molecular weight heparin and ultralow molecular weight
heparin contain a higher proportion of these components. Pentasaccharide is a high
affinity, low molecular weight fragment of heparin. Aprosulate mimics heparin fragments
with almost no ATIII affinity. The data presented in this study provides strong evidence
on the different role of ATIII and charge density independent of molecular weight. It
is likely that if pentasaccharide is hypersulfated, its ability to interact with HC-II would
be enhanced.
Synthetic antithrombotic agents offer several potential advantages over the
classic heparin-type anticoagulant agents. Whereas heparin is polycomponent in nature,
a synthetic agent can be made with a high degree of purity. Product homogeneity would
be beneficial in two respects. First, the agent could be administered on a gravimetric or
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to determine the chemical structure of a given agent. For this study, mass spectral analysis
was only made for aprosulate and GL-522-Y- L As these agents possess symmetrical
structures, their fragmentation patterns are more easily understood. Practical considerations
limit the usefulness of this technique for the structural determination of heparin.
Fragmentation patterns of heparin would be djfficult to interpret as multiple species are
present in the initial preparation.
The molecular heterogeneity of heparin contributes significantly to its
pharmacologic effects. The polycomponent nature of this product is largely due to
components of varying chain length which also ex.bibit differi__ng degrees of sulfation and
binding to antithrombin ill. The synthetic analogues used in these investigations are highly
pure compounds which do not exhibit structural heterogeneity. The three physicochemical
methods used to characterize the molecular and structural profile of heparin provide
information on the molecular weight, molecular m~s distribution, degree of sulfation, and
the absolute molecular mass. The results obtained using gel pem1eation chromatography,
NMR, and mass spectral analysis are consistent with the proposed structure of each agent.
The purity of each agent was also consistent with their specifications. By utilizing these

three different methods, reliable information of the molecular and structural characteristics
of heparin and its synthetic analogues was obtained.

~omparative

Shi dies_an. .SERPIN Modulation

Heparin is known to promote both antitltrombin III and heparin cofactor II
mediated anti.protease activities. In the amidolytic assay systems used here, it was possible
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molar basis. Heparin must be dosed on the basis of activity units as it is a mixture of
many components whose biologic activity varies with molecular size. Second, the range
of biologic activity may be more limited than that observed with heparin, potentially
providing a more specific approach to treat various disorders.
In this study, the relative role of SER.PIN activation to clarify the mechanisms

of action of heparin was investigated by studying the biologic effects of synthetic heparin
analogues in a variety of in vitro assays and in vivo animal models. The in vitro systems
were chosen so that the effect of these agents on various steps of the coagulation cascade
could be determined. Two models of thrombosis were chosen so that the effect of these
agents on thrombogenesis induced by varying triggers could be studied. The hemostatic
compromising effects of these agents were compared in a rabbit ear bleeding model. By
performing these studies in a integrated fashion, the importance of SERPIN activation
to the anticoagulant and antithrombotic actions of heparin was determined. While this
study does not address the vascular effects of heparin and its analogues, an attempt has
been made to measure the pharmacodynamic effects in terms of the endogenous release
of vascular markers such as TFPI. Such data may provide information on the vascular
modulation by heparin and its analogues. Dedicated studies on tissue culture on their
expression of various antithrombotic mediators such as TFPI and heparan sulfate may
also be useful to support the data presented in this dissertation.

A. Physical Characterization of Heparin and Various Analo&nes
As aprosulate, GL-522-Y-1, and pentasaccbaride are homogeneous compounds,
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their molecular weights can be calculated based on their chemical structure. Since heparin
is polycomponent, however, its average molecular weight was determined using gel
permeation chromatography. This technique, which separates the components of the
heparin mixture based on molecular size, has previously been used to characterize the
molecular weight profiles of heparins, low molecular weight heparins and other
glycosaminoglycans (Ahsan et al., 1994; Ahsan et al., 1995; Nieduszynski, 1989). By
using the appropriate buffers, the effect of charge density on chromatographic separation
can be neutralized and separations are made based on hydrodynamic size. This analysis
was important so that the activities of all agents could be compared on a molar basis.
A number of methods have been used to characterize the molecular weight of
heparins. These include viscometry (Mathews et al., 1971), low angle laser light scatter
(Patat et al., 1959), NMR (Desai et al., 1995), ultracentrifugation (Lasker et al., 1966),
and gel permeation chromatography

(Ahsan et al.,

1994).

Gel permeation

chromatography offers the advantages of minimal sample preparation and handling and
a rapid tum around time. In order to obtain molecular weight data from the HPLC
elution profiles, however, the columns used require calibration. These calibrators are
optimally derived from a similar material as that being analyzed. Three different
calibrations were used in these studies. The first consisted of nineteen fractions of
heparin of varying molecular weight. These calibrators were produced by fractionation
of heparin. The homogeneity of these samples is increased relative to unfractionated
heparin by a series of chromatographic steps. The molecular weights of these calibrators
have previously been reported (Ahsan et al. , 1994).
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The elution profile of heparin was observed to take the form of a Gaussian
distribution, indicating the presence of multiple species. Dispersity, a measure of
heterogeneity, was observed to be higher for heparin than for the other agents. The
molecular weight of heparin was determined to be 10.5 lcDa by this analysis. The weight
average molecular weight value for GL-522-Y-1 was the most discrepant with its known
formula weight. It was determined that due to its chemical nature, GL-522-Y-1 was being
bound by the packing material in the HPLC column thereby skewing the elution profile.
For this reason, the elution profile of GL-522-Y-1 was not analyzed using the other
calibrants. The dispersities determined for aprosulate and pentasaccharide were closer to

1.0.
Each of these two analogues represented homogenous and chemically pure
compounds that can be used to study the SAR relationship in heparin. Since aprosulate
is highly sulfated in comparison to heparin and pentasaccharide, it's retention on the
chromatographic column was different than that of a comparably sized heparin chain.
This resulted in a falsely lowered molecular weight value. With both the HMC and the
19 narrow range calibrators, the molecular weight was lower than the calculated formula
weight. Since both methods utilized heparin derived products of a lower charge density,
these structural differences contributed to the altered molecular mass distribution.
Regardless of these differences, the dispersity of aprosulate was noted to be near 1.
The molecular weights of these agents were also detennined based on two other
calibrations which have been developed for profiling low molecular weight heparins. One
of these calibrators, F913B, was proposed to be the European Pharmacopoeial calibration
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standard for low molecular weight heparins {van Declem et al., 1991). Each of these
calibrants is a mixture of partially degraded heparins. It has previously been shown that
the effectiveness of these calibrators was dependent on the weight range of the sample
(Ahsan et al., 1994). With both calibrators, coded HMC and F913B, the molecular
weights determined for aprosulate and pentasaccharide were much lower than their true
formula weights. This was likely due to the fact that these agents fall at the extreme low
end of the calibration curve. The molecular weight of heparin determined with the two
calibrations varied from 9.9 to 12.8 kDa. The difference in molecular weights calculated
using these two methods is due to the difference in composition of the calibrants (Ahsan
et al., 1994). The HMC calibrant contains a larger fraction of higher molecular weight
material. This difference in molecular weights using these two methods is consistent with
that published for several heparins and low molecular weight heparins (Ahsan et al.,
1994).
To calculate molar concentrations and dosages, the known formula weights of
the synthetic analogues were used along wjth the weight average molecular weight of
heparin as determined by the 19 calibrator method. This method is of major value in the
study of the molecular mass distribution profile of heparin and low molecular weight
heparin as the distribution profile and various other parameters can be calculated.
NMR spectroscopy is a valuable technique for the analysis of heparins. This
technique provides both information describing the primary structure of heparin as well
as its solution conformation. With regard to the primary structure, major components of
the heparin chain such as glucosamine and iduronic acid residues can be identified,
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sulfate content at various positions can be ascertained, and the configuration of the
disaccharide linkage (a or fi) can be detennined. NMR analysis is also a powerful tool
for determining the solution confonnation of the heparin chain. The measured chemical
shifts are dependent on the molecular environment of the nucleus and the size of
interproton coupling constants is dependent upon the dihedral angle formed between
adjacent C-H bonds. Thus, it can be determined whether adjacent hydrogen moieties are
positioned cis or trans to each other. NMR spectra can provide information on the purity
of the sample. As the intensity of a given peak is related to the amount of substance
present, purity can be readily assessed. Recently, NMR spectroscopy has been used to
determine the calibration free molecular weight of heparin (Desai et al., 1995).
Because of the polycomponent nature of heparin, peaks in the NMR spectra tend
to overlap. In order to make specific assignments for various peaks, the peaks must be
clearly resolved. The spectra of the agents used in this dissertation were obtained using
300 and 500 MHz instruments so as to obtain high resolution spectra.
The degree of sulfation of the heparin used in these studies was characterized
by integrating certain peak areas of the 13C spectra. By this analysis, it was shown that
in this heparin, 76 % of the 6-0H groups were sulfated and that 88 % of the amino
groups were sulfated. More importantly, it is possible to estimate the amount of high
affinity ATIII binding sites present in the sample by detennining the percentage of 3-0
sulfate. For this heparin, it was estimated that 7 % of the chains contained ATIII binding
sites. This is in contrast to the pentasaccharide which has an ATill binding site on every
molecule. No peaks related to other glycosaminoglycans such as dennatan sulfate or
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heparan sulfate were present in these spectra, indicating a pure heparin sample. This is
important as dermatans and heparans exhibit variable effects on the coagulation system.
The spectra of aprosulate and GL-522-Y-1 are much simpler than those of
heparin or pentasaccharide.

Each structure is symmetrical, and contains no

microheterogeneities in sulfation as does heparin. In each of these spectra, all peaks
could be assigned. The purity of each agent was confirmed by the lack of extraneous
peaks.
1

H NMR spectra are complementary to the

13

C spectra obtained on a given

sample. 1H spectra are not as easily used for the rapid characterization of the purity of
polysaccharides such as heparin due to the overlap of signals and a poorer resolution
compared to that observed in 13 C spectra. The 1H spectra are beneficial, however, for the
determination of the secondary structure of such agents (Casu, 1989). Based upon
coupling constants and nuclear Overhauser enhancements, conformation data can be
obtained.
Mass spectral analysis provides information on the molecular weight and
structural features of tested agents. By examining the fragmentation pattern, it is possible
to determine the chemical structure of a given agent. For this study, mass spectral
analysis was only made for aprosulate and GL-522-Y- L As these agents possess
symmetrical structures, their fragmentation patterns are more easily understood. Practical
considerations limit the usefulness of this technique for the structural determination of
heparin. Fragmentation patterns of heparin would be dfflicult to interpret as multiple
species are present in the initial preparation.
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The molecular heterogeneity of heparin contributes significantly to its
pharmacologic effects. The polycomponent nature of this product is largely due to
components of varying chain length which also exhibit differing degrees of sulfation and
binding to antithrombin ill. The synthetic analogues used in these investigations are
highly pure compounds which do not exhibit structural heterogeneity. The three
physicochemical methods used to characterize the molecular and structural profile of
heparin provide information on the molecular weight, molecular mass distribution, degree
of sulfation, and the absolute molecular mass. The results obtained using gel permeation
chromatography, NMR, and mass spectral analysis are consistent with the proposed
structure of each agent. The purity of each agent was also consistent with their
specifications. By utilizing these three different methods, reliable information of the
molecular and structural characteristics of heparin and its synthetic analogues was
obtained.

B. Comparative Studies on SERPIN Modulation
Heparin is known to promote both antithrombin

m and heparin cofactor II

mediated antiprotease activities. In the amidolytic assay systems used here, it was
possible to examine the effect of each analogue on a distinct SERPIN mediated event.
It was observed that heparin more strongly inhibited thrombin via antithrombin ill than

by heparin cofactor II. The IC 50 value determined for ATIII mediated thrombin inhibition
was 60 fold lower than the value determined for the HCII system. This is consistent with
the data of Griffith which demonstrates an apparent ~ of 150 nM for the thrombin-HCII
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reaction compared with 35 nM for the thrombin-ATIII reaction (Griffith et al., 1983) and
data which demonstrates a 5 fold higher NaCl concentration required to elute ATilI from
heparin agarose compared with that needed for HCII (Yamagishi et al., 1984; Griffith
et al., 1985; Tran et al., 1986). In the ATIII mediated antithrombin assay, maximal
inhibition of approximately 95 % relative to unsupplemented control was observed. In
the HCII assay, however, a maximal inhibition of only 80 % was observed. Several
assays were performed in which either the concentration of HCII, the concentration of
heparin or the concentrations of both were increased two fold relative to the standard
assay. In these systems, the maximal inhibition remained at 80 %. This can be explained
by taking into account the reported

Vmax

values of 0.9 and 3.8 nM/min/ng heparin for the

HCII-thrombin and ATIII-thrombin reactions, respectively (Griffith et al., 1983). As the
kinetics of thrombin interaction with HCII are slower than with ATIII, it is possible that
some portion of the thrombin in the assay can interact with the substrate before being
inhibited by HCII.
The synthetic analogues exhibited a more selective SERPIN inhibitory profile
than heparin. Pentasaccharide was the only analogue to mediate significant antiprotease
actions via ATilI. Due to its molecular size, pentasaccharide only inhibits factor Xa. It
has been shown previously that a heparin chain length of 18 monosaccharides is
minimally required to catalyze the inhibition ofthrombin by ATIII (Laurent et al., 1978;
Oosta et al., 1981; Holmer et al., 1981; Lane et al., 1984; Danielsson et al., 1986).
Pentasaccharide only promotes small increases in the HCII mediated antithrombin
activity. It does so at relatively high concentrations compared to those required for ATIII
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mediated Xa inhibition. While data is not currently available, a pentasaccharide with
higher charge density may exhibit appreciable activity via HCII. The activation of HCII
by glycosaminoglycans has been shown to be dependent on the charge density of the
GAG rather than on a specific sequence as with the case of ATIIl (Hurst et al. 1983).
Neither aprosulate nor GL-522-Y-l produced significant antiprotease actions via
antithrombin mas they lack the proper 3-0 sulfate conformation needed for high affinity
binding. Despite differences in their chemical structure and the functional groups
providing the negative charge, GL-522-Y-1 and aprosulate inhibited thrombin via HCII
with similar potency. This potency was approximately 20 fold lower than that observed
with heparin. Kinetics models of the inhibition of thrombin by HCII suggest that it is
necessary for heparin to bind both HCII and thrombin to achieve a catalytic effect
(Tollefsen, 1989). Studies with thrombin mutants suggest that an allosteric model rather
than a template model better describes the inhibition of thrombin by heparin cofactor II
(Sheehan et al., 1994). In the case of ATIII mediated inhibition of thrombin, a minimal
chain length of 18 saccharide units is required for heparin to inhibit thrombin. It is
possible that the weaker potency of aprosulate and GL-522-Y-1 in inhibiting thrombin
via HCII is due to their smaller molecular size.
Although both aprosulate and GL-522-Y-1 produced comparable inhibitory
effects mediated by HCII, there was a clear dissociation between the anticoagulant and
antithrombotic actions of these two agents. This suggests that aprosulate may have
additional functional properties in addition to its. interaction with HCII. This data also
suggests that HCII alone may have a relatively minor role in the production of
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anticoagulant and antithrombotic responses. Such properties as the non-specific binding
of these analogues to fibrinogen and other coagulation factors and direct effects on the
generation of various protease during activation may be contributory to their actions.

C.

Endo~enous

Release of TFPI by Heparin and Heparin Analogues

In addition to antithrombin III and heparin cofactor II, other endogenous
modulators of the coagulation system are known to exist. These include protein C which
acts to limit procoagulant activity by inactivating factors Va and VIIla, protease nexins
which have been shown to inhibit thrombin, activated protein C, and factor Xia, and
tissue factor pathway inhibitor, a multi-Kunitz inhibitor of factors Vila and Xa.
Tissue factor pathway inhibitor is a recently recharacterized Kunitz-type protease
inhibitor which may be an important mediator of heparin's actions. It is known that
heparin administration causes an increase in plasma TFPI levels (Ariens et al., 1994;
Warn-Cramer et al., 1993). Additionally, it has been reported that heparin and related
glycosaminoglycans are capable of binding to TFPI (Valentin et al., 1994) and can
promote a synergistic anticoagulant action (Wun, 1992). Based on these studies, it has
been suggested that TFPI may be just as important as ATIII and HCII for the
anticoagulant actions of heparin (Valentin et al., 1992) and may significantly contribute
to the antithrombotic actions of heparin and heparin analogues (Ostergaard et al., 1993).
In phase I clinical trials using human volunteers, the effect of the synthetic
analogues on TFPI release was investigated. In addition, because of the molecular
homology of TFPI in non-human primates, additional experimental studies were carried
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out in non-human primates. TFPI levels were measured using functional and
immunologic assays. The functional and immunologic assays for TFPI can potentially
give different results. In the ELISA assay, TFPI is detected by a monoclonal antibody
directed against the first Kunitz domain. This assay, therefore, measures the total TFPI
content of the sample. Carboxy truncation of the TFPI molecule is known to result in a
reduced antiprotease activity (Nordfang et al., 1991). The functional assay, therefore,
may only measure a fraction of the TFPI present in plasma, that which is not truncated.
Intravenous administration of GL-522-Y-1 to non-human primates was observed
to rapidly increase the levels of functional TFPI activity measured as Xa inhibition. The
antigenic TFPI levels measured in the samples of one of these treated monkeys correlated
highly with the functional TFPI levels (r = 0.976) indicating that full-length, functional
TFPI is released upon GL-522-Y-1 administration. Administration of pentasaccharide at
doses up to 500 µglkg did not elevate the plasma TFPI antigen levels in non-human
primates. Despite this, a dose-dependent anticoagulant effect was observed suggesting
that the release of TFPI does not contribute to the anti-Xa effects of pentasaccharide. It
has been suggested that glycosaminoglycan binding to TFPI may be dependent not only
on the total sulfate content, but also on the localization of the charged groups (Valentin
et al., 1994). Calixarenes such as GL-522-Y-l have been shown to be in a folded
conformation in solution which may act to fonn a region of high negative charge
(Atwood et al., 1992; Gutsche et al., 1981). Based on charge density alone,
pentasaccharide would be expected to release TFPI. Both unfractionated heparin and
various low molecular weight heparins have been shown to increase plasma TFPI levels
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following intravenous and subcutaneous administration (Ari.ens et al., 1994; WamCramer et al., 1993; Bara et al., 1993; Holst et al., 1993; Vogel, 1995). The number
of sulfate groups per saccharide in heparin is not markedly different from that in
pentasaccharide. The size of the pentasaccharide molecule appears to play a role in its
inability to release TFPI.
The effects of aprosulate on plasma TFPI levels were investigated as part on two
phase I clinical trials. In the PALLAS study, aprosulate was administered daily for a
period of seven days. It was observed that aprosulate increased plasma TFPI antigen
levels within 15 minutes after subcutaneous administration and peak levels were achieved
45 to 60 minutes post-administration. The TFPI antigen levels were observed to correlate
with anticoagulant activity measured by the APTT and plasma drug levels determined
using the Heptest®. Repeated administration of aprosulate did not deplete endogenous
TFPI stores following seven days of treatment (Jeske et al., 1995). The time course of
TFPI levels and the time to peak levels were not significantly different on days 1 and 7
of the study. Limited data from the DELPHI dose-escalation study indicates that
aprosulate dose-dependently increases the plasma TFPI antigen levels. As in the PALLAS
trial, dosing of aprosulate on alternate days for a period of 12 days did not deplete the
TFPI stores.
The significance of the heparin releasable TFPI to the pharmacologic effects of
heparin remains unknown at this time. To date, no TFPI deficient individuals have been
identified. Since small amounts of tissue factor generation on the cell surface is sufficient
to initiate thrombogenesis, circulating levels of TFPI may be sufficient to blunt the
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thrombogenic effects of tissue factor. It is also unknown as to whether any of the
synthetic analogues are capable of interacting with and potentiating the activity of TFPI.
Studies presented in the literature have indicated that in in vitro systems, heparin
potentiates the anticoagulant activity of TFPI. The mechanism for this effect has not been
fully elucidated. Heparin and its analogues may also directly interact with circulating
and released TFPI and alter its pharmacodynamic or phannacokinetic behavior. These
interactions may be charge dependent and result in certain modifications of TFPI
molecules resulting in increased functionality.

D. Comparative

Anticoa~lant

Profile

The anticoagulant potency of the heparin analogues was compared in human and
rabbit plasma using global clotting tests such as the prothrombin time, activated partial
thromboplastin time, Heptest® and the thrombin time. In these assays, different triggers
are used to activate the coagulation system in distinct locations. In the prothrombin time,
a rabbit brain tissue thromboplastin is used to activate factor VII and the extrinsic
pathway of coagulation. This assay is routinely used to monitor oral anticoagulant
therapy as it is sensitive to low levels or inhibition of factor VIla (Hirsh et al., 1994).
In the APIT, a micronized silica solution is used to activate the contact system. This
assay is used clinically to monitor heparin therapy as the heparin-ATIII complex inhibits
most of the intrinsic pathway enzymes (Noureddine, 1995). The Heptest® and the
thrombin time are more specific clot based assays. The Heptest® is designed to measure
the inhibition of the conversion of prothrombin to thrombin. This is achieved by using
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bovine factor Xa as an activator of coagulation. As thrombin is ultimately formed prior
to reaching the assay endpoint, this assay is also sensitive to the antithrombin actions of
different agents. The thrombin time measures the conversion of fibrinogen to fibrin
following the addition of a known amount of thrombin to plasma. Thus, each of these
assays provide a distinct point in the coagulation cascade for the evaluation of the
anticoagulant effects of various drugs.
The anticoagulant potency of heparin and related drugs is dependent on several
factors. Due to the differing and more limited mechanisms of action of the heparin
analogues, the procoagulant trigger will influence the systems in which these agents are
active. In addition, the dilution of the plasma with the assay reagents will affect the
anticoagulant activity observed. In the thrombin time assay, 200 µL of plasma is used
to determine the clotting time, whereas in the other clotting assays, 100 µL of plasma is
used. In the thrombin time, therefore, twice as much anticoagulant is present in the
system as is present in the other assays. Lastly, the anticoagulant potency of each agent
was compared based on agent concentrations required to increase the clotting time to 100
seconds. In the various assays, baseline clotting times in normal human plasma ranged
from 12.0

± 0.2 seconds in the PT to 37.3 ± 4.0 seconds in the AP1T. A clotting time

of 100 seconds is therefore, a three fold increase over baseline in the APTI', but more
than 8 fold in the PT. This approach to comparing the potencies of each agent was used
due to the fact that a maximal anticoagulant activity was not observed. Clotting times
were artificially limited to a maximum of 300 seconds based on the linear range of the
assays.
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Heparin exhibited the broadest anticoagulant effect, prolonging clotting times in

all assays. This is consistent with the known range of activities of heparin. The primary
targets of the heparin-ATIIl complex are Xa and thrombin. Heparin is also a potent
inhibitor of factor IXa (Barrow et al., 1994; Beguin et al., 1991) and recent reports
indicate that heparin-ATIIl can also inhibit factor VIla (Rao et al., 1995; Rao et al.,
1993; Lawson et al., 1993). The observed anticoagulant potencies range from 0.08

0.05 µMin the 5 U thrombin time to 6.2

+ 2.1 µ.Min the PT.

±

The strongest effects are

observed in the assays in which intrinsic pathway enzymes are involved. Identical
potencies are noted in the Heptest® and APTT where the observed anticoagulant activity
of heparin is dependent on its ability to inhibit both factors Xa and thrombin. The
thrombin time assay was the most sensitive to the anticoagulant actions of heparin. This
is due to the biochemical nature of the assay systems. In the thrombin time assay, active
enzyme is added to plasma containing the test agent. In the APIT and Heptest®, active
thrombin is generated following an activation process further upstream in the coagulation
cascade.
Aprosulate exhibited a weaker anticoagulant activity consistent with its more
limited SERPIN mediated antiprotease activity. The potency of aprosulate in the APTT
and the Heptest® was 10 to 25 times weaker than that of heparin. Whereas in the APTT
heparin would be expected to limit thrombin formation by inhibiting the upstream
intrinsic pathway enzymes as well as inhibit any throm bin that is formed, aprosulate can
only promote the inhibition of thrombin once it has been formed. Similarly in the
Heptest® assay, heparin-ATIIl is capable of inhibiting the supplemented bovine Xa as
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well as any thrombin which may be formed. Aprosulate which only activates HCII may
not inhibit the added Xa and thereby limit the amount of thrombin formed. In addition,
the inhibition of thrombin by HCII is kinetically slower than thrombin inhibition by
ATiii. The free thrombin can therefore promote feedback activation reactions of other
coagulation enzymes such as factor VIII. This is also observed in the weaker potency of
aprosulate in the thrombin time assay.
Pentasaccharide which has been shown to inhibit Xa via ATIII but not thrombin
was active only in the Heptest®. Single targeting ofXa results in pentasaccharide's lower
potency compared to heparin in this assay. Inhibition of Xa would be expected to prolong
the APTT as activation of the intrinsic pathway results in Xa generation. The lack of
effect of pentasaccharide in the APTT may be related to the inability of the
pentasaccharide-ATIII complex to inhibit prothrombinase bound Xa as other ATIII
independent Xa inhibitors such as antistasin and DX-9065a concentration dependently
prolong the APIT (Vlasuk et al., 1991; Hara et al., 1994).
Based on the concentration response of GL-522-Y-l in the amidolytic HCII
assay, it would be expected that GL-522-Y-1 would also demonstrate appreciable
anticoagulant activity similar to aprosulate. GL-5 22-Y-1, however, demonstrated almost
no in vitro anticoagulant activity. The AP1T was the only assay which showed a weak
prolongation of the clotting time. Thus, it appears that the direct inhibition of thrombin
by GL-522-Y-1 observed in the HCII assay may not be relevant to the anticoagulant
effects as measured with the APTT assay. This observation further reinforces the concept
that thrombin generation inhibition is more important in the mediation of the
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anticoagulant activity of heparins than the direct inhibition of proteases. The plasma
based systems using the thrombin generation process to determine the inhibitory actions
of various agents therefore provide a polycomponent assay system where different actions
of various agents can be differentiated.
Amidolytic antiprotease assays were used to examine the effect of these heparin
analogues at two specific stages of coagulation. These results were largely consistent with
those obtained in the amidolytic SERPIN activity assays. The difference between these
systems and the SERPIN activation systems is the presence of plasma. In these systems,
each test agent was supplemented to plasma. The activities measured can, therefore, be
the result of that agent's interaction with multiple cofactors. Both heparin and aprosulate
were observed to inhibit the amidolytic activity of thrornbin. The potency of aprosulate
was lower than that of heparin consistent with the ability of heparin to inhibit thrombin
via both ATIII and HCII. Interestingly, GL-522-Y-l did not demonstrate any
antithrombin effects in this assay. Hin fact the inhibition of thrombin which was seen
in the HCII activity assay is not SERPIN related, this finding in the anti-Ila assay may
be partially explained by the lower concentrations of GL-522-Y-1 in this assay. In the
HCII assay, the highest concentration of GL-522-Y- l studied was 26.5 µM. Due to
plasma dilution in the anti-Iia assay, however, the highest GL-522-Y-l assay
concentration tested was 3.4 µM. An alternate explanation for the lack of antiprotease
activity in the anti-Ila assay by GL-522-Y-l may be related to the protein binding ability
of this agent. While the protein binding profile ofGL-522-Y-1 was not determined, other
sulfonate containing polymers have been shown to bind to a variety of plasma proteins
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(Santerre et al.,_ 1992).
Both heparin and pentasaccharide were observed to inhibit Xa amidolytic activity
in this assay. The potency of pentasaccharide was only 2 fold lower than that of heparin
in the plasma based assay. In the plasma-free system, heparin was observed to be more
than 30 fold stronger than pentasaccharide. The IC 5() values for both agents were higher
in the plasma based assays than in the plasma-free systems. The difference in the relative
potency of pentasaccharide is largely due to a marked increase in heparin levels required
to inhibit Xa activity in the plasma based systems. This may be related to endogenous
protein binding of heparin. Low molecular weight heparins are suggested to have a lesser
affinity for heparin binding proteins (Young et aL, 1994). It would be expected that
pentasaccharide, which is even smaller than the low molecular weight heparins, would
exhibit even less protein binding.
The anticoagulant activity of the heparin analogues was also examined following
supplementation to normal rabbit pool plasma. In the rabbit plasma, the baseline clotting
times were significantly lower in human plasma in the APTT, Heptest®, and the thrombin
time assays. Baseline PT's were significantly lower in rabbit plasma than in human
plasma. Differences in relative potencies observed with the different agents were minor
when compared to the results obtained in the NHP systems. The most notable difference
in potency was observed in the Heptest®, where ail agents required higher concentrations
to prolong the clotting time to 100 seconds. For both aprosulate and pentasaccharide,
three fold more agent was required to prolong the clotting time to 100 seconds despite
a higher baseline clotting time. GL-522-Y-1 exhibited less anticoagulant activity in rabbit
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plasma than in human plasma. In the amidolytic antiprotease assays, heparin was equally
potent in rabbit and human plasma with respect to both thrombin and factor Xa
inhibition. In these assays, pentasaccharide exhibited a 2.5 fold lower potency in the antiXa assay in rabbit plasma compared to its potency in human plasma. This corresponds
to the three fold difference in potency observed in the Heptest®. Whereas aprosulate
exhibited a potency of 1.05

+

0.05 µ.M in the anti-Ila assay in human plasma, no

inhibition of thrombin was observed in the rabbit plasma system. While this may explain
the weaker effects of aprosulate in the Heptest®, it does not explain why the potency of
aprosulate is higher in rabbit plasma in the thrombin time assay. These differences in
clotting time may be attributable to differences in coagulation factor levels in rabbit
plasma compared with human plasma. Most clotting factor levels in rabbit plasma are
elevated relative to human plasma levels, particularly factors VII, IX, XI and V. In
addition to the differences in the coagulation process, vascular lining and cellular factors
also contribute to the differences in the hemostatic responses in different species.
As discussed previously, pentasaccharide and aprosulate exhibit differential
specificity to ATIII and HCil. These differences, together with the compositional
differences between rabbit and human plasma, may account for the observed potency
differences noted in this study. In addition, spedes dependent differences in the function
of TFPI have been documented (Warn-Cramer et al., 1992). Such differences may also
exist in the functional properties of other S ERPINs and contribute to the observed
differences in the anticoagulant actions of various heparin analogues.
The anticoagulant effect of a given agent can be markedly different in whole
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blood compared to the effect in plasma. For coagulation assays, platelet poor plasma
prepared from citrated whole blood is generally used. Addition of citrate removes
calcium ions from solution, thereby preventing coagulation as the formation of activated
factors VII, IX, X, and thrombin are calcium dependent (Davie et al., 1991).
Recalcification of the plasma in global clotting assays results in a dilution of plasmatic
coagulation factors. Additionally, platelet poor plasma does not contain the platelets, red
cells or white cells normally found in whole blood. Platelets are known to contain both
procoagulant material and heparin neutralizing agents in their granules as well to provide
a procoagulant surface upon activation (Majerus et al., 1987; Davie et al., 1991).
Macrophages and monocytes also may provide procoagulant surfaces (Altieri, 1993;
Edwards et al., 1992) and be involved in complex interactions with platelets.
To study the anticoagulant effects of heparin analogues in whole blood, celite
activated clotting times and thrombelastography were used on supplemented, freshly
drawn human blood. Celite is an activator of the intrinsic pathway. When the analogues
were tested on an equimolar basis, the activated clotting time was markedly prolonged
by aprosulate, appearing to indicate that the potential to inhibit thrombin is more
important than inhibition of factor Xa to produce this effect. Pentasaccharide produced
a stronger anticoagulant effect that aprosulate in the TEG analysis. This may be due to
pentasaccharide's ability to limit the generation of thrombin by inhibiting factor Xa.
Although unfractionated heparin and pentasaccharide exhibit very strong anti-Xa
activities which are mediated by ATIII, the relative prolongation of the whole blood ACT
was not proportional to the respective anti-Xa potency of those agents. Aprosulate
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produced the strongest effect in this assay, whereas GL-522-Y-1 produced a comparable
response to pentasaccharide. This observation is suggestive that in whole blood, factor
Xa inhibition has a relatively minor role in the mediation of whole blood clot formation.
Aprosulate may have additional cellular mediated effects which can partially account for
its stronger effect.
Pentasaccharide exhibited stronger anticoagulant effects in comparison to
aprosulate and GL-522-Y-1 in the TEG analysis. It appears that ATilI mediated Xa
inhibition may be more important in the mediation of the anticoagulant activity of this
agent. It is somewhat paradoxical that there is a different potency profile of these
analogues in each whole blood assay. While heparin is a strong anticoagulant,
pentasaccharide and aprosulate exhibited a differential behavior. This observation points
to the fact that assay dependent variations are observed and may depend on several
factors such as the trigger mechanisms involved in such assays.

These observations

clearly suggest that activation mechanisms are the primary determinant of the relative
anticoagulant effects of heparin and its analogues. In contrast to heparin, the analogues
certainly alter the coagulation process at specific sites.

E. Protease Generation Assays
For a complete understanding of the anticoagulant and antithrombotic
mechanisms of action of various drugs, it is necessary to analyze the actions of these
agents at various steps in the coagulation process. In addition to direct antiprotease
activities, a given agent can also modulate the formation of active proteases. To identify
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these activities, protease generation was measured continuously in a fibrinogen deficient
plasma system. By using fibrinogen deficient plasma, it was possible to monitor the
formation of active factor X or thrombin using amidolytic substrates. The absence of
fibrinogen renders the plasma unclottable. In fibrinogen clotting systems fibrin
polymerization would result in aberrant changes in optical density. Methods to defibrinate
normal human plasma are known (Dupouy, et al. 1988; Prentice et al., 1993). Use of
these defibrinations, however, may result in factor level alterations. It is also possible to
use ELISA technology to measure levels of Fl .2 and factor X activation peptide as
indices of protease generation.
In the fibrinogen deficient plasma systems used here, heparin is expected to
exhibit a potent inhibitory effect. Not only is the heparin-ATIII complex capable of
preventing thrombin generation by inhibiting intrinsic pathway enzymes, but by directly
inhibiting thrombin, heparin limits thrombin feedback activation reactions. Heparin was
observed to be a potent inhibitor of Xa and thromb.in generation following thromboplastin
induced activation, with IC50 values of 0.6 and 2.1 ,uM determined, respectively. The
four fold higher amount of heparin needed for thrombin generation inhibition is
consistent with the additional amplification step present in its generation. In both systems,
GL-522-Y-1 also inhibited protease generation, but exhibited a lower potency than
heparin. This may be related to the more limited antiprotease actions of this agent.
Neither aprosulate nor pentasaccharide promoted substantial inhibition in these assay
systems. The lack of effect by aprosulate suggests that the inhibition by GL-522-Y-1 is
not related to HCII mediated thrombin inhibition. The lack of effect by pentasaccharide
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is unexpected in light of the data from Lonneau et al. which indicates that
pentasaccharide is a potent inhibitor of protease generation (Lormeau et al., 1993),
particularly following activation of the extrinsic pathway. Plasma dilution in this assay
may be an explanation for this discrepancy. The relatively high plasma dilution (1:24
final dilution) used in this assay results in a lack of ATilI through which pentasaccharide
can act. In the work of Lonneau, protease generation was measured in undiluted
difibrinated plasma where the relative proportions of various plasma proteins were
significantly different from the system used in these studies.
Following activation of the intrinsic pathway, GL-522-Y-1 was observed to
inhibit both thrombin and factor Xa generation. Inhibition following intrinsic activation
was observed to be more potent than following extrinsic activation. Aprosulate inhibited
thrombin and factor Xa generation with similar potencies. This is in contrast to the lack
of effect observed with this agent following extrinsic activation. Pentasaccharide dosedependently inhibited Xa generation following intrinsic activation. The pentasaccharideATIII complex has not been shown to inhibit proteases other than Xa, indicating that this
effect may reflect direct Xa inhibition. Neither aprosulate nor GL-522-Y-1 has been
shown to produce direct inhibition of Xa however these agents inhibited activities, yet
inhibited Xa generation with a potency approximately 20 fold higher than that of
pentasaccharide. These results indicate that these agents may exhibit other non-SERPIN
mediated activities as these agents do not activate ATIII and HCII does not inhibit
coagulation proteases beside thrombin (Tollefsen, 1989).
To further define the protease generation modulatory actions of these agents,
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non-plasmatic assay systems were utilized. In these systems, prothrombin complex
concentrates were used to provide the necessary coagulation factors. These concentrates
contain factors II, VII, IX, and X (Konyne®) or their activated fonns (FEIBA®). These
systems allow the modulatory actions of these agents to be assessed in the absence of
endogenous cofactors such as ATTII and HCII and other plasma components. Also
missing from these systems are cofactors factors V and VIII which enhance "tenase" and
prothrombinase activity. Both GL-522-Y-1 and heparin inhibit thrombin generation in the
FEIBA®based system, indicating a non-SERPIN mediated inhibition of protease activity.
Heparin did not inhibit Xa generation in the same system, however. Smaller levels of
inhibition were noted in the Konyne® based systems. Previous studies with the Konyne®
based systems have shown an increased effect by heparin with ATIII supplementation
(Kaiser et al., 1994). The difference in heparin's activity may also be related to
differences in ATIII content of the prothrombin complex concentrates (Kohler et al.,
1990). Some of these concentrates are supplemented with heparin to reduce their
thrombogenicity. If HCII contamination is present in the Konyne®, this may also explain
the inhibitory effects of aprosulate in this system.
To examine the modulation of the intrinsic pathway in the absence of plasma,
a factor VIII:C mediated Xa generation system was used. In this system, the ability of
an agent to inhibit conversion of X to Xa by factor IXa in the presence of factor VIII is
determined. Previous work has indicated that heparin is capable of directly inhibiting IXa
activity at concentrations lower than those normally achieved during antithrombotic
therapy (Barrow et al., 1994). This study also demonstrated that this inhibition of IXa
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activity was ATilI independent as low and high affinity heparins exhibited similar

~

values. It is also known that the activity of factor IXa is inhibited by the heparin-ATIII
complex (Jordan et al., 1980). It is not known what effect the addition of ATIII to the
system of Barrow et al. would have on Xa generation. Data obtained with the heparin
analogues suggests the presence of non-HCII mediated actions of aprosulate and GL-522Y-l. Both agents were observed to dose-dependently inhibit Xa amidolytic activity in this
system in the absence of plasma derived cofactors. Studies by Sugidachi et al. have
confirmed the direct inhibitory effects of aprosulate on the IXa/VIIIa complex (Sugidachi
et al., 1994).
The direct inhibition of the IXa/FVIIIa complex by heparin and like agents may
also explain the inhibitory effect observed in the FEIBA® and the Konyne® based
systems. In both systems, factor IX is activated by the tissue factor/VIIa complex. This
IXa could potentially be inhibited by heparin or a synthetic heparin analogue. Alternately,
a FVIII contaminant of the prothrombin complex may be the site of inhibition of these
agents. Levels of IXa and VIII in each prothrombin complex may explain the differing
effects of the synthetic analogues in each different system.
It is interesting to note that heparin produces measurable anticoagulant effects,

whereas the heparin analogues produce relatively weaker effects in the global tests.
However, the relative inhibitory effects of these agents are stronger in the protease
generation tests. This indicates that protease generation inhibition actions of heparin
analogues may depend on their direct interactions with the component of the coagulation
network resulting in an alteration of their function.
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F. Cellular Modulation
The endothelium is important for the maintenance of hemostasis. Endothelial
cells produce several antithrombotic materials including PGI2 , TFPI and tPA (Davie et
al., 1992). The majority of the vascular system's TFPI is thought to be stored bound to
endothelial glycosaminoglycans (Werling et al., 1993). Endothelial cells are known to
constitutively produce several glycosaminoglycans. A heparan sulfate has been isolated
which exhibits anticoagulant activity. Heparin is known to modulate the production of
heparan sulfate by endothelial cells (Nader et al., 1989). To study the effects of these
heparin analogues on the modulation of glycosaminoglycan synthesis, each agent was
supplemented to the culture media of rabbit aortic endothelial cells. Incorporation of 35 S
into the glycosaminoglycan was measured by scintillation counting and used as an index
of glycosaminoglycan modulation. Glycosaminoglycan production was measured in two
areas, the culture media and associated with the cells.
Heparin, as had been previously been published, concentration dependently
increased the amount of heparan sulfate in the culture media. At heparin concentrations
above 1 µM, the heparan sulfate levels were significantly elevated relative to control
treated cultures. Both aprosulate and GL-522-Y-1 were also able to concentration
dependently increase the amount of heparan sulfate in the media, though statistical
significance was achieved at higher concentrations than with heparin. Heparin's
modulation of glycosaminoglycan synthesis by endothelial cells was limited to heparan
sulfate measured in the media. Heparan sulfate associated with the cells was not effected
by heparin supplementation. The synthesis of chondroitin sulfate was also not effected
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by heparin. The actions of aprosulate and GL-522-Y-1 were not as specific as those of
heparin. Cell associated chondroitin sulfate was increased following incubation with
aprosulate at concentrations above 10 ,uM. GL-5 22-Y-1 significantly increased cell
associated chondroitin and heparan sulfates. Due to a wide variation among cultures and
its lower molecular weight and lesser charge density, pentasaccharide did not
significantly increase glycosaminoglycan synthesis. The mean level of cell associated
chondroitin sulfate was elevated by pentasaccharide (p > 0.05).
To compare the potency of each agent for inducing heparan sulfate synthesis,
the concentration required to increase the number of C.P .M. 2 fold over control was
determined for each agent. Heparin and GL-522-Y-l exhibited a higher potency than
aprosulate or pentasaccharide for promoting heparan sulfate synthesis. Heparin and GL522-Y-1 supplementation resulted in a doubling of the C.P.M. at concentrations of 3.3
and 4.5 µM, respectively. Aprosulate was relatively ineffective at promoting heparan
sulfate synthesis, with a doubling concentration of 41 µ.M. Supplementation of
pentasaccharide did not result in an increase in heparan sulfate production.
TFPI is known to be produced by and bound to endothelial cells (Osterud et al.,
1995). For this reason, attempts were made to measure TFPI levels in aliquots of the
culture media. Due to limitations in specificity of the anti-TFPI antibodies, TFPI levels
could not be measured in these samples. The anti-TFPI antibodies used in the ELISA
TFPI assay are directed against human TFPI. Cross reactivity of these antibodies with
rabbit TFPI could not be demonstrated using the standard assay conditions. Additional
studies were also performed using rabbit aortic smooth muscle cell cultures to determine
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the specificity of this effect. No significant increases in heparan or chondroitin sulfate
production by smooth muscle cells were observed following supplementation of any of
the agents.
Heparin analogues were found to produce variable effects on the synthesis of
various glycosaminoglycans by different cell cultures. The observed rank order for
heparan sulfate synthesis was found to be heparin > GL-522-Y-l > aprosulate >
pentasaccharide. The physiologic effects of these effects remain to be determined. Studies
with phorbol esters suggest that the release of heparan suHate may be one of the
responses of the cell to a mitogenic stimulus (Porcionatto et al., 1994).
The consequences of cellular modulation produced by heparin and its analogues
are largely dependent on the route and duration of therr use. In the acute settings, these
effects may be rather limited. However, in chronic and sub-chronic settings, such effects
may be amplified at different levels. Thus, both the efficacy and safety of these agents
may be dependent on the duration of therapy.

G. Platelet Studies
Platelets play an important role in the hemostatic process. Platelets adhere to
damaged areas of the blood vessel wall fonning the first line of defense against blood
loss. These platelets become activated in this process through interaction with vessel wall
collagen. A large number of other agonists have also been shown to activate platelets
(Packham et al., 1994). Heparin's effect on this process has not definitively been
elucidated. Studies have shown heparin to both promote and inhibit platelet activation
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responses. This may be related to the concentration of heparin used in these studies. To
determine the effect of the synthetic analogues on platelet function, several agonists were
used to promote aggregation in platelet rich plasma supplemented with each agent. To
make platelet rich plasma, citrated whole blood is gently centrifuged to remove red and
white blood cells. In this assay, platelet aggregation is monitored by measuring light
transmittance through the plasma sample. Prior to agonist addition, platelet rich plasma
is relatively opaque due to platelets in suspension. As platelets aggregate, the larger
aggregates fall out of solution and light transmittance is increased. While this assay
allows for the easy determination of the effect of agents on the final aggregation
response, the system is somewhat unphysiologic. Different components of the aggregation
response such as platelet activation, receptor expression, or granule release can not be
studied. Additionally, platelet interaction with white cells during the activation process
does not occur.
In these studies, platelet rich plasma was supplemented with 10 µg/mL of the
heparin analogues. Aggregation was induced by a number of known platelet agonists
including ADP, epinephrine, collagen, arachidonic acid, and thrombin. Addition of
optimal concentrations of these agonists resulted in strong aggregation responses. Heparin
and aprosulate supplementation resulted in an attenuation of the proaggregatory response
to thrombin. Heparin produced a stronger inhlbitfon than aprosulate despite a lower
molar concentration. Neither pentasaccharide nor GL-522-Y-l were able to inhibit
thrombin induced aggregation. The effects of the other agonists were not modulated by
any of the agents at the concentration tested.
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In these studies, heparin and its analogues were used at a relatively high
concentration of 10 ,ug/mL. At concentrations below 2.5 µg/mL, heparin is known to
augment platelet aggregation induced by such agonists as low concentrations of ADP
(Brace et al., 1986). Similarly, the effects of other agonists can also be augmented. Thus,
the platelet modulation was only observed in terms of the inhibitory responses.
Heparin induced thrombocytopenia is an increasingly common side-effect of
heparin therapy. In patients with HIT, heparin administration results in a dramatic
decrease in platelet number due to consumption. HIT patients rarely bleed, but rather
present with arterial thrombi which can lead to loss of limb or life. The mechanism for
this pathology is largely unknown. Current hypotheses suggest that upon administration,
heparin combines with endogenous platelet factor 4 to fonn. a neoantigen (Chong et al.,
1982). The antibody to heparin-PF4 activates platelets via the Fella receptor (Chong et
al., 1993). The endothelium is also postulated to play a role in this process. Quantities
of this epitope can be measured using a highly sensitive ELISA method. The initial
results with this methodology, however, indicate a lack of correlation between clinically
observed HIT and the generation of antibodies (Raible et al., 1995).
Several assays are used to help make the clinical diagnosis of HIT. These
include

14

C-serotonin release assays, platelet aggregation, immunoblots, and ELISA

assays (Walenga et al., 1996). To identify whether any of the heparin analogues were
capable of generating a HIT response, an aggregation assay was set up in which platelet
rich plasma from normal donors is mixed with serum collected from known HIT positive
individuals and the heparin analogues. An aggregation response indicates the potential
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to cause IDT. The platelet aggregation assays for IIlT are known to be effected by a
number of variables. One is the source of the platelet rich plasma. Plasmas from all
volunteers do not react in the same manner to IDT serum. The reason for this is not
known, though it may be related to individual differences in platelet Fe receptor genotype
(Warkentin et al., 1995). In a study performed on five individuals using 17 different IDT
sera, the least aggregable PRP reacted with 29 % of the test sera while the most
aggregable reacted with 82 % of the sera (Chong et al., 1993). In the studies with the
heparin analogues, 5 to 10 volunteers were used for each concentration of heparin
analogue. To account for individual variations, each analogue was tested on each donors
plasma. Using an inappropriate heparin concentration has also been shown to reduce the
accuracy of the assay.
In this assay system, heparin produced a concentration dependent increase in the
level of platelet aggregation at concentrations from 5.5 to 22 µg/mL. This corresponds
to a heparin level of 0.9 to 3.5 U/mL. The only heparin analogue observed to cause a
IDT response was aprosulate. As with heparin, aprosulate produced a statistically
significant increase in the aggregation level at concentrations above 11 µg/mL. On a
molar basis, this concentration of aprosulate is 4 .5 fold higher than the concentration of
heparin. Neither GL-522-Y-1 nor pentasaccharide promoted a HIT response. Reports in
the literature have indicated that the size of the heparin chain is an important factor in
determining whether a IDT response will be generated (Greinacher et al., 1995). While
pentasaccharide has a similar composition to heparin, :it is below the critical size to illicit
an antigenic response. The other critical factor for the production of a IDT response by
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heparin-like agents is the degree of sulfation. Agents with a higher degree of sulfation
tend to produce higher amounts of HIT responses. Aprosulate contains four sulfates per
saccharide unit, twice as many as pentasaccharide and GL-522-Y-1 on a similarly sized
backbone. Pentasaccharide provides a suitable alternative antithrombotic agent which may
be completely free of any heparin induced thrombocytopenic effects. This agent has
already been compared in a large number of people using the HIT aggregation assay.
This data indicates that it may be used as a substitute for heparin.
The fact that pentasaccharide is devoid of any thrombocytopenic potential makes
this analogue especially attractive for use in patients who exhibit this syndrome.
However, because of the lower antiplatelet effects, its use may be limited for
prophylactic indications.

H. Antithrombotic Effects
To study the antithrombotic activity of the heparin analogues and to determine
the relative role of SERPIN modulation on this activity, two animal models of thrombosis
were utilized. In the rabbit stasis thrombosis model, a hypercoagulable state is mimicked
by administration of an activated prothrombin complex concentrate. This administration
serves to increase plasma levels of coagulation factors II, IX and X. Additionally, it
provides activated factor VII to initiate clot fonnation. Diminution of blood flow
achieved by ligating the ends of the vessel segments serves to augment the prothrombotic
environment. This thrombogenic environment simulates venous thrombosis where both
blood flow and the activation of coagulation play a role in the development of a
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thrombus.
The rat jugular vein clamping model was also used to characterize the
antithrombotic activity of each agent. In this model, endothelial damage and subsequent
exposure of the underlying tissue leads to the formation of a prothrombotic locus. Tissue
factor present subendothelially is exposed to the flowing blood where it can complex with
FVII and initiate coagulation. Additionally, collagen from the vessel wall can activate
platelets. Blood flow through the damaged area is partially maintained in this model.
With both models, studies were perfonned during the light cycles of the animals.
Several studies have examined the effect of circadian rhythm on the hemostatic system.
Studies in man have indicated that the time of venepuncture does not influence the plasma
levels of factor VII or fibrinogen (Miller et al., 1995). Additionally, it has been shown
that the level of platelet aggregation and blood coagulation are increased during the
morning hours, whereas fibrinolytic activity was observed to be decreased at this time
of day (Decousus et al., 1991). In a study perfonned in rats, levels of factors II, VII and
X were observed to be higher during the light cycle whereas factor IX levels were not
influenced by the time of day (Soulban et al., 1989). The levels of factor V and ATIII
in humans have also shown no circadian variations (Haus et al., 1990). The effect of
heparin administered by constant infusion has been shown to peak in the early morning
and to have its minimal effect around noon (Krulder et al., 1994). It has been suggested
that the extent of circadian change in the hemostatic system is not of sufficient magnitude
to cause diagnostic problems (Haus et al., 1990) and that further studies are need to
ascertain the clinical significance of such variations (Labrecque et al., 1991). During the
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course of the studies performed here, significant differences in antithrombotic activity in
animals treated in the morning or afternoon were not observed.
Ever since its introduction by Wessler, the rabbit model of jugular stasis
thrombosis has been extensively used for the pbannacologic screening of antithrombotic
agents (Wessler et al., 1959). The development of low molecular weight heparins was
facilitated by the use of this model The phannacodynamk effects of antithrombotic
agents have also been investigated using this model and by analyzing blood samples postadministration. While several different thrombogenic triggers have been used (Fareed et
al., 1985), in this investigation, a commercially available activated prothrombin complex
concentrate (FEIBA®) was employed. These complexes provide a uniform activation of
the coagulation process in which the inhibitory effects of heparin and its analogues can
be readily assessed.
The antithrombotic activity of each agent was detennined in the rabbit stasis
thrombosis model following a 10 and 20 minute stasis period. The prothrombotic
environment was much stronger following 20 minutes stasis than after only 10 minutes
as evidenced by the mean clot score of 3.6 after 20 minutes versus 2.9 after 10 minutes.
The longer period of stasis led to a larger generation of activated coagulation factors. All
agents were tested following intravenous administration and a 5 minute circulation time.
By using this route of administration and short circulation time, little clearance or
metabolism of each of the heparin analogues is likely to have occurred. In this system,
each agent produced a dose-dependent reduction in thrombus formation. Despite differing
mechanisms of action, each agent is able to completely suppress thrombogenesis when
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administered at the appropriate dose. The most potent agents were those which were
capable of mediating protease inhibition via antithrombin

m. Both heparin and

pentasaccharide were notably more potent than either aprosulate or GL-522-Y-1. While
the sole inhibition of factor Xa was observed to be effective for limiting thrombogenesis,
concurrent inhibition of thrombin was seen to enhance antithrombotic activity. The
apparent ED50 following intravenous administration for pentasaccharide was 20.6
nmoVkg, while that for heparin was 1.7 nmol/kg.

The relative antithrombotic actions of aprosulate and GL-522-Y -1 were
considerably weaker than that of heparin. On a molar basis, the antithrombotic potencies
of aprosulate and GL-522-Y-1 were observed to be 55 and 390 fold lower than the
potency of heparin, respectively. The most likely explanation for this finding is the
multiple sites at which the heparin-ATIII complex is capable of producing its action.
While the heparin-ATIII complex can inhibit Yarious serine proteases to differing
degrees, thrombin is the only coagulation protease known to be inhibited by HCII
(Tollefsen, 1989). A certain degree of this difference may also be due to the kinetic
differences in protease inhibition by the different SERPINs. To elucidate the role of
kinetics, an agent with sole ability to inhibit thrombin via antithrombin III would be
required. No such agent is currently available. In Light of the similar SERPIN profile of
GL-522-Y-1 and aprosulate, it was surprising to observe the 7 fold difference in

antithrombotic potency of these agents. The lower potency antithrombotic activity of GL522-Y-1 is understandable when considering the in virro anticoagulant activity of these

agents. When a maximal intravenous dose of 5 mglkg GL-522-Y-1 was administered to
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the rabbits, a plasma concentration no more than 100 µ.g/mL would be expected. At these
concentrations, GL-522-Y-1 produced no plasmatic anticoagulant effect after in vitro
supplementation to rabbit pool plasma. It is evident from these observations that the in

vitro antiprotease activity of these agents may not be the sole mediator of the
antithrombotic effect.
The stronger prothrombotic environment was evident after 20 minutes stasis
time. A weaker antithrombotic activity was observed with each agent though the same
rank order potency was observed. Only with the highest doses of each agent was a
significant antithrombotic action

observed.

For heparin,

a weak progressive

antithrombotic activity was observed at doses ranging from 0. 6 to 2.4 nmol/kg. At doses
higher than 2.4 nmol/kg was a significant antithrombotic activity observed. No effect on
clot score was observed with pentasaccharide doses up to 29 nmol/kg. ED50 values
extrapolated from the dose-response curves for heparin and pentasaccharide were
approximately 2 fold higher following 20 minutes stasis time than were calculated
following 10 minutes stasis. ED 50 values for aprosulate and GL-522-Y-1 could not be
calculated from this data due to the relative :ineffecHveness of these agents. GL-522-Y-1
was particularly ineffective in preventing thrombus formation as clot scores below

+3

were not observed.
It is of interest to note that the relative antithrombotic effects of heparin did

differ at 10 and 20 minutes stasis time and the ED5()s were in close proximity. In the case
of pentasaccharide, a lag in the antithrombotic response at the lower doses was noted.
Similarly, the antithrombotic actions of aprosulate and GL-52-Y-l were considerably
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lower when the 20 minute endpoint was used. This data clearly suggests that in contrast
to heparin, which is a polycomponent drug, the heparin analogues did not exhibit a
buffering capacity for the stronger thrombogenic environment. Thus, additional factors
which may play a role in a prolonged thrombogenesis may not be inhibited by ATilI or
HCII.
When an antithrombotic agent is administered subcutaneously, pharmacokinetic
and bioavailability considerations become important in assessing the observed
antithrombotic activity. Plasma drug levels are influenced by the extent of drug
absorption as well as the time needed for the absorption to occur. Drug absorption and
drug metabolism may occur simultaneously following subcutaneous administration. In
these studies, each agent was administered subcutaneously two hours prior to the
initiation of thrombus formation. As with the intravenous studies, all agents produced
dose-dependent but weaker antithrombotic effects. The dose-range where each agent was
effective was higher following subcutaneous administration than following intravenous
administration. The subcutaneous absorption of each synthetic analogue was better than
that of heparin. Ratios of the ED5()s following subcutaneous and intravenous
administration were calculated to compare the absorption of each agent. This ratio was
lowest for pentasaccharide, where less than 6 fold higher doses were required
subcutaneously compared to intravenous administration. Ratios of 18.6, 23.6 and 25.3
were determined for GL-522-Y-l, aprosulate, and heparin, respectively. This was most
dramatically seen with the pentasaccharide whose potency was less than three fold lower
than heparin following subcutaneous administration, but 12 fold lower following
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intravenous administration.
When the ratios of the subcutaneous and the intravenous antithrombotic effects
at a single time point (5 minutes for IV and 120 minutes for SC) were calculated,
heparin, aprosulate, and GL-522-Y-l exhibited a similar behavior. Pentasaccharide
exhibited a considerably smaller ratio. While these studies do not predict bioavailability,
they suggest that pentasaccharide's behavior in producing an antithrombotic response was
distinct from the other analogues. This data also suggests that at the time points of the
observation, pentasaccharide was absorbed to a greater degree than the other agents
studied.
As with the intravenous studies, a twenty minute stasis period produced a
stronger thrombogenic challenge. Aprosulate, heparin and pentasaccharide produced
dose-dependent antithrombotic effects following subcutaneous administration and 20
minutes stasis time. An ED50 value for GL-522-Y-l was not detennined as it failed to
prevent thrombus formation after 20 minutes stasis. Pentasaccharide and heparin were
relatively stronger in inhibiting clot formation, with ED50 values of 0.067 and 0.289
µmollkg, respectively. Aprosulate was at least 10 fold less potent with an ED50 value of

2. 6 µmol/kg. For aprosulate and heparin, the ED5() value calculated from the doseresponse curves following 20 minutes stasis were nearly equal to those determined
following 10 minutes stasis. The ED50 value for pentasaccharide was more than two fold
higher following 20 minutes stasis compared to 10 minutes stasis.
Heparin is conventionally standardized in tenns of United States Pharmacopoeia!
(USP) units per milligram (van Dedem et al. , 1981). No standardization methods for any
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of the analogues studied here have been made available. All of these agents are known
to produce specific effects but their potency relative to heparin can not be measured using
the USP assay. Most of these agents exhibit less than 5 USP units/mg potency. Thus, the
results of the inhibitory actions can not be compared in biologically standardized manner.
On a gravimetric basis, pentasaccharide and GL-522-Y-1 exhibit comparable
mass whereas that of aprosulate was nearly two fold higher. On the other hand, heparin
has a 4 to 5 fold higher molecular mass. While a direct comparison of the analogues on
a molar basis is valid, in the case of heparin, due to the presence of different molecular
species ranging in molecular mass for 1,000 to 50,000 Da, and varying in their
proportions, this comparison may not be entirely valid. Since the interaction of heparin
with ATIII and HCII is known to occur stoichiometrically, the comparison of these
agents on a molar basis may be relevant. The antithrombotic activities of these agents are
also depicted in gravimetric amounts in the individual tables. It should be noted that
potency ratios markedly change when the results are calculated in terms of gravimetric
doses. For pharmacologic comparisons, the molar doses of each agent appear ideal. For
clinical applications, a gravimetric dosage is more conventionally accepted.
SERPIN affinity did not predict the duration of antithrombotic activity. In a
time-dependent study, doses of each agent which exhibited equal antithrombotic activity
were administered intravenously to rabbits and stasis was induced at various time points
following administration. In interpreting the data from this study, it is important to note
that the doses used for each agent were different. More than 10 fold more
pentasaccharide on a molar basis was used to achieve the equivalent antithrombotic effect
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of heparin. While pentasaccharide has been shown to exhibit a prolonged elimination
half-life in humans (Boneu et al., 1995), a molar equivalent dosage of heparin
administered to rabbits would also be expected to exhibit a prolonged antithrombotic
effect as the elimination of heparin is known to be dose dependent (Gilman et al., 1985).
Administration of such a dose of heparin, however, would most likely be limited
by its hemorrhagic tendencies. At doses which were antithrombotically equivalent,
pentasaccharide was observed to have the longest duration of antithrombotic activity of
any of the agents tested, producing a significant antithrombotic effect 6 hours postadministration. It has been shown previously that ATIIl bound pentasaccharide has a
similar half-life to native antithrombin ill (van Amsterdam, 1994) while unbound
pentasaccharide is rapidly cleared from the circulation. ATilI affinity alone, however,
does not ensure a long plasma half-life. The antithrombotic activity of heparin was
rapidly diminished. By 60 minutes, clot scores were nearly at baseline levels. Aprosulate
and GL-522-Y-1 exhibited effective antithrombotic activity for time periods between the
duration of action of heparin and pentasaccharide.
To compare the duration of the antithrombotic effect of each agent following
intravenous administration, the time to reach a half maximal clot score ( + 1.45) was
determined. Heparin exhibited the shortest duration of action. Following a 30 minute
circulation time, clot scores of 1.5 were achieved. The duration of activity for aprosulate
and GL-522-Y-1 were 2 to 3 fold longer than heparin. Pentasaccharide exhibited the
longest duration of activity. A circulation time of nearly 3 hours was required before clot
scores returned to half maximal levels. Following a 20 minute stasis period, the loss of
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antithrombotic activity occurred more rapidly. For pentasaccharide, a half maximal clot
score was attained after a 40 minute circulation time. The 22 minute time calculated for
heparin was nearly the same as following 10 minutes stasis. Neither aprosulate nor GL522-Y-1 produced clot scores which were below

+1. 8 after any circulation times.

The time course of antithrombotic activity was also determined following
subcutaneous administration. At the doses chosen, GL-522-Y-1, heparin, and
pentasaccharide produced identical antithrombotic activity after a 2 hour circulation time.
Aprosulate produced a stronger antithrombotic action at 2 hours. This difference was not
statistically significant. Heparin exhibited the shortest duration of antithrombotic efficacy,
with clot scores returning to half maximal values following a circulation time of 160
minutes. GL-522-Y-1 and pentasaccharide requrred somewhat longer times to return to
the half maximal clot score. Aprosulate exhibited the longest duration of activity. This
is likely related to the increased activity observed after 2 hours circulation time.
Following 20 minutes stasis time, only aprosulate decreased clot scores below the half
maximal value of

+ 1.8

after a 2 hour circulation time. With aprosulate, the time to

return to a half maximal clot score was more than 4 hours.
Anticoagulant activity was measured in blood samples obtained during the course
of the stasis thrombosis experiments in order to determine the relative importance of
these effects on the antithrombotic activity. Anticoagulant activity was determined in
whole blood using the ACT and TEG and in platelet poor plasma samples using global
clotting assays. Following intravenous administration, the ACT was dose dependently
increased by aprosulate and GL-522-Y-1, This increase in anticoagulant activity was
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correlated with the antithrombotic activity observed at these doses (r = 0.96 and 0.99
for aprosulate and GL-522-Y-1, respectively). Neither heparin nor pentasaccharide
produced significant increases in the clotting time following intravenous administration.
The ACT values for animals treated with these agents did not correlate well with the
antithrombotic activity observed. Clinically, the ACT is used to monitor high dose
heparin therapy. In these situations, a clotting time of 300 seconds is considered to reflect
a complete anticoagulant state. This clotting time corresponds to an approximate heparin
concentration of 2 to 3 U/mL. The doses used in this study are, however, to low to cause
an increase in the clotting time. The highest dose of heparin used was 50 µglkg. By
estimating the blood volume of a rabbit to be approximately 50 mLs/kg (Schalm et al.,
1975), the maximal heparin concentration to be expected based on this assumption was

1 µg/kg ( = 0.1 U/mL).
Following subcutaneous administration, theantithrombotic activity of GL-522-Yl also demonstrated a strong correlation with the ACT determined ex vivo (r = 0.99).
As in the intravenous studies, heparin treatment did not result in a strong correlation.
The increase in ACT produced by pentasaccharide correlated with the antithrombotic
activity (r = 0.90). The doses of pentasaccharide administered subcutaneously were five
times higher than those in the intravenous study. Because of pentasaccharide's high
bioavailability and slow clearance, plasma pentasaccharide levels were likely higher
following subcutaneous administration than after intravenous administration. ACT
measurements in native whole blood provide a more physiologic method to assess the
anticoagulant actions of various agents.
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The anticoagulant activity in whole blood was also determined using the TEG.
The time to initial clot fonnation (R-time) was correlated with antithrombotic activity.
For aprosulate and GL-522-Y-1, this correlation was high following intravenous
administration (r = 0.91and0.99 foraprosulate and GL-522-Y-l, respectively). As with
the ACT, heparin displayed a poorer correlation. Pentasaccharide did not produce a dosedependent increase in R-time following intravenous administration. Following
subcutaneous administration, GL-522-Y-l demonstrated a weak dose-dependent increase
in R-time which correlated well with antithrombotic activity (r = 0.98). Neither heparin
nor pentasaccharide administration produced as good a correlation.
Ex vivo anticoagulant responses were also determined on plasma samples using

the global clotting assays. None of the agents was able to dose-dependently prolong the
prothrombin time following either intravenous or subcutaneous administration. It was
observed in vitro that of these agents, only heparin demonstrated a weak prolongation of
the clotting time in this assay. The doses used in the rabbits were, however, too low to
cause an anticoagulant effect measurable by the PT. The prothrombin time in nonnal
rabbit plasma was significantly increased by heparin only a concentrations above 6

µglmL.
Using the APTT assay, only aprosulate produced a significant dose-dependent
increase in clotting time. The anticoagulant activity of aprosulate correlated with the
antithrombotic activity (r = 0.85). The AP'IT was not a sensitive measure of the activity
of GL-522-Y-1 or pentasaccharide. While the APIT is used clinically to monitor heparin
therapy, higher levels of heparin are needed to significantly prolong the clotting time.
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Heparin exhibited a dose-dependent increase in AP1T following subcutaneous
administration (r = 0.98) which correlated to the antithrombotic activity.
In the Heptest®, coagulation is initiated by the addition of activated factor X to
the test plasma. Agents capable of inhibiting this factor Xa would be expected to prolong
the clotting time. Following both intravenous and subcutaneous administration of heparin
and pentasaccharide, the Heptest® clotting time was dose-dependently prolonged. This
dose-dependent anticoagulant state was correlated with antithrombotic activity for both
agents (r > 0.90).
The inhibition of thrombin as measured by the 2. 5 U thrombin time was
correlated with antithrombotic activity of all agents with the exception of pentasaccharide.
Following intravenous administration, aprosulate, GL-522-Y-1, and heparin all dosedependently increased thrombin inhibition. The inhibition of thrombin correlated well
with the antithrombotic activity (r > 0.90). Following subcutaneous administration, only
heparin treatment led to an increase in thrombin inhibition which correlated with
antithrombotic activity.
The release of TFPI was measured in rabbit plasma samples obtained during the
course of the intravenous dose-response studies with the stasis thrombosis model. For this
analysis, samples from rabbits treated with the highest dose of each agent were analyzed.
At these doses, equivalent antithrombotic activity was observed. To measure the TFPI
levels, a functional assay was modified which was based on the assay of Sandset (Sandset
et al, 1987). In this assay, incubation times were lengthened to compensate for the
decreased anticoagulant potency of rabbit TFPI (Warn-Cramer et al., 1992). Aprosulate,
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GL-522-Y-l, and pentasaccharide produced mild, statistically insignificant increases in
the TFPI levels post-administration despite being administered at higher gravimetric
dosages than heparin. This is in contrast to the stronger release observed with these
agents in other species (Jeske et al., 1995). Heparin was the only agent which
significantly increased TFPI levels relative to control treatment.
The e.t vivo pharmacologic studies pe:rfonned on the blood samples collected
from animals treated with heparin or its analogues, were suggestive of the relevance of
plasmatic effects of each agent to their antithrombotic activity. The degree of thrombin
or Xa inhibition was not proportional to the expected antithrombotic activity using
heparin as a reference drug. This again suggests that heparin is a polyfunctional drug
targeting multiple sites while the analogues produce their actions at certain sites related
to their affinity and specificity for various cofactors. For each analogue, a distinct e.t vivo
assay effect-antithrombotic response is obtained. Thus a single assay to predict the
antithrombotic actions of heparin and its analogues may not be practical.
The e.t vivo analysis also indicates that the vascular interactions of heparin and
its analogues are not measurable by ex vivo assays. The TFPI release is also agent
specific. Additional effects on platelets and white cells may also be contributing to the
antithrombotic actions of these agents.
The formation of a thrombus may not be solely induced by a plasmatic
hypercoagulable state. In the normal vasculature, the intact endothelium provides a
nonthrombogenic surface over which the blood flows. The nonthrombogenic properties
of the endothelium are in part due to release of such agents as prostacyclin which
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prevents platelet aggregation, the presence of TFPI and heparin-like glycosaminoglycans,
and the synthesis of fibrinolytic activators (Roberts et al., 1992). Disruption of the
endothelium not only limits the beneficial effects enumerated above, but also exposes
subendothelial tissue factor and collagen which serve to activate the coagulation and
platelet processes, respectively. This process was modelled using a rat model of jugular
vein clamping. In this model, repeated clamping of the jugular vein with a hemostat
causes endothelial disruption. This vessel damage has previously been shown
histologically (Raake et al., 1989). These studies clearly demonstrated endothelial damage
which eventually results in the exposure of collagen and tissue factor. The number of
clampings required to cause vascular occlusion are an index of antithrombotic activity.
For this study, an experimental procedure was stopped when the clamping number
reached 15. Above 15 clampings, excessive mechanical damage of the vessel led to
bleeding from the clamping site, preventing an accurate dete.nnination of the time for
thrombus formation.

Potency was assessed in this model by determining the dose

required to double the number of clampings needed in saline treated rats to cause
vascular occlusion.
Intravenous and subcutaneous treatment protocols were used to study the
antithrombotic properties of the heparin analogues in response to this thrombogenic
trigger. Following intravenous administration, each agent exhibited a dose-dependent
increase in the number of vascular clampings required to induce thrombus formation. The
same rank order potency was observed as in the stasis thrombosis model with heparin
being the most potent of the agents studied. The effective doses in the jugular vein
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clamping model were higher than the doses required prevent clot formation in the stasis
thrombosis model. 25 nmol/kg heparin was required to double control clamping numbers.
Pentasaccharide, aprosulate, and GL-522-Y-1 were 3, 12, and 150 fold less potent than
heparin, respectively. For each agent this dose exceeded the dose in the stasis thrombosis
model which completely inhibited clot formation following intravenous administration.
In the subcutaneous administration protocol, the pharrnacologic activity of
heparin was hindered by its low bioavailability. Pentasaccharide was the most potent
agent with this treatment protocol. The dose of pentasaccharide which doubled the
baseline clamping number following subcutaneous administration was only 50 % higher
than the dose determined following intravenous administration. GL-522-Y-1 was also
well absorbed following subcutaneous administration. The dose to double baseline was
less than two fold higher than the dose producing the same effect following intravenous
administration. Heparin was nearly as potent as pentasaccharide following subcutaneous
administration. The dose to double the number of baseline clampings, however, was
nearly 6 fold higher than the dose determined following intravenous administration.
The antithrombotic profile of heparin and its analogues is also highly suggestive
that non-serpin mediated actions contribute to the overall mechanism of heparin and its
analogues. TFPI and other release mediators are known to significantly modulate these
effects. Additional factors such as the modulation of selectin may also contribute to the
antithrombotic actions of these agents.
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I.

Hemorrha~ic

Effects

Hemorrhagic complications are associated with anticoagulant therapy and to a
greater degree when an anticoagulant in overdosed. Most commonly, this bleeding
tendency is observed as oozing from a surgical incision or from a site of catheter
insertion. To mimic these clinical situations a rabbit ear bleeding model was utilized
which has previously been used to measure the hemorrhagic tendency of a wide variety
of anticoagulant agents (Cade et al., 1984). In this model, five incisions were made in
the rabbit ear avoiding major vessels. Red blood cells were collected in a saline bath for
a standard amount of time and quantitated by hemocytometer.
The

dose-response

relationship

was

determined following

intravenous

administration of each agent. A bleeding index was determined to compare the potency
of these agents. The bleeding index was calculated as the dose which elicited the loss of
threefold more blood cells than observed in saline treated rabbits. Heparin and GL-522Y- l were observed to dose-dependently increase blood loss. For heparin, a bleeding
index of 45 nmol/kg was determined. This dose was nearly 10 fold higher than the dose
of heparin which completely inhibited clot fonnation in the stasis thrombosis model. For
GL-522-Y-l, a bleeding index of 1.8 µ.mol!kg was determined. In the rabbit stasis
thrombosis model, this dose did not to completely inhibit clot formation following
intravenous administration. By comparing the slopes of the blood cell vs. dose curves for
GL-522-Y-l and heparin, it is noted that heparin produces a more potent hemorrhagic
effect. A slope of 2.5 x 109 RBCs!Ll(µ.moUkg) was determined. For GL-522-Y-l, a
slope of 0.13 x 109 RBCs/L/(µmol/kg) was determined. Aprosulate doubled the amount
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of blood loss relative to saline treatment. This increase was not dose-dependent over the
dose range studied. Pentasaccharide did not significantly increase the amount of blood
loss in this model at doses 50 fold higher than the dose which was completely effective
in the stasis thrombosis model.
In the subcutaneous administration protocol, both heparin and GL-522-Y-1
produced a hemorrhagic effect. As following intravenous administration, the bleeding
index for heparin was higher than the antithrombotically effective dose ( = 7 fold). For
GL-522-Y-1, the dose determined for the bleeding index was antithrombotically
ineffective in the stasis thrombosis model. Aprosulate administration promoted a
statistically significant increase in bleeding at doses above 4 µmol/kg. Blood loss did not
reach levels of 3 fold baseline at doses below 8 .4 1tmol/kg. Pentasaccharide did not
produce a significant blood loss a dose 40 fold higher than that which was completely
effective in the stasis thrombosis model.
The time dependence on blood loss was exammed following intravenous and
subcutaneous administration. At five minutes post-mtravenous administration, heparin,
GL-522-Y-l, and aprosulate produced statistically significant mcreases in blood loss. By
60 minutes post-administration, neither heparin nor aprosulate produced a significant
blood loss. GL-522-Y-1 was observed to have a longer duration of hemorrhagic effects
than the other agents. GL-522-Y-1 significantly increased bleeding at time points out to
120 minutes post-intravenous administration and followmg subcutaneous administration,
GL-522-Y-1 induced blood loss which was progressively decreased such that by 6 hours
baseline values were observed.
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It has been shown that the topical administration od heparin results in enhanced

bleeding from small blood vessels (Cruz et al., 1967). As the hemorrhagic tendencies
persisted following irrigation of the wound, it was suggested that heparin may be binding
to a specific site in the wound. Heparin was shown to inhibit the hydrolysis of ATP by
myosin ATPase (Cruz et al., 1967) and subsequently it was demonstrated that heparin
binds to myosin ATPase with high affinity (Tersariol et al., 1992). It was also shown in
human patients that topical administration of ATP reduces blood loss produced by
heparin following cardiopulmonary bypass operations (Garcia et al., 1994). ATP is
believed to displace heparin from the surgical lesions which may be related to its
hemorrhagic actions.
To determine the relative safety of each agent, the bleeding index was divided
by the ED50 calculated from the dose response curves

mthe stasis thrombosis model.

Following intravenous administration, a ratio of 26.5 was calculated for heparin. The
ratio for GL-522-Y-1 was nearly 10 fold lower than calculated for heparin. Exact values
could not be determined for aprosulate and pentasaccharide due to their minimal bleeding
effects. Based on the data obtained, aprosulate was at least as safe as heparin with a ratio
calculated to be greater than 22. Pentasaccharide was much safer than any of the other
agents tested with a ratio calculated to be greater than 140 following intravenous
administration. Following subcutaneous administration, the ratio calculated for heparin
was lower than following intravenous administration. This ratio was determined to be 15.
The ratio for GL-522-Y-1 could not be calculated as all doses tested produced
hemorrhagic effects greater than the bleeding index level Due to low levels of bleeding,
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exact ratios for aprosulate and pentasaccharide could not be determined.
From these studies, it appears that hemorrhagic actions can be separated from
anticoagulant and antithrombotic activities. While heparin was the most potent
antithrombotic agent and exhibited anticoagulant activity in all global assays, it did not
promote bleeding at antithrombotically effective doses. Pentasaccharide also displayed
potent antithrombotic activity in both animal models and a similar anti-Xa activity as
heparin, yet did not promote bleeding at doses more than 10 fold higher than those which
were antithrombotically effective. Aprosulate also did not promote a dose-dependent
bleeding effect despite requiring higher doses than heparin or pentasaccharide to prevent
thrombus formation (Sugidachi et al., 1993). This is

m contrast to GL-522-Y-l

which

promoted a strong hemorrhagic effect at doses which did not completely block thrombus
formation.

.I. Structure Adivity Relationship
From the obvervations on the bleeding actions of heparin and its analogues, it
is obvious that non-plasmatic processes also contribute to the bleeding effects.

The

release of TFPI and other vascular modulation may be important and should be
investigated further.

Because of the relatively inert effects of pentasaccharide in the

bleeding models, it can be stated that agents with direct anti-Xa effects may not produce
bleeding effects.
Heparin's chemical structure is complex in nature, contaIDing iduronic acid
residues which can adopt a number of energetically favorable solution conformations as
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well as varyingly placed sulfate groups which result in a high degree of polyanionic
character (Torri et al., 1985). On the other hand, sulfated glucuronic acid and
glucosamine residues behave differently. These physicochemical characteristics of heparin
allow it to interact with a variety of endogenous proteins and cellular sites.
The interaction with ATIII is dependent upon a specific sequence. The ATill
binding sequence represents a specific consensus region which is mimicked by the
synthetic pentasaccharide in this dissertation. The :interaction with other proteins such as
HCII and tissue factor pathway inhibitor is dependent on other characteristics such as
charge density and molecular size. One report has shown that a hexasaccharide
component of heparin exhibits a high specific activjty when determined with purified
HCII (Linhardt et al., 1986). Additional studies designed to discover a minimal sequence
which activates HCII have not confinned this find:ing (Maimone et al., 1988). By
designing agents which mimic various structural features of heparin, it is possible to
mimic some of the specific biologic functions of this agent. Pentasaccharide, aprosulate,
and GL-522-Y-1 are different analogues wrnch were designed using such rationales.
Additional strategies include hypersulfation of naturally occurring polymers
resulting in such products as pentosan polysulfate and MPS. These agents still exhibit
structural heterogeneity and produce their pharmacologic effects at several sites. Thus,
these agents would not be suitable to determine the structure activity relationship in
heparin. These agents have been investigated for their non-ATIII mediated effects.
The synthetic analogues used in this research offer specific probes to delineate
the role of SERPINs as well as the degree of sulfation on the biologic effects of heparin.
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The heparin analogues chosen for these studies exhibit more selective interactions with
the endogenous inhibitors ATIII and HCII than heparin. In addition, while the anionic
character of both pentasaccharide and aprosulate is derived from sulfate groups as in
heparin, GL-522-Y-1 possesses sulfonate groups.
The synthetic pentasaccharide represents the minimal heparin sequence which
binds ATIII with high affinity. It was shown by fractionation of native heparin that this
sequence was required for the activation of ATIII (Rosenberg et al., 1979; Lindahl et al.,
1979; Choay et al., 1980). This irregular sequence of heparin contains a single
glucosamine unit which is sulfated at the 3-0 position and gives heparin its ability to bind
ATIII (Atha et al., 1985; Petitou, 1984). Removal of this sulfate group has been shown
to abolish the interaction of pentasaccharide with ATIII. Due to its low molecular weight,
pentasaccharide-ATIII complexes only inhibit Xa and Xa amplified processes. It was
speculated that due to the critical role of Xa in the formation of thrombin, a specific Xa
inhibitor would be an effective antithrom botic agent. This agent is currently in phase II
clinical development for the prophylaxis of deep venous thrombosis. Additional
indications for its use may include the prophylaxis or treatment of arterial thrombosis and
the treatment of stroke. Initial studies have also demonstrated that pentasaccharide may
be useful in preventing clotting in extracorporeal circuits such as in hemodialysis.
Because of its low molecular weight, pentasaccharide exhibits an almost 100 %
bioavailability after subcutaneous administration. Additional molecular manipulations of
pentasaccharide have resulted in the development of" super pentasaccharides" with higher
anti-Xa potencies (up to 1200 U/mg) and much longer hall-lives (Meuleman et al.,
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1991). These pentasaccharide derivatives are made by adding additional 3-0 sulfate
groups to the other glucosamine residues of the molecule. Kinetics studies with these
derivatives has indicated that the increased anti-Xa potencies observed are primarily due
to an increase in ATIII affinity brought about by the addition of 3-0 sulfate groups. It
is therefore projected that several pentasaccharide analogues will be developed for
indication specific applications in thrombotic and cardiovascular disorders (Carrie et al.,
1994).
It remains speculative as to the potential that the super pentasaccharides may

release TFPI upon administration. It has been shown in this work and in the work of
others (Boneu et al., 1995) that plasma TFPI levels are not affected by pentasaccharide
administration. It is also known, however, that the release of TFPI into the plasma is
dependent upon the anionic charge density of the glycosarninoglysan. In addition, it has
been shown in this dissertation that low molecular weight polyanions of high charge
density release TFPI. One could, therefore, hypothesize that the superpentasaccharides
may also be releasers of TFPI.
Aprosulate is produced from low molecular weight building blocks with the
purpose of creating an agent which is antithrombotic yet exhibits reduced anticoagulant
activity. The high sulfate content of this agent not only allows for its interaction with
plasma proteins, but also eliminates structural heterogeneity. which can preclude dosing
of the agent on a gravimetric basis.
Aprosulate provided a unique tool to differentially investigate the role of HCII
in the mediation of the antithrombotic actions of heparin. Owing to its low molecular

291
weight and high degree of sulfation, this agent mimicked heparin and produced sizable
antithrombotic actions in various models which warranted its clinical development.
Aprosulate also produced a sizable release of TFPI from vascular sites. This observation
confirmed the role of charge density on TFPI release as pentasaccharide did not produce
the same effect. Despite a similar molecular weight to pentasaccharide, the function of
aprosulate differed markedly from pentasaccharide and provided a tool to differentiate
the activity of this agent in terms of HCII activity. The clinical development of this agent
and its analogues is in progress and is contingent upon a favorable safety to efficacy
ratio.
GL-522-Y-1 is an aromatic polysulfonate whose structure is markedly different
from aprosulate and pentasaccharide. Studies with other sulfonate containing polymers,
most notably polyvinyl sulfonate, have indicated that such agents provide an
antithrombotic surface when they are surface immobilized. This molecule provided a tool
where the functional properties of a different type of sulfoxide group can be studied. One
of the objectives for studying this agent was to investigate the vascular uptake and
endogenous binding of sulfur containing agents in the mediation of antithrombotic
actions.
In the GPC studies, it is clear that this agent is capable of binding to solid
matrices. It appears that sulfonate containing molecules can also produce antithrombotic
effects. This agent also provided evidence that the activation of HCII is not specific to
sulfate molecules, but also sulfonate moieties. Polysulfonates have been developed as
antiviral agents but have also shown their antithrombotic and hemostatic compromising
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actions. These agents, therefore, can also mimic some of heparin's actions. Currently,
polysulfonates are developed for various indications including the production of nonthrombogenic surfaces.
Sulfate groups play an important role in mediating the biologic activities of
glycosaminoglycans. Desulfated heparins exhibit weaker anticoagulant and antithrombotic
activities than their normally sulfated precursors. Sulfate groups on heparin have been
shown to interact with positively charged amino acids of ATIII. Loss of one sulfate group
in particular has been shown to completely abrogate the anticoagulant and antithrombotic
activity of pentasaccharide while oversulfation has been shown to increase the affinity of
the molecule for ATIII and to increase the anti-Xa potency of this agent. Increased
sulfate content also results in higher affinity to HCII and increases the release of TFPI
from vascular stores. Sulfate content is also thought to detennine an agent's potential to
cause heparin induced thrombocytopenia. Higher sulfate content leads to a larger IDT
response (Greinacher et al., 1992). The degree and type of sulfation was observed to
determine the effects of glycosaminoglycans on platelet and leukocyte function (Rajtar
et al., 1993). For many of these effects, the saccharidic backbone of the agent is not as
important as its anionic character. Other negatively charged agents such as defibrotide
which derive their polyanionic character from phosphate groups are also known to
modulate the vascular system.
The synthetic analogues used in these studies were of similar size, but of
distinctly different structure. GL-522-Y-l contains an aromatic backbone whereas
pentasaccharide and aprosulate and saccharidic in nature. Different sugar residues make
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up pentasaccharide and aprosulate and the conformational characteristics of the agents are
different. The higher molecular weight of aprosulate relative to GL-522-Y-1 and
pentasaccharide is largely due to the additional sulfate residues it contains. The distinct
chemical structures of these agents translate into differing biologic profiles.
Each of the synthetic analogues is single targeting with respect to the plasma
SERPINs ATIII and HCil. In both in vitro anticoagulant assays and in vivo
antithrombotic models, such single targeting agents were less potent than heparin. The
importance of ATIII is observed in both models of thrombosis. In each case, the agents
which were capable of inhibiting serine proteases vfa ATIII exhibited more potent
antithrombotic activity than those that did not. ln this case, the single targeting of factor
Xa provided a potent inhibition of thrombogenesis. Additional increases in the chain
length of pentasaccharide may provide further evidence on the differential role of
thrombin and Xa inhibition in the control of thrombogenesis. Hypersulfation of
pentasaccharide may also further support the role of charge density in the release of TFPI
and the interaction with HCil. Additional manipulations of the structure of
pentasaccharide may provide a useful approach in the development of heparin analogues
with specific therapeutic applications.
Sole targeting of HCil produces a distinctly weaker in vivo biologic effect than
that observed following the activation of A TIIl. This can be the result of HCil' s ability
to only inhibit thrombin as opposed to the multiple sites of inhibition of ATIII. In
addition, the widely differing biologic profiles of GL-522-Y-1 and aprosulate suggest the
importance of other factors in mediating the actions of these agents. One such action may
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be the inhibition of the factor IXa/VIIla complex. Aprosulate was observed to inhibit this
function 20 fold more potently than GL-522-Y-l. A second possible difference in the
mechanisms of action of these agents is their interaction with TFPI. Both agents have
been shown to increase plasma TFPI levels following administration. Reports in the
literature have shown that heparin and other glycosaminoglycans can potentiate the
protease inhibitory actions of TFPI, thus making TFPI another heparin cofactor.
Aprosulate is made of saccharidic groups and is sulfated like heparin. It can be postulated
that based on these structural similarities, that aprosulate may also be capable of
potentiating the actions of TFPI. No such effect has yet been shown for aromatic
polysulfonates.
Selectins are known to play a role in the inflammatory process (Rosen et al. ,
1994) and may also be involved in some of the cellular interactions involved in the
hemostatic process (Turner, 1992). Heparin interaction with P- and L-selectins has been
demonstrated (Skinner et al., 1989). The binding of heparin oligosaccharides to these
selectins has been shown to be size dependent with a hexasulfated tetrasaccharide shown
to be an effective inhibitor (Nelson et al., 1993). Additionally, it was shown in this study
that tetrasaccharides with more sulfate moieties bound selectins better than those with less
sulfate groups. It was concluded in this study that small, non-anticoagulant heparin
oligosaccharides can effectively block neutrophil accumulation in models of acute
inflammation. In another study, it has been shown that substitution of sulfate groups for
sialic acid on Lewis x molecules results in enhanced selectin affinity (Yuen et al., 1994).
These studies point to the potential use of sulfated heparin analogues for the modulation
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of selectin function.
From the SAR standpoint, it appears that the overall pharmacologic actions of
heparin and its analogues depends on their molecular and structural makeup. While
serpin affinity may be important in the case of heparin and pentasaccharide, other
analogues such as aprosulate and GL 522-Y-1 produce several direct effects on both the
cellular and plasmatic components. There is no report on the contribution of various
functional groups and their relevance to the biochemical and pharmacologic effects of
heparin and its analogues. However, it is clear that charge density, molecular weight and
specific oligosaccharide consensus sequence interaction with ligands play a crucial role
in the mediation of the effects of these agents. From the integrated studies carried out
in the dissertation, it can be generalized that the serpin mteractions represent one of
many different effects of these agents. The overall antithrombotic/anticoagulant actions
of these agents not only depend on the structure, but also endogenous interactions and
their relative pharmacodynamic interactions detennme the pharrnacologic actions. Thus,
it is possible to develop selective modulators of the hemostatic process by considering
the SAR relationship which is exhibited by these agents.
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CHAPTER VI

SUMMARY
1. Heparin and pentasaccharide mediated antiprotease activities via activation of ATIII.

Due to molecular weight considerations, pentasaccharide was limited to inhibiting factor
xa. Heparin, aprosulate, and GL-522-Y-1 promoted thrombin inhibition via HCII
activation whereas pentasaccharide did not promote this process.

2. Heparin exhibited the broadest anticoagulant activity due to its ability to directly and
indirectly modulate the coagulation process at multiple sites in the coagulation network
as measured by using various global and specific clotting tests.

3. The anticoagulant activity of each heparin analogue was relatively weaker in
comparison to heparin. Despite their differing specificity towards ATIII and HCII, both
the pentasaccharide and aprosulate directed their anticoagulant activity against the
intrinsic pathway of coagulation. GL-522-Y-1 exhibited almost no anticoagulant activity
measurable by global clotting assays.

4. Heparin produced the strongest inhibition of protease generation in both ATIII and
non-ATIII mediated systems. Pentasaccharide exhibited only limited actions against Xa
in the intrinsically activated systems whereas aprosnlate exhibited inhibition of both Xa
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and thrombin generation in the intrinsically activated systems.

5. GL-522-Y-1 also demonstrated a potent inhibition of protease generation in most assay
systems used. While the complete mechanism of action for this agent remains unclear,
this effect may be related to inhibition of the factor IXa/VIIIa complex.

6. Heparin, aprosulate, and GL-522-Y-1 promoted an .increase in heparan sulfate by
cultured endothelial cells. On the other hand, pentasaccharide did not produce any such
effect. None of the agents exhibited any effects on glycosaminoglycan synthesis in
smooth muscle cell cultures.

7. The high degree of sulfation of aprosulate resulted in a HIT response similar to that
produced by heparin. Despite having the same backbone as heparin, pentasaccharide did
not produce a IIlT response. In the experimental system used, GL-522-Y-1 did not
exhibit a IIlT response.

8. Protease inhibition mediated by ATilI led to a strong antithrombotic effect by heparin
and pentasaccharide. Activation of HCIT by aprosulate and GL-522-Y-1 produced a
relatively weaker antithrombotic effect. A rank order potency of heparin

>

pentasaccharide > aprosulate > GL-522-Y-1 was observed following intravenous and
subcutaneous administration in the rabbit stasis thrombosis model.
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9 . In the time dependent studies, the duration of antithrombotic activity was shortest for
heparin. Following intravenous administration, pentasaccharide was observed to have the
longest duration of action. However, following subcutaneous administration, aprosulate
exhibited the longest duration of action.

10. When tissue factor initiated thrombogenesis as seen in the rat model of thrombosis,
comparatively higher doses of each agent were required to prevent clot fonnation as
those which were effective in the stasis thrombosis model In the intravenous studies, the
same rank order potent as in the stasis thrombosis model was observed. In the
subcutaneous studies, pentasaccharide was observed to be more potent than heparin in
this model. Aprosulate and GL-522-Y-l were both less potent than heparin following
subcutaneous administration.

11. The hemorrhagic effects of these agents appears not to be unrelated to their effects
on SERPINs. Heparin and GL-522-Y-1 promoted blood loss in a rabbit ear bleeding
model. Neither aprosulate nor pentasaccharide were observed to produce an increased
blood loss relative to control.

12. TFPI release in both human studies and animal models was observed to be dependent
on both degree of anionic character and on molecular size as both aprosulate and GL522-Y-1 caused an increase in plasmatic TFPI levels following parenteral administration.
Pentasaccharide administration did not elevate TFPI antigen levels.
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CHAPTER VII
CONCLUSIONS
Unfractionated heparin represents a polyphannacologic agent, targeting several
endogenous sites including plasmatic SERPINs, vascular modulation through the release
of such active substances as TFPI and tPA, the modulation of leukocytic and platelet
selectins and by altering the charge density characteristics of the vasculature. The results
obtained with the heparin analogues studied in this investigation support this hypothesis.
The role of ATill clearly appears to be important for the mediation of anticoagulant and
antithrombotic effects whereas interactions with HCII play a relatively minor role in the
mediation of the pharmacologic actions of heparin. The use of specific analogues of
heparin with differential SERPIN interaction profiles provided unique molecular probes
to accomplish the intended objective of this dissertation. It is concluded that
pentasaccharide behaves as a specific analogue of heparin and it can be molecularly
manipulated to exhibit additional properties of heparin through alteration of charge
density and saccharidic chain extension.

Additional molecular manipulation of

pentasaccharide and related analogues in terms of increased degree of sulfation,
positioning of the functional groups or branching of the chain may lead to agents with
polyfunctional characteristics which may be useful in the control of the thrombotic
process at multiple sites.
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APPENDIX A.
HPLC PROFILES OF HEPARIN AND ITS ANALOGUES
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Figure 76. The HPLC elution profile of aprosulate as detected by refractive index (A.) and
ultraviolet (B.) detectors.
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Figure 77. The HPLC elution profile of GL-522-Y-1 as detected by refractive index (A.) and
ultraviolet (B.) detectors.
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Figure 78. The HPLC elution profile of heparin as detected by refractive index (A.) and
ultraviolet (B.) detectors.
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Figure 79. The HPLC elution profile of pentasaccharide as detected by refractive index (A.) and
ultraviolet detectors (B.)
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enclosed in this letter
We would like to wish you good luck :or the completion of your dissertation
Yours sincerely,

a,__~
l<J.C~

L- _./\..-..
Dr. M. Hashimoto

Dr. W Raake
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TELECOPY MESSAGE
AN/TO (COMPANY)

Loyola U11iversrty Chicago, Illinois

zu H.i.NOENITO niE ATTE1mo>1 OF

Prof. Jawed Fareed

FAJOlo.

001 705 216 6660

VON/FROM

LUITPOLD PHARMA GMBH

ABrE!LUNGIOEPARTME~o

Cli11ical Research Z

BEARBEITERIORIGINATO!l

Dr. Eckenbef'\l er cJo Luitpold Pharma

DATUM/CATE:

02. 02. 94

SEITENZAHUTOTAl NlJNBER OF PAGES

Draft Report PAL.l.AS·s1udy

Dear Prof. Fareed,

By parcel service I am se11ding )1011 1he draft repCJrt of this study. If you have any comments or
proposals

tor addi1io11al

evaltJatio~s

we ca11 include this i11to the final version.

You may use 1he results of tile coagulatio11 meas11reme11ts for the paper presented at the GTHmeeting and a ffaal

p~IJlica1io11

:il>out the whole study as discussed eartier. I have already informed

Walter Jeske, that he may usethesecjata for histl'lesis.

As mentioned eartier the i11'1estigators involved 1n this study have been Andreas Kllmmerert, Peter
Wyld and Sylvia r.laas as

a scie11tiflc consultant .ind myself as the Luitpold Study Director. These

pe=ns should ba considened

a:s

co-:1L1thors 111 runtier publications.

As you know, tile ?ro1ect aprosulate has been st01>1>ed and I am working on another different project.
Nevertheless I willt~ tot:ilte tile opponunityt() meet yCJu and your co-workers at the Munich meeting.

Looking forwaro to yCJur answer
best regards

~.,,~
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369-9~00

FAX (4-15) 368--01()9

FACSIMILE COVER. SHEET
COMPA.""lY:

Prof. Jawed F~ Wal1cr Jeska
FROM: Bill Choy, Ph.D.
Mmlager - Aaian Oper.itiom
Hemoscuis :Ruean:ll I:..ab/1..oyola U. Med Cecter

FAX .r.

708-216-6660

RE:

Walter Jeslu:' d!Jaermio11

TO:

DATE;

F&bruary 20, 1996 3:20pm PDST

ti OP PAGES, INCLUDING nDS ONE: 1

I've read Chapter 3 of the tl:lo&ll. Alth~g.11 tile ;peidf!c ellU.JIJCI1Iiol ta tile figures were left
blanlc ill the tcia:, I can '1JUI almoc all oftll= figulea vllicll tile tex1 allud=a to. On this
basis, I ftnd the inform.atk>n ill tll.is chapter s11ppoxc, di.Iectly or indim:tly, GLS22/Y-1 aa an
antithromboFQic apnt aa flJed l!l Gcm.labl' palelJt ;pp.llcadom. Thus, on behalf of
Genelabs, I will allow you to ]Jlli>ll~ y ~ of tbe illfonmtion I have read. As you
promiaed last mOllth, please sax! a. fi1Il c;.cpJ or t.llil tfleai.t to mo after tbe defense.
cc: Jen Cheu- VP/ Asian Opcraiclm
Mcliada Gritftth. General Ci>WUd
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P/F# 454-3 has been issued approving- ::he experimental design submitted. Upon
funding of this project, please contact me at ex. 64288 with the appropriate
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issued approving the purchase of t.~e animals requested.
Please verify me Lnfornation beLo'W; i f corrections are required, please
notify me immediatel7. .1l.I!inal purchases are processed via Barbara Isdale in
the Animal Research Facility; she can be reached at ex. 69178.
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TABLE 10
MOLECULAR WEIGHT DETERMINATION OF HEPARIN AND
ITS SYNTIIETIC ANALOGUES USING GEL
PERMEATION CHROMATOGRAPHY
Calibra.nt: Nineteen Narrow Range Fractions
Detector: UV

Wt. Avg. Mol.
Wt. (Da)

HPLC/Formula
Weight

Dispersity

Aprosulate

2,357

0.987

1.017

GL-522-Y-1

1,291

0.868

1.150

Heparin

10,523

Pentasaccharide

1,584

1.228

0.917

1.018

The molecular weight profile of aprosulate, GL-522-Y-1, heparin, and pentasacch:µide
was determined by gel permeation chromatography. Wt. Avg. Mol. Wt. is the weight
average molecular weight as detennined by HPLC. HPLC/Formula Weight is the ratio
of the weight average molecular weight and the known formula weight of the agent.
This is not determinable for heparin a5 the formula weight is not known.
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TABLE 11
MOLECULAR WEIGHT DETERMINATION OF HEPARIN AND
ITS SYNTHETIC ANALOGUES USING GEL
PERMEATION CHROMATOGRAPHY

Calibrant: Nineteen Narrow Range Fractions
Detector: RI

Aprosulate

GL-522-Y-1

Wt. Avg. Mol.
Wt. (Da)

HPLC/Formula
Weight

Dispersity

2,173

0.910

1.019

999

0.671

1.023

Heparin

10,062

Pentasaccharide

1,407

1.329

0.814

1.026

The molecular weight profile of aprosulate, GL-522-Y-l, heparin, and pentasaccharide
was determined by gel permeation chromatography. Wt. Avg. Mol. Wt. is the weight
average molecular weight as detennined by HPLC. HPLC/Formula Weight is the ratio
of the weight average molecular weight and the known formula weight of the agent. This
is not determinable for heparin as the formula weight is not known.
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TABLE 12
MOLECULAR WEIGHT DETERMINATION OF HEPARIN AND
ITS SYNTHETIC ANALOGUES USING GEL
PERMEATION CHROMATOGRAPHY
Calibrant: HMC
Detector: RI

Aprosulate

Wt. Avg. Mal.
Wt. (Da)

HPLC/Formula
Weight

Dispersity

1,773

0.742

1.022

GL-522-Y-1

Heparin

9,877

Pentasaccharide

1,103

1.413

0.638

1.031

The molecular weight profile of aprosulllte, GL-522-Y-1, heparin, and pentasaccharide
was determined by gel permeation chromatography. Wt. Avg. Mol. Wt. is the weight
average molecular weight as detennined by HPLC. HPLC/Formula Weight is the ratio
of the weight average molecular wejght and the known formula weight of the agent. This
is not determinable for heparin as the formula weight is not known.
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TABLE 13
MOLECULAR WEIGHT DETERMINATION OF HEPARIN AND
ITS SYNTHETIC ANALOGUES USING GEL
PERMEATION CHROMATOGRAPHY
Calibrant: F913B
Detector: RI

Aprosulate

Wt. Avg. Mol.
Wt. (Da)

HPLC/Formula
Weight

Dispersity

1,598

0.669

1.024

GL-522-Y-1

Heparin

12,782

Pentasaccharide

1,013

1.639

0.586

1.043

The molecular weight profile of aprosulate, G L-522-Y-1, heparin, and pentasaccharide
was determined by gel permeation chromatography. Wt. Avg. Mol. Wt. is the weight
average molecular weight as determined by HPLC. HPLC/Formula Weight is the ratio
of the weight average molecular weight and the known formula weight of the agent. This
is not determinable for heparin as the fonnula weight is not known.
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TABLE 14
t 3C

NMR SIGNAL ASSIGNMENTS FOR UNFRACTIONATED HEPARIN
Chemical Shift (ppm)

Assignment

24

13

56

A-C-2-NAc

58.5

A-C-3-0S03

60

A-C-2-NS03

62

A-C-6-0H

69

A-C-6-0S03

99

A-C-1-NS03

101

IdA-C-l-2S03

C NMR spectrum of unfractionated heparin was detected using a Bruker AC300 NMR
spectrometer at 75 :MHz. All chemical shifts are relative to an internal sodium-3(trimethylsilyl)-propionate standard. A = glucosarnine, IdA = iduronic acid, NAc =
N-acetlyated, OS03 = 0-sulfated, NS03 = N-sulfated.
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TABLE 15
1

H NMR SIGNAL ASSIGNMENTS FOR THE 3-0 SULFATED
AMINOSUGAR OF PENTASACCHARIDE
Chemical Shift (ppm)

Assignment

5.5

H-1

3.4

H-2

4.3

H-3

4.0

H-4

4.1

H-5

4.5

H-6

Proton NMR spectrum of the 3-0 sulfated amino sugar of pentasaccharide was detected
using a Bruker AMX500 NMR spectrometer at 500 MHz. All chemical shifts are relative
to an internal sodium-3-(trimethylsilyl)-propionate standard.
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TABLE 16
13

13

C-NMR SIGNAL ASSIGNMENTS FOR APROSULATE

Chemical Shift (ppm)

Assignment

68.0

C6

68.S

C6'

73.S

cs

77.0

C4'

77.1

C4

77.2

C2'

77.S

C2

78.0

C3

78.3

C3'

79.S

CS'

103

Cl

C NMR spectrum of aprosulate was detected using a Bruker AC300 NMR spectrometer
at 7S MHz. All chemical shifts are relative to an internal sodium-3-(trimethylsilyl)propionate standard. C2 is carbon nucleus 2 of the closed sugar ring of aprosulate. C2'
is carbon nucleus 2 of the open chain s.ugar of aprosulate.
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TABLE 17
1

H-NMR SIGNAL ASSIGNMENTS FOR APROSULATE

Chemical Shift (ppm)

Assignment

4.238

H5

4.395 I 4.416

H6

4.523 I 4.549

H2

4.658 I 4/679 I 4.689

H6'

4. 713 I 4. 722 I 41731

H3

4.747 I 4.763

H4'

4.800

HOD (solvent)

5.005 I 51021 ! 51037

H3"

5.082 ! 5.099

H5'

5.073

j

5.146 I 5.163

H2'

5.223 I 51233

H4

Proton NMR spectrum of aprosulate was de1ected using a Bruker AC300 NMR
spectrometer at 300 MHz. All chemical shifts are relative to an internal sodium-3(trimethylsilyl)-propionate standard. H2 is the proton on carbon 2 of the closed sugar
ring of aprosulate. H2' is the proton on the second carbon of the open chain sugar of
aprosulate.
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TABLE 18
13

C NMR SIGNAL ASSIGNMENT FOR GL-522-Y-l

Chemical Shift (ppm)

Assignment

33.0

128.8

CH

130.8

138.0

C-OH

155.5
13

C NMR spectrum of GL-522-Y-l was detected using a Bruker AC300 NMR
spectrometer at 75 MHz. All chemical shifts are relative to an internal sodium-3(trimethylsilyl)-propionate standard.
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TABLE 19
1

H NMR SIGNAL ASSIGNMENTS FOR GL-522-Y-1

Chemical Shift (ppm)

Assignment

4.2

1

4.7

HOD (solvent)

7.7

CH

H NMR spectrum of GL-522-Y-1 was de1ected using a Bruker AC300 NMR
spectrometer at 300 MHz. All chemical shifts are rela1ive to an internal sodium-3(trimethylsily1)-propionate standard.
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TABLE 20
SERPIN MEDIATED INillBITION OF THROMBIN AND FACTOR Xa BY
APROSULATE

% Inhibition

Concentration
ATIII/Ila

ATIII/Xa

µglmL

µM

40

16.75

20

8.38

+ 2.2
2.5 + 2.5

10

4.19

4.5 ± 3.5

5

2.09

1.6

2.5

1.05

3.2 ± 2.8

1.25

0.52

1.8 ± 1.6

0.625

0.26

2.0 ± 2.5

+ 12.5
7.6 + 9.5
4.6 + 6.3
3.2 + 5.5
5.0 + 5.8
2.6 + 4.4
4.5 + 7.8

0.312

0.13

1.8 ± 2.2

3.3

2.0

+ 2.8

12.8

± 5.8

HCII/Ila

79.2
77.4
70.9
58.8
39.1
23.9
15.5
11.6

± 2.2*
± 1.9*
± 2.6*
± 4.6*
± 8.0*
± 5.1 *
± 4.5*
± 4.3*

All results represent the mean ± 1 standard deviation of three determinations. µM
amounts are final assay concentrations based on a fonnula molecular weight of 2388
Da. ATIII, antithrombin m; HCII, heparin cofactor II; Ila, thrombin; Xa factor Xa.
All percent inhibitions were calculated based on an unsupplemented saline control.
Statistically significant differences between treatment and control were determined by
one way ANOVA followed by the Newman-Keuls multiple comparison test. * p < 0.05
was considered statistically significant. ATIII/Ila: p = 0.636, dF = 26, F = 0.767.
ATIII/Xa: p = 0.640, dF = 26, F = 0.762. HCII!Ila: p < 0.0001, dF = 26, F =
152.9.
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TABLE 21
SERPIN:MEDIATED INHIBITION OF THROMBIN AND FACTOR Xa BY
GL-522-Y-1

% Inhibition

Concentration
µg!mL

µM

ATDI/Ila

ATill/Xa

HCII/Ila

40

26.88

0±0

25.0 ± 9.3

77.8 ± 2.3*

20

13.44

0.7

10

6.72

2.7 ± 4.6

5

3.36

2.8 ± 2.8

2.5

1.68

3.2 ± 4.6

1.25

0.84

4.1 ± 5.1

0.625

0.42

3.9 ± 5.8

0.312

0.21

1.3

± 18.2
18.3 ± 16.0
15.6 ± 13.8
10.2 ± 10.6
10.6 ± 11.3
10.0 ± 11.4
5.6 ± 9.6

± 1.6*
73.9 ± 0.8*
66.9 ± 0.5*
58.0 ± 3.2*
47.3 ± 2.8*
31.7 ± 3.2*
23.5 + 5.4*

± 1.2

± 2.3

21.7

76.6

All results represent the mean + I standard deviation of three determinations. µM
amounts are final assay concentrations based on a formula molecular weight of 1488
Da. ATIII, antithrombin III; HCil, heparin cofactor II; Ila, thrombin; Xa factor Xa.
All percent inhibitions were clllculated based on an unsupplemented saline control.
Statistically significant differences between treatment and control were determined by
one way ANOV A followed by the Newman-Keuls multiple comparison test. * p < 0.05
was considered statistically signillcant. ATDl!Ila: p = 0.963, dF = 26, F = 0.283.
ATIII/Xa: p = 0.316, dF = 26, F = 1.27. HCII! Ila: p < 0.0001, dF = 26, F =
302.8.
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TABLE 22
SERPIN MEDIATED INHIBITION OF THROMBIN AND FACTOR Xa BY
HEPARlN

3 Inhibition

Concentration
µg/mL

µM

40

3.81

80.9 ± 1.3*

20

1.90

80.8 ± 0.5*

10

0.95

80.0 ± 0.3*

5

0.48

78.3 ± 0.4*

2.5

0.24

76.3 ± 2.5*

1.25

0.12

0.625

0.06

0.312

0.03

+
93 .9 +
93.2 +

0.156

0.015

92.3 ± 1.2'

76.2 ± 11.0*

0.078

0.0075

90.4 ± 0.9*

59.5

0.039

0.0038

84.0 ± 0.9*

35.2 ± 16.2*

0.020

0.0019

69.2

+

24.5 ± 18.6*

0.010

0.0009

48.5 ± 1.6'

ATIIl/Ila

94.4

1.1'
1.1'
1.1'

0.9*

ATIII/Xa

+
95.0 +
93.1 +
98.0

16.3

HCIDIIa

0.3*

68.4 ± 0.7*

2.6*

55.0 ± 2.0*

3.4*

40.0 ± 6.8*

+ 16.6*

+

12.8

All results represent the mean ± 1 standard deviation of three determinations. µM
amounts are final assay concentrations based on a molecular weight of 10490. ATIII,
antithrombin ill; HCII, heparin cofactor II; Ila, thrombin; Xa factor Xa. All percent
inhibitions were calculated based on an unsnpplemented saline control. Statistically
significant differences between treatment and control were determined by one way
ANOVA followed by the Newman-Keuls multiple comparison test. * p < 0.05 was
considered statistically significant. ATIII!IIa : p < 0.0001, dF = 26, F = 268.3.
ATIII/Xa: p < 0.0001, dF = 26, F = 31.9. HCII/IIa: p < 0.0001, dF = 16, F =
337.8.
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TABLE 23
SERPIN MEDIATED INIIlBITION OF THROMBIN AND FACTOR Xa BY
PENTASACCHARIDE

% Inhibition

Concentration
ATilI(ITa

µglmL

µM

40

23.20

20.1 ± 3.o·

20

11.60

13.5

+ 7.7

10

5.80

12.0

± 7.6

5

2.90

8.8

2.5

1.45

6.6

1.25

0.73

0.625

0.36

0.312

0.18

0.156

0.09

0.078

0.045

0.039

0.023

± 3.6
4.3 ± 1.9
3.2 ± 2.8

0.020

0.011

2.1

0.010

0.0057

6.5

+ 2. 1•
11.4 + 2.3·
8.1 + 0.4"
14.9

5.2

± 2.8
± 3.1

ATIII/Xa

97.2
97.1
96.3
91.1
80.5
59.6
36.0
21.1

± 0.3*
± 0.8*
± 0.5*
± 4.1 *
± 5.7*
± 8.1 *
± 6.3*
± 5.1*

HCII/Ila

4.4
6.5
6.1

±
±
±
±
±

7.0
5.8
5.5
5.6
5.5

All results represent the mean ± 1 standard deviation of three determinations. µM
amounts are final assay concentrations based on a fonnula molecular weight of 1728
Da. ATITI, antithrombin ill; HCil, heparin cofactor II; Ila, thrombin; Xa factor Xa.
All percent inhibitions were calculated based on an unsupplemented saline control.
Statistically significant differences between treatment and control were determined by
one way ANOVA followed by the Newman-Keuls multiple comparison test.• p < 0.05
was considered statistically significant. ATIIIfIIa: p < 0.0001, dF = 26, F = 11.4.
ATITI/Xa: p < 0.0001, dF = 16, F = 204.2. HCIIfIIa: p = 0.0182, dF = 26, F
= 3.24.
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TABLE 24
IN VITRO ANTICOAGULANT ACTIVITY OF APROSULATE IN BLOOD BANK PLASMA
Concentration
(µg/mL)

(µM)

PT
(sec)

APTT

(sec)

Heptest
(sec)

5UTI
(sec)

0.7 ± 0.7

154.9 ± 36.r

37.5 ± 2.3*

0.6 ± 0.5

33.4 ± 3.2·

0.5 ± 0.6

14.5 ± 0.3·

>300*

>300*

>300*

50.0

20.94

13.3

>300"

173.1 ± 22.1·

25.0

10.47

± 0.3·
13.3 ± 0.2*

198.8

133.6 ± 43_5•

12,5

:5.23

13.0 ± 0.4*

138.2 ± 17.3*

6.25

2.62

12.8 ± 0.3*

79.6 ± 2.9*

3.12

1.31

12.9 ± 0.3·

60.5 ± 2.4

1.56

0.65

12.4

± 0.1

49.0 ± 3.1

±
27.9 ±
22.6 ±
19.9 ±

0.78

0.33

12.2 ± 0.2

44.6 ± 4.1

17.5

0

0

± 0.2

37.3 ± 4.0

16.5 ± 0.9

12.0

±

± 0.6

>300"

41.88

48.8

Anti-Xa
(% lnhib)

± 4.0*
38.3 ± 1.7*

100.0

± 49.5*

Anti-Ila
(% Inhib)

4.8

41.5

2.3

28.7

± 5.8

41.6

± 3.7·

0.7

±

31.8

3.8

± 2.4
24.4 ± 1.8

15.7 ± 3.2*

1.0 ± 0.9

1.8

23.l ± 2.1

12.9 ± 2.5·

0.7 ± 0.7

1.5

23.1

± 2.6·

0.5 ± 0.7

± 0.2

20.2 ± 0.7

6.8

0

1.0

1.1

0

All results represent the mean± 1 standard deviation of four determinations. Molar values were calculated based on a formula weight
of 2388 Da for aprosulate and represent the plasma aprosulate concentration. Statistical analysis of the data was made using one way
ANOVA followed by the Newman-Keuls multiple comparison test for each assay. * indicates statistical significance compared to
unsupplemented baseline plasma (p < 0.05). PT: dF = 35, F = 30.7, P < 0.0001. APTT: dF = 35, F = 147.9, P < 0.0001.
Heptest : dF = 35, F = 145.0, P < 0.0001. SU TI : dF = 35, F = 372.4, P < 0.0001. Anti-Ila: dF = 35, F = 152.4, P <
0.0001. Anti-Xa: dF = 35, F = 0.726, P =0.667.
w
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TABLE 2S
IN VITRO ANTICOAGULANT ACTIVITY OF GL-S22-Y-1 IN BLOOD BANK PLASMA

Concentration

PT

7.0 ± 2.3*

5.9 ± 2.4*

67.2

22.8 ± 1.9*

112.0 ± 4.4*

34.0

50.0

33.6

19.5 ± 1.4·

79.2 ± 9.2*

22.0 ± 3.8

19.3 ± 5.5

5.0

± 1.7*

0±0

25.0

16.8

15.8

± 1.4*

59.3 ± 6.7'

19.3 ± I.I

19.5 ± 4.9

1.0 ± 0.8

0±0

12.5

8.4

14.1 ± 1.0

48.8 ± 3.5*

17.2 ± 1.0

20.1 ± 5.9

0±0

0±0

6.25

4.2

12.2 ± 1.4

42.4 ± 2.7

15.6 ± 1.3

20.9

± 5.9

0±0

0±0

3.12

2.1

12.7 ± 0.6

38.9 ± 1.3

17.5 ± 1.1

20.3 ± 5.3

0±0

0±0

1.56

1.05

12.3 ± 0.2

35.8 ± 3.1

18.0 ± 1.5

19.3 ± 8.2

0±0

0±0

0.78

0.53

12.2 ± 0.9

34.S ± 2.2

18.2 ± 1.6

20.8 ± 5.6

0±0

0±0

0

0

12.9 ± 0.7

35.4 ± 1.7

17.0 ± 1.4

20.1 ± 3.9

0±0

0±0

(µ.M)

100.0

± 8.3'

SUTT

Anti-Xa
(% Inhib)

(sec)

(µ.g/ mL)

Heptest
(sec)

Anti-Ila
(% Inhib)

APTT
(sec)

(sec)

21.S

± 8.2

All results represent the mean ± I standard deviation of four determinations. Molar values were calculated based on a formula weight
of 1488 Da for GL-S22-Y -1 and represent the plasma GL-S22-Y-1 concentration. Statistical analysis of the data was made using one
way ANOVA followed by the Newman-Keuls multiple comparison test for each assay. •indicates statistical significance compared
to unsupplemented baseline plasma (p < 0.05). PT : dF = 35, F = 128.6, P < 0.0001. APTT: dF = 3S, F = 393.1, P <
0.0001. Heptest: dF = 35, F = 30.7, P < 0.0001. SU TT: dF = 35, F = 0.181, P < 0.996. Anti-Ila: dF = 3S, F = 28.7,
P < 0.0001. Anti-Xa : dF = 3S, F = 24.2, P < 0.0001
~
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TABLE 26
IN VITRO ANTICOAGULANT ACTIVITY OF HEPARIN IN BLOOD BANK PLASMA
Concentration

PT
(sec)

APTT
(sec)

Heptest

SUTT

(sec)

(sec)

Anti-Ila
(% lnhib)

Anti-Xa
(% Inhib)

(µg/mL)

(µM)

100.0

9.53

214.S ±
99.6*

>300*

>300*

>300*

94.1

± 0.9*

97.4

± 0.2·

50.0

4.77

82.2 ±
44.7

>300*

>300*

>300*

93.6

±

0.5*

97.3

± 0.3*

25.0

2.38

>300*

>300'

>300'

93.3

± 0.3·

96.5

12.5

1.19

± 6.8
18.48 ±

> 300*

>300*

>300*

92.6

± 0.6*

80.5

± 0.5*
± 0.6*

± 10.8'
96.4 ± 5.5*
67.3 ± 4.8·
37.3 ± 7_5·
17.7 ± 1.0

>300*

92.4

± O.T
87.6 ± 1.5*

64.8

± 4.7*

43.7

± 6.1*
± 3.7·

27.9

± 3.7'
± 5.3*
± 3.4*

28.4

2.2
6.25

0.60

15.1

3.12

0.30

13.8

1.56

0.15

13.8

0.78

0.07

13.8

0

0

± 0.8
± 1.1
± 0.3
± 2.3

14.6 ± 2.1

± 31.3*
95.6 ± 21.5*
52.6 ± 5.1

272.9

40.4

± 2.4

31.1 ± 4.0

155.7

>300*
246.2
90.5
23.7

±

107.6*

± 72.3*
± 1.5

69.1
24.8

0±0

11.2

0±0

All results represent the mean ± 1 standard deviation of four determinations. Molar values were calculated based on a molecular
weight of I 0492 Da for heparin and represent the plasma heparin concentration. Statistical analysis of the data was made using one
way ANOV A followed by the Newman-Keuls multiple comparison test for each assay. * indicates statistical significance compared
to unsupplemented baseline plasma (p < O.OS). PT : dF = 3S, F = lSS.4, P < 0.0001. APTT : dF = 3S, F = 39S.3, P <
0.0001. Heptest: dF = 3S, F = 2474.3, P < 0.0001. SU TT: dF = 3S, F = 238.0, P < 0.996. Anti-Ila: dF = 3S, F = 808.7,
P < 0.0001. Anti-Xa: dF = 3S, F = 696.6, P < 0.0001
~
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TABLE 27
IN VITRO ANTICOAGULANT ACTIVITY OF PENTASACCHARIDE IN BLOOD BANK PLASMA
Concentration

PT
(sec)

APTT
(sec)

Heptest
(sec)

SUTT
(sec)

Anti-Ila

Anti-Xa

(% Inhib)

(% Inhib)

0.7 ± 0.6

97.8 ± 0.1*

(µg/mL)

(µM)

100.0

58.0

13.7 ± 0.2

79.3 ± 9.3*

299.6 ± 0.9*

36.4 ± 11.2*

50.0

29.0

12.9 ± 0.6

60.8 ± 5.6*

256.8 ± 50.2*

28.8 ± 5.8

0.5

25.0

14.5

12.9

± 0.7

46.2 ± 9.7

197.8 ± 66.9*

27.2 ± 2.3

1.4 ± 0.3

97.2 ± 0.2*

12.5

7.25

12.9 ± 0.8

43.8

± 37. 7•

25.9 ± 1.5

0.7 ± 1.0

96.8 ±

6.25

3.63

12.4 ± 0.9

40.9 ± 5.0

162.4 ± 49.3*

25.5 ± 0.5

1.1

3.12

1.81

12.6

± 1.1

38.5 ± 5.7

135.1 ± 37.9*

24.2 ± 0.5

1.0 ± 0.7

156

0.91

12.0 ± 1.0

35.4

± 34_3•

23.7 ± 1.3

0.4 ± 0.4

85.5 ± 1.5"
64.3 ± 3.9·

0.78

0.45

12.0 ± 0.9

35.2 ± 5.7

± 0.4

41.9 ± 3.4*

± 6.6

± 5.6

163.9

112.2

93.3±21.1"

23.9

± 3.1

0.4

± 0.5

± 1.3

97.8

94.3

± 0.1*

o.r

± 2.1·

0
0
12.2 ± 1.3
31.8 ± 3.1
18.0 ± 3.4
22.9 ± 1.5
0±0
0±0
All results represent the mean± 1 standard deviation of four determinations. Molar values were calculated based on a formula weight
of 1728 Da for pentasaccharide. Statistical analysis of the data was made using one way ANOV A followed by the Newman-Keuls
test for each assay. * indicates statistical significance compared to unsupplemented baseline plasma (p < 0.05). PT: dF = 35, F
= 1.53, P = 0.194. APTT: dF = 35, F = 21.6, P < 0.0001. Heptest: dF = 35, F = 18.7, P < 0.0001. SU TT: dF = 35,
F = 3.46, P = 0.0072. Anti-Ila : dF = 35, F = 1.55, P = 0.186. Anti-Xa : dF = 35, F = 1235, P < 0.0001
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TABLE 28
IN VITRO ANTICOAGULANT ACTIVITY OF APROSULATE IN NORMAL RABBIT PLASMA

Concentration

APTT
(sec)

Heptest

(sec)

PT

(sec)

5UTT
(sec)

Anti-Ila

Anti-Xa

(% Inhib)

(% Inhib)

(µg/mL)

(µM)

100.0

41.88

7.4±0.1*

>300"

133.7 ± 7.9*

>300"

20.5

± 2.6"

0

50.0

20.94

7.3 ± 0.1·

260.6 ± 16.s·

93.1 ± 21.7*

>300*

12.1 ± 5.6"

0

25.0

10.47

6.9

± 18.4"

45.4 ± 5.0

>300·

4.4 ± 2.4

0

12.5

5.23

6.8 ± 0.1

122.1 ± 20.6*

38.1 ± 4.7

117.8

± 1.2

0

6_25

2_62

6.8 ± 0.3

88.4 ± 2.1·

33.3 ± 6.3

45.8 ± 2.7*

0

0

3.12

1.31

6.2 ± 0.3

69.2

29.5 ± 5.9

36.6 ± 5.2*

5.1 ± 8.8

0

1.56

0.65

6.5

± 0.2

56.7

± 4.4
± 8.1

27_5 ± 4.8

33.1 ± 2.5*

0

0

0.78

0.33

6.4 ± 0.1

50.5 ± 0.8

27.0 ± 3.3

29.1 ± 2.0

0

0

0

0

6.3 ± 0.4

45.0

± 2.3

25.7 ± 2.5

27.8

± 0.5

0

0

± 0.2·

153.5

± 3.1"

0.7

All results represent the mean ± 1 standard deviation of three determinations. Molar values were calculated based on a formula
weight of 2388 Da for aprosulate and represent the plasma aprosulate concentration. Statistical differences versus control were
determined for each assay using one way ANOVA followed by the Newman-Keuls multiple comparison test. *p < 0.05 vs. control.
PT: dF = 26, F = 10.6, p < 0.0001. APTT: dF = 26, F = 211 p < 0.0001. Heptest: dF = 26, F = 55.1, p < 0.0001. SU
TT: dF = 26, F = 8222.5, p < 0.0001. Anti-Ila: dF = 26, F = 11.2, p < 0.0001. Anti-Xa: dF = 26, F = 1.0, P = 1.0.
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TABLE 29
IN VITRO ANTICOAGULANT ACTIVITY OF GL-S22-Y-l IN NORMAL RABBIT PLASMA

(sec)

APTT
(sec)

Concentration

PT

Heptest
(sec)

SUTT
(sec)

Anti-Ila

Anti-Xa

(% Inhib)

(% Inhib)

(µg/mL)

(µM)

100.0

67.2

7.0 ± 0.1

49.4 ± 1.1

26.7

50.0

33.6

6.6 ± 0.2

49.4 ± 0.3

26.8 ± 3.9

28.4 ± 0.9

0±0

0±0

25.0

16.8

6.4

±

26.6 ± 3.7

28.3 ± 0.4

0.7 ± 1.2

0±0

12.5

8.4

6.8

6.25

4.2

3.12

± 0.1
± 0.5

48.8

1.1

± 5.5

± 3.5

29.6

±

±

0.9

9.2

± 1.4.

± 0.9

0±0

±0

48.6 ± 0.8

26.3

6.3 ± 0.2

46.5 ± 1.4

26.0 ± 3.2

27.2 ± 1.2

0±0

0±0

2.1

5.9 ± 0.6

44.1 ± 3.4

25.9

± 2.7

25.7 ± 2.3

0±0

0±0

1.56

1.05

6.0 ± 0.2

43.7

± 2.0

25.6

± 2.8

26.1

± 2.0

0±0

0±0

0.78

0.53

6.0 ± 0.3

46.2 ± 3.4

26.1 ± 2.0

26.1 ± 1.2

0±0

0±0

0

0

± 0.4

45.0 ± 2.3

2S.7 ± 2.5

27.8 ± 0.5

0±0

0±0

6.3

27.7

0.9

0.5

0

All results represent the mean ± 1 standard deviation of three determinations. Molar values were calculated based on a formula
weight of 1488 Da for GL-S22-Y-l and represent the plasma GL-S22-Y-l concentration. Statistical differences versus control were
determined for each assay using one way ANOVA followed by the Newman-Keuls multiple comparison test. *p < 0.05 vs. control.
PT: dF = 26, F = , p = . APTT: dF = 26, F = 4057, p < 0.0001. Heptest: dF = 26, F = 0.0482, p = 0.9999. SU TT:
dF = 26, F = 2.97, p = 0.0263. Anti-Ila: dF = 26, F = 58.8, p < 0.0001. Anti-Xa: dF = 26, F = 1.0, P = 1.0000.
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TABLE 30
IN VITRO ANTICOAGULANT ACTIVITY OF HEPARIN IN NORMAL RABBIT PLASMA
Concentration

PT
(sec)

APTT
(sec)

Heptest
(sec)

5UTT
(sec)

>300*

>300*

>300*

>300*

>300*

>300*

(µg/mL)

(µM)

100.0

9.53

50.0

4.77

± 1.2*
14.7 ± 0.4*

25.0

2.38

11.9

± 0.5*

>300*

>300·

12.5

1.19

9.9

± 0_5·

>300*

6.25

0.60

7.9 ± 0.5·

>300'

3.12

0.30

7.0

>300*

1.56

0.15

6.6

± 0.2
± 0.3

0.78

0.07

6.3

0

0

16.9

± 0.1
6.3 ± 0.4

74.5

± 7.1*
± s.s·

45.0

± 2.3

104.5

Anti-Ila
(% Inhib)

Anti-Xa
(% Inhib)

± 0.8*

>300'

± 2.2·
90.6 ± 2.5*
91.3 ± 0.4*

93.4

>300*

>300*

91.7

± 1.1*

90.3

>300·

>300*

87.1

± 1.9*

74.0

>300'

33.9

± 3_5•

8.2

± 2.1*

± 7.7·

90.2

10.0·

>300*

± 2.4·
50.4 ± 1.3·

39.2 ± 1.4*

>300*

36.3

204.4
73.8

25.7

±

± 2.5

27.8 ± 0.5

76.8

± 2.0·

0±0

95.6

95.5 ± 0.4*

± o.s·
± 1.1*

± 2.7*
44.2 ± 2.6*

0±0

AU results represent the mean ± 1 standard deviation of three determinations. Molar values were calculated based on a molecular
weight of 10492 Da for heparin and represent the plasma heparin concentration. Statistical differences versus control were determined
for each assay using one way ANOVA followed by the Newman-Keuls multiple comparison test. *p < 0.05 vs. control. PT: dF =
26, F = 159.2, p < 0.0001. APTT: dF = 26, F = , p < 0.0001. Heptest: dF = 26, F = 2457.7, p = 0.0001. SU TT : dF
= 26, F = 889114.1, p < 0.0001. Anti-Ila: dF = 26, F = 1041, p < 0.0001. Anti-Xa: dF = 26, F = 1225.2, P < 0.0001.
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TABLE 31
IN VITRO ANTICOAGULANT ACTIVITY OF PENTASACCHARIDE IN NORMAL RABBIT PLASMA
Concentration

PT
(sec)

APTT
(sec)

Heptest
(sec)

SUTT
(sec)

(µg/mL)

(µM)

100.0

58.0

6.4 ± 0.1

110.9 ± 5.8*

185.0 ± 10.7*

43.9 ± 1.8*

50.0

29.0

6.2 ± 0.3

99.8

± 2.2·

164.4 ± 9.7·

39.2

25.0

14.5

6.3 ± 0.1

87.3 ± 3.4*

139.6 ± 0.6·

7.25

6.4 ± 0.2

73.7 ± 8.8·

6.25

3.63

6.4 ± 0.1

3.12

1.81

1.56

Anti-Ila
(% Inhib)

Anti-Xa
(% Inhib)

o.r

97.8 ± 0.1 *

10.0 ± 2.0·

97.8 ± 0.1·

38.2 ± 0.4*

0±0

97.2 ± 0.2·

123.6 ± 12.s·

31.4 ± 1.2°

0±0

96.s ±

65.3 ± 8.2·

99.2 ± t. t•

31.1 ± 0.2·

0±0

94.3 ± 2.1'

6.4±0.1

64.5 ± 0.4*

84.4 ± 3.1·

28.2 ± 0.5

0±0

85.5 ± 1.5*

0.91

6.2 ± 0.3

60.9 ± 4.4'

65.2 ± 4.2'

27.5

± 0.4

0±0

64.3 ± 3.9*

0.78

0.45

6.3 ± 0.5

53.6 ± 6.4

46.8 ± 2.7'

26.5 ± 1.0

0±0

41.9 ± 3.4'

0

0

6.3 ± 0.4

45.0 ± 2.3

25.7 ± 2.5

27.8 ± 0.5

0±0

0±0

12.5

± 1.4•

10.5 ±

o.r

All results represent the mean ± I standard deviation of three determinations. Molar values were calculated based on a fommla
weight of 1728 Da for pentasaccharide and represent the plasma pentasaccharide concentration. Statistical differences versus control
were determined for each assay using one way ANOV A followed by the Newman-Keuls multiple comparison test. *p < 0.05 vs.
control. PT: dF = 26, F = 0.283, p = 0.9643. APTT: dF = 26, F = 49.2, p < 0.0001. Heptest : dF = 26, F = 192.1, p =
0.0001. 5U TT: dF = 26, F = 123.8, p < 0.0001. Anti-Ila: dF = 26, F = 122.9, p < 0.0001. Anti-Xa: dF = 26, F = 926.2,
p < 0.0001.
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TABLE 32

EFFECT OF APROSULATE ON THE FVIlI: C MEDIATED GENERATION
OF FACTOR Xa GENERATION
Concentration

µM

µgfrnL

% Inhibition

41.88

100.0

98.4 ± 1.1 *

20.94

50.0

92.6 ± 5.0*

10.47

25.0

84.8 ± 7.2*

5.23

12.5

74.7 ± 5.6*

2.62

6.2

64.5 ± 9.2*

1.31

3.1

52.9 ± 9.8*

0.65

1.6

44.8 ± 9.6*

0.33

0.8

28.6 ± 7.7*

All results represent the mean + 1 standard deviation of three determinations. µM
concentrations were calculated based on a formula molecular weight of 2388 Da. All
percent inhibitions were based on an unsupplemented control. Statistically significant
differences between treatment and control were determined by one way ANOVA (dF
= 23, F = 65, p < 0.0001) followed by the Newman-Keuls multiple comparison test.
*p < 0. 05 was considered statistically significant.
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TABLE 33
EFFECT OF GL-522-Y-1 ON THE FVIII:C MEDIATED INIIlBITION
OF FACTOR Xa GENERATION
Concentration

µM

/Lg/mL

% Inhibition

67.20

100.0

33.60

50.0

16.80

25.0

8.40

12.5

4.20

6.2

2.10

3.1

1.05

1.6

0.53

0.8

± 0.5*
58.8 ± 4.2*
32.8 ± 1.7*
21.2 ± 3.3*
18.6 ± 2.1·
12.0 ± 3.7*
13.7 ± 0.7*
3.6 ± 0.0
99.7

All results represent the mean ± 1 standard deviation of three determinations. µM
concentrations were calculated based on a formula molecular weight of 1488 Da. All
percent inhibitions were based on an unsupplemented control Statistically significant
differences between treatment and control were determined by one way ANOVA (dF
= 23, F = 975, p < 0.0001) followed by the Newman-Keuls multiple comparison test.
*p < 0.05 was considered statistically significant.
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TABLE 34
EFFECT OF HEPARIN ON TIIE FVIIl:C MEDIATED INHIBITION
OF FACTOR Xa GENERATION
Concentration
µM

µ.gJmL

0.038

0.4

99.7

0.019

0.2

99.7

0.010

0.1

99.7

0.005

0.05

96.4

0.0025

0.025

61.2

0.0012

0.012

39.2

0.0006

0.006

36.8

0.0003

0.003

30.3

% Inhibition

± 0.3*
± 0.3*
± 0.3*
± 2.0*
± 8.0*
± 8.4*
± 1.0*
± 0.4*

All results represent the mean ± 1 standard deviation of three determinations. µM
concentrations were calculated based on a weight average molecular weight of 10492
Da. All percent inhibitions were based on an unsupplemented control. Statistically
significant differences between treatment and control were determined by one way
ANOVA (dF = 23, F = 975, p < 0.0001) followed by the Newman-Keuls multiple
comparison test. *p < 0. 05 was considered statistically significant.
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TABLE 35
EFFECT OF PENTASACCHARIDE ON TIIB FVIII: C MEDIATED INIIlBITION
OF FACTOR Xa GENERATION
Concentration

µM

µ,gfmL

58.00

100.0

29.00

50.0

14.50

25.0

7.25

12.5

3.63

6.2

1.81

3.1

0.91

1.6

0.45

0.8

% Inhibition

± 10.9*
77.3 ± 8.3*
74.9 ± 7.7*
70.8 ± 8.7*
67.9 ± 7.0*
67.9 ± 6.5*
62.3 ± 6.8*
52.6 ± 7.1 *

82.4

All results represent the mean + 1 standard deviation of three determinations. µM
concentrations were calculated based on a formula molecular weight of 1728 Da. All
percent inhibitions were based on an unsupplemented control. Statistically significant
differences between treatment and control were determined by one way ANOVA (dF
= 23, F = 346, p < 0.0001) followed by the Newman-Keuls multiple comparison test.
*p < 0.05 was considered statistically significant.
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TABLE 36
EFFECT OF APROSULATE ON PROTEASE GENERATION FOLLOWING ACTIVATION
OF THE INTRINSIC AND EXTRINSIC PATHWAYS
% Inhibition

Concentration
µg/mL

Extrinsic Ila

Extrinsic Xa

Intrinsic Ila

Intrinsic Xa

33.3

79.5

11.1 ± 2.1 •

5.2 ± 1.5*

75.6 ± 4.8·

91.3 ± 3.7*

16.7

39.8

8.1 ± 2.9*

0.7 ± 0.7

70.6 ± 4.6*

92.2 ± 3.1 •

8.4

19.9

2.0 ± 1.6

0.1 ± 0.1

65.4 ± 5.2 •

92.0 ± 4.2"

4.2

9.9

0.6 ± 1.4

0±0

55.1 ± 10.6·

91.5 ± 4.6·

2.1

5.0

0±0

0±0

17.2 ± 25.5

67.7 ± 24.0*

1.05

2.5

0±0

0±0

0±0

42.7 ± 21.2·

0.52

1.2

0±0

0±0

0±0

20.5 ± 18.7

0.26

0.6

0±0

0 ± 0

0±0

8.4 ± 10.0

0

0

0±0

0±0

0±0

0±0

µM

All results represent the mean ± 1 standard deviation of three determinations. µM amounts are final assay concentrations based on
a formula molecular weight of 2388 Da. All percent inhibitions were calculated based on an unsupplemented control. Statistically
significant differences between supplemented and control samples were determined by one way ANOV A followed by the NewmanKeuls multiple comparison test (Ext Ila; dF = 26, F = 27.3, p < 0.0001. Ext Xa; dF = 26, F = 29.2, p < 0.0001. Int Ila; dF
= 26, F = 37.9, p < 0.0001. Int Xa; dF = 26, F = 22.4, p < 0.0001). * p < 0.05 was considered statistically significant. w
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TABLE 37
EFFECT OF GL-522-Y-l ON PROTEASE GENERATION FOLLOWING ACTIVATION OF THE INTRINSIC AND
EXTRINSIC PATHWAYS

% Inhibition

Concentration
µg/mL

Extrinsic Ila

Extrinsic Xa

Intrinsic Ila

Intrinsic Xa

33.3

49.6

97.7 ± 3.9*

98.3 ± 3.o·

100 ± O*

99.9 ± 0.2·

16.7

24.8

77.8 ± 7.o·

80.4 ± 9.5*

100 ± o·

100 ± o·

8.4

12.4

54.7

4.2

6.2

26.6 ± 14.2"

36.8 ± 13.1"

84.0 ± 5.1*

93.8 ± 6.9*

2.1

3.1

10.8 ± 0.1

14.6 ± 7.5

28.4 ± 33.5*

81.9 ± 7.0*

1.05

1.5

4.7

0.52

0.8

0.2 ± 0.2

0.5 ± 0.6

0±0

7.4 ± 6.6

0.26

0.4

0±0

0.2 ± 0.3

0±0

2.1 ± 3.0

0

0

0 ± 0

0±0

0±0

0±0

µM

All results represent the mean

± 5.7*

± 3.1

57.2

1.6

± 5.2*

±

± 1 standard deviation of three determinations.

1.0

99.4

0.4

± 1.0*

± 0.7

96.3

27.2

± 3.2*

±

19.8*

µM amounts are final assay concentrations based on

a formula molecular weight of 1488 Da. All percent inhibitions were calculated based on an unsupplemented control. Statistically
significant differences between supplemented and control samples were determined by one way ANOV A followed by the NewmanKeuls multiple comparison test (Ext Ila; dF = 26, F = 123.2, p < 0.0001. Ext Xa; dF = 26, F = 111.3, p < 0.0001. Int Ila;
dF = 26, F = 55.5, p < 0.0001. Int Xa; dF = 26, F = 102.9, p < 0.0001). * p < 0.05 was considered statistically significant.
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TABLE 38
EFFECT OF HEPARIN ON PROTEASE GENERATION FOLLOWING ACTIVATION
OF THE INTRINSIC AND EXTRINSIC PATHWAYS

% Inhibition

Concentration
µM

µg/mL

Extrinsic Ila

Extrinsic Xa

Intrinsic Ila

Intrinsic Xa

33.3

349.4

100 ± o·

97.3 ± 0.9*

29.7 ± 1.7*

79.6 ± 1.0*

16.7

174.7

98.7 ± 1.1*

96.2 ± 1.0·

29.2 ± 2.5"

80.1 ± 2.5"

8.4

87.4

93.4 ± 2.1 •

94.9 ± o.4·

29.7 ± 2.0·

81.9 ± 1.6*

4.2

43.7

54.2

± 5.4·

92.6 ± 0.3·

28.9 ± 3.3·

80.1 ± 2.s·

2.1

21.8

1.7 ± 1.9

85.6 ± 0.7*

24.1

1.05

10.9

0±0

68.5 ± 2.3·

23.5 ± 5.9*

84.7 ± 1.3*

0.52

5.6

0±0

47.8 ± 2.3*

7.8 ± 13.5

86.7 ± 2.1'

0.26

2.7

0±0

27.7 ± 2.2·

0±0

68.3 ± 6.5'

0

0

0±0

0±0

0±0

0±0

± 4.9'

81.3

± 2.8'

All results represent the mean ± 1 standard deviation of three determinations. µM amounts are final assay concentrations based on
a formula molecular weight of 10492 Da. All percent inhibitions were calculated based on an unsupplemented control. Statistically
significant differences between supplemented and control samples were determined by one way ANOVA followed by the NewmanKeuls multiple comparison test (Ext Ila; dF = 26, F = 1577.5, p < 0.0001. Ext Xa; dF = 26, F = 1880.7, p < 0.0001. Int Ila;
dF = 26, F = 16.9, p < 0.0001. Int Xa; dF = 26, F = 294.4, p < 0.0001). * p < 0.05 was considered statistically significant.
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TABLE 39
EFFECT OF PENTASACCHARIDE ON PROTEASE GENERATION FOLLOWING ACTIVATION
OF THE INTRINSIC AND EXTRINSIC PATHWAYS

% Inhibition

Concentration
µg/mL

Extrinsic Ila

Extrinsic Xa

Intrinsic Ila

Intrinsic Xa

33.3

57.5

0±0

0±0

0±0

53.3 ± 12.7*

16.7

28.8

0±0

0±0

0±0

29.2 ± 13.7*

8.4

14.4

0±0

0±0

0±0

16.3 ± 9.5

4.2

7.2

0±0

0±0

0±0

8.9 ± 6.1

2.1

3.6

0±0

0±0

0±0

4.1

1.05

1.8

0±0

0±0

0±0

1.2 ± 0.6

0.52

0.9

0±0

0±0

0±0

0.4

0.26

0.4

0±0

0±0

0±0

1.3 ± 1.3

0

0

0±0

0±0

0±0

0±0

µM

± 3.2
± 0.4

All results represent the mean ± 1 standard deviation of three determinations. µM amounts are final assay concentrations based on
a formula molecular weight of 1728 Da. All percent inhibitions were calculated based on an unsupplemented control. Statistically
significant differences between supplemented and control samples were determined by one way ANOV A followed by the NewmanKeuls multiple comparison test (Ext Ila; dF = 26, F = 1.0, p = 1.0 Ext Xa; dF = 26, F = 1.0, p = 1.0. Int Ila; dF = 26, F =
1.0, p = 1.0. Int Xa; dF = 26, F = 17.9, p < 0.0001). * p < 0.05 was considered statistically significant.
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TABLE 40
EFFECT OF APROSULATE ON GLYCOSAMINOGLYCAN SYNTHESIS IN ENDOTHEUAL CELL CULTURE
CS Med 1

HS Med2

CS Cell3

HS Cell4

0

2.71 ± 0.43

1.06 ± 0.26

0.84 ± 0.13

1.30 ± 0.21

0.04

1.87 ± 0.31

0.77 ± 0.12

0.76 ± 0.01

1.20±0.17

0.41

2.22 ± 0.06

0.92 ± 0.07

0.85 ± 0.09

1.17 ± 0.10

4.18

2.72

Dose (µM)

-----

± 0.13

1.32

± 0.23

0.73

± 0.02

1.12

± 0.04

20.9

2.87 ± 0.10

1.61 ± 0.28

1.02 ± 0.16

0.97 ± 0.21

41.8

2.99 ± 0.06

2.14 ± 0.01·

1.46 ± 0.04*

0.91 ± 0.15

All results represent the mean ± SEM of three individual culture dishes. Confluent rabbit endothelial cells were incubated with
aprosulate and 35S containing buffer for 18 hours. Glycosaminog1ycan production was determined by scinti1lation counting. 1
Chondroitin sulfate in culture media (C.P.M.'s x 105). 2 Heparan sulfate in culture media (C.P.M.'s x 106>. 3 Chondroitin sulfate
on endothelial cel1s (C.P.M.'s x 105). 4 Heparan sulfate on endothe1ia1 ce11s (C.P.M. 's x 106). Statistical comparison of the C.P.M. 's
at each concentration with that of unsupplemented controls was made by one way ANOVA followed by the Newman-Keuls test. (CS
Med; dF = 17, F = 10.5, p = 0.0005. HS Med; dF = 17, F = 21.2, p < 0.0001. CS Cell; dF = 17, F = 25.4, p < 0.0001.
HS Cell; dF = 17, F = 2.56, p = 0.0847). "p < 0.05 vs. control is considered statistically significant.
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TABLE 41
EFFECT OF GL-522-Y-1 ON GLYCOSAMINOGLYCAN SYNTHESIS IN ENDOTHELIAL CELL CULTURE
Dose (µM)

CS Med 1

0

1.45

0.07

1.29

0.67

1.43

6.70

1.30

± 0.12
± 0.22
± 0.02
± 0.16

33.5

1.70 ± 0.36

67.0

1.58

± 0.19

HS Med2

CS Cell3

HS Cell4

0.33

± 0.10
0.31 ± 0.06
0.42 ± 0.03
0.78 ± 0.08

0.95

± 0.08
1.31 ± 0.01
1.51 ± 0.11·
1.30 ± 0.25

± 0.02
1.14 ± 0.02
1.36 ± 0.04*
1.24 ± 0.29

1.10 ± 0.19*

1.70 ± 0.08*

1.81 ± 0.13*

1.11

± o.1s·

1.70

± 0.06*

0.76

1.91

± 0. 12·

± SEM of three individual culture dishes. Confluent rabbit endothelial cells were incubated with GL522-Y- l and :ns containing buffer for 18 hours. Glycosaminoglycan production was determined by scintillation counting. 1 Chondroitin
sulfate in culture media (C.P.M. 's x 105). 2 Heparan sulfate in culture media (C.P.M. 's x 106). 3 Chondroitin sulfate on endothelial
cells (C.P.M. 's x 105). 4 Heparan sulfate on endothelial cells (C.P.M. 's x 106). Statistical comparison of the C.P.M. 's at each
concentration with that of unsupplemented controls was made by one way ANOV A followed by the Newman-Keuls test (CS Med;
dF = 17, F = 1.80, p = 0.1867. HS Med; dF = 17, F = 31.6, p < 0.0001. CS Cell; dF = 17, F = 16.5, p < 0.0001. HS Cell;
dF = 17, F = 28.3, p < 0.0001). *p < 0.05 vs. control is considered statistically significant.

All results represent the mean
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TABLE 42
EFFECT OF HEPARIN ON GLYCOSAMINOGLYCAN SYNTIIESIS IN ENDOTHELIAL CELL CULTURE
Dose (µM)

CS Med 1

CS Cen3
HS Med

0

HS Cell4

2

0.76 ± 0.05

2.60 ± 0.24

0.55

± 0.07

8.40 ± 1.18

±

0.0095

0.93

0.20

2.86 ± 0.13

0.56

± 0.07

8.44 ± 0.59

0.095

1.08 ± 0.32

3.73 ± 0.20

0.69 ± 0.5

9.48 ± 0.66

0.95

1.03 ± 0.22

4.21

± 0.53"

0.88 ± 0.26

7.56

± 2.02

4.77

0.93 ± 0.25

5.77

± 0.62*

0.52

± 0.06

9.45

± 3.03

9.50

0.84

6.76 ± 0.18*

1.05

± 0.08

9.24 ± 0.69

± 0.07

All results represent the mean ± SEM of three individual culture dishes. Confluent rabbit endothelial cells were incubated with
heparin and 35S containing buffer for 18 hours. Glycosaminoglycan production was detennined by scintillation counting. 1 Chondroitin
sulfate in culture media (C.P.M.'s x 105). 2 Heparan sulfate in culture media (C.P.M. 's x 105). 3 Chondroitin sulfate on endothelial
cells (C.P.M. 's x 101). 4 Heparan sulfate on endothelial cells (C.P.M. 's x 105). Statistical comparison of the C.P.M. 's at each
concentration with that of unsupplemented controls was made by one way ANOV A followed by the Newman-Keuls test (CS Med;
dF = 17, F = 0.959, p = 0.4793. HS Med; dF = 17, F = 59.9, p < 0.0001. CS Cell; dF = 17, F = 2.44, p = 0.0950. HS Cell;
dF = 17, F = 0.655, p = 0.6636). ·p < 0.05 vs. control is considered statistically significant.
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TABLE 43
EFFECT OF PENTASACCHARIDE ON GLYCOSAMINOGLYCAN SYNTHESIS IN ENDOTHELIAL CELL CULTURE
Dose (µM)

CS Med 1

HS Med2

CS Cell3

HS Cell4

0

7.70 ± 1.17

8.52 ± 0.28

6.65 ± 0.53

3.28 ± 0.54

0.058

7.74 ± 0.30

8.61 ± 0.34

6.55 ± 1.03

3.36 ± 0.48

0.58

7.58 ± 0.44

9.33 ± 0.04

6.80 ± 0.01

4.09

± 0.43

5.8

7.83

± 0.32

8.58 ± 1.38

3.85

± 0.05

29.0

7.53 ± 1.32

7.51 ± 0.57

8.50 ± 0.02

3.76 ± 0.40

58.0

6.63 ± 0.28

8.84

± 0.39

9.09

± 0.18

9.78

± 0.07

4.71

± 0.70

All results represent the mean ± SEM of three individual culture dishes. Confluent rabbit endothelial cells were incubated with
pentasaccharide and 35S containing buffer for 18 hours. Glycosaminoglycan production was determined by scintillation counting. 1
Chondroitin sulfate in culture media (C.P.M.'s x 104). 2 Heparan sulfate in culture media (C.P.M.'s x Hf). 3 Chondroitin sulfate
on endothelial cells (C.P.M. 's x 104). 4 Heparan sulfate on endothelial cells (C.P.M. 's x 1£Yi). Statistical comparison of the C.P.M. 's
at each concentration with that of unsupplemented controls was made by one way ANOV A followed by the Newman-Keuls test (CS
Med; dF = 17, F = 0.964, p = 0.4770. HS Med; dF = 17, F = 11.0, p = 0.0004. CS Cell; dF = 17, F = 9.86, p = 0.0006.
HS Cell; dF = 17, F = 3.63, p = 0.0313). *p < 0.05 vs. control is considered statistically significant.
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TABLE 44
EFFECT OF APROSULATE, GL-522-Y-1, HEPARIN AND PENTASACCHARIDE ON AGONIST INDUCED PLATELET
AGGREGATION IN PLATELET RICH PLASMA
Aprosulate

GL-522-Y-1

Heparin

Pentasaccharide

Control

Epinephrine

68.1 ± 4.9

66.1 ± 4.1

73.9 ± 0.7

63.3 ± 7.4

66.0 ± 6.0

ADP 1:4

72.0 ± 3.9

69.1

± 4.5

71.6 ± 1.6

66.9 ± 4.3

65.4 ± 3.8

ADP 1:8

61.0 ± 7.1

60.2 ± 6.4

68.6

± 5.3

58.8 ± 1.5

53.9 ± 7.7

Arachidonic Acid

78.5

± 0.8

68.8 ± 7.0

77.8 ± 0.8

69.3 ± 7.1

78.3 ± I.I

± o.8·

89.1 ± 2.7

93.7 ± 0.9

± 1.6

74.7 ± 1.4

Thrombin

Collagen

46.6 ± 11.3·
76.4

±

1.3

91.8

±

I.I

74.8 ± 1.3

6.7

75.5 ± 1.7

75.9

All results represent the mean (± SEM) percent aggregation of 10 volunteers. All test agents were supplemented at a final
concentration of 10 µM. Epinephrine = 10 µglmL; ADP = 1.15 and 0.58 µglmL; Arachidonic acid = 300 µg/mL; Thrombin =
1 U/mL; Collagen = 0.8 µg/mL. All agonist concentrations represent final assay concentrations. Statistical comparisons vs. control
for each agonist were made by one way ANOVA and the Newman Keuts test (Epinephrine; dF = 49, F = 5.98, p = 0.0006. ADP
1:4; dF = 49, F = 6.13 p = 0.0005. ADP 1:8; dF = 49, F = 5.98, p = 0.0006. Arachidonic Acid; dF = 49, F = 12.4, p <
0.0001. Thrombin; dF = 49, F = 532, p < 0.0001. Collagen; dF = 49, F = 2.15 p = 0.0900). •p < 0.05 was considered
statistically significant.
w

Ul

N

,,,

TABLE 45
EFFECT OF APROSULATE, GL-522-Y-l, HEPARIN AND PENTASACCHARIDE ON AGONIST INDUCED PLATELET
AGGREGATION IN PLATELET RICH PLASMA
Aprosulate

GL-522-Y-1

Heparin

Pentasaccharide

21.8

± 3.5

1.2

41.2

±

30.6

± 2.3

31.5

± 2.8

41.8

± 4.6

47.9

± 2.8

Epinephrine

22.5

± 2.7

20.7

± 2.6

25.5

± 2.2

21.7 ± 3.1

ADP 1:4

39.4

±

1.8

39.5

±

1.3

41.3

±

1.0

38.6

±

ADP 1:8

31.2

±

1.8

31.8

±

1.9

36.5

± 2.1

Arachidonic Acid

45.2

± 2.3

42.4

± 4.4

46.7

± 2.2

Thrombin

21.9

± 2.8·

74.6

± 8.0

3.8 ± 0.2·

Collagen

40.9

±

41.l

±

40.4

2.2

1.9

± 2.0

Control

50.8 ± 4.7
41.0

± 1.9

1.9

61.5 ± 3.0
43.l

± 2.7

All results represent the mean (± SEM) slope of the aggregation response of 10 volunteers. All test agents were supplemented at
a final concentration of 10 µM. Epinephrine = 10 µg/mL; ADP = 1.15 and 0.58 µg/mL; Arachidonic acid = 300 µg/mL; Thrombin
= I U/mL; Collagen = 0.8 µg/mL. All agonist concentrations represent final assay concentrations. Statistical comparisons were
made by one way ANOVA and the Newman Keuls test (Epinephrine; dF = 49, F = 4.10, p = 0.0065. ADP 1:4; dF = 49, F =
6.49 p = 0.0003. ADP 1:8; dF = 49, F = 11.6, p < 0.0001. Arachidonic Acid; dF = 49, F = 6.01, p = 0.0006. Thrombin;
dF = 49, F = 410.6, p < 0.0001. Collagen; dF = 49, F = 2.32 p = 0.0710). *p < 0.05 was considered statistically significant.
w

VI

w

r
354

TABLE 46
COMPARATIVE EFFECT OF SYNTHETIC HEPARIN ANALOGUES IN A
HEPARIN INDUCED THROM:BOCYTOPENIA SCREENING ASSAY

µ.g/m.L

µM

8.3

Saline

Aprosulate

GL-522-Y-1

Heparin

Pentasaccharide

% Aggregation

± 1.1

5.5

2.30

11.0

4.61

21.7

9.21

± 1.9
18.9 ± 1.6*
21.2 ± 4.2*

5.5

3.70

10.4

± 3.3"

11.0

7.39

7.8

± 0.9

21.7

14.78

5.0

± 1.3

5.5

0.52

11.0

l.05

21.7

2.10

5.5

3.18

11.0

6.37

21.7

12.73

9.0

± 1.7*
15.5 ± 1.4"
22.2 ± 5.5*
11.6

± 0.2
5.9 ± 0.3
6.6 ± 1.1
3.4

Results represent the mean ± SEM of 10 volunteers. Aggregation was induced by the
test agent and lilT positive serum. Statistical analysis was made by one way ANOVA
followed by the Newman Keuls test (aprosulate; dF = 39, F = 70.8, p < 0.0001. GL522-Y-1; dF = 39, F = 13.5, p < 0.0001. heparin; dF = 39.3, F = 39.3, p <
0.0001. pentasaccharide; dF = 39, F = 64.9, p < 0.0001). p < 0.05 represents a
statistically significant increase in aggregation VS'. control.
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TABLE 47

ANTITHROMBOTIC EFFECT OF SYNTHETIC HEPARIN ANALOGUES IN
A RABBIT MODEL OF STASIS TIIROMBOSIS
Dose
(nmol/kg)

(mglkg)

0.1 mL/kg

Saline

Clot Score
10 minutes

Clot Score
20 Minutes

2.9 ± 0.1

3.6 ± 0.3

Aprosulate

42.0
104.7
209.4

0.10
0.25
0.50

2.8 ± 0.3
1.2 ± 0.21
0.2 ± 0.2'

3.3 ± 0.3
3.0 ± 0.0
2.2 ± 0.4*

GL-522-Y-1

67.0
776.0
1940.0
3880.0

0.10
1.00
2.50
5.00

2.6 + 0.2·
1.6 ± 0.3*
1.0 ± 0.3 1
0.4 ± 0.21

3.4
2.9
3.2
2.8

0.6
1.2
2.4
4.8

0.01
0.01
0.02
0.05

0.8 ± 0.2
1.8 ± 0.5
1.2 ± 0.6*
0.0 ± 0.0'

3.6 ± 0.3
3.0 ± 0.0
2.4 ± 0.2
0.2 ± 0.2#

7.2
14.5
29.0
58.0

0.01
0.02
0.05
0.10

2.4 ± 0.3
1.8±0.4"
1.2 ± 0.2'
0.2 ± 0.2 1

3.0 ± 0.0
3.0 ± 0.0
2.8 ± 0.2
1.2 ± 0.2#

Heparin

Pentasaccharide

± 0.1
± 0.1
± 0.2
± 0.2

All doses, with the exception of saline, are expressed in nmol/kg administered 5
minutes prior to injection of the thrombogenic challenge. Clot Score 10 minutes and
Clot Score 20 minutes are expressed as mean ± S.E.M. of the clot scores obtained
after stasis times of 10 and 20 minutes, respectively. Each treatment group contained
5 rabbits. Statistical comparisons were made using the Kruskal-Wallis test for each
agent followed by the Mann-Whitney U test for specific comparisons. p < 0.05 vs.
control. #p < 0.01 vs. control.
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TABLE 48

ANTITHROMBOTIC EFFECT OF SYNTHETIC HEPARIN ANALOGUES IN
A RABBIT MODEL OF STASIS 1EROMBOSIS
Agent

Dose
(µmol/kg)

Saline

Aprosulate

GL-522-Y-1

Heparin

Pentasaccharide

(mg/kg)

0.1 mL/kg

Clot Score
10 minutes

2.9

Clot Score
20 Minutes

+ 0.1

3.6

± 0.3

1.047

2.5

2.7 ± 0.1

2.9

± 0.1

2.094

5.0

1.4

2.0

± 0.2·

4.188

10.0

0.5

+ 0.2#
+ 0.1#

1.4

± 0.1#

6.720

10.0

2.4

13.440

20.0

1.2

+ 0.2
+ 0.4#

20.160

30.0

0.8 ± 0.4#

± 0.2
3.2 ± 0.2
3.8 ± 0.2

0.024

0.25

0.048

0.50

± 0.3
1.2 ± 0.2#

± 0.3
2.5 ± 0.2

0.095

1.00

0.0

± 0.<1

1.0

0.073

0.12

1.8

+ 0.2#

0.145

0.25

1.2 ± 0.2#

0.290

0.50

0.4

± 0.5
2.4 ± 0.4
1.8 ± 0.4*

2.6

± 0.2#

3.6

3.4

± 0.4#

3.0

All doses, with the exception of saline, are expressed :in 1-'mol/kg administered 2 hours
prior to injection of the thrombogenic challenge. Clot Score 10 minutes and Clot
Score 20 minutes are expressed as mean + S.E.M. of the clot scores obtained after
stasis times of 10 and 20 minutes, respectively. Each treatment group contained 5
rabbits. Statistical comparisons were made using the Kruskal-Wallis test for each agent
followed by the Mann-Whitney U test for specific comparisons. p < 0.05 vs.
control. #p < 0.01 vs. control.
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TABLE 49
TIME DEPENDENCE OF THE ANTITim.O:MBOTIC ACTIVITY OF
SYNTIIBTIC HEPARIN ANALOGUES IN A RABBIT STASIS THROMBOSIS
MODEL FOLLOWING INTRAVENOUS ADMINISTRATION
Circulation
Time

Clot Score
10 minutes

Clot Score
20 minutes

Saline

5 min.

2.9

+

0.1

3.6

Aprosulate

5 min.

0.2

± 0.2#

2.2

(209 nmol/kg; 500
µglkg)

60 ntin.

1.4

± 0.3#

± 0.4*
3.0 ± 0.0

120 min.

2.4

+

0.3

3.4

± 0.3

5 min.
60 min

0.4

2.8

1.4

+ 0.2#
+ 0.2·

2.8

± 0.2
± 0.2

120 min.

1.6

+ o.i-

3.0

± 0.0

Heparin

5 min.

0.0

± 0.0#

0.2

(4. 77 nmol/kg; 50
µglkg)

30 min.

1.6

± 0.3·

± 0.2#
2.6 ± 0.3

60 ntin.

2.4

+ 0.3

3.2

Pentasaccharide

5 min.

0.2

± 0.2#

1.2

(58.0 nmol/kg; 100
µglkg)

120 min.

1.3

± 0.3

± 0.2#
3.3 ± 0.3

240 min.

1.8

± 0.2·

3.2

GL-522-Y-1
(3880 nmol/kg; 5
mg/kg)

± 0.3

± 0.2

± 0.2

Clot Score 10 minutes and Clot Score 20 minutes are expressed as mean ± S .E.M.
of the clot scores obtained after stasis times of 10 and 20 minutes, respectively. Each
treatment group contained 4-5 rabbits. Statistical comparisons were made using the
Kruskal-Wallis test for each agent followed by the Mann-Whitney U test for specific
comparisons. *p < 0.05 vs. control. 11p < 0.01 YS. control.
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TABLE 50
TIME DEPENDENCE OF THE ANTITHRO:MBOTIC ACTIVITY OF
SYNTI:IETIC HEPARIN ANALOGUES IN A RABBIT STASIS THROMBOSIS
MODELFOLLOWINGSUBCUTANEOUSADMINISTRATION
Agent (dose)

Circulation
Time

Saline

5 min.

2.9

±

0.1

3.6

± 0.3

Aprosulate

2 hrs.

0.5

+ 0.1,f

1.4

(4.19 µmol/kg; 10.0
mg/kg)

4 hrs.

0.8

±

0.2,f

i.s

± 0.1 1
± o.s·

6 hrs.

2.2

+

0.2

3.2

+ 0.2

GL-522-Y-1

2 hrs.

1.2

3.2

(13.44 µmol/kg; 20.0
mg/kg)

3 hrs.

1.4

+ 0.4"
+ 0.3"

3.0

±
±

0.0

4 hrs.

2.4

+ 0.3

3.0

±

0.0

Heparin

2 hrs.

1.2

2.5

(0.048 µmol/kg; 500
µg/kg)

4 hrs.

± 0.2#
2.0 + 0.7

3.3

+ 0.4
± 0.4

6 hrs.

2.4

+ 0.3

3.2

±

0.2

Pentasaccharide

2 hrs.

1.2 ± 0.2·

2.4

0.4

(0.145 µmol/kg; 250
µglkg)

4 hrs.

1.5 ± 0.3·

2.8

±
±

0.3

6 hrs.

2.2

+ 0.2

3.4

±

0.3

Clot Score
10 minutes

Clot Score
20 minutes

0.2

Clot Score 10 minutes and Clot Score 20 minutes are expressed as mean ± S.E.M.
of the clot scores obtained after stasis times of lO and 20 minutes, respectively. Each
treatment group contained 4-5 rabbits. Statistical comparisons were made using the
Kruskal-Wallis test for each agent followed by the Mann-Whitney U test for specific
comparisons. ·p < 0.05 vs. control. #p < 0.01 vs. control.
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TABLE 51

ANTITHROMBOTIC EFFECT OF SYNTHETIC HEPARIN ANALOGUES
FOLLOWING IN1'RAVENOUS ADMINISTRATION IN A RAT
WGULAR VEIN CLAMPING MODEL
Dose
(µmol/kg)

GL-522-Y-1

Heparin

Pentasaccharide

(µg/kg)

0.1 rnlJkg

Saline
Aprosulate

II of Clampings

4.4

± 0.3

0.105

250

0.209

500

6.0 ± 0.7
8.2 ± 0.4·

0.419

1000

10.6 ± o.8·

1.047

2000

13.0

1.941

2500

3.882

5000

7.764

10000

11.646

15000

± 1.0
8.8 ± 0.4*
12.8 ± o.8·
13.0 ± 1.1 *

0.012

125

5.6 ± 0.6

0.024

250

0.048

500

0.095

1000

0.029

50

0.058

100

0.145

250

0.290

500

+

1.9*

6.4

± 0.94*
10.8 ± 1.1 *
> 15*

8.0

5.6 ± o.s·
8.4 ± 0.3*
11.4 ± o.5·
13.6 ± o.8·

All doses, with the exception of saline are expressed as µmo1Jkg. ,umole dosages of
each agent were calculated based on the formula molecular weights of 2388, 1488,
and 1728 Da for aprosulate, GL-522-Y-1, and pentasaccharide, respectively, and a
weight average molecular weight of I 0492 for heparin. The number of clampings
represent the mean ± S.E.M. of 5 rats. Statistical comparisons were made by one
way analysis of variance followed by the Newman-Keuls test. *p < 0.05 vs. control.
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TABLE 52

ANTITIIRO:MBOTIC EFFECT OF SYNTHETIC HEPARIN ANALOGUES
FOLLOWING SUBCUTANEOUS ADMlNISTRATION IN A RAT
JUGULAR VEIN CLAMPING MODEL
# of Clampings

Dose
(µmol/kg)

(mg/kg)

0.1 mLfkg

GL-522-Y-1

1.047

2.5

2.094

5.0

4.188

10.0

8.375

20.0

20.161
0.060

0.6

0.119

1.25

0.238

11.0

0.477

2.5
5.0

0.036

0.06

0.073

0.12

4.6 ± 0.3
7.4 ± 0.5·

0.145

0.25
0.50

10.6 ± 0.9*
12.0 ± 0.6*

6.720
13.441

Heparin

Pentasaccharide

5.8 ± 0.4
8.8 ± 0.4.

5.0
10.0
20.0
30.0

3.360

0.290

11.2
13.8

± 0.6·
± 0.9·

6.4 ± 0.6
7.4 ± 1.0·

o.r
12.8 ± o.r
±

All doses, with the exception of saline are expressed as µmol/kg. µmole dosages of
each agent were calculated based on the formula molecular weights of 2388, 1488,
and 1728 Da for aprosulate, GL-522-Y-1, and penta.saccharide, respectively, and a
weight average molecular weight of 10492 for heparin. The number of clampings
represent the mean ± S .E.M. of 5 rats. Statistical comparisons were made by one
way analysis of variance followed by the Newman-Keuls test. ·p < 0.05 vs. control.
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TABLE 53
HEMORRHAGIC EFFECT OF HEPARJN ANALOGUES FOLLOWING

INTRAVENOUS AD1\.1INISTRATION
Dose

µ.moll mg/kg
kg

Saline

Aprosulate

GL-522-Y-1

Heparin

Pentasaccharide

0.1 mL/kg

RBC's
5 min

0.07

+ 0.04

RBC's
15 min

0.07

± 0.03

2.5

+ o.o4·
0.15 + 0.06·

0.08 ± 0.01

2.09

5.0

0.11 ± o.o5·

0.10

1.68

2.5

0.17 ± 0.06

0.15 ± 0.05

3.36

5.0

0.54

0.54 ± 0.11·

6.72

10.0

+ 0.16·
0.87 + 0.13·

0.42

1.0

1.05

0.16

+ 0.05

0.09 ± 0.02

± 0.05

1.19

± 0.23•

0.08

± 0.04

0.02

0.25

0.11

0.05

0.50

0.22 ± 0.10

0.07 ± 0.01

0.10

1.00

0.31

+ 0.19*

0.13 ± 0.06

0.58

1.00

0.05

+ 0.02

0.03 ± 0.01

1.45

2.50

0.04 ± 0.01

0.05 ± 0.01

2.90

5.00

0.04

+ 0.01

0.04 ± 0.02

All results represent the mean ± S.E.M. blood cell loss (x la9/liter) in five rabbits
per treatment goup. Each agent was administered intravenously via the left marginal
ear vein. After five minutes, five standardized incisions were made in the non-vascular
portion of the right ear. Blood cells were collected for 10 minutes. After 10 minutes,
five incisions were made on the left ear and the blood cells collected for 10 minutes.
Blood cells were quantitated using a hemocytometer. Statistical comparisons were
made using one way ANOVA followed by the Newman-Keuls test. p < 0.05 vs.
control was considered to be statistically significant.
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TABLE 54
HEM:ORRHAGIC EFFECT OF HEPARIN ANALOGUES FOLLOWING
SUBCUTANEOUS ADlYIINISTRATION

RBC's (x 109/L)

Dose
~mollk

Saline

Aprosulate

GL-522-Y-1

Heparin

Pentasaccharide

mg/kg

0.1 mL/kg

0.11

± 0.04

± 0.03
0.16 ± 0.04
0.18 ± 0.05·
0.22 ± 0.05·

1.05

2.5

2.09

5.0

4.19

10.0

8.38

20.0

1.68

2.5

3.36

5.0

6.72

10.0

± 0.13
0.90 ± 0.38*
0.97 ± 0.54.

13.44

20.0

1.19

0.24

2.5

0.22

0.48

5.0

± 0.07
0.21 ± 0.06

0.95

10.0

o.55

1.91

20.0

5.80

10.0

11.60

20.0

0.09

0.48

±

0.55*

± o.2s·
2.00 ± 0.01 •
± 0.04
0.15 + 0.07
0.18

All results represent the mean ± S.E.M. blood cell loss (x 109/liter) in five rabbits
per treatment group. Each agent was administered subcutaneously in the abdominal
region. After 3 hours, five standardized incisions were made in the non-vascular
portion of the right ear. Blood cells were collected for 10 minutes. Blood cells were
quantitated using a hemocytometer. Statistical comparisons were made using one way
ANOVA followed by the Newman-Keuls test. "p < 0. 05 vs. control was considered
to be statistically significant.
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TABLE 55
TIME DEPENDENCE ON THE HEMORRHAGIC EFFECT OF HEPARIN
ANALOGUES FOLLOWING INTRAVENOUS ADMINISTRATION

Saline

Aprosulate

Dose

Tline

0.1 mLJkg

5 min.

0.10

0.42 µmoUkg

5 min.

0.15

(LO mg/kg)

30 min.
60 min.
120 min.

GL-522-Y-1

Heparin

Pentasaccharide

RBC's
(x 109/L)

±

0.01

± 0.01*
0.15 ± 0.01*
0.11 ± 0.01
0.11 ± 0.01

6.72 µmollkg

5 min.

0.87

(10.o mg/kg)

60 min.

1.37

120 min.

0.39

± 0.13*
± 0.29*
± 0.12*

0.95 µmo1/kg

5 min.

3.06

±

1.4*

(10.0 mg/kg)

60 min.

0.82

0.15

120 min.

0.38

±
±

2. 90 µmol/kg

5 min.

(5.0 mg/kg)

30min.

60 min.

0.08

± 0.02*
0.02 ± 0.01*
0.01 ± 0.01
0.04

All results represent the mean + S.E.M. blood cell loss (x Hf/liter) in five rabbits per
treatment group. Each agent was administered intravenously via the left marginal ear
vein. After varying circulation times, five standardized incisions were made in the nonvascular portion of the right ear. Blood cells were collected for 10 minutes. Blood cells
were quantitated using a hemocytometer. Statistical comparisons were made using one
way ANOVA followed by the Newman-Keuls tes1. p < 0. 05 YS. control was considered
to be statistically significant.
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TABLE 56
TIME DEPENDENCE OF TIIE HEMORRHAGIC EFFECT OF HEPARIN
ANALOGUES FOLLOWING SUBCUTANEOUS ADMINISTRATION

Saline

Aprosulate

GL-522-Y-1

Heparin

Dose

Time

RBC's (x 109/L)

0.1 mLJkg

3 hrs.

0.11 ± 0.04

2. 09 µmol/kg

1 hr.

0.16±0.01·

(5.0 mg/kg)

2 hrs.

0.20 ± 0.02·

4 hrs.

0.19 ± 0.02·

6 hrs.

0.13 ± 0.01

3.36 µmol/kg

3 hrs.

0.90 ± 0.38.

(5.0 mg/kg)

4.5 hrs.

0.42 ± 0.16·

6 hrs.

0.06 ± 0.02

0.48 µmol/kg

3 hrs.

0.21 ± 0.02·

(5.0 mg/kg)

6 hrs.

0.14 ± 0.01

All results represent the mean ± S.E.M. blood cell loss (x I<f!liter) in five rabbits per
treatment group. Each agent was administered subcutaneously in the abdominal region.
After varying absorption times, five standardized incisions were made in the non-vascular
portion of the right ear. Blood cells were collected for 10 minutes. Blood cells were
quantitated using a hemocytometer. Statistical comparisons were made using one way
ANOVA followed by the Newman-Keuls test. "p < 0. 05 vs. control was considered to
be statistically significant.
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TABLE 57
EFFECT OF INTRAVENOUS ADMINISTRATION OF HEPARIN
ANALOGUES ON THE CEUTE ACT IN RABBITS

Aprosulate

GL-522-Y-1

Heparin

Pentasaccharide

Dose

n

Fold Increase

100 µg!kg

5

250 µg!kg

5

500 µg!kg

4

± 0.04
1.05 ± 0.02
1.12 ± 0.12

1.0 mg/kg
2.5 mg/kg

s
s

5.0 mg/kg

4

± 0.03·
1.15 ± 0.02·
1.21 ± 0.02·

6.25 µg!kg

5

1.00

12.5 µg!kg

4

25.0 µg!kg

3

50.0 µ.g!kg

5

± 0.02
1.03 ± 0.03
0.98 ± 0.03

12.5 µglkg

4

25.0 µg!kg

5

50.0 µglkg

5

100.0

~g/kg

5

1.01

1.11

± 0.01

1.03

± 0.01
1.02 ± 0.02
1.08 ± 0.03
1.05 ± 0.02
1.00

Celite activated clotting times were determined a1 baseline and at 5 minutes postadministration of the test agent to New Zealand white rabbits. Fold increases were
calculated relative to individual baselines. Statis1icalcomparisons were made using one
way ANOVA followed by the Newman-Keuls test. p < 0.05 vs saline treatment was
considered statistically significant.

366
TABLE 58
EFFECT OF SUBCUTANEOUS ADMINISTRATION OF HEPARIN
ANALOGUES
ON THE CEUTE ACT IN RABBITS

GL-522-Y-1

Heparin

Pentasaccharide

Dose

n

10 mg/kg

5

20 mg/kg

4

30 mg/kg

5

250 µg/kg

3

500 µg/kg

5

± 0.09
1.16 ± 0.04*

1000 µg/kg

5

1.14

125 µg/kg

5

250 µg/kg

5

500 µg!kg

4

± 0.04
1.06 ± 0.04
1.12 ± 0.03

Fold Increase

± 0.02
1.15 ± 0.06
1.21 ± 0.09
1.06

1.15

± 0.02

1.06

Celite activated clotting times were determined at baseline and at 2 hours postadministration of the test agent to New Zealand white rabbits. Fold increases were
calculated relative to individual baselines. Statistical comparisons were made using one
way ANOVA followed by the Newman-Keuls test. "p < 0.05 vs saline treatment was
considered statistically significant.
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TABLE 59
EFFECT OF INTRAVENOUS ADMINISTRATION OF HEPARIN
ANALOGUES ON THE R-TIME.
Dose
Saline

n

R-time (fold increase)

5

1.05

± 0.22

Aprosulate

100 µg/kg
250 µg/kg
500 µg/kg

5
4
5

0.78
1.54
3.97

± 0.02
± 0.35
± 1.92

GL-522-Y-l

0.1
1.0
2.5
5.0

5
4

5
5

0.89
1.34
1.82
2.33

±
±
±
±

0.49
0.23
0.29
0.71

6.25 µg/kg
12.5 µg/kg
25.0 µ.g/kg
50.0 µ.g/kg

5
3
4
5

0.81
1.35
1.21
1.22

±
±
±
±

0.18
0.39
0.21
0.30

25.0 µ.g/kg
50.0 µ.g/kg
100.0 µ.g/kg

5
3
5

1.92
1.46
1.35

± 0.54
± 0.33
± 0.22

Heparin

Pentasaccharide

mg/kg
mg/kg
mg/kg
mg/kg

TEG analysis of whole rabbit blood was made at baseline and after administration of
the test agent. Fold increase was calculated relative to each rabbit's baseline.
Statistical significance was assessed for each agent using one way ANOVA followed
by the Newman-Keuls multiple comparison test. All p values are for treatment versus
saline treated control animals.
Aprosulate : p = 0.146
GL-52-Y-1 : p = 0.168
Heparin: p = 0.636
Pentasaccharide : p = 0.388
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TABLE 60
EFFECT OF SUBCUTANEOUS ADMINISTRATION OF HEPARIN
ANALOGUES ON TIIE R-TIME IN RABBITS

Dose

Heparin

Pentasaccharide

R-time (Fold Increase)

5

1.05

± 0.22

10 mg/kg

4

1.11

± 0.26

20 mg/kg

4

1.40

+ 0.68

30 mg/kg

5

1.42

± 0.26

250 µgfkg

4

500 µg!kg

5

1000 µglkg

5

± 0.39
1.12 ± 0.21
2.52 ± 0.75

125 µgfkg

3

1.31

250 µg/kg

5

1.18

500 µg/kg

4

1.58

Saline

GL-522-Y-1

n

1.60

+ 0.11
± 0.19
± 0.10

TEG analysis of whole rabbit blood was made at baseline and after administration of
the test agent. Fold increase was calculated relative to each rabbit's baseline.
Statistical significance was assessed for each agent using one way ANOVA followed
by the Newman-Keuls multiple comparison test. All p values are for treatment versus
saline treated control animals.
GL-52-Y-1 : p = 0.842
Heparin : p = 0.113
Pentasaccharide : p = 251
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TABLE 61
EX VIVO ANTICOAGULANT ACTIVITY MEASURED IN RABBIT
SAMPLES USING THE PT ASSAY
Dose (,ug/kg)

1.04

± 0.10

100

0.93

250

0.86

500

1.06

±
±
±

1000

± 0.17
1.05 ± 0.03
1.15 ± 0.06

Saline

Aprosulate

GL-522-Y-1

2500
5000

Heparin

0.05
0.02
0.02

1.13

50.0

± 0.03
0.96 ± 0.02
1.03 + 0.06

25.0

1.04

50.0

1.03

100.0

1.02 ± 0.02

12.5
25.0

Pentasaccharide

Clotting time (fold increase)

0.97

+ 0.03
+ 0.05

All treatments were administered intravenously 5 minutes prior to administration of
the thrombogenic challenge. Blood samples were drawn at baseline and immediately
before administration of the thrombogenic challenge. All results represent the mean
± SEM of 5 rabbits. Statistical comparisons were made using one way ANOVA
followed by the Newman Keuls test. p < 0. 05 was considered statistically
significant.
By ANOVA:
aprosulate; p = 0.082
GL-522-Y-1; p = 0.836
Heparin; p = 0.723
Pentasaccharide; p = 0.994
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TABLE 62
EX VIVO ANTICOAGULANT ACTIVITY MEASURED IN RABBIT
SAMPLES USING THE APTT ASSAY
Dose (µg/kg)
Saline

Aprosulate

0.97

Heparin

Pentasaccharide

± 0.04

500

± 0.06"
1.20 ± 0.03"
1.51 ± 0.06"

1000

1.36

2500

1.04

5000

1.00

± 0.37
± 0.17
± 0.07

12.5

1.28

± 0.09

25.0

1.03

100
250

GL-522-Y-1

Clotting time (fold increase)

1.16

50.0

± 0.15
1.19 ± 0.16

25.0

1.15

50.0
100.0

± 0.06
1.22 ± 0.12
1.10 ± 0.09

All treatments were administered intravenously 5 minutes prior to administration of
the thrombogenic challenge. Blood samples were drawn at baseline and immediately
before administration of the thrombogenic challenge. All results represent the mean
± SEM of 5 rabbits. Statistical comparisons were made using one way ANOVA
followed by the Newman Keuls test. "p < 0. 05 was considered statistically
significant.

By ANOVA:
aprosulate; p < 0.001
GL-522-Y-1; p = 0.534
Heparin; p = 0.277
Pentasaccharide; p = 0. 22 7
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TABLE 63
EX VIVO ANTICOAGULANT ACTIVITY :MEASURED IN RABBIT
SAMPLES USING THE HEPTEST ASSAY

Dose (µg/kg)

0.89 ± 0.06

Saline

Aprosulate

500

± 0.26
1.30 ± 0.26
1.35 ± 0.11

1000

1.13 ± 0.11

2500

1.12 ± 0.02

5000

1.38 ± 0.20

12.5

1.13 ± 0.12

25.0
50.0

± 0.04
1.42 ± 0.16·

25.0

1.90 ± 0.31*

50.0

2.38 ±

100.0

2.72 ± 0.09·

100
250

GL-522-Y-1

Heparin

Pentasaccharide

Clotting time (fold increase)

1.60

1.05

o.2s·

All treatments were administered intravenously 5 minutes prior to administration of
the thrombogenic challenge. Blood samples were drawn at baseline and immediately
before administration of the thrombogenic challenge. All results represent the mean
± SEM of 5 rabbits. Statistical comparisons were made using one way ANOVA
followed by the Newman Keuls test. p < 0. 05 was considered statistically
significant.

By ANOVA:
aprosulate; p = 0.117
GL-522-Y-1; p = 0.070
Heparin; p = 0.020
Pentasaccharide; p < 0. 001
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TABLE 64
EX VIVO ANTICOAGULANT ACTIVITY MEASURED IN RABBIT
SAMPLES USING THE 2.5 U TT ASSAY
Dose (µg/kg)

1.14 ± 0.08

Saline

Aprosulate

GL-522-Y-1

100

1.17 ± 0.04

250

1.38

+ 0.22

500

2.57

± 0.67

1000

5000

± 0.14
1.84 ± 0.34
1.86 ± 0.70

12.5

1.46

25.0

2.80

2500

Heparin

Pentasaccharide

Clotting time (fold increase)

1.50

+ 0.03

50.0

± 0.66*
3.18 ± 0.15*

25.0

1.19

50.0

± 0.16
1.21 ± 0.09

100.0

+ 0.14

1.14

All treatments were administered intravenously 5 minutes prior to administration of
the thrombogenic challenge. Blood samples were drawn at baseline and immediately
before administration of the thrombogenic challenge. All results represent the mean
+ SEM of 5 rabbits. Statistical comparisons were made using one way ANOVA
followed by the Newman Keuls test. p < 0. 05 was considered statistically
significant.
By ANOVA:
aprosulate; p = 0.036
GL-522-Y-1; p = 0.549
Heparin; p = 0.001
Pentasaccharide; p = 0. 967
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TABLE 65
EX VIVO ANTICOAGULANT ACTIVITY :MEASURED IN RABBIT
SAMPLES USING THE PT ASSAY
Dose (mg/kg)

1.04

±

10.0

1.09

20.0

1.04

30.0

1.04

± 0.05
± 0.03
± 0.03

0.25

±
0.96 ±
1.14 ±

Saline

GL-522-Y-l

Heparin

0.50

1.00

Pentasaccharide

Clotting time (fold Increase)

1.02

0.10

0.04
0.08
0.06

0.125

1.13

+ 0.11

0.250

1.07

0.500

1.23

±
±

0.09
0.13

All treatments were administered subcutaneously 2 hours prior to administration of the
thrombogenic challenge. Blood samples were drawn at baseline and immediately
before administration of the thrombogenic challenge. All results represent the mean
± SEM of 5 rabbits. Statistical comparisons were made using one way ANOVA
followed by the Newman Keuls test. p < 0. 05 was considered statistically
significant.
By ANOVA:
GL-522-Y-1; p = 0.912
Heparin; p = 0 .403
Pentasaccharide; p = 0.626
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TABLE 66
EX VIVO ANTICOAGULANT ACTIVITY MEASURED IN RABBIT
SAMPLES USING TIIB APTT ASSAY
Dose (mg/kg)
Saline

GL-522-Y-1

Heparin

Pentasaccharide

Clotting time (fold Increase)
0.97

+ 0.04

20.0

± 0.13
0.79 ± 0.14

30.0

1.27

± 0.19

0.25

1.14

+ 0.12

0.50
1.00

± 0.11
1.34 + 0.36

0.125

1.30 + 0.20

0.250

1.24

+

0.500

1.20

± 0.09

10.0

1.00

1.21

0.21

All treatments were administered subcutaneously 2 hours prior to administration of the
thrombogenic challenge. Blood samples were drawn at baseline and immediately
before administration of the thrombogenic challenge. All results represent the mean
± SEM of 5 rabbits. Statistical comparisons were made using one way ANOVA
followed by the Newman Keuls test. ~p < 0.05 was considered statistically
significant.

By ANOVA:
GL-522-Y-1; p = 0.139
Heparin; p = 0. 623
Pentasaccharide; p = 0.468
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TABLE 67
EX VIVO ANTICOAGULANT ACTIVITY MEASURED IN RABBIT
SAMPLES USING TIIB HEPTEST ASSAY

Dose (mg/kg)
Saline

GL-522-Y-1

0.89

10.0
20.0
30.0

Heparin

0.25

0.50
1.00

Pentasaccharide

Clotting time (fold Increase)

0.125
0.250
0.500

± 0.06

± 0.13
1.15 ± 0.10
1.46 ± 0.18*
1.27

± 0.03
1.42 ± 0.10
2.01 ± 0.33*
1.07

± 0.32
2.05 ± 0.34
3.25 ± 0.45*
1.85

All treatments were administered subcutaneously 2 hours prior to administration of the
thrombogenic challenge. Blood samples were drawn at baseline and immediately
before administration of ti'le thrombogenic challenge. All results represent the mean
± SEM of 5 rabbits. Statistical comparisons were made using one way ANOVA
followed by the Newman Keuls test. p < 0.05 was considered statistically
significant.
By ANOVA:
GL-522-Y-1; p = 0.036
Heparin; p = 0.002
Pentasaccharide; p = 0.001
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TABLE 68
EX VIVO ANTICOAGULANT ACTIVITY :MEASURED IN RABBIT
SAMPLES USING TIIB 2.5 U TT ASSAY
Dose (mgJkg)

1.14

±

10.0

1.14

20.0

1.18

30.0

0.79

± 0.07
± 0.28
± 0.10

0.25

± 0.15
3.11 ± 0.85
5.31 ± 1.00*

Saline

GL-522-Y-1

Heparin

0.50

LOO

Pentasaccharide

Clotting time (fold Increase)

0.125
0.250
0.500

0.08

1.58

±
1.37 ±
1.25 ±
1.16

0.23
0.15
0.17

All treatments were administered subcutaneously 2 hours prior to administration of the
thrombogenic challenge. Blood samples were drawn at baseline and immediately
before administration of the thrombogenic challenge. All results represent the mean
± SEM of 5 rabbits. Statistical comparisons were made using one way ANOVA
followed by the Newman Keuls test. •p < 0.05 was considered statistically
significant.
By ANOVA:
GL-522-Y-1; p = 0.297
Heparin; p = 0.002
Pentasaccharide; p = 0. 757
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